Consolidated_NN
cash_NN
flow_NN
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002 2002 2001_CD
Notes_NN
000_CD
000_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
28a_JJ
302,321_CD
202,876_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
:_:
Interest_NN
and_CC
other_JJ
income_NN
received_VBD
15,434_CD
13,077_CD
Interest_NN
paid_VBN
8,458_CD
8,122_CD
Interest_NN
element_NOMZ
of_PIN
finance_NN
lease_NN
rentals_NN
45_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
6,931_CD
4,955_CD
Taxation_NOMZ
:_:
Overseas_NN
corporation_NOMZ
tax_NN
paid_VBN
73,145_CD
44,982_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
:_:
Purchase_NN
of_PIN
long-term_JJ
investment_NOMZ
2,957_CD
Purchase_NN
of_PIN
intangible_JJ
fixed_JJ
assets_NN
15,470_CD
20,159_CD
Purchase_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
15,014_CD
9,593_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
44,103_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
fixed_JJ
assets_NN
3,200_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
542_CD
4,974_CD
Net_JJ
cash_NN
inflow_NN
outflow_NN
for_PIN
capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
11,204_CD
21,578_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
:_:
Purchase_NN
of_PIN
subsidiary_NN
undertaking_GER
11,647_CD
Expenses_NN
of_PIN
acquisitions_NOMZ
235_CD
16,450_CD
Net_JJ
cash_NN
acquired_VBN [WZPAST]
with_PIN
subsidiary_NN
undertakings_GER
33_CD
44,452_CD
Net_JJ
cash_NN
outflow_NN
inflow_NN
from_PIN
acquisitions_NOMZ
11,849_CD
28,002_CD
Cash_NN
inflow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
235,462_CD
169,273_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
:_:
Decrease_NN
increase_NN
in_PIN
cash_NN
placed_VBN [WZPAST]
on_PIN
short-term_JJ
deposit_NN
28b_JJ
254,561_CD
325,479_CD
Financing_GER
:_:
Issue_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
1,050_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
3,985_CD
46,961_CD
Expenses_NN
of_PIN
share_NN
issues_NN
23,584_CD
Capital_NN
element_NOMZ
of_PIN
finance_NN
leases_NN
28b_JJ
74_CD
Net_JJ
decrease_NN
increase_NN
in_PIN
debt_NN
during_PIN
the_DT
year_NN
28b_JJ
832_CD
182,808_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
financing_VBG
3,079_CD
207,235_CD
Increase_VPRT
in_PIN
cash_NN
in_PIN
the_DT
year_NN
28b_JJ
493,102_CD
51,029_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
this_DEMO
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
25_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
1_CD
Accounting_GER
policies_NN
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
applicable_JJ
accounting_GER
standards_NN
and_CC
under_IN
United_NN
Kingdom_NN
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
UK_NN
GAAP_NN
._.
The_DT
particular_JJ
accounting_GER
policies_NN
adopted_VBN [WZPAST]
by_PIN
the_DT
directors_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
consistently_RB
throughout_PIN
the_DT
year_NN
and_CC
the_DT
preceding_JJ
year_NN
,_,
are_VPRT [PASS]
described_VBN
below_PLACE
._.
a_DT
Accounting_GER
convention_NOMZ
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
cost_NN
convention_NOMZ
._.
b_NN
Basis_NN
of_PIN
consolidation_NOMZ
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
incorporate_VPRT
the_DT
financial_JJ
statements_NOMZ
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_CC
all_QUAN
its_PIT
subsidiary_NN
undertakings_GER
drawn_VBN
up_RP
to_PIN
31_CD
December_NN
each_QUAN
year_NN
._.
c_NN
Acquisitions_NOMZ
and_PHC
disposals_NN
On_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
including_VBG [PRESP]
an_DT
interest_NN
in_PIN
an_DT
associated_VBN
undertaking_GER
,_,
fair_JJ
values_NN
are_VPRT [PASS]
attributed_VBN
to_PIN
the_DT
Groups_NN
share_NN
of_PIN
net_JJ
separable_JJ
assets_NN
._.
Where_RB
the_DT
cost_NN
of_PIN
the_DT
acquisition_NOMZ
exceeds_VPRT
the_DT
fair_JJ
values_NN
attributable_JJ
to_PIN
such_JJ
net_JJ
assets_NN
,_,
the_DT
diference_NN
is_VPRT [PASS]
treated_VBN
as_IN
purchased_VBN
goodwill_NN
and_CC
capitalized_VBN
in_PIN
the_DT
balance_NN
sheet_NN
in_PIN
the_DT
year_NN
of_PIN
acquisition_NOMZ
._.
Prior_RB
to_PIN
the_DT
implementation_NOMZ
of_PIN
FRS_NN
10_CD
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
1998_CD
,_,
purchased_VBD
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
directly_RB
to_PIN
reserves_NN
and_CC
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
reinstated_VBN
._.
The_DT
profit_NN
or_CC
loss_NN
on_PIN
the_DT
disposal_NN
of_PIN
a_DT
previously_TIME
acquired_VBN
business_NOMZ
includes_VPRT
the_DT
attributable_JJ
amount_NN
of_PIN
any_QUAN
purchased_VBN
goodwill_NN
relating_VBG [WZPRES]
to_PIN
that_DEMO
business_NOMZ
not_XX0
previously_TIME
charged_VBN
through_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
results_NN
and_PHC
cash_NN
flows_NN
relating_VBG [WZPRES]
to_PIN
a_DT
business_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
and_CC
the_DT
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
from_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
up_IN
to_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
d_LS
Intangible_JJ
assets_NN
goodwill_NN
For_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
including_VBG [PRESP]
an_DT
interest_NN
in_PIN
an_DT
associated_VBN
undertaking_GER
,_,
purchased_VBD
goodwill_NN
is_VPRT [PASS]
capitalized_VBN
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
it_PIT
arises_VPRT
and_PHC
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
economic_JJ
life_NN
up_IN
to_PIN
a_DT
maximum_NN
of_PIN
20_CD
years_NN
._.
The_DT
directors_NN
regard_VPRT
20_CD
years_NN
as_IN
a_DT
reasonable_JJ
maximum_NN
for_PIN
the_DT
estimated_VBN [PRIV]
useful_JJ
economic_JJ
life_NN
of_PIN
goodwill_NN
since_OSUB
it_PIT
is_VPRT [BEMA]
difficult_PRED
to_TO
make_VB
projections_NOMZ
exceeding_VBG [WZPRES]
this_DEMO
period_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
any_QUAN
impairment_NOMZ
._.
The_DT
asset_NN
is_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [PASS]
impaired_VBN
to_PIN
the_DT
extent_NN
that_TOBJ
the_DT
carrying_VBG
amount_NN
exceeds_VPRT
the_DT
recoverable_JJ
amount_NN
._.
The_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Capitalised_VBN
purchased_VBN
goodwill_NN
in_PIN
respect_NN
of_PIN
subsidiaries_NN
is_VPRT [PASS]
included_VBN
within_PIN
intangible_JJ
assets_NN
._.
Capitalised_NN
purchased_VBD
goodwill_NN
relating_VBG [WZPRES]
to_PIN
associates_NN
is_VPRT [PASS]
included_VBN
within_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
associate_NN
._.
Goodwill_NN
which_WDT [WHSUB]
arose_VBD
on_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
prior_RB
to_PIN
the_DT
implementation_NOMZ
of_PIN
FRS_NN
10_CD
which_WDT
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
reserve_NN
as_IN
a_DT
matter_NN
of_PIN
accounting_GER
policy_NN
,_,
remains_VPRT
eliminated_VBN
in_PIN
that_DEMO
reserve_NN
and_CC
will_PRMD
be_VB [PASS]
charged_VBN
or_CC
credited_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
appropriate_JJ
on_PIN
the_DT
subsequent_JJ
disposal_NN
of_PIN
the_DT
business_NOMZ
to_PIN
which_WDT [PIRE]
it_PIT
relates_VPRT
._.
e_LS
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
Intellectual_NN
property_NN
,_,
including_VBG
trademarks_NN
,_,
for_PIN
products_NN
with_PIN
an_DT
immediate_JJ
defined_VBN
revenue_NN
stream_NN
and_CC
acquired_VBN
for_PIN
valuable_JJ
consideration_NOMZ
,_,
are_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
in_PIN
equal_JJ
annual_JJ
instalments_NOMZ
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
life_NN
of_PIN
the_DT
product_NN
generally_RB
not_XX0
exceeding_VBG
20_CD
years_NN
._.
Intellectual_NN
property_NN
with_PIN
no_DT
defined_VBN
revenue_NN
stream_NN
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
on_PIN
acquisition_NOMZ
._.
f_LS
Tangible_JJ
assets_NN
Depreciation_NOMZ
is_VPRT [PASS]
not_XX0
provided_VBN
on_PIN
freehold_JJ
land_NN
._.
All_QUAN
other_JJ
tangible_JJ
fixed_JJ
assets_NN
are_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
less_JJ
accumulated_VBN
depreciation_NOMZ
and_CC
any_QUAN
provision_NN
for_PIN
impairment_NOMZ
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
less_JJ
estimated_VBN [PRIV]
residual_JJ
value_NN
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
at_PIN
the_DT
following_JJ
annual_JJ
rates_NN
:_:
Freehold_NN
buildings_GER
2-5_CD
%_NN
per_PIN
annum_NN
Office_NN
furniture_NN
and_PHC
fittings_GER
10-25_CD
%_NN
per_PIN
annum_NN
Equipment_NOMZ
and_CC
other_JJ
10-25_CD
%_NN
per_PIN
annum_NN
g_NN
Investments_NOMZ
Except_PIN
as_IN
stated_VBN [PUBV]
below_PLACE
,_,
investments_NOMZ
held_VBD [PRIV]
as_IN
fixed_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
provision_NN
for_PIN
any_QUAN
impairment_NOMZ
._.
In_PIN
the_DT
consolidated_JJ
accounts_NN
,_,
shares_NN
in_PIN
joint_JJ
ventures_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
._.
The_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
includes_VPRT
the_DT
Groups_NN
share_NN
of_PIN
pre-tax_JJ
profits_NN
and_CC
attributable_JJ
taxation_NOMZ
of_PIN
the_DT
joint_JJ
ventures_NN
based_VBN [WZPAST]
on_PIN
audited_JJ
financial_JJ
statements_NOMZ
for_PIN
the_DT
financial_JJ
year_NN
._.
In_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
,_,
the_DT
investment_NOMZ
in_PIN
joint_JJ
ventures_NN
is_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
of_PIN
the_DT
joint_JJ
ventures_NN
._.
In_PIN
the_DT
Company_NN
balance_NN
sheet_NN
,_,
for_PIN
investments_NOMZ
in_PIN
subsidiaries_NN
acquired_VBN [WZPAST]
for_PIN
consideration_NOMZ
including_VBG [WZPRES]
the_DT
issue_NN
of_PIN
shares_NN
qualifying_VBG [WZPRES]
for_PIN
merger_NN
relief_NN
,_,
advantage_NN
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
taken_VBN
of_PIN
this_DEMO
relief_NN
and_CC
the_DT
share_NN
premium_NN
of_PIN
the_DT
shares_NN
issued_VBN
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
cost_NN
._.
Current_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
h_NN
Stocks_NN
Stocks_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Cost_NN
incurred_VBN [WZPAST]
in_PIN
bringing_VBG
each_QUAN
product_NN
to_PIN
its_PIT
present_JJ
location_NOMZ
and_PHC
condition_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
purchase_NN
costs_NN
calculated_VBN [PRIV] [WZPAST]
on_PIN
a_DT
first-in_PIN [STPR]
,_,
first-out_PIN
basis_NN
,_,
including_VBG
transport_NN
._.
Net_JJ
realisable_JJ
value_NN
is_VPRT [PASS]
based_VBN
on_PIN
estimated_VBN [PRIV]
normal_JJ
selling_GER
price_NN
less_RB
further_JJ
costs_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
to_PIN
completion_NOMZ
and_PHC
disposal_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
obsolete_JJ
,_,
slow_JJ
moving_VBG [SUAV]
or_CC
defective_JJ
items_NN
where_RB
appropriate_JJ
._.
26_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
1_CD
Accounting_GER
policies_NN
continued_VBD
i_FPP1
Deferred_JJ
taxation_NOMZ
Deferred_VBN
tax_NN
is_VPRT [PASS]
provided_VBN
in_PIN
full_JJ
on_PIN
timing_NN
differences_NN
which_WDT [WHSUB]
result_VPRT
in_PIN
an_DT
obligation_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
to_TO
pay_VB
more_EMPH
tax_NN
,_,
or_CC
a_DT
right_NN
to_TO
pay_VB
less_JJ
tax_NN
,_,
at_PIN
a_DT
future_JJ
date_NN
,_,
at_PIN
rates_NN
expected_VBN [PRIV]
to_TO
apply_VB
when_RB
they_TPP3
crystallise_VPRT
based_VBN
on_PIN
current_JJ
tax_NN
rates_NN
and_PHC
law_NN
._.
Timing_NN
differences_NN
arise_VPRT
from_PIN
the_DT
inclusion_NN
of_PIN
items_NN
of_PIN
income_NN
and_PHC
expenditure_NN
in_PIN
taxation_NOMZ
computations_NOMZ
in_PIN
periods_NN
different_JJ
from_PIN
those_DEMO
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
not_XX0
provided_VBN
on_PIN
timing_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
unremitted_JJ
earnings_GER
of_PIN
subsidiaries_NN
and_PHC
associates_NN
where_RB
there_EX
is_VPRT
no_SYNE
commitment_NOMZ
to_TO
remit_VB
these_DEMO
earnings_GER
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
regarded_VBN
as_IN
more_EMPH
likely_JJ
than_PIN
not_XX0
that_DEMO
they_TPP3
will_PRMD
be_VB [PASS]
recovered_VBN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
j_NN
Turnover_NN
The_DT
Group_NN
recognizes_VPRT [PRIV]
turnover_NN
when_RB
:_:
there_EX
is_VPRT
persuasive_JJ
evidence_NN
of_PIN
an_DT
arrangement_NOMZ
:_:
delivery_NN
of_PIN
products_NN
has_VPRT [PEAS]
occurred_VBN
or_CC
services_NN
have_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
:_:
the_DT
sellers_NN
price_NN
to_PIN
the_DT
buyer_NN
is_VPRT [PASS]
fixed_VBN
or_CC
determinable_JJ
:_:
and_ANDC
collectibility_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
Revenues_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
VAT_NN
and_CC
similar_JJ
taxes_NN
,_,
trade_NN
discounts_NN
and_CC
intra-Group_JJ
transactions_NOMZ
._.
The_DT
principal_JJ
components_NN
of_PIN
the_DT
Groups_NN
turnover_NN
and_CC
their_TPP3
respective_JJ
accounting_GER
treatments_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Product_NN
sales_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
net_JJ
upon_PIN
shipment_NOMZ
to_PIN
customers_NN
._.
Provisions_NN
for_PIN
certain_JJ
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
provided_VBN
for_PIN
as_IN
reductions_NOMZ
to_PIN
net_JJ
turnover_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
Licensing_GER
and_PHC
development_NOMZ
fees_NN
represent_VPRT
revenues_NN
derived_VBN [WZPAST]
from_PIN
licence_NN
agreements_NOMZ
and_CC
from_PIN
collaborative_JJ
research_NN
and_PHC
development_NOMZ
arrangements_NOMZ
._.
Initial_JJ
licence_NN
fees_NN
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
separable_PRED
from_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
activities_NOMZ
,_,
even_RB
where_RB
such_JJ
fees_NN
are_VPRT [BEMA]
nonrefundable_PRED
and_CC
not_XX0
creditable_JJ
against_PIN
research_NN
and_PHC
development_NOMZ
services_NN
to_TO
be_VB [PASS]
rendered_VBN
._.
Initial_JJ
licence_NN
fees_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
licence_NN
term_NN
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
agreement_NOMZ
._.
In_PIN
circumstances_NN
where_RB
initial_JJ
licence_NN
fees_NN
are_VPRT [BEMA]
not_XX0
for_PIN
a_DT
defined_VBN
period_NN
,_,
revenues_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patent_NN
to_PIN
which_WDT [PIRE]
the_DT
licence_NN
relates_VPRT
._.
During_PIN
the_DT
term_NN
of_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
,_,
the_DT
Group_NN
receives_VPRT
non-refundable_JJ
milestones_NN
as_IN
certain_JJ
technical_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
._.
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
achievement_NOMZ
of_PIN
milestones_NN
._.
The_DT
Group_NN
also_RB
receives_VPRT
non-refundable_JJ
clinical_JJ
milestones_NN
when_RB
certain_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
during_PIN
the_DT
clinical_JJ
phases_NN
of_PIN
development_NOMZ
,_,
such_JJ
as_IN
the_DT
submission_NN
of_PIN
clinical_JJ
data_NN
to_PIN
a_DT
regulatory_JJ
authority_NOMZ
._.
These_DEMO
clinical_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
receivable_NN
._.
If_COND
milestone_NN
payments_NOMZ
are_VPRT [BEMA]
creditable_PRED
against_PIN
future_JJ
royalty_NN
payments_NOMZ
,_,
the_DT
milestones_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
released_VBN
over_IN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
royalties_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
._.
Royalty_NN
income_NN
relating_VBG [WZPRES]
to_PIN
licensed_JJ
technology_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
earned_VBN
._.
No_SYNE
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
consideration_NOMZ
,_,
the_DT
value_NN
or_CC
receipt_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
dependent_PRED
on_PIN
future_JJ
events_NN
,_,
future_JJ
performance_NN
,_,
or_CC
refund_NN
obligations_NOMZ
._.
k_NN
Research_NN
and_PHC
development_NOMZ
Research_NN
and_PHC
development_NOMZ
expenditure_NN
includes_VPRT
funded_VBN
and_CC
unfunded_JJ
expenditure_NN
and_CC
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
l_NN
Pensions_NN
The_DT
Group_NN
contributes_VPRT
to_PIN
personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_NN
of_PIN
employees_NN
._.
Contributions_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
become_VPRT
payable_JJ
._.
Differences_NN
between_PIN
contributions_NOMZ
payable_JJ
and_CC
contributions_NOMZ
actually_RB
paid_VBN
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
either_DT
accruals_NN
or_CC
prepayments_NOMZ
in_PIN
the_DT
balance_NN
sheet_NN
._.
m_NN
Foreign_NN
currency_NN
Transactions_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
functional_JJ
currency_NN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
dates_NN
of_PIN
the_DT
transactions_NOMZ
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
are_VPRT [PASS]
retranslated_VBN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
that_DEMO
date_NN
._.
With_PIN
the_DT
exception_NOMZ
of_PIN
US_FPP1
dollar_NN
balances_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
,_,
these_DEMO
translation_NOMZ
differences_NN
are_VPRT [PASS]
dealt_VBN
with_PIN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
rates_NN
of_PIN
exchange_NN
during_PIN
the_DT
period_NN
and_CC
their_TPP3
balance_NN
sheets_NN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Exchange_NN
differences_NN
arising_VBG [WZPRES]
from_PIN
the_DT
translation_NOMZ
of_PIN
the_DT
opening_GER
net_JJ
assets_NN
and_CC
on_PIN
foreign_JJ
currency_NN
borrowings_GER
,_,
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
hedge_VPRT
the_DT
Groups_NN
investments_NOMZ
in_PIN
such_JJ
operations_NOMZ
,_,
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
._.
All_QUAN
other_JJ
exchange_NN
differences_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
n_JJ
Leases_NN
Assets_NN
acquired_VBD
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
capitalized_VBN
at_PIN
their_TPP3
fair_JJ
value_NN
on_PIN
the_DT
inception_NOMZ
of_PIN
the_DT
leases_NN
and_CC
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
period_NN
of_PIN
lease_NN
and_CC
the_DT
useful_JJ
economic_JJ
lives_NN
of_PIN
the_DT
assets_NN
._.
The_DT
finance_NN
charges_NN
are_VPRT [PASS]
allocated_VBN
over_IN
the_DT
period_NN
of_PIN
the_DT
lease_NN
in_PIN
proportion_NOMZ
to_PIN
the_DT
capital_NN
amount_NN
outstanding_JJ
and_CC
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Operating_VBG
lease_NN
rentals_NN
are_VPRT [PASS]
charged_VBN
to_TO
profit_VB
and_CC
loss_NN
in_PIN
equal_JJ
amounts_NN
over_IN
the_DT
lease_NN
term_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
27_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
1_CD
Accounting_GER
policies_NN
continued_VBD
o_JJ
Finance_NN
costs_NN
Finance_NN
costs_NN
of_PIN
debt_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
term_NN
of_PIN
the_DT
debt_NN
at_PIN
a_DT
constant_JJ
rate_NN
on_PIN
the_DT
carrying_VBG
amount_NN
._.
p_NN
Debt_NN
Debt_NN
is_VPRT [SPAU] [PASS]
initially_TIME
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
the_DT
net_JJ
proceeds_NN
after_IN
deduction_NOMZ
of_PIN
issue_NN
costs_NN
._.
The_DT
carrying_VBG
amount_NN
is_VPRT [BYPA]
increased_VBN
by_PIN
the_DT
finance_NN
cost_NN
in_PIN
respect_NN
of_PIN
the_DT
accounting_GER
period_NN
and_CC
reduced_VBN
by_PIN
payments_NOMZ
made_VBN [WZPAST]
in_PIN
the_DT
period_NN
._.
Convertible_JJ
debt_NN
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
liability_NOMZ
as_OSUB
long_NULL
as_NULL
there_EX
is_VPRT
no_SYNE
genuine_JJ
commercial_JJ
possibility_NOMZ
that_TOBJ
the_DT
option_NOMZ
to_TO
issue_VB
ordinary_JJ
shares_NN
or_CC
American_JJ
Depository_NN
Shares_NN
will_PRMD
be_VB [PASS]
exercised_VBN
._.
No_SYNE
gain_NN
or_CC
loss_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
conversion_NN
._.
q_NN
Government_NOMZ
grants_NN
Government_NOMZ
grants_NN
in_PIN
respect_NN
of_PIN
funded_JJ
research_NN
and_PHC
development_NOMZ
expenditure_NN
are_VPRT [PASS]
credited_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
the_DT
related_JJ
expenditure_NN
is_VPRT [PASS]
incurred_VBN
._.
r_NN
Derivative_JJ
financial_JJ
instruments_NOMZ
The_DT
Group_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
reduce_VB
exposure_NN
to_PIN
foreign_JJ
exchange_NN
risk_NN
and_PHC
interest_NN
rate_NN
movements_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
speculative_JJ
purposes_NN
._.
For_PIN
a_DT
forward_RB
foreign_JJ
exchange_NN
contract_NN
to_TO
be_VB [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
the_DT
instrument_NOMZ
must_NEMD
be_VB [PASS]
related_VBN
to_PIN
actual_JJ
foreign_JJ
currency_NN
assets_NN
or_CC
liabilities_NOMZ
or_CC
to_PIN
a_DT
probable_JJ
commitment_NOMZ
._.
It_PIT
must_NEMD
involve_VB
the_DT
same_JJ
currency_NN
or_CC
similar_JJ
currencies_NN
as_IN
the_DT
hedged_VBN
item_NN
and_CC
must_NEMD [SPAU]
also_RB
reduce_VB
the_DT
risk_NN
of_PIN
foreign_JJ
currency_NN
exchange_NN
movements_NOMZ
on_PIN
the_DT
Groups_NN
operations_NOMZ
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
on_PIN
these_DEMO
contracts_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
,_,
or_CC
as_IN
adjustments_NOMZ
to_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
fixed_JJ
assets_NN
,_,
only_DWNT
when_RB
the_DT
hedged_VBN
transaction_NOMZ
has_VPRT [PEAS]
itself_PIT
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
Groups_NN
accounts_NN
._.
For_PIN
an_DT
interest_NN
rate_NN
swap_NN
to_TO
be_VB [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
the_DT
instrument_NOMZ
must_NEMD
be_VB [PASS]
related_VBN
to_PIN
actual_JJ
assets_NN
or_CC
liabilities_NOMZ
or_CC
a_DT
probable_JJ
commitment_NOMZ
and_CC
must_NEMD
change_VB
the_DT
nature_NN
of_PIN
the_DT
interest_NN
rate_NN
by_PIN
converting_VBG
a_DT
fixed_JJ
rate_NN
to_PIN
a_DT
variable_JJ
rate_NN
or_CC
vice_NN
versa_RB
._.
Interest_NN
differentials_NN
under_IN
these_DEMO
swaps_NN
are_VPRT [BYPA]
recognized_VBN [PRIV]
by_PIN
adjusting_VBG
net_JJ
interest_NN
payable_JJ
over_IN
the_DT
periods_NN
of_PIN
the_DT
contracts_NN
._.
If_COND
an_DT
instrument_NOMZ
ceases_VPRT
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
hedge_NN
,_,
for_CONJ
example_NULL
because_CAUS
the_DT
underlying_VBG
hedged_JJ
position_NOMZ
is_VPRT [PASS]
eliminated_VBN
,_,
the_DT
instrument_NOMZ
is_VPRT [PASS]
marked_VBN
to_PIN
market_NN
and_CC
any_QUAN
resulting_JJ
profit_NN
or_CC
loss_NN
recognized_VBN [PRIV] [WZPAST]
at_PIN
that_DEMO
time_NN
._.
s_PRP
Employee_NN
share_NN
schemes_NN
In_PIN
accordance_NN
with_PIN
UITF_NN
Abstract_NN
17_CD
Employee_NN
share_NN
schemes_NN
,_,
the_DT
cost_NN
of_PIN
awards_NN
to_PIN
employees_NN
that_TSUB
take_VPRT
the_DT
form_NN
of_PIN
shares_NN
or_CC
rights_NN
to_PIN
shares_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
charge_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
amount_NN
recognized_VBN [PRIV]
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
difference_NN
between_PIN
the_DT
market_NN
value_NN
at_PIN
date_NN
of_PIN
grant_NN
and_CC
the_DT
underlying_JJ
share_NN
and_CC
any_QUAN
exercise_NN
price_NN
,_,
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
period_NN
the_DT
shares_NN
are_VPRT [PASS]
vested_VBN
,_,
with_PIN
a_DT
corresponding_JJ
credit_NN
to_PIN
reserves_NN
._.
t_NN
Related_VBN
party_NN
transactions_NOMZ
In_PIN
accordance_NN
with_PIN
the_DT
exemptions_NOMZ
in_PIN
FRS_NN
8_CD
Related_VBN
party_NN
disclosures_NN
,_,
transactions_NOMZ
between_PIN
Group_NN
companies_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
disclosed_VBN [PUBV]
since_OSUB
Group_NN
accounts_NN
are_VPRT [BEMA]
prepared_PRED
and_CC
include_VPRT
the_DT
results_NN
of_PIN
all_QUAN
subsidiary_NN
undertakings_GER
._.
u_NN
Significant_NN
accounting_GER
estimates_VPRT [PRIV]
Sales_NN
deductions_NOMZ
primarily_RB
consist_VPRT
of_PIN
statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
agencies_NN
,_,
contractual_JJ
rebates_NN
with_PIN
health-maintenance_NN
organizations_NOMZ
,_,
product_NN
returns_NN
,_,
and_ANDC
trade_NN
discounts_NN
._.
Provisions_NN
for_PIN
rebates_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
with_PIN
estimates_NN
of_PIN
future_JJ
utilisation_NOMZ
derived_VBN [WZPAST]
from_PIN
historical_JJ
trends_NN
._.
Provisions_NN
for_PIN
product_NN
returns_NN
and_PHC
trade_NN
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
with_PIN
estimates_NN
based_VBN [WZPAST]
upon_PIN
past_JJ
activity_NOMZ
levels_NN
and_PHC
duration_NOMZ
of_PIN
time_NN
in_PIN
the_DT
processing_GER
of_PIN
deductions_NOMZ
._.
28_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
2_CD
Turnover_NN
and_PHC
segment_NOMZ
information_NOMZ
a_DT
Turnover_NN
and_PHC
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
The_DT
directors_NN
believe_VPRT [PRIV]
that_THVC
there_EX
is_VPRT
one_CD
business_NOMZ
segment_NOMZ
._.
Licensing_VBG
Product_NN
and_CC
Other_JJ
sales_NN
development_NOMZ
Royalties_NN
revenues_NN
Total_JJ
Year_NN
to_PIN
31_CD
December_NN
2002 000 000 000_CD
000_CD
000_CD
Turnover_NN
596,313_CD
2,041_CD
114,146_CD
27_CD
712,527_CD
Cost_NN
of_PIN
product_NN
sales_NN
95,042_CD
95,042_CD
Distribution_NOMZ
costs_NN
167,095_CD
167,095_CD
Funded_VBN
research_NN
and_PHC
development_NOMZ
costs_NN
5,041_CD
5,041_CD
334,176_CD
3,000_CD
114,146_CD
27_CD
445,349_CD
Unfunded_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
121,105_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
794,499_CD
Expenses_NN
not_XX0
allocated_VBN
general_JJ
overheads_NN
62,890_CD
Operating_GER
loss_NN
533,145_CD
Share_NN
of_PIN
joint_JJ
ventures_NN
operating_VBG [WZPRES]
loss_NN
559_CD
Finance_NN
charges_NN
,_,
net_JJ
6,931_CD
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
526,773_CD
General_NN
overheads_NN
have_VPRT [PEAS]
not_XX0
been_VBN [BYPA]
allocated_VBN
by_PIN
business_NOMZ
activity_NOMZ
as_IN
management_NOMZ
does_VPRT
not_XX0
run_VB
the_DT
business_NOMZ
in_PIN
this_DEMO
way_NN
._.
Licensing_VBG
Product_NN
and_CC
Other_JJ
sales_NN
development_NOMZ
Royalties_NN
revenues_NN
Total_JJ
Year_NN
to_PIN
31_CD
December_NN
2001 000 000 000_CD
000_CD
000_CD
Turnover_NN
508,626_CD
3,810_CD
66,132_CD
1,801_CD
580,369_CD
Cost_NN
of_PIN
product_NN
sales_NN
83,149_CD
83,149_CD
Distribution_NOMZ
costs_NN
147,400_CD
147,400_CD
Funded_VBN
research_NN
and_PHC
development_NOMZ
costs_NN
4,358_CD
4,358_CD
278,077_CD
548_CD
66,132_CD
1,801_CD
345,462_CD
Unfunded_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
99,468_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
121,438_CD
Expenses_NN
not_XX0
allocated_VBN
general_JJ
overheads_NN
48,134_CD
Operating_GER
profit_NN
76,422_CD
Finance_NN
charges_NN
,_,
net_JJ
4,955_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
81,377_CD
General_NN
overheads_NN
have_VPRT [PEAS]
not_XX0
been_VBN [BYPA]
allocated_VBN
by_PIN
business_NOMZ
activity_NOMZ
as_IN
management_NOMZ
does_VPRT
not_XX0
run_VB
the_DT
business_NOMZ
in_PIN
this_DEMO
way_NN
._.
c_NN
An_DT
analysis_NN
of_PIN
net_JJ
operating_GER
expenses_NN
2002 2001 000 000_CD
Distribution_NOMZ
costs_NN
167,095_CD
147,400_CD
Research_NN
and_PHC
development_NOMZ
126,146_CD
103,826_CD
Administrative_JJ
expenses_NN
857,389_CD
169,572_CD
1,150,630_CD
420,798_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
29_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
2_CD
Turnover_NN
and_PHC
segment_NOMZ
information_NOMZ
continued_VBD
d_SYM
Analysis_NN
of_PIN
continuing_VBG
and_PHC
discontinuing_VBG
operations_NOMZ
Continuing_VBG [WZPRES]
Discontinued_NN
Total_NN
Continuing_GER
Discontinued_NN
Total_NN
2002 2002 2002 2001_CD
2001_CD
2001_CD
Turnover_NN
696,552_CD
15,975_CD
712,527_CD
563,249_CD
17,120_CD
580,369_CD
Cost_NN
of_PIN
sales_NN
91,208_CD
3,834_CD
95,042_CD
78,781_CD
4,368_CD
83,149_CD
Gross_NN
profit_NN
605,344_CD
12,141_CD
617,485_CD
484,468_CD
12,752_CD
497,220_CD
Net_JJ
operating_GER
expenses_NN
1,146,947_CD
3,683_CD
1,150,630_CD
415,496_CD
5,302_CD
420,798_CD
Operating_GER
loss_NN
profit_NN
541,603_CD
8,458_CD
533,145_CD
68,972_CD
7,450_CD
76,422_CD
The_DT
total_JJ
figures_NN
for_PIN
continuing_VBG
operations_NOMZ
in_PIN
2002_CD
include_VPRT
the_DT
following_JJ
amounts_NN
relating_VBG [WZPRES]
to_PIN
acquisitions_NOMZ
:_:
turnover_NN
653,000_CD
,_,
cost_NN
of_PIN
sales_NN
1,637,000_CD
,_,
gross_JJ
loss_NN
984,000_CD
,_,
net_JJ
operating_GER
expenses_NN
847,000_CD
and_CC
operating_VBG
loss_NN
1,831,000_CD
._.
3_CD
Operating_GER
loss_NN
profit_NN
Operating_GER
loss_NN
profit_NN
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
crediting_VBG
charging_VBG
:_:
2002 2001 000 000_CD
Government_NOMZ
grant_NN
1,855_CD
1,824_CD
Research_NN
and_PHC
development_NOMZ
126,146_CD
103,826_CD
Auditors_NN
remuneration_JJ
audit_NN
fees_NN
Group_NN
600_CD
515_CD
Company_NN
20_CD
20_CD
non-audit_JJ
fees_NN
Group_NN
933_CD
1,245_CD
Company_NN
48_CD
48_CD
Operating_GER
lease_NN
rentals_NN
plant_NN
and_PHC
machinery_NN
2,332_CD
2,101_CD
other_JJ
2,264_CD
1,891_CD
Impairment_NOMZ
of_PIN
goodwill_NN
and_CC
other_JJ
intangible_JJ
fixed_JJ
assets_NN
631,447_CD
3,092_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
fixed_JJ
assets_NN
owned_VBN
8,995_CD
7,092_CD
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
78_CD
Amortisation_NOMZ
of_PIN
goodwill_NN
138,513_CD
96,710_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
fixed_JJ
assets_NN
15,466_CD
14,544_CD
Profit_NN
on_PIN
sale_NN
of_PIN
discontinued_VBN
operations_NOMZ
2,006_CD
Loss_NN
on_PIN
sales_NN
of_PIN
fixed_JJ
assets_NN
854_CD
7,646_CD
4_CD
Directors_NN
remuneration_NOMZ
,_,
interests_NN
and_PHC
transactions_NOMZ
Aggregate_JJ
remuneration_NOMZ
The_DT
total_JJ
amounts_NN
for_PIN
directors_NN
remuneration_NOMZ
and_CC
other_JJ
benefits_NN
were_VBD
as_IN
follows_VPRT
:_:
2002 2001 000 000_CD
Emoluments_NOMZ
2,300_CD
2,019_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
2,754_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
2,962_CD
22,005_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
383_CD
103_CD
5,645_CD
26,881_CD
No_SYNE
fees_NN
were_VBD [BEMA]
payable_PRED
to_PIN
third_JJ
parties_NN
in_PIN
respect_NN
of_PIN
directors_NN
services_NN
for_PIN
either_DT
year_NN
._.
30_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
4_CD
Directors_NN
remuneration_NOMZ
,_,
interests_NN
and_PHC
transactions_NOMZ
The_DT
number_NN
of_PIN
directors_NN
who_WP [WHSUB]
were_VBD
members_NN
of_PIN
a_DT
Company_NN
pension_NN
scheme_NN
was_VBD
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Number_NN
Number_NN
Money_NN
purchase_NN
schemes_NN
4_CD
3_CD
Contributions_NOMZ
paid_VBN [WZPAST]
by_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
these_DEMO
directors_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
remuneration_NOMZ
report_NN
on_PIN
page_NN
20_CD
._.
The_DT
above_PLACE
amounts_NN
for_PIN
remuneration_NOMZ
include_VPRT
the_DT
following_VBG
in_PIN
respect_NN
of_PIN
the_DT
highest_JJ
paid_VBN
director_NN
:_:
2002 2001 000 000_CD
Aggregate_NN
emoluments_NOMZ
1,144_CD
258_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
2,754_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
2,836_CD
21,437_CD
3,980_CD
24,449_CD
Further_JJ
disclosures_NN
relating_VBG [WZPRES]
to_PIN
directors_NN
remuneration_NOMZ
and_PHC
interests_NN
in_PIN
transactions_NOMZ
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
remuneration_NOMZ
report_NN
._.
5_CD
Staff_NN
costs_NN
Particulars_NN
of_PIN
employee_NN
costs_NN
including_VBG [WZPRES]
executive_JJ
directors_NN
remuneration_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2002 2001 000 000_CD
Wages_NN
and_PHC
salaries_NN
79,383_CD
78,888_CD
Social_NN
security_NOMZ
costs_NN
7,761_CD
7,608_CD
Pension_NN
contributions_NOMZ
4,702_CD
3,123_CD
91,846_CD
89,619_CD
The_DT
Group_NN
operates_VPRT
an_DT
Inland_NN
Revenue_NN
approved_VBD
employee_NN
share_NN
option_NOMZ
scheme_NN
and_CC
has_VPRT [PEAS]
taken_VBN
advantage_NN
of_PIN
the_DT
exemption_NOMZ
given_VBN [WZPAST]
in_PIN
UITF_NN
Abstract_NN
17_CD
Employee_NN
share_NN
schemes_NN
from_PIN
recognizing_VBG [PRIV]
a_DT
charge_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
the_DT
discount_NN
on_PIN
the_DT
options_NOMZ
._.
The_DT
average_JJ
monthly_JJ
number_NN
of_PIN
people_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
during_PIN
the_DT
year_NN
was_VBD
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Number_NN
Number_NN
Manufacturing_GER
and_PHC
distribution_NOMZ
292_CD
236_CD
Sales_NN
and_PHC
marketing_GER
791_CD
704_CD
General_NN
and_CC
administrative_JJ
298_CD
220_CD
Research_NN
and_PHC
development_NOMZ
424_CD
315_CD
1,805_CD
1,475_CD
6_CD
Finance_NN
charges_NN
,_,
net_JJ
2002 2001 000 000_CD
Investment_NOMZ
income_NN
15,434_CD
13,077_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
8,458_CD
8,122_CD
Finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
45_CD
8,503_CD
8,122_CD
Finance_NN
charges_NN
,_,
net_JJ
Investment_NOMZ
income_NN
15,434_CD
13,077_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
8,503_CD
8,122_CD
6,931_CD
4,955_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
31_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
7_CD
Tax_NN
on_PIN
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
The_DT
tax_NN
charge_NN
comprises_VPRT
:_:
2002 2001 000 000_CD
Current_JJ
tax_NN
UK_NN
corporation_NOMZ
tax_NN
76_CD
Overseas_NN
corporation_NOMZ
tax_NN
66,461_CD
46,879_CD
Adjustment_NOMZ
to_PIN
prior_JJ
year_NN
tax_NN
charge_NN
UK_NN
corporation_NOMZ
tax_NN
1,190_CD
Overseas_NN
corporation_NOMZ
tax_NN
196_CD
2,049_CD
67,455_CD
44,906_CD
Deferred_JJ
tax_NN
Origination_NOMZ
and_PHC
reversal_NN
of_PIN
timing_NN
differences_NN
5,829_CD
762_CD
Total_JJ
deferred_JJ
tax_NN
5,829_CD
762_CD
Total_JJ
tax_NN
on_PIN
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
61,626_CD
45,668_CD
The_DT
differences_NN
between_PIN
the_DT
total_JJ
current_JJ
tax_NN
shown_VBN [PRIV]
above_PLACE
and_CC
the_DT
amount_NN
calculated_VBN [PRIV] [WZPAST]
by_PIN
applying_VBG
the_DT
standard_JJ
rate_NN
of_PIN
UK_NN
corporation_NOMZ
tax_NN
to_PIN
the_DT
profit_NN
before_IN
tax_NN
is_VPRT
as_IN
follows_VPRT
:_:
2002 2001 000 000_CD
Group_NN
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
tax_NN
526,773_CD
81,377_CD
Tax_NN
on_PIN
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
at_PIN
standard_JJ
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
2001_CD
:_:
30_CD
%_NN
158,032_CD
24,413_CD
Effects_NN
of_PIN
:_:
Expenses_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
9,247_CD
782_CD
Non_NN
deductible_JJ
goodwill_NN
225,749_CD
29,090_CD
Additional_JJ
tax_NN
benefits_NN
non_VPRT
taxable_JJ
income_NN
1,796_CD
4,090_CD
Utilisation_NOMZ
of_PIN
tax_NN
losses_NN
9,255_CD
256_CD
Capital_NN
taxes_NN
and_PHC
withholding_GER
taxes_NN
550_CD
4,360_CD
Different_JJ
tax_NN
rates_NN
on_PIN
overseas_PLACE
earnings_GER
24,341_CD
6,582_CD
Deferred_JJ
tax_NN
liability_NOMZ
5,829_CD
762_CD
Adjustments_NOMZ
to_PIN
tax_NN
charge_NN
in_PIN
respect_NN
of_PIN
previous_JJ
periods_NN
994_CD
2,049_CD
Group_NN
current_JJ
tax_NN
charge_NN
for_PIN
period_NN
67,455_CD
44,906_CD
The_DT
Group_NN
earns_VPRT
a_DT
significant_JJ
proportion_NOMZ
of_PIN
its_PIT
profits_NN
in_PIN
the_DT
US_FPP1
._.
The_DT
US_FPP1
statutory_JJ
federal_JJ
tax_NN
rate_NN
is_VPRT [BEMA]
higher_PRED
than_PIN
that_DEMO
of_PIN
the_DT
UK_NN
:_:
profits_NN
being_VBG [WZPRES] [PASS]
taxed_VBN
at_PIN
35_CD
%_NN
._.
In_PIN
the_DT
future_NN
,_,
changes_NN
in_PIN
US_FPP1
tax_NN
law_NN
may_POMD
affect_VB
the_DT
Group_NN
tax_NN
charge_NN
._.
No_SYNE
current_JJ
tax_NN
deduction_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
the_DT
write-down_NN
of_PIN
goodwill_NN
that_TSUB
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
8_CD
Loss_NN
profit_NN
attributable_JJ
to_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_DT
loss_NN
for_PIN
the_DT
financial_JJ
year_NN
dealt_VBD
with_PIN
in_PIN
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
was_VBD [BEMA]
7,038,000_CD
2001_CD
:_:
profit_NN
of_PIN
1,643,000_CD
._.
As_IN
provided_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
no_SYNE
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
presented_VBN
in_PIN
respect_NN
of_PIN
the_DT
Company_NN
._.
32_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
9_CD
Loss_NN
earnings_GER
per_PIN
share_NN
Loss_NN
earnings_GER
per_PIN
share_NN
EPS_NN
has_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
for_PIN
each_QUAN
period_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
during_PIN
those_DEMO
periods_NN
._.
The_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
diluted_JJ
earnings_GER
per_PIN
share_NN
has_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
for_PIN
the_DT
effects_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
._.
No_SYNE
such_JJ
amounts_NN
were_VBD [PASS]
included_VBN
in_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
2002_CD
as_IN
their_TPP3
inclusion_NN
would_PRMD
be_VB [BEMA]
anti-dilutive_PRED
in_PIN
a_DT
loss_NN
making_VBG [WZPRES]
period_NN
._.
The_DT
$_$
400_CD
million_CD
convertible_JJ
loan_NN
note_NN
is_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
calculation_NOMZ
of_PIN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
for_PIN
diluted_JJ
earnings_GER
per_PIN
share_NN
in_PIN
2002_CD
and_CC
2001_CD
as_IN
it_PIT
was_VBD [BEMA]
not_XX0
dilutive_PRED
._.
The_DT
zero_CD
coupon_NN
convertible_JJ
loan_NN
note_NN
included_VBD
in_PIN
2001_CD
has_VPRT
no_SYNE
impact_NN
on_PIN
the_DT
numerator_NN
for_PIN
diluted_JJ
earnings_GER
per_PIN
share_NN
._.
Basic_JJ
and_PHC
diluted_JJ
2002 2001 000 000_CD
Loss_NN
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
588,399_CD
35,709_CD
The_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
each_QUAN
year_NN
are_VPRT
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Number_NN
Number_NN
Total_NN
for_PIN
basic_JJ
EPS_NN
500,687,594_CD
412,183,058_CD
Conversion_NN
of_PIN
convertible_JJ
debt_NN
289,101_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
6,270,923_CD
Exercise_NN
of_PIN
warrants_NN
919,029_CD
Total_JJ
for_PIN
diluted_VBN
EPS_NN
500,687,594_CD
419,662,111_CD
10_CD
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
Group_NN
Company_NN
000_CD
000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2002_CD
321,756_CD
10,068_CD
Additions_NOMZ
15,470_CD
13,600_CD
Transfer_NN
to_PIN
goodwill_NN
note_NN
11_CD
2,755_CD
Disposals_NN
49,115_CD
Foreign_JJ
exchange_NN
24,408_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
260,948_CD
23,668_CD
Amortisation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2002_CD
61,906_CD
933_CD
Charge_NN
for_PIN
the_DT
year_NN
15,466_CD
1,345_CD
Impairment_NOMZ
17,464_CD
Disposals_NN
11,442_CD
Foreign_JJ
exchange_NN
5,850_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
77,544_CD
2,278_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2001_CD
259,850_CD
9,135_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
183,404_CD
21,390_CD
During_PIN
the_DT
second_JJ
quarter_NN
of_PIN
2002_CD
,_,
and_ANDC
included_VBD
within_PIN
additions_NOMZ
for_PIN
the_DT
year_NN
,_,
the_DT
Group_NN
purchased_VBD
SOLARAZE_NN
for_PIN
13.6_CD
million_CD
._.
The_DT
impairment_NOMZ
was_VBD [BEMA]
in_PIN
respect_NN
of_PIN
write-downs_NN
made_VBN [WZPAST]
to_PIN
non-strategic_JJ
products_NN
that_TSUB
are_VPRT [SPAU] [BYPA]
no_RB
longer_RB
marketed_VBN
by_PIN
the_DT
Group_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
33_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
11_CD
Intangible_JJ
assets_NN
goodwill_NN
Group_NN
Company_NN
000_CD
000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2002_CD
2,764,478_CD
Transfer_NN
in_PIN
from_PIN
intellectual_JJ
property_NN
note_NN
10_CD
2,755_CD
Acquisition_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
note_NN
14_CD
7,066_CD
Foreign_JJ
exchange_NN
7_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
2,774,292_CD
Amortisation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2002_CD
120,900_CD
Charge_NN
for_PIN
the_DT
year_NN
138,513_CD
Impairment_NOMZ
613,983_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
873,396_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2001_CD
2,643,578_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
1,900,896_CD
At_PIN
31_CD
December_NN
2002_CD
,_,
an_DT
impairment_NOMZ
charge_NN
was_VBD [PASS]
booked_VBN
in_PIN
relation_NOMZ
to_PIN
goodwill_NN
which_WDT [WHSUB]
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
._.
A_DT
discounted_JJ
cash_NN
flow_NN
model_NN
was_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
recoverable_JJ
value_NN
of_PIN
the_DT
business_NOMZ
and_CC
the_DT
impairment_NOMZ
charge_NN
is_VPRT [PASS]
included_VBN
within_PIN
net_JJ
operating_GER
expenses_NN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
A_DT
range_NN
of_PIN
discount_NN
rates_NN
between_PIN
8-10_CD
%_NN
were_VBD [PASS]
applied_VBN
to_PIN
probability_NOMZ
adjusted_VBN
forecasts_NN
._.
34_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
12_CD
Tangible_JJ
assets_NN
continued_VBD
The_DT
net_JJ
book_NN
value_NN
of_PIN
the_DT
Groups_NN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
agreements_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2002 2001 000 000_CD
Buildings_GER
3,848_CD
Equipment_NOMZ
and_CC
other_JJ
61_CD
3,909_CD
All_QUAN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
arrangements_NOMZ
are_VPRT [BEMA]
short_JJ
leases_NN
with_PIN
a_DT
life_NN
of_PIN
less_JJ
than_PIN
50_CD
years_NN
._.
b_NN
Company_NN
Office_NN
furniture_NN
Equipment_NOMZ
and_CC
and_CC
fittings_GER
other_JJ
Total_JJ
000 000 000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2002_CD
1,459_CD
3,591_CD
5,050_CD
Additions_NOMZ
149_CD
2,389_CD
2,538_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
1,608_CD
5,980_CD
7,588_CD
Depreciation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2002_CD
645_CD
1,964_CD
2,609_CD
Charge_NN
304_CD
1,034_CD
1,338_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
949_CD
2,998_CD
3,947_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2001_CD
814_CD
1,627_CD
2,441_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
659_CD
2,982_CD
3,641_CD
The_DT
net_JJ
book_NN
value_NN
of_PIN
the_DT
Companys_NN
equipment_NOMZ
includes_VPRT
61,000_CD
2001_CD
:_:
nil_NN
in_PIN
respect_NN
of_PIN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
35_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
13_CD
Fixed_VBN
asset_NN
investments_NOMZ
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Subsidiary_NN
undertakings_GER
3,435,332_CD
3,400,281_CD
Other_JJ
investments_NOMZ
37,345_CD
45,045_CD
559_CD
1,898_CD
37,345_CD
45,045_CD
3,435,891_CD
3,402,179_CD
Principal_NN
Group_NN
investments_NOMZ
The_DT
parent_NN
company_NN
and_CC
the_DT
Group_NN
have_VPRT
investments_NOMZ
in_PIN
the_DT
following_JJ
subsidiary_NN
undertakings_GER
and_CC
other_JJ
investments_NOMZ
which_WDT [WHSUB]
principally_RB
affected_VBD
the_DT
profits_NN
or_CC
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
._.
To_TO
avoid_VB
a_DT
statement_NOMZ
of_PIN
excessive_JJ
length_NN
,_,
details_NN
of_PIN
investments_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
significant_PRED
have_VPRT [PEAS]
been_VBN [PASS]
omitted_VBN
._.
Country_NN
of_PIN
incorporation_NOMZ
or_CC
principal_NN
business_NOMZ
Holding_VBG [PRIV] [WZPRES]
address_NN
Principal_NN
activity_NOMZ
%_NN
Subsidiary_NN
undertakings_GER
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
US_FPP1
Intermediate_NN
holding_VBG [PRIV] [WZPRES]
company_NN
100_CD
Shire_NN
Pharmaceuticals_NN
Limited_NN
UK_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
Shire_NN
Pharmaceutical_NN
Development_NOMZ
Limited_NN
UK_NN
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
Shire_NN
International_NN
Licensing_GER
BV_NN
Netherlands_NN
Licensing_GER
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
Shire_NN
Laboratories_NN
Inc_NN
US_FPP1
Development_NOMZ
and_PHC
licensing_GER
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
Shire_NN
Supplies_NN
US_FPP1
,_,
LLC_NN
US_FPP1
Holder_NN
of_PIN
intellectual_JJ
property_NN
100_CD
Shire_NN
France_NN
SA_NN
France_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
Shire_NN
Deutschland_NN
GmbH_NN
&_CC
Co_NN
K_NN
G_NN
Germany_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
Shire_NN
US_FPP1
Inc_NN
US_FPP1
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Limited_NN
Ireland_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
Shire_NN
Italia_NN
SpA_NN
Italy_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
Shire_NN
Pharmaceuticals_NN
Iberica_NN
SL_NN
Spain_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
Shire_NN
Pharmaceuticals_NN
Development_NOMZ
US_FPP1
Inc_NN
US_FPP1
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
Shire_NN
BioChem_NN
Inc_NN
Canada_NN
Research_NN
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
Shire_NN
Finance_NN
Limited_NN
Cayman_NN
Islands_NN
Issuer_NN
of_PIN
convertible_JJ
notes_NN
100_CD
Shire_NN
Biologics_NN
Inc_NN
US_FPP1
Research_NN
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
Shire_NN
Pharmaceutical_NN
Contracts_NN
Limited_NN
UK_NN
Marketing_GER
of_PIN
phamaceuticals_NN
100_CD
Shire_NN
US_FPP1
Manufacturing_GER
Inc_NN
US_FPP1
Manufacturer_NN
of_PIN
phamaceuticals_NN
100_CD
Held_VBN [PRIV]
directly_RB
by_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc._NN
._.
All_QUAN
subsidiary_NN
undertakings_GER
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Subsidiary_NN
undertakings_GER
Company_NN
Amount_NN
Shares_NN
in_PIN
due_JJ
from_PIN
subsidiary_NN
subsidiary_NN
undertakings_GER
undertakings_GER
Total_JJ
Cost_NN
000 000 000_CD
At_PIN
1_CD
January_NN
2002_CD
3,200,583_CD
199,698_CD
3,400,281_CD
Additions_NOMZ
10,165_CD
10,165_CD
Net_JJ
drawdown_NN
of_PIN
loans_NN
24,886_CD
24,886_CD
Interest_NN
on_PIN
intra-Group_JJ
loan_NN
4,412_CD
4,412_CD
Write_VB [PUBV]
down_IN
of_PIN
investment_NOMZ
in_PIN
subsidiary_NN
undertaking_GER
4,412_CD
4,412_CD
At_PIN
31_CD
December_NN
2002_CD
3,206,336_CD
228,996_CD
3,435,332_CD
Included_VBN
in_PIN
the_DT
amounts_NN
due_RB
from_PIN
subsidiary_NN
undertakings_GER
is_VPRT [BEMA]
an_DT
amount_NN
of_PIN
96.6_CD
million_CD
due_JJ
from_PIN
Shire_NN
Holdings_GER
Europe_NN
Limited_NN
,_,
a_DT
Group_NN
company_NN
._.
This_DEMP
relates_VPRT
to_PIN
Unsecured_NN
Convertible_NN
Redeemable_NN
Loan_NN
Stock_NN
1997-2002_CD
._.
With_PIN
effect_NN
from_PIN
30_CD
June_NN
2002_CD
the_DT
terms_NN
of_PIN
the_DT
loan_NN
were_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
it_PIT
now_TIME
bears_VPRT
interest_NN
at_PIN
1_CD
%_NN
above_PLACE
LIBOR_NN
._.
36_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
13_CD
Fixed_VBN
asset_NN
investments_NOMZ
continued_VBD
Other_JJ
investments_NOMZ
Group_NN
Company_NN
Other_JJ
Other_JJ
investments_NOMZ
Total_JJ
investments_NOMZ
Total_JJ
000 000 000 000_CD
At_PIN
1_CD
January_NN
2002_CD
45,045_CD
45,045_CD
1,898_CD
1,898_CD
Additions_NOMZ
7,697_CD
7,697_CD
Disposals_NN
5,282_CD
5,282_CD
1,339_CD
1,339_CD
Foreign_JJ
exchange_NN
4,306_CD
4,306_CD
At_PIN
31_CD
December_NN
2002_CD
43,154_CD
43,154_CD
559_CD
559_CD
Provisions_NN
for_PIN
impairment_NOMZ
At_PIN
1_CD
January_NN
2002_CD
Written_VBN [PUBV]
off_PIN
5,809_CD
5,809_CD
At_PIN
31_CD
December_NN
2002_CD
5,809_CD
5,809_CD
Net_JJ
book_NN
value_NN
At_PIN
31_CD
December_NN
2001_CD
45,045_CD
45,045_CD
1,898_CD
1,898_CD
At_PIN
31_CD
December_NN
2002_CD
37,345_CD
37,345_CD
559_CD
559_CD
a_DT
Investments_NOMZ
in_PIN
private_JJ
companies_NN
i_FPP1
GeneChem_NN
funds_NN
The_DT
Group_NN
has_VPRT [PEAS]
made_VBN
investments_NOMZ
in_PIN
two_CD
venture_NN
capital_NN
funds_NN
._.
The_DT
fund_NN
managers_NN
distribute_VPRT
income_NN
to_PIN
the_DT
partners_NN
of_PIN
the_DT
funds_NN
in_PIN
respect_NN
of_PIN
dividends_NN
or_CC
realized_VBN [PRIV] [THATD]
gains_NN
made_VBN [WZPAST]
on_PIN
sale_NN
of_PIN
investments_NOMZ
._.
In_PIN
March_NN
1997_CD
,_,
the_DT
Group_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
make_VB
an_DT
investment_NOMZ
of_PIN
11.8_CD
million_CD
CAN$_NN
30.0_CD
million_CD
in_PIN
the_DT
GeneChem_NN
Technologies_NN
Venture_NN
Fund_NN
L._NN
P._NN
a_DT
venture_NN
capital_NN
fund_NN
sponsored_VBN [WZPAST]
by_PIN
a_DT
Group_NN
subsidiary_NN
,_,
GeneChem_NN
Financial_NN
Corporation_NOMZ
._.
This_DEMO
CAN$_NN
100.0_CD
million_CD
Fund_NN
invests_VPRT
in_PIN
advanced_JJ
academic_JJ
research_NN
projects_NN
and_CC
early_TIME
stage_NN
private_JJ
or_CC
public_JJ
companies_NN
in_PIN
the_DT
area_NN
of_PIN
genomics_NN
and_CC
related_VBN
technologies_NN
for_PIN
human_JJ
application_NOMZ
._.
Our_FPP1
partners_NN
in_PIN
this_DEMO
fund_NN
are_VPRT [BEMA]
a_DT
select_JJ
group_NN
of_PIN
financial_JJ
investors_NN
._.
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
invested_VBN
10.6_CD
million_CD
CAN$_NN
27.0_CD
million_CD
in_PIN
the_DT
GeneChem_NN
Technologies_NN
Venture_NN
Fund_NN
L._NN
P._NN
and_CC
is_VPRT
,_,
therefore_CONJ
,_,
committed_VBN
to_TO
investing_VBG
a_DT
further_JJ
1.2_CD
million_CD
CAN$_NN
3.0_CD
million_CD
into_PIN
this_DEMO
Fund_NN
._.
In_PIN
September_NN
2000_CD
,_,
the_DT
Group_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
invest_VB
5.9_CD
million_CD
CAN$_NN
15.0_CD
million_CD
in_PIN
the_DT
GeneChem_NN
Therapeutics_NN
Venture_NN
Fund_NN
L._NN
P._NN
This_DEMO
CAN$_NN
135.0_CD
million_CD
fund_NN
invests_VPRT
in_PIN
genomics_NN
companies_NN
focusing_VBG [WZPRES]
on_PIN
cancer_NN
and_CC
infectious_JJ
diseases_NN
._.
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
had_VBD [PEAS]
invested_VBN
2.7_CD
million_CD
CAN$_NN
6.8_CD
million_CD
and_CC
the_DT
Group_NN
has_VPRT [PEAS]
committed_VBN
to_TO
invest_VB
a_DT
further_JJ
3.2_CD
million_CD
CAN$_NN
8.2_CD
million_CD
in_PIN
the_DT
GeneChem_NN
Therapeutics_NN
Venture_NN
Fund_NN
L._NN
P._NN
The_NN
manager_NN
and_CC
general_JJ
partners_NN
of_PIN
these_DEMO
funds_NN
are_VPRT [SPAU] [PASS]
wholly_RB
owned_VBN
subsidiaries_NN
of_PIN
the_DT
Group_NN
._.
The_DT
underlying_JJ
funds_NN
have_VPRT [PEAS]
not_XX0
been_VBN [BEMA]
consolidated_PRED
because_CAUS
the_DT
operational_JJ
substance_NN
of_PIN
the_DT
funds_NN
are_VPRT [BEMA]
such_OSUB
that_NULL
the_DT
other_JJ
partners_NN
have_VPRT
the_DT
ability_NOMZ
to_TO
veto_VB
investment_NOMZ
decisions_NN
._.
ii_FW
EGS_NN
Healthcare_NN
fund_NN
In_PIN
November_NN
2000_CD
,_,
the_DT
Group_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
invest_VB
up_RP
to_PIN
6.2_CD
million_CD
$_$
10.0_CD
million_CD
in_PIN
various_JJ
EGS_NN
healthcare_NN
funds_NN
._.
EGS_NN
is_VPRT [BEMA]
a_DT
private_JJ
equity_NOMZ
company_NN
that_TSUB
makes_VPRT
investments_NOMZ
in_PIN
healthcare_NN
companies_NN
that_TSUB
focus_VPRT
mainly_RB
on_PIN
biotechnology_NN
and_PHC
specialty_NN
pharmaceuticals_NN
._.
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
invested_VBN
3.2_CD
million_CD
$_$
5.1_CD
million_CD
in_PIN
EGS_NN
healthcare_NN
funds_NN
and_CC
the_DT
Group_NN
is_VPRT
,_,
therefore_CONJ
,_,
committed_VBN
to_TO
invest_VB
a_DT
further_JJ
3.0_CD
million_CD
$_$
4.9_CD
million_CD
into_PIN
these_DEMO
funds_NN
._.
b_NN
Investments_NOMZ
in_PIN
public_JJ
companies_NN
As_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
held_VBD [PRIV]
8.8_CD
million_CD
of_PIN
investments_NOMZ
in_PIN
public_JJ
companies_NN
2001_CD
:_:
9.5_CD
million_CD
._.
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
there_EX
were_VBD
no_SYNE
new_JJ
investments_NOMZ
made_VBN [WZPAST]
in_PIN
public_JJ
companies_NN
._.
On_PIN
29_CD
July_NN
2002_CD
,_,
the_DT
Groups_NN
7.1_CD
million_CD
$_$
11.1_CD
million_CD
preference_NN
share_NN
investment_NOMZ
in_PIN
Immunogen_NN
Inc._NN
was_VBD [PASS]
converted_VBN
into_PIN
a_DT
common_JJ
stock_NN
holding_GER
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
impaired_VBD
the_DT
cost_NN
of_PIN
investments_NOMZ
in_PIN
public_JJ
companies_NN
by_PIN
0.9_CD
million_CD
._.
Current_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
and_ANDC
as_CONJ
a_NULL
result_NULL
,_,
any_QUAN
market_NN
gains_NN
or_CC
losses_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
market_NN
value_NN
of_PIN
listed_VBN
investments_NOMZ
was_VBD [BEMA]
0.8_CD
million_CD
above_PLACE
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
2001_CD
:_:
nil_NN
._.
There_EX
are_VPRT
no_SYNE
other_JJ
differences_NN
between_PIN
cost_NN
and_PHC
market_NN
value_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
37_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
14_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
Acquisitions_NOMZ
On_PIN
27_CD
September_NN
2002_CD
,_,
the_DT
Group_NN
acquired_VBD
100_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Atlantic_NN
Pharmaceutical_NN
Services_NN
Inc._NN
._.
APS_NN
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
11.9_CD
million_CD
including_VBG
0.2_CD
million_CD
acquisition_NOMZ
costs_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
net_JJ
assets_NN
acquired_VBN [WZPAST]
was_VBD [BEMA]
4.8_CD
million_CD
,_,
resulting_VBG [PRESP]
in_PIN
7.1_CD
million_CD
of_PIN
goodwill_NN
being_VBG [WZPRES] [PASS]
capitalized_VBN
on_PIN
the_DT
balance_NN
sheet_NN
._.
The_DT
transaction_NOMZ
was_VBD [PASS]
accounted_VBN
for_PIN
using_VBG
acquisition_NOMZ
accounting_GER
._.
The_DT
loss_NN
profit_NN
after_IN
taxation_NOMZ
of_PIN
APS_NN
was_VBD
as_IN
follows_VPRT
:_:
Loss_NN
profit_NN
after_IN
tax_NN
Results_NN
prior_RB
to_PIN
acquisition_NOMZ
000_CD
1_CD
January_NN
2002_CD
to_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
1,071_CD
Preceding_VBG
financial_JJ
year_NN
ended_VBD
31_CD
December_NN
2001_CD
45_CD
The_DT
following_JJ
table_NN
summarises_VPRT
the_DT
adjustments_NOMZ
made_VBD
to_PIN
book_NN
value_NN
of_PIN
the_DT
major_JJ
category_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
acquired_VBN
to_TO
arrive_VB
at_PIN
the_DT
fair_JJ
values_NN
included_VBN [WZPAST]
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
The_DT
cash_NN
flow_NN
effects_NN
of_PIN
the_DT
acquisition_NOMZ
are_VPRT [PASS]
given_VBN
in_PIN
note_NN
28b_CD
._.
Accounting_GER
Fair_NN
Book_NN
policy_NN
value_NN
to_PIN
value_NN
aligment_NOMZ
Revaluation_NOMZ
Group_NN
000 000 000 000_CD
Fixed_JJ
assets_NN
Tangible_JJ
assets_NN
7,331_CD
470_CD
7,801_CD
Current_JJ
assets_NN
Stocks_NN
235 681 916_CD
Debtors_NN
2,240_CD
1,049_CD
1,191_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
33_CD
33_CD
Total_JJ
assets_NN
9,839_CD
470_CD
368_CD
9,941_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Trade_NN
creditors_NN
611_CD
611_CD
Finance_NN
leases_NN
4,169_CD
4,169_CD
Other_JJ
creditors_NN
345_CD
345_CD
Total_JJ
liabilities_NOMZ
5,125_CD
5,125_CD
Net_JJ
assets_NN
4,714_CD
470_CD
368_CD
4,816_CD
Goodwill_NN
7,066_CD
11,882_CD
000_CD
Satisfied_VBN
by_PIN
:_:
Cash_NN
consideration_NOMZ
11,647_CD
Expenses_NN
of_PIN
acquisition_NOMZ
235_CD
11,882_CD
At_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
,_,
a_DT
realignment_NOMZ
of_PIN
certain_JJ
accounting_GER
policies_NN
and_PHC
revaluation_NOMZ
of_PIN
certain_JJ
assets_NN
was_VBD [PASS]
undertaken_VBN
in_PIN
order_NN
to_TO
bring_VB
those_DEMO
of_PIN
APS_NN
in_PIN
line_NN
with_PIN
the_DT
remainder_NN
of_PIN
the_DT
Group_NN
._.
38_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
14_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
continued_VBD
Disposals_NN
The_NN
Group_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
its_PIT
Over_IN
The_DT
Counter_NN
OTC_NN
portfolio_NN
on_PIN
27_CD
December_NN
2002_CD
._.
This_DEMP
was_VBD [PASS]
sold_VBN
to_PIN
Perdue_NN
Pharmaceuticals_NN
Inc_NN
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
44.1_CD
million_CD
$_$
71.0_CD
million_CD
._.
The_DT
following_JJ
table_NN
summarises_VPRT
the_DT
major_JJ
categories_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
attributed_VBD
to_PIN
the_DT
OTC_NN
portfolio_NN
at_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
000_CD
Intangible_JJ
assets_NN
37,673_CD
Stocks_NN
2,327_CD
Sundry_NN
debtors_NN
2,828_CD
Other_JJ
creditors_NN
1,063_CD
Profit_NN
on_PIN
sale_NN
2,006_CD
43,771_CD
Satisfied_VBN
by_PIN
:_:
Cash_NN
consideration_NOMZ
44,103_CD
Deferred_JJ
consideration_NOMZ
620_CD
Expenses_NN
of_PIN
disposal_NN
952_CD
43,771_CD
15_CD
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
The_DT
Group_NN
owns_VPRT
50_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
of_PIN
Qualia_NN
Computing_GER
Inc._NN
._.
Qualia_NN
,_,
a_DT
company_NN
involved_VBN [WZPAST]
in_PIN
the_DT
development_NOMZ
of_PIN
Computer_NN
Aided_VBD
Detection_NOMZ
technologies_NN
with_PIN
various_JJ
applications_NOMZ
in_PIN
the_DT
area_NN
of_PIN
life_NN
sciences_NN
._.
Qualia_NN
has_VPRT
a_DT
31_CD
March_NN
year-end_NN
,_,
however_CONJ
,_,
the_DT
results_NN
disclosed_VBN [PUBV] [WZPAST]
are_VPRT [BEMA]
for_PIN
the_DT
period_NN
to_PIN
31_CD
December_NN
2002_CD
._.
The_DT
Company_NN
exchanged_VBD
its_PIT
interests_NN
in_PIN
certain_JJ
trade_NN
investments_NOMZ
for_PIN
a_DT
50_CD
%_NN
investment_NOMZ
in_PIN
Qualia_NN
on_PIN
30_CD
September_NN
2002_CD
._.
No_SYNE
goodwill_NN
arose_VBD
on_PIN
the_DT
transaction_NOMZ
._.
In_PIN
accordance_NN
with_PIN
FRS_NN
9_CD
,_,
Associates_NN
and_CC
joint_JJ
ventures_NN
,_,
the_DT
following_VBG
information_NOMZ
regarding_VBG [WZPRES]
the_DT
Groups_NN
share_NN
in_PIN
Qualia_NN
is_VPRT [PASS]
disclosed_VBN [PUBV]
:_:
2002_CD
2001_CD
Qualia_NN
000_CD
000_CD
Turnover_NN
762_CD
Loss_NN
before_IN
tax_NN
559_CD
Taxation_NOMZ
Loss_NN
after_IN
tax_NN
559_CD
Fixed_VBN
assets_NN
2,648_CD
Current_JJ
assets_NN
2,434_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
342_CD
16_CD
Stocks_NN
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Raw_NN
materials_NN
and_PHC
consumables_NN
4,862_CD
5,873_CD
Work_NN
in_PIN
progress_NN
8,520_CD
12,548_CD
Finished_VBN
goods_NN
and_PHC
goods_NN
for_PIN
resale_NN
17,189_CD
13,659_CD
30,571_CD
32,080_CD
There_EX
is_VPRT
no_SYNE
material_NN
difference_NN
between_PIN
the_DT
balance_NN
sheet_NN
value_NN
of_PIN
stocks_NN
and_CC
their_TPP3
replacement_NOMZ
cost_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
39_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
17_CD
Deferred_JJ
tax_NN
asset_NN
Deferred_JJ
tax_NN
Group_NN
000_CD
At_PIN
1_CD
January_NN
2001_CD
22,272_CD
Charged_VBN
to_TO
profit_VB
and_CC
loss_NN
account_NN
762_CD
Acquisition_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
184_CD
Exchange_NN
adjustment_NOMZ
502_CD
At_PIN
31_CD
December_NN
2001_CD
22,196_CD
Credited_VBN
to_TO
profit_VB
and_CC
loss_NN
account_NN
5,829_CD
Exchange_NN
adjustment_NOMZ
2,518_CD
At_PIN
31_CD
December_NN
2002_CD
25,507_CD
Included_VBN
in_PIN
the_DT
above_PLACE
balance_NN
at_PIN
31_CD
December_NN
2002_CD
is_VPRT [BEMA]
an_DT
amount_NN
of_PIN
3,861,000_CD
2001_CD
:_:
8,845,000_CD
which_WDT
is_VPRT [BEMA]
due_PRED
after_IN
more_EMPH
than_PIN
one_CD
year_NN
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
and_CC
unprovided_JJ
as_IN
follows_VPRT
:_:
Unprovided_JJ
Provided_VBN
Unprovided_NN
Provided_VBD
2002 2001 2002 2001_CD
Group_NN
000 000 000 000_CD
Accelerated_JJ
capital_NN
allowances_NN
18,676_CD
18,284_CD
Other_JJ
timing_NN
differences_NN
11,300_CD
17,146_CD
Tax_NN
losses_NN
available_JJ
92,283_CD
32,883_CD
85,873_CD
23,334_CD
Deferred_JJ
tax_NN
asset_NN
92,283_CD
25,507_CD
85,873_CD
22,196_CD
Amounts_NN
unprovided_JJ
principally_RB
represent_VPRT
the_DT
deferred_JJ
tax_NN
assets_NN
arising_VBG [WZPRES]
from_PIN
overseas_PLACE
tax_NN
operating_GER
loss_NN
carryforwards_NN
and_PHC
capital_NN
loss_NN
carryforwards_NN
._.
The_DT
utilisation_NOMZ
of_PIN
operating_VBG
loss_NN
carryforwards_NN
is_VPRT
,_,
however_CONJ
,_,
restricted_VBN [PASTP]
to_PIN
the_DT
taxable_JJ
income_NN
of_PIN
the_DT
subsidiary_NN
generating_VBG [WZPRES]
the_DT
losses_NN
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Group_NN
will_PRMD
realize_VB [PRIV]
the_DT
benefits_NN
of_PIN
the_DT
provided_VBN
deferred_VBN
tax_NN
assets_NN
._.
However_CONJ
,_,
the_DT
amount_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
considered_VBN [PRIV]
realisable_JJ
could_POMD
be_VB [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
if_COND
estimates_NN
of_PIN
taxable_JJ
income_NN
are_VPRT [PASS]
revised_VBN
._.
Company_NN
The_DT
Company_NN
has_VPRT
no_DT
provided_VBN
or_CC
unprovided_JJ
deferred_VBN
tax_NN
assets_NN
._.
The_DT
amount_NN
shown_VBN [PRIV]
above_PLACE
is_VPRT [BEMA]
the_DT
gross_JJ
asset_NN
represented_VBN [WZPAST]
by_PIN
non-current_JJ
marketable_JJ
securities_NOMZ
._.
A_DT
related_JJ
liability_NOMZ
of_PIN
approximately_RB
5.2_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
note_NN
21_CD
._.
40_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
19_CD
Current_JJ
asset_NN
investments_NOMZ
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
141,800_CD
328,252_CD
321,031_CD
Commercial_JJ
paper_NN
54,564_CD
169,145_CD
196,364_CD
497,397_CD
321,031_CD
There_EX
is_VPRT
no_SYNE
material_NN
difference_NN
between_PIN
book_NN
value_NN
and_CC
fair_JJ
value_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
and_CC
2001_CD
._.
20_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Convertible_JJ
debt_NN
Zero_NN
coupon_NN
convertible_JJ
unsecured_JJ
loan_NN
stock_NN
1,032_CD
1,032_CD
Other_JJ
creditors_NN
Bank_NN
loans_NN
note_VPRT [PRIV]
21_CD
ii_FW
389_CD
1,976_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
162_CD
32_CD
Trade_NN
creditors_NN
29,153_CD
39,254_CD
862_CD
1,827_CD
Amounts_NN
due_JJ
to_PIN
other_JJ
Group_NN
undertakings_GER
218,219_CD
39,197_CD
Overseas_PLACE
corporation_NOMZ
tax_NN
8,835_CD
17,043_CD
Other_JJ
taxation_NOMZ
and_CC
social_JJ
security_NOMZ
2,416_CD
5,762_CD
367_CD
188_CD
Other_JJ
creditors_NN
2,033_CD
2,883_CD
197_CD
527_CD
Accruals_NN
and_CC
deferred_VBN
income_NN
88,897_CD
91,311_CD
5,630_CD
4,610_CD
131,885_CD
158,229_CD
225,307_CD
46,349_CD
131,885_CD
159,261_CD
225,307_CD
47,381_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
secured_VBN
on_PIN
the_DT
assets_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
._.
21_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Group_NN
Company_NN
2002 2001 2002 2001_CD
Notes_NN
000 000 000 000_CD
Convertible_JJ
debt_NN
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011_CD
i_FPP1
243,547_CD
268,178_CD
Other_JJ
creditors_NN
Bank_NN
loans_NN
ii_FW
778_CD
1,705_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
3,757_CD
36_CD
Amounts_NN
due_JJ
to_PIN
other_JJ
Group_NN
undertakings_GER
252,258_CD
276,643_CD
Other_JJ
creditors_NN
9,247_CD
7,949_CD
13,782_CD
9,654_CD
252,294_CD
276,643_CD
257,329_CD
277,832_CD
252,294_CD
276,643_CD
Included_VBN
within_PIN
other_JJ
creditors_NN
is_VPRT [BEMA]
5,196,000_CD
relating_VBG
to_PIN
the_DT
SERP_NN
31_CD
December_NN
2001_CD
:_:
7,797,000_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
41_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
21_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
continued_VBD
Subject_JJ
to_PIN
the_DT
conditions_NOMZ
below_PLACE
,_,
borrowings_GER
are_VPRT [BEMA]
repayable_PRED
as_IN
follows_VPRT
:_:
Group_NN
Company_NN
2002 2001 2002 2001_CD
Notes_NN
000 000 000 000_CD
Convertible_JJ
loan_NN
notes_NN
:_:
i_FPP1
Between_PIN
one_CD
and_CC
two_CD
years_NN
243,547_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
268,178_CD
Bank_NN
loans_NN
:_:
ii_FW
Between_PIN
one_CD
and_CC
two_CD
years_NN
389_CD
1,705_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
389_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
:_:
Between_PIN
one_CD
and_CC
two_CD
years_NN
158_CD
36_CD
After_IN
five_CD
years_NN
3,599_CD
248,082_CD
269,883_CD
36_CD
i_FPP1
$_$
400_CD
million_CD
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011_CD
The_DT
$_$
400_CD
million_CD
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
due_JJ
2011_CD
,_,
were_VBD [PASS]
issued_VBN
on_PIN
15_CD
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
._.
The_DT
notes_NN
bear_VPRT
interest_NN
of_PIN
2_CD
%_NN
per_PIN
annum_NN
,_,
paid_VBD
semi-annually_RB
in_PIN
arrears_NN
._.
The_DT
convertible_JJ
notes_NN
are_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
Shire_NN
and_CC
are_VPRT [BEMA]
convertible_PRED
into_PIN
redeemable_JJ
preference_NN
shares_NN
of_PIN
the_DT
Issuer_NN
which_WDT [WHOBJ]
upon_PIN
issuance_NN
will_PRMD
be_VB [SPAU] [PASS]
immediately_TIME
exchanged_VBN
for_PIN
either_DT
i_FPP1
Shire_FW
common_JJ
shares_NN
or_CC
ii_FW
Shire_FW
ADSs_FW
,_,
or_CC
iii_NN
at_PIN
the_DT
Issuers_NN
option_NOMZ
,_,
a_DT
cash_NN
amount_NN
based_VBN [WZPAST]
upon_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
volume-weighted_JJ
average_NN
prices_NN
of_PIN
common_JJ
shares_NN
on_PIN
the_DT
fourth_JJ
through_PIN
eighth_JJ
business_NOMZ
days_NN
following_VBG [WZPRES]
conversion_NN
._.
At_PIN
the_DT
choice_NN
of_PIN
investors_NN
,_,
each_QUAN
$_$
1,000_CD
of_PIN
nominal_JJ
value_NN
notes_NN
can_POMD
be_VB [PASS]
converted_VBN
into_PIN
49.62_CD
Shire_NN
common_JJ
shares_NN
subject_JJ
to_PIN
adjustment_NOMZ
or_CC
16.54_CD
Shire_NN
ADSs_NN
subject_NN
to_PIN
adjustment_NOMZ
at_PIN
any_QUAN
time_NN
up_RP
to_PIN
21_CD
August_NN
2011_CD
._.
Alternatively_CONJ
,_,
investors_NN
can_POMD
choose_VB
to_TO
receive_VB
repayment_NOMZ
of_PIN
the_DT
nominal_JJ
principal_NN
in_PIN
cash_NN
either_CC
at_PIN
the_DT
maturity_NOMZ
date_NN
of_PIN
21_CD
August_NN
2011_CD
or_CC
by_PIN
exercising_VBG
a_DT
put_NN
option_NOMZ
on_PIN
any_QUAN
of_PIN
the_DT
three_CD
put_VBD
dates_NN
being_VBG [WZPRES] [BEMA]
21_CD
August_NN
2004_CD
,_,
21_CD
August_NN
2006_CD
and_CC
21_CD
August_NN
2008_CD
._.
At_PIN
the_DT
option_NOMZ
of_PIN
the_DT
Company_NN
,_,
repayment_NOMZ
can_POMD
be_VB [PASS]
made_VBN
in_PIN
the_DT
form_NN
of_PIN
Shire_NN
common_JJ
shares_NN
or_CC
ADSs_NN
._.
The_DT
number_NN
of_PIN
common_JJ
shares_NN
that_TOBJ
a_DT
note_NN
holder_NN
would_PRMD
receive_VB
would_PRMD
be_VB [PASS]
based_VBN
on_PIN
the_DT
notional_JJ
principal_NN
of_PIN
the_DT
notes_NN
divided_VBN [WZPAST]
by_PIN
95_CD
%_NN
of_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
volume-weighted_JJ
average_JJ
price_NN
of_PIN
common_JJ
shares_NN
on_PIN
the_DT
five_CD
trading_GER
days_NN
after_IN
the_DT
Company_NN
gives_VPRT
notice_NN
of_PIN
the_DT
exercise_NN
of_PIN
its_PIT
option_NOMZ
._.
Such_JJ
notice_NN
will_PRMD
be_VB [BEMA]
on_PIN
or_CC
before_IN
the_DT
tenth_NN
business_NOMZ
day_NN
preceding_VBG [WZPRES]
the_DT
repayment_NOMZ
put_VBD
date_NN
._.
On_PIN
or_CC
after_IN
21_CD
August_NN
2004_CD
,_,
the_DT
Company_NN
may_POMD
redeem_VB
,_,
for_PIN
cash_NN
,_,
all_QUAN
or_CC
part_NN
of_PIN
the_DT
notes_NN
provided_VBD
the_DT
ordinary_JJ
share_NN
price_NN
has_VPRT [PEAS]
exceeded_VBN
$_$
26.20_CD
sterling_GER
equivalent_NN
at_PIN
the_DT
time_NN
for_PIN
20_CD
of_PIN
the_DT
30_CD
consecutive_JJ
dealing_VBG
days_NN
in_PIN
the_DT
period_NN
prior_RB
to_PIN
redemption_NOMZ
._.
The_DT
decision_NN
as_IN
to_PIN
whether_IN
a_DT
note_NN
holder_NN
would_PRMD
exercise_VB
a_DT
put_NN
option_NOMZ
will_PRMD
depend_VB
on_PIN
a_DT
number_NN
of_PIN
factors_NN
particularly_RB
the_DT
price_NN
of_PIN
Shire_NN
shares_NN
at_PIN
the_DT
put_JJ
date_NN
and_CC
the_DT
likelihood_NN
of_PIN
Shires_NN
share_NN
price_NN
exceeding_VBG [WZPRES]
the_DT
conversion_NN
threshold_NN
price_NN
._.
The_DT
conversion_NN
threshold_NN
price_NN
is_VPRT [BEMA]
12.52_CD
for_PIN
ordinary_JJ
shares_NN
._.
If_COND
the_DT
price_NN
of_PIN
Shire_NN
ordinary_JJ
shares_NN
at_PIN
the_DT
first_JJ
put_JJ
date_NN
of_PIN
21_CD
August_NN
2004_CD
remains_VPRT
at_PIN
a_DT
level_NN
similar_JJ
to_PIN
the_DT
year_NN
end_NN
price_NN
of_PIN
3.97_CD
,_,
it_PIT
is_VPRT [BEMA]
quite_RB
possible_PRED
that_THAC
note_NN
holders_NN
will_PRMD
choose_VB
to_TO
exercise_VB
their_TPP3
put_JJ
options_NOMZ
._.
The_DT
Group_NN
currently_RB
has_VPRT
adequate_JJ
resources_NN
from_PIN
which_WDT [PIRE]
it_PIT
could_POMD
satisfy_VB
repayment_NOMZ
of_PIN
the_DT
entire_JJ
convertible_JJ
debt_NN
principal_NN
of_PIN
$_$
400_CD
million_CD
._.
ii_FW
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
The_DT
Group_NN
has_VPRT
a_DT
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
outstanding_JJ
of_PIN
1.2_CD
million_CD
CAN$_NN
5.0_CD
million_CD
._.
This_DEMO
facility_NOMZ
is_VPRT [BEMA]
non-interest_JJ
bearing_GER
and_CC
is_VPRT [BEMA]
repayable_PRED
in_PIN
annual_JJ
instalments_NOMZ
of_PIN
0.5_CD
million_CD
CAN$_NN
1.2_CD
million_CD
commencing_VBG
in_PIN
May_POMD
2002_CD
._.
42_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
22_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
The_DT
financial_JJ
review_NN
on_PIN
pages_NN
3_CD
to_PIN
5_CD
provide_VPRT
an_DT
explanation_NOMZ
of_PIN
the_DT
role_NN
that_TOBJ
financial_JJ
instruments_NOMZ
have_VPRT [PEAS]
had_VBN
during_PIN
the_DT
year_NN
._.
The_DT
explanation_NOMZ
summarises_VPRT
the_DT
objectives_NN
and_PHC
policies_NN
for_PIN
holding_VBG [PRIV]
or_CC
issuing_VBG
financial_JJ
instruments_NOMZ
and_CC
similar_JJ
contracts_NN
,_,
and_ANDC
the_DT
strategies_NN
for_PIN
achieving_VBG
those_DEMO
objectives_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
during_PIN
the_DT
year_NN
._.
No_SYNE
foreign_JJ
exchange_NN
,_,
interest_NN
rate_NN
or_CC
other_JJ
derivative_JJ
contracts_NN
were_VBD [PASS]
entered_VBN
into_PIN
or_CC
transacted_VBN
during_PIN
2002_CD
or_CC
2001_CD
._.
The_DT
numerical_JJ
disclosures_NN
in_PIN
this_DEMO
note_NN
deal_NN
with_PIN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
as_IN
defined_VBN
in_PIN
FRS_NN
13_CD
,_,
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
:_:
disclosures_NN
._.
Certain_JJ
financial_JJ
assets_NN
such_JJ
as_IN
investments_NOMZ
in_PIN
subsidiary_NN
companies_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
scope_NN
of_PIN
these_DEMO
disclosures_NN
._.
As_IN
permitted_VBN
by_PIN
FRS_NN
13_CD
,_,
short-term_JJ
debtors_NN
and_PHC
creditors_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
from_PIN
the_DT
disclosures_NN
,_,
other_JJ
than_PIN
the_DT
currency_NN
disclosures_NN
._.
Interest_NN
rate_NN
profile_NN
The_DT
currency_NN
and_PHC
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
,_,
excluding_VBG
short-term_JJ
debtors_NN
at_PIN
31_CD
December_NN
2002_CD
,_,
are_VPRT
as_RB
below_PLACE
._.
Current_JJ
asset_NN
investments_NOMZ
comprise_VPRT
institutional_JJ
cash_NN
funds_NN
,_,
commercial_JJ
paper_NN
and_CC
marketable_JJ
securities_NOMZ
as_IN
detailed_VBN
in_PIN
note_NN
19_CD
._.
Weighted_JJ
Weighted_NN
Weighted_NN
average_JJ
average_JJ
average_JJ
interest_NN
interest_NN
interest_NN
Financial_NN
Financial_NN
period_NN
rate_NN
rate_NN
instruments_NOMZ
instruments_NOMZ
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Total_JJ
Currency_NN
Days_NN
%_NN
%_NN
000 000 000_CD
Pounds_NN
sterling_GER
2_CD
3.4_CD
3.9_CD
14,298_CD
3,296_CD
17,594_CD
US_FPP1
dollars_NN
60_CD
1.5_CD
1.9_CD
426,017_CD
237,011_CD
663,028_CD
Euro_NN
6_CD
3.1_CD
6,437_CD
3,891_CD
10,328_CD
Canadian_JJ
dollars_NN
131_CD
2.9_CD
2,128_CD
61,718_CD
63,846_CD
448,880_CD
305,916_CD
754,796_CD
The_DT
benchmark_NN
rates_NN
for_PIN
floating_VBG
rate_NN
assets_NN
are_VPRT
primarily_RB
:_:
US_FPP1
dollar_NN
7_CD
day_NN
,_,
1_CD
month_NN
and_CC
3_CD
month_NN
LIBID_NN
,_,
and_ANDC
pounds_NN
sterling_GER
7_CD
day_NN
LIBID_NN
._.
The_DT
currency_NN
and_PHC
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
excluding_VBG [WZPRES]
short-term_JJ
debtors_NN
at_PIN
31_CD
December_NN
2001_CD
are_VPRT
as_RB
below_PLACE
._.
Weighted_JJ
Weighted_NN
Weighted_NN
average_JJ
average_JJ
average_JJ
interest_NN
interest_NN
interest_NN
Financial_NN
Financial_NN
period_NN
rate_NN
rate_NN
instruments_NOMZ
instruments_NOMZ
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Total_JJ
Currency_NN
Days_NN
%_NN
%_NN
000 000 000_CD
Pounds_NN
sterling_GER
4.1_CD
28,186_CD
28,186_CD
US_FPP1
dollars_NN
96_CD
1.8_CD
2.1_CD
332,314_CD
117,725_CD
450,039_CD
Euro_NN
3_CD
3.1_CD
3.4_CD
4,507_CD
2,815_CD
7,322_CD
Canadian_JJ
dollars_NN
33_CD
3.1_CD
2.5_CD
9,682_CD
83,602_CD
93,284_CD
374,689_CD
204,142_CD
578,831_CD
The_DT
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2002_CD
was_VBD
as_IN
follows_VPRT
:_:
Floating_VBG
Fixed_NN
Interest_NN
free_JJ
Total_JJ
Currency_NN
000 000 000 000_CD
Canadian_JJ
dollars_NN
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
1,167_CD
1,167_CD
US_FPP1
dollars_NN
convertible_JJ
debt_NN
243,547_CD
243,547_CD
Total_JJ
243,547_CD
1,167_CD
244,714_CD
The_DT
$_$
400_CD
million_CD
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
due_JJ
2011_CD
were_VBD [PASS]
issued_VBN
on_PIN
15_CD
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
._.
For_PIN
further_JJ
information_NOMZ
on_PIN
the_DT
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
,_,
see_VPRT [PRIV]
note_NN
21_CD
i._NN
Weighted_VBN
average_JJ
period_NN
to_PIN
maturity_NOMZ
of_PIN
interest_NN
free_JJ
government_NOMZ
loans_NN
is_VPRT [BEMA]
28_CD
months_NN
._.
The_DT
benchmark_NN
for_PIN
determining_VBG [SUAV] [PRIV]
the_DT
interest_NN
payments_NOMZ
for_PIN
the_DT
floating_VBG
interest_NN
liabilities_NOMZ
is_VPRT [BEMA]
Canadian_JJ
prime_JJ
rate_NN
4.0_CD
%_NN
at_PIN
31_CD
December_NN
2002_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
43_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
22_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
The_DT
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2001_CD
was_VBD
as_IN
follows_VPRT
:_:
Floating_VBG
Fixed_NN
Interest_NN
free_JJ
Total_JJ
Currency_NN
000 000 000 000_CD
Canadian_JJ
dollars_NN
bank_NN
loans_NN
1,550_CD
1,550_CD
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
2,131_CD
2,131_CD
US_FPP1
dollars_NN
convertible_JJ
debt_NN
268,178_CD
1,032_CD
269,210_CD
Total_JJ
1,550_CD
268,178_CD
3,163_CD
272,891_CD
The_DT
weighted_JJ
average_JJ
period_NN
to_PIN
maturity_NOMZ
of_PIN
the_DT
convertible_JJ
debt_NN
is_VPRT [BEMA]
one_CD
year_NN
._.
Currency_NN
exposures_NN
The_DT
Groups_NN
objectives_NN
in_PIN
managing_VBG
the_DT
currency_NN
exposures_NN
arising_VBG [WZPRES]
from_PIN
its_PIT
net_JJ
investment_NOMZ
overseas_PLACE
in_CONJ
other_NULL
words_NULL
,_,
its_PIT
structural_JJ
currency_NN
exposures_NN
are_VPRT
to_TO
maintain_VB [PUBV]
a_DT
low_JJ
cost_NN
of_PIN
borrowings_GER
and_CC
minimize_VB
currency_NN
related_VBN
exposures_NN
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
structural_JJ
currency_NN
exposures_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
Groups_NN
currency_NN
exposures_NN
:_:
in_CONJ
other_NULL
words_NULL
,_,
those_DEMO
transactional_JJ
or_CC
non-structural_JJ
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
the_DT
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Such_JJ
exposures_NN
comprise_VPRT
the_DT
monetary_JJ
assets_NN
and_CC
monetary_JJ
liabilities_NOMZ
of_PIN
the_DT
Group_NN
that_TSUB
are_VPRT [PASS]
not_XX0
denominated_VBN
in_PIN
the_DT
operating_GER
or_CC
functional_JJ
currency_NN
of_PIN
the_DT
operating_VBG
unit_NN
involved_VBN
,_,
other_JJ
than_PIN
certain_JJ
non-sterling_JJ
borrowings_GER
treated_VBN
as_IN
hedges_NN
of_PIN
net_JJ
investments_NOMZ
in_PIN
overseas_PLACE
operations_NOMZ
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
these_DEMO
exposures_NN
were_VBD
as_IN
follows_VPRT
:_:
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
Pounds_NN
US_FPP1
sterling_GER
dollars_NN
Euro_NN
Other_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Group_NN
operation_NOMZ
000 000 000 000_CD
000_CD
Pounds_NN
sterling_JJ
330,714_CD
242_CD
49_CD
331,005_CD
Euro_NN
1,268_CD
1,830_CD
3,098_CD
Canadian_JJ
dollars_NN
1,702_CD
662_CD
301_CD
40_CD
2,705_CD
2,970_CD
333,206_CD
543_CD
89_CD
336,808_CD
The_DT
exposures_NN
at_PIN
31_CD
December_NN
2001_CD
for_PIN
comparison_NN
purposes_NN
were_VBD
as_IN
follows_VPRT
:_:
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
liabilities_NOMZ
Pounds_NN
US_FPP1
sterling_GER
Dollars_NN
Euro_NN
Other_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Group_NN
operation_NOMZ
000 000 000 000_CD
000_CD
Pounds_NN
sterling_JJ
32,622_CD
2,115_CD
1,400_CD
36,137_CD
Euro_NN
147_CD
96_CD
51_CD
Canadian_JJ
dollars_NN
18,811_CD
24,729_CD
43,540_CD
18,664_CD
57,447_CD
2,115_CD
1,400_CD
79,626_CD
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
The_DT
maturity_NOMZ
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2002_CD
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
Convertible_NN
Bank_NN
loan_NN
stock_NN
loans_NN
Total_NN
Group_NN
000 000 000_CD
Less_RB
than_PIN
one_CD
year_NN
389_CD
389_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
243,547_CD
389_CD
243,936_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
389 389 243_CD
,547_CD
1,167_CD
244,714_CD
See_VB [PRIV]
note_NN
21_CD
i_FPP1
and_CC
21_CD
ii_NN
for_PIN
further_JJ
information_NOMZ
on_PIN
convertible_JJ
loan_NN
stock_NN
and_PHC
bank_NN
loans_NN
respectively_RB
._.
44_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
22_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
Borrowing_GER
facilities_NOMZ
The_DT
Group_NN
had_VBD
no_SYNE
undrawn_JJ
committed_JJ
borrowing_GER
facilities_NOMZ
at_PIN
31_CD
December_NN
2002_CD
2001_CD
:_:
4,820,000_CD
._.
Fair_NN
values_VPRT
The_DT
market_NN
price_NN
of_PIN
the_DT
convertible_JJ
loan_NN
stock_NN
2011_CD
as_RB
at_PIN
31_CD
December_NN
2002_CD
was_VBD
$_$
92.19_CD
compared_VBN
with_PIN
an_DT
issue_NN
price_NN
of_PIN
$_$
100_CD
._.
If_COND
the_DT
loan_NN
is_VPRT [PASS]
not_XX0
converted_VBN
into_PIN
equity_NOMZ
,_,
it_PIT
would_PRMD
be_VB [BEMA]
repayable_PRED
at_PIN
$_$
100_CD
per_PIN
note_NN
._.
The_DT
total_JJ
fair_JJ
value_NN
of_PIN
the_DT
debt_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
above_PLACE
market_NN
price_NN
,_,
was_VBD [BEMA]
229.0_CD
million_CD
$_$
368.8_CD
million_CD
compared_VBN
to_PIN
a_DT
book_NN
value_NN
of_PIN
248.5_CD
million_CD
._.
In_CONJ
addition_NULL
,_,
as_RB
at_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
fair_JJ
value_NN
of_PIN
listed_VBN
investments_NOMZ
was_VBD [BEMA]
0.8_CD
million_CD
above_PLACE
book_NN
value_NN
2001_CD
:_:
nil_NN
._.
There_EX
were_VBD
no_SYNE
other_JJ
material_NN
differences_NN
between_PIN
the_DT
book_NN
values_NN
and_CC
fair_JJ
values_NN
of_PIN
all_QUAN
other_JJ
Group_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
31_CD
December_NN
2002_CD
2001_CD
:_:
nil_NN
._.
Gains_NN
and_PHC
losses_NN
on_PIN
hedges_NN
The_DT
Group_NN
had_VBD
no_SYNE
foreign_JJ
exchange_NN
,_,
interest_NN
rate_NN
or_CC
other_JJ
derivative_JJ
contracts_NN
outstanding_JJ
at_PIN
31_CD
December_NN
2001_CD
or_CC
31_CD
December_NN
2002_CD
._.
23_CD
Called-up_JJ
share_NN
capital_NN
Number_NN
Ordinary_NN
shares_NN
000_CD
000_CD
Authorised_VBN
At_PIN
31_CD
December_NN
2001_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
800,000_CD
40,000_CD
At_PIN
31_CD
December_NN
2002_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
800,000_CD
40,000_CD
Allotted_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1_CD
January_NN
2002_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
481,821_CD
24,091_CD
Issued_VBN
on_PIN
exercise_NN
of_PIN
options_NOMZ
for_PIN
cash_NN
consideration_NOMZ
1,941_CD
97_CD
Issued_VBN
on_PIN
conversion_NN
of_PIN
zero_CD
coupon_NN
note_NN
268_CD
14_CD
Issued_VBN
on_PIN
exchange_NN
of_PIN
exchangeable_JJ
shares_NN
314_CD
15_CD
At_PIN
31_CD
December_NN
2002_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
484,344_CD
24,217_CD
Number_NN
Special_JJ
ordinary_JJ
voting_NN
shares_NN
exchangeable_JJ
shares_NN
000_CD
000_CD
Authorised_VBN
At_PIN
31_CD
December_NN
2001_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
of_PIN
0.00001_CD
p_NN
17,500_CD
At_PIN
31_CD
December_NN
2002_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
of_PIN
0.00001_CD
p_NN
17,500_CD
Allotted_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1_CD
January_NN
2002_CD
5,979_CD
Exchanged_VBN
for_PIN
ordinary_JJ
shares_NN
105_CD
At_PIN
31_CD
December_NN
2002_CD
5,874_CD
Authorised_JJ
share_NN
capital_NN
The_DT
authorised_JJ
share_NN
capital_NN
of_PIN
the_DT
Company_NN
,_,
at_PIN
31_CD
December_NN
2002_CD
,_,
was_VBD [BEMA]
40,000,000_CD
divided_VBN
into_PIN
799,999,965_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
and_CC
17,500,000_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
exchangeable_JJ
shares_NN
of_PIN
0.00001_CD
p_NN
each_QUAN
._.
Issue_NN
of_PIN
ordinary_JJ
shares_NN
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
the_DT
Company_NN
allotted_VBD
314,376_CD
ordinary_JJ
shares_NN
with_PIN
a_DT
nominal_JJ
value_NN
of_PIN
15,718_CD
on_PIN
the_DT
exchange_NN
of_PIN
special_JJ
ordinary_JJ
voting_NN
shares_NN
exchangeable_JJ
shares_NN
following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
._.
These_DEMO
shares_NN
were_VBD [PASS]
issued_VBN
at_PIN
a_DT
premium_NN
of_PIN
3,404,458_CD
._.
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
the_DT
Company_NN
allotted_VBD
a_DT
total_NN
of_PIN
267,572_CD
ordinary_JJ
shares_NN
with_PIN
a_DT
nominal_JJ
value_NN
of_PIN
13,378_CD
to_PIN
Arenol_NN
Corporation_NOMZ
or_CC
its_PIT
nominee_NN
broker_NN
in_PIN
consideration_NOMZ
for_PIN
the_DT
conversion_NN
of_PIN
debt_NN
._.
These_DEMO
shares_NN
were_VBD [PASS]
issued_VBN
at_PIN
a_DT
premium_NN
of_PIN
940,516_CD
._.
Issue_NN
of_PIN
special_JJ
ordinary_JJ
voting_NN
shares_NN
The_DT
Company_NN
exchanged_VBD
104,792_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
during_PIN
the_DT
year_NN
._.
Each_QUAN
of_PIN
these_DEMO
shares_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
three_CD
ordinary_JJ
shares_NN
and_CC
is_VPRT [BEMA]
exchangeable_PRED
into_PIN
ordinary_JJ
shares_NN
or_CC
ADSs_NN
,_,
at_PIN
a_DT
rate_NN
of_PIN
one_CD
exchangeable_JJ
share_NN
for_PIN
three_CD
ordinary_JJ
shares_NN
or_CC
one_CD
exchangeable_JJ
share_NN
for_PIN
one_CD
ADS_NN
,_,
at_PIN
any_QUAN
time_NN
at_PIN
the_DT
request_NN
of_PIN
the_DT
holder_NN
._.
Only_DWNT
BioChem_NN
shareholders_NN
with_PIN
Canadian_JJ
residency_NN
had_VBD
the_DT
option_NOMZ
to_TO
receive_VB
exchangeable_JJ
shares_NN
for_PIN
their_TPP3
shares_NN
of_PIN
BioChem_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
The_DT
exchangeable_JJ
shares_NN
were_VBD [BYPA]
issued_VBN
by_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
a_DT
company_NN
incorporated_VBN
under_IN
the_DT
Canada_NN
Business_NOMZ
Corporations_NOMZ
Act_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
the_DT
Company_NN
,_,
and_ANDC
is_VPRT [PASS]
listed_VBN
on_PIN
the_DT
Toronto_NN
Stock_NN
Exchange_NN
._.
Holders_NN
of_PIN
the_DT
exchangeable_JJ
shares_NN
are_VPRT [PASS]
entitled_VBN
to_PIN
dividend_NN
and_CC
other_JJ
rights_NN
that_TSUB
are_VPRT [BEMA]
economically_RB
equivalent_PRED
to_PIN
those_DEMO
of_PIN
ordinary_JJ
shares_NN
._.
Through_PIN
a_DT
voting_NN
trust_NN
and_CC
by_PIN
means_NN
of_PIN
special_JJ
voting_NN
shares_NN
in_PIN
Shire_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
trustee_NN
,_,
holders_NN
of_PIN
exchangeable_JJ
shares_NN
are_VPRT [PASS]
entitled_VBN
to_TO
vote_VB [SUAV]
at_PIN
shareholder_NN
meetings_GER
of_PIN
the_DT
Company_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
45_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
23_CD
Called-up_JJ
share_NN
capital_NN
continued_VBD
As_IN
at_PIN
31_CD
December_NN
2002_CD
5,874,112_CD
exchangeable_JJ
shares_NN
remained_VBD
unconverted_JJ
._.
The_DT
Company_NN
can_POMD
redeem_VB
all_QUAN
outstanding_JJ
exchangeable_JJ
shares_NN
for_PIN
ordinary_JJ
shares_NN
after_IN
11_CD
May_POMD
2011_CD
,_,
or_CC
earlier_TIME
if_COND
the_DT
total_JJ
number_NN
of_PIN
exchangeable_JJ
shares_NN
falls_VPRT
below_PLACE
1_CD
million_CD
._.
The_DT
exchangeable_JJ
shares_NN
are_VPRT [PASS]
included_VBN
as_IN
part_NN
of_PIN
share_NN
capital_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
to_TO
present_VB
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
consolidated_JJ
Groups_NN
capital_NN
structure_NN
,_,
which_WDT [SERE]
differs_VPRT
from_PIN
the_DT
Companies_NN
Act_NN
1985_CD
requirements_NOMZ
to_TO
reflect_VB [PRIV]
these_DEMO
amounts_NN
as_IN
minority_NOMZ
interests_NN
,_,
as_IN
they_TPP3
will_PRMD
become_VB
and_PHC
are_VPRT [BEMA]
equivalent_PRED
to_PIN
ordinary_JJ
shares_NN
._.
Share_NN
warrants_NN
On_PIN
24_CD
April_NN
2002_CD
the_DT
Company_NN
issued_VBN
741,812_CD
share_NN
warrants_NN
,_,
at_PIN
4.885_CD
per_PIN
warrant_NN
,_,
and_ANDC
on_PIN
21_CD
November_NN
2002_CD
the_DT
Company_NN
issued_VBD
a_DT
further_JJ
604,595_CD
share_NN
warrants_NN
,_,
at_PIN
4.895_CD
per_PIN
warrant_NN
,_,
both_DT
issues_NN
being_VBG [WZPRES] [PASS]
made_VBN
to_PIN
Technology_NN
Partnership_NN
Canada_NN
,_,
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
between_PIN
Shire_NN
BioChem_NN
Inc._NN
and_CC
the_DT
Government_NOMZ
of_PIN
Canada_NN
._.
Each_QUAN
warrant_NN
grants_NN
a_DT
right_NN
to_TO
subscribe_VB
for_PIN
a_DT
corresponding_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
within_PIN
five_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
issue_NN
of_PIN
each_QUAN
warrant_NN
._.
Convertible_JJ
loan_NN
notes_VPRT [PRIV]
The_DT
$_$
400_CD
million_CD
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
due_JJ
2011_CD
were_VBD [PASS]
issued_VBN
on_PIN
15_CD
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
._.
The_DT
Groups_NN
directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
share_NN
options_NOMZ
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
following_JJ
share_NN
option_NOMZ
plans_NN
:_:
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
2000_CD
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Holdings_GER
Ltd_NN
Share_NN
Options_NOMZ
Scheme_NN
SHL_NN
Scheme_NN
,_,
the_DT
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
,_,
the_DT
Richwood_NN
Stock_NN
Options_NOMZ
Plan_NN
Richwood_NN
Plan_NN
,_,
the_DT
Roberts_NN
Stock_NN
Option_NOMZ
Plans_NN
Roberts_NN
Plan_NN
and_CC
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
._.
The_DT
highest_JJ
and_PHC
lowest_JJ
market_NN
prices_NN
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
were_VBD [BEMA]
8.835_CD
and_CC
3.755_CD
respectively_RB
._.
For_PIN
further_JJ
details_NN
see_VPRT [PRIV]
the_DT
directors_NN
remuneration_JJ
report_NN
on_PIN
pages_NN
11_CD
to_PIN
20_CD
._.
24_CD
Reserves_NN
Profit_NN
Share_NN
Exchangeable_NN
Capital_NN
Other_NN
and_PHC
loss_NN
premium_NN
shares_NN
reserves_NN
reserves_NN
account_VPRT
Group_NN
000 000 000 000_CD
000_CD
As_IN
at_PIN
1_CD
January_NN
2002_CD
3,206,280_CD
194,972_CD
2,755_CD
24,247_CD
58,439_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
3,405_CD
3,420_CD
Arenol_NN
conversion_NN
941_CD
Options_NOMZ
exercised_VBN
3,886_CD
Foreign_JJ
exchange_NN
adjustment_NOMZ
62,739_CD
Retained_VBN
loss_NN
for_PIN
the_DT
year_NN
588,399_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
3,214,512_CD
191,552_CD
2,755_CD
24,247_CD
709,577_CD
The_DT
cumulative_JJ
goodwill_NN
resulting_VBG [WZPRES]
from_PIN
acquisitions_NOMZ
that_TSUB
has_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
off_PIN
directly_RB
to_PIN
reserves_NN
amounts_NN
to_PIN
208,194,000_CD
as_IN
at_PIN
31_CD
December_NN
2002_CD
and_CC
31_CD
December_NN
2001_CD
._.
The_DT
capital_NN
and_CC
other_JJ
reserves_NN
arose_VBD
in_PIN
relation_NOMZ
to_PIN
various_JJ
Group_NN
reconstructions_NOMZ
and_CC
certain_JJ
financing_GER
transactions_NOMZ
,_,
and_ANDC
are_VPRT [BEMA]
not_XX0
distributable_PRED
._.
Profit_NN
Share_NN
Exchangeable_NN
Capital_NN
Other_NN
and_PHC
loss_NN
premium_NN
shares_NN
reserves_NN
reserves_NN
account_VPRT
Company_NN
000 000 000 000_CD
000_CD
As_IN
at_PIN
1_CD
January_NN
2002_CD
3,206,744_CD
194,972_CD
1,674_CD
18,079_CD
2,730_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
3,405_CD
3,420_CD
Arenol_NN
conversion_NN
941_CD
Options_NOMZ
exercised_VBN
4,347_CD
Foreign_JJ
exchange_NN
adjustment_NOMZ
6,162_CD
Retained_VBN
loss_NN
for_PIN
the_DT
year_NN
7,038_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
3,215,437_CD
191,552_CD
1,674_CD
18,079_CD
15,930_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
49_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
25_CD
Reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
Group_NN
shareholders_NN
funds_NN
2002 2001 000 000_CD
Loss_NN
profit_NN
for_PIN
the_DT
year_NN
588,399_CD
35,709_CD
Other_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
year_NN
62,739_CD
6,640_CD
651,138_CD
29,069_CD
Share_NN
capital_NN
issued_VBN
1,951,648_CD
Issue_NN
of_PIN
exchangeable_JJ
shares_NN
563,897_CD
Issue_NN
expenses_NN
23,584_CD
Arenol_NN
conversion_NN
955_CD
Proceeds_NN
on_PIN
exercise_NN
of_PIN
employee_NN
share_NN
options_NOMZ
3,983_CD
46,961_CD
Net_JJ
additions_NOMZ
to_PIN
shareholders_NN
funds_NN
646,200_CD
2,567,991_CD
Opening_GER
shareholders_NN
funds_NN
as_IN
restated_VBN
3,393,906_CD
825,915_CD
Closing_GER
shareholders_NN
funds_NN
2,747,706_CD
3,393,906_CD
The_DT
cumulative_JJ
foreign_JJ
exchange_NN
differences_NN
on_PIN
translation_NOMZ
amount_NN
to_PIN
47,522,000_CD
loss_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
and_CC
9,056,000_CD
gain_NN
as_IN
at_PIN
31_CD
December_NN
2001_CD
._.
26_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
a_DT
Operating_GER
leases_VPRT
The_DT
Group_NN
leases_VPRT
property_NN
,_,
computer_NN
and_PHC
office_NN
equipment_NOMZ
and_PHC
motor_NN
vehicles_NN
on_PIN
short-term_JJ
leases_NN
._.
The_DT
rents_NN
payable_JJ
under_IN
property_NN
leases_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
renegotiation_NOMZ
at_PIN
various_JJ
intervals_NN
specified_VBN [WZPAST]
in_PIN
the_DT
leases_NN
._.
The_DT
Group_NN
pays_VPRT
for_PIN
substantially_RB
all_QUAN
of_PIN
the_DT
insurance_NN
,_,
maintenance_NN
and_PHC
repair_NN
of_PIN
these_DEMO
assets_NN
._.
The_DT
minimum_JJ
annual_JJ
rentals_NN
under_IN
the_DT
foregoing_VBG
leases_NN
are_VPRT
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Land_NN
and_PHC
Motor_NN
Land_NN
and_PHC
Motor_NN
buildings_GER
Equipment_NOMZ
vehicles_NN
buildings_GER
Equipment_NOMZ
vehicles_NN
Group_NN
000 000 000 000_CD
000_CD
000_CD
Operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
within_PIN
1_CD
year_NN
179_CD
333_CD
50_CD
768_CD
4_CD
120_CD
within_PIN
2_CD
5_CD
years_NN
1,263_CD
1,827_CD
902 522 725_CD
2,277_CD
after_IN
5_CD
years_NN
245_CD
1_CD
1,687_CD
2,161_CD
952_CD
1,290_CD
729_CD
2,397_CD
2002_CD
2001_CD
Land_NN
and_PHC
Motor_NN
Land_NN
and_PHC
Motor_NN
buildings_GER
Equipment_NOMZ
vehicles_NN
buildings_GER
Equipment_NOMZ
vehicles_NN
Company_NN
000 000 000 000_CD
000_CD
000_CD
Operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
within_PIN
1_CD
year_NN
22_CD
145_CD
within_PIN
2_CD
5_CD
years_NN
145_CD
89_CD
114_CD
after_IN
5_CD
years_NN
145 111 145 114_CD
50_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
26_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
b_NN
Capital_NN
commitments_NOMZ
i_FPP1
Interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
The_DT
Company_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
subscribe_VB
for_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totalling_VBG [WZPRES]
23,905,000_CD
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
an_DT
amount_NN
of_PIN
17,028,000_CD
has_VPRT [PEAS]
been_VBN [PASS]
subscribed_VBN
._.
Shire_NN
is_VPRT
,_,
therefore_CONJ
,_,
committed_VBN
to_TO
investing_VBG
a_DT
further_JJ
6,877,000_CD
._.
Further_JJ
information_NOMZ
regarding_VBG [WZPRES]
these_DEMO
interests_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
note_NN
13_CD
a._NN
ii_FW
Fluviral_NN
The_NN
Company_NN
has_VPRT
a_DT
ten-year_JJ
contract_NN
with_PIN
the_DT
Canadian_JJ
government_NOMZ
to_TO
assure_VB
a_DT
state_NN
of_PIN
readiness_NOMZ
in_PIN
the_DT
case_NN
of_PIN
an_DT
influenza_NN
pandemic_JJ
worldwide_NN
epidemic_NN
and_CC
to_TO
manufacture_VB
influenza_NN
vaccine_NN
for_PIN
all_QUAN
Canadian_JJ
citizens_NN
in_PIN
such_JJ
an_DT
event_NN
._.
Under_IN
the_DT
contract_NN
,_,
Shire_NN
Biologics_NN
will_PRMD [SPAU]
also_RB
supply_VB
the_DT
Government_NOMZ
of_PIN
Canada_NN
with_PIN
a_DT
substantial_JJ
proportion_NOMZ
of_PIN
its_PIT
annual_JJ
influenza_NN
vaccine_NN
requirements_NOMZ
over_IN
the_DT
ten-year_JJ
period_NN
._.
Subject_JJ
to_PIN
mutual_JJ
agreement_NOMZ
,_,
the_DT
contract_NN
can_POMD
be_VB [PASS]
renewed_VBN
for_PIN
a_DT
further_JJ
period_NN
of_PIN
between_PIN
one_CD
and_CC
ten_CD
years_NN
from_PIN
2011_CD
._.
The_DT
concept_NN
of_PIN
a_DT
state_NN
of_PIN
readiness_NOMZ
against_PIN
an_DT
influenza_NN
pandemic_JJ
requires_VPRT [SUAV]
the_DT
development_NOMZ
of_PIN
sufficient_JJ
infrastructure_NN
and_PHC
capacity_NOMZ
in_PIN
Canada_NN
to_TO
provide_VB
100_CD
%_NN
of_PIN
domestic_JJ
vaccine_NN
needs_NN
in_PIN
the_DT
event_NN
of_PIN
an_DT
influenza_NN
pandemic_NN
._.
Canada_NN
would_PRMD
require_VB [SUAV]
32_CD
million_CD
doses_NN
of_PIN
single_JJ
strain_NN
monovalent_JJ
flu_NN
vaccine_NN
within_PIN
a_DT
production_NOMZ
period_NN
of_PIN
16_CD
weeks_NN
._.
Shire_NN
Biologics_NN
has_VPRT [SPAU] [PEAS]
therefore_CONJ
begun_VBN
to_TO
expand_VB
its_PIT
current_JJ
production_NOMZ
capacity_NOMZ
in_PIN
order_NN
to_TO
meet_VB
this_DEMO
objective_NN
within_PIN
a_DT
five-year_JJ
period_NN
._.
A_DT
performance_NN
bond_NN
equal_JJ
to_PIN
10_CD
%_NN
of_PIN
the_DT
minimum_NN
estimated_VBN [PRIV]
contract_NN
value_NN
in_PIN
any_QUAN
year_NN
would_PRMD
become_VB
payable_JJ
to_PIN
the_DT
Canadian_JJ
government_NOMZ
if_COND
contracted_VBN
penalty_NN
clauses_NN
were_VBD [PASS]
triggered_VBN
._.
Shire_NN
Biologics_NN
is_VPRT [PASS]
committed_VBN
to_TO
investing_VBG
11.5_CD
million_CD
in_PIN
the_DT
construction_NOMZ
of_PIN
a_DT
new_JJ
global_JJ
vaccine_NN
research_NN
center_NN
in_PIN
Laval_NN
,_,
Canada_NN
._.
The_DT
completion_NOMZ
of_PIN
this_DEMO
project_NN
is_VPRT [PASS]
planned_VBN
for_PIN
mid_JJ
2004_CD
._.
Under_IN
the_DT
Technology_NN
Partnerships_NN
Canada_NN
TPC_NN
agreement_NOMZ
,_,
Shire_NN
could_POMD
be_VB [BEMA]
eligible_PRED
for_PIN
a_DT
government_NOMZ
investment_NOMZ
of_PIN
approximately_RB
2.2_CD
million_CD
._.
c_NN
Contingent_JJ
liabilities_NOMZ
Shire_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
proceedings_GER
considered_VBN [PRIV]
typical_JJ
to_PIN
its_PIT
business_NOMZ
,_,
including_VBG [PRESP]
those_DEMP
set_VBN
out_PIN
below_PLACE
._.
Although_CONC
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
regarding_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
the_DT
legal_JJ
proceedings_GER
referred_VBD
to_PIN
below_PLACE
,_,
Shire_NN
believes_VPRT [PRIV]
that_THVC
they_TPP3
will_PRMD
not_XX0
have_VB
a_DT
materially_RB
adverse_JJ
effect_NN
on_PIN
the_DT
Groups_NN
financial_JJ
position_NOMZ
._.
i_FPP1
Phentermine_NN
Shire_NN
US_FPP1
,_,
Inc._NN
._.
Shire_NN
US_FPP1
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
11_CD
lawsuits_NN
still_RB
pending_VBG
,_,
in_PIN
both_DT
US_FPP1
federal_JJ
and_CC
state_NN
courts_NN
,_,
which_WDT [SERE]
seek_VPRT
damages_NN
for_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
personal_JJ
injury_NN
arising_VBG [WZPRES]
from_PIN
phentermine_NN
products_NN
supplied_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
by_PIN
Shire_NN
US_FPP1
and_CC
several_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
._.
Shire_NN
US_FPP1
,_,
formerly_TIME
known_VBN [PRIV]
as_IN
Shire_NN
Richwood_NN
Inc._NN
has_VPRT [PEAS]
been_VBN [PASS]
sued_VBN
as_IN
a_DT
manufacturer_NN
and_PHC
distributor_NN
of_PIN
phentermine_NN
,_,
an_DT
anorectic_NN
used_VBN [WZPAST]
in_PIN
the_DT
short-term_JJ
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
one_CD
of_PIN
the_DT
products_NN
addressed_VBN [WZPAST]
by_PIN
the_DT
lawsuits_NN
._.
The_DT
suits_NN
relate_VPRT
to_TO
phentermine_VB
either_CC
alone_RB
or_CC
together_RB
with_PIN
fenfluramine_NN
or_CC
dexenfluramine_NN
._.
The_DT
lawsuits_NN
generally_RB
allege_VPRT [PUBV]
the_DT
following_VBG
claims_NN
:_:
the_DT
defendants_NN
marketed_VBN
phentermine_NN
and_CC
other_JJ
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
misled_VBD
users_NN
about_IN
the_DT
products_NN
and_PHC
territory_NN
dangers_NN
associated_VBN [WZPAST]
with_PIN
them_TPP3
:_:
the_DT
defendants_NN
failed_VBD
adequately_RB
to_PIN
test_NN
phentermine_NN
individually_RB
and_ANDC
when_RB
taken_VBN
in_PIN
combination_NOMZ
with_PIN
the_DT
other_JJ
drugs_NN
:_:
and_ANDC
the_DT
defendants_NN
knew_VBD [PRIV]
or_CC
should_NEMD
have_VB [PEAS]
known_VBN [PRIV]
about_IN
the_DT
negative_JJ
effects_NN
of_PIN
the_DT
drugs_NN
and_CC
should_NEMD
have_VB [PEAS]
informed_VBN
the_DT
public_JJ
about_IN
such_JJ
risks_NN
and_CC
or_CC
failed_VBD
to_TO
provide_VB
appropriate_JJ
warning_GER
labels_NN
._.
Shire_NN
US_FPP1
had_VBD [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
a_DT
total_NN
of_PIN
3,804_CD
such_JJ
phentermine_NN
lawsuits_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
Shire_NN
US_FPP1
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
as_IN
a_DT
defendant_NN
in_PIN
3,756_CD
cases_NN
._.
Shire_NN
US_FPP1
is_VPRT
awaiting_VBG
the_DT
furtherance_NN
of_PIN
proceedings_GER
in_PIN
the_DT
remaining_VBG
37_CD
lawsuits_NN
._.
Shire_NN
US_FPP1
became_VBD
involved_VBN
with_PIN
phentermine_NN
through_PIN
its_PIT
acquisition_NOMZ
of_PIN
certain_JJ
assets_NN
of_PIN
Rexar_NN
Pharmacol_NN
Corporation_NOMZ
Rexar_NN
in_PIN
January_NN
1994_CD
._.
In_CONJ
addition_NULL
to_PIN
Shire_NN
US_FPP1
potentially_RB
incurring_VBG
liability_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
own_JJ
production_NOMZ
of_PIN
Oby-Cap_NN
,_,
a_DT
phentermine_JJ
product_NN
,_,
the_DT
plaintiffs_NN
may_POMD [SPAU]
additionally_RB
seek_VB
to_TO
impose_VB
liability_NOMZ
on_PIN
Shire_NN
US_FPP1
as_IN
successor_NN
to_PIN
Rexar_NN
._.
Shire_NN
US_FPP1
intends_VPRT [SUAV]
vigorously_RB
to_TO
defend_VB
all_QUAN
the_DT
lawsuits_NN
and_CC
pursue_VB
all_QUAN
available_JJ
reasonable_JJ
defences_NN
._.
Shire_NN
US_FPP1
denies_VPRT [PUBV]
liability_NOMZ
on_PIN
a_DT
number_NN
of_PIN
grounds_NN
including_VBG [WZPRES]
lack_NN
of_PIN
scientific_JJ
evidence_NN
that_DEMO
phentermine_NN
,_,
properly_RB
described_VBN
,_,
causes_VPRT
the_DT
alleged_JJ
side_NN
effects_NN
and_CC
that_THVC
Shire_NN
US_FPP1
did_VBD
not_XX0
promote_VB
phentermine_NN
for_PIN
long-term_JJ
combined_VBN
use_NN
as_IN
part_NN
of_PIN
the_DT
fen_NN
phen_NN
diet_NN
._.
Accordingly_RB
,_,
Shire_NN
US_FPP1
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
any_QUAN
and_CC
all_QUAN
claims_NN
made_VBN [WZPAST]
against_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
phentermine_NN
._.
Legal_JJ
expenses_NN
have_VPRT [PEAS]
been_VBN [BYPA]
paid_VBN
by_PIN
Eon_NN
Labs_NN
Manufacturing_GER
Inc._NN
._.
Eon_NN
,_,
the_DT
supplier_NN
to_PIN
Shire_NN
US_FPP1
,_,
or_CC
Eons_NN
insurance_NN
carriers_NN
but_CC
such_JJ
insurance_NN
is_VPRT [SPAU] [PASS]
now_TIME
exhausted_VBN
._.
Eon_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
defend_VB
and_PHC
indemnify_VB
Shire_NN
US_FPP1
in_PIN
this_DEMO
litigation_NOMZ
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
dated_VBN
30_CD
November_NN
2000_CD
made_VBD
between_PIN
Eon_NN
and_PHC
Shire_NN
US_FPP1
._.
At_PIN
the_DT
present_JJ
stage_NN
of_PIN
litigation_NOMZ
,_,
Shire_NN
is_VPRT [BEMA]
unable_PRED
to_TO
estimate_VB [PRIV]
the_DT
level_NN
of_PIN
future_JJ
legal_JJ
costs_NN
after_IN
taking_VBG
into_PIN
account_NN
any_QUAN
available_JJ
product_NN
liability_NOMZ
insurance_NN
and_CC
enforceable_JJ
indemnities_NOMZ
._.
To_PIN
the_DT
extent_NN
that_TOBJ
any_QUAN
legal_JJ
costs_NN
are_VPRT [BYPA]
not_XX0
covered_VBN
by_PIN
insurance_NN
or_CC
available_JJ
indemnities_NOMZ
,_,
these_DEMP
will_PRMD
be_VB [PASS]
expensed_VBN
as_IN
incurred_VBN
._.
It_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
at_PIN
this_DEMO
time_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
legal_JJ
outcome_NN
or_CC
financial_JJ
implications_NOMZ
of_PIN
any_QUAN
of_PIN
these_DEMO
claims_NN
._.
ii_FW
ADDERALL_NN
Shires_NN
extended_VBD
release_NN
once_TIME
daily_JJ
version_NN
of_PIN
ADDERALL_NN
,_,
ADDERALL_NN
XR_NN
,_,
is_VPRT [BYPA]
covered_VBN
by_PIN
US_FPP1
patent_NN
no._NN
._.
In_PIN
January_NN
2003_CD
Shire_NN
received_VBD
a_DT
Paragraph_NN
IV_NN
notice_NN
from_PIN
Barr_NN
alleging_VBG [PUBV] [THATD] [WZPRES]
that_DEMP
this_DEMO
patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
not_XX0
infringed_VBN
by_PIN
Barrs_NN
extended_VBD
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
the_DT
subject_NN
of_PIN
a_DT
Barr_NN
pending_VBG [WZPRES]
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
ANDA_NN
application_NOMZ
._.
On_PIN
24_CD
February_NN
2003_CD
Shire_NN
Laboratories_NN
Inc._NN
filed_VBD
suit_NN
against_PIN
Barr_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
Patent_NN
with_PIN
respect_NN
to_PIN
this_DEMO
ANDA_NN
._.
The_DT
Hatch-Waxman_NN
Act_NN
provides_VPRT
for_PIN
an_DT
automatic_JJ
stay_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
of_PIN
FDA_NN
approval_NN
for_PIN
Barrs_NN
ANDA_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
to_TO
allow_VB [SUAV]
the_DT
Court_NN
to_TO
resolve_VB [SUAV]
the_DT
patent_NN
infringement_NOMZ
lawsuit_NN
._.
However_CONJ
,_,
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
that_TOBJ
the_DT
Group_NN
will_PRMD
be_VB [BEMA]
successful_PRED
in_PIN
the_DT
suit_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Group_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Barr_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended_JJ
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
application_NOMZ
._.
This_DEMP
may_POMD
have_VB
a_DT
material_NN
adverse_JJ
impact_NN
on_PIN
the_DT
Groups_NN
results_NN
and_CC
financial_JJ
position_NOMZ
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Group_NN
does_VPRT
not_XX0
prevail_VB
in_PIN
the_DT
suit_NN
,_,
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
could_POMD
not_XX0
be_VB [PASS]
launched_VBN
before_IN
October_NN
2004_CD
,_,
the_DT
current_JJ
expiry_NN
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
51_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
26_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
In_PIN
November_NN
2002_CD
Shire_NN
received_VBD
approval_NN
from_PIN
the_DT
FDA_NN
for_PIN
a_DT
new_JJ
formulation_NOMZ
of_PIN
ADDERALL_NN
which_WDT [WHSUB]
is_VPRT [PASS]
patent_NN
protected_VBN
._.
In_PIN
January_NN
2003_CD
Shire_NN
received_VBD
a_DT
Paragraph_NN
IV_NN
notice_NN
from_PIN
Barr_NN
alleging_VBG [PUBV] [THATD] [WZPRES]
that_DEMP
this_DEMO
patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
not_XX0
infringed_VBN
by_PIN
Barrs_NN
7.5_CD
mg_NN
,_,
12.5_CD
mg_NN
and_CC
15mg_JJ
mixed_JJ
amphetamine_NN
salt_NN
products_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
taken_VBN
no_SYNE
action_NOMZ
with_PIN
respect_NN
to_PIN
this_DEMO
notice_NN
and_PHC
Barr_NN
announced_VBD [PUBV]
in_PIN
March_NN
2003_CD
that_DEMO
it_PIT
has_VPRT [SPAU] [PEAS]
now_TIME
received_VBN
FDA_NN
approval_NN
and_CC
180_CD
days_NN
exclusivity_NOMZ
for_PIN
these_DEMO
strengths_NN
._.
The_DT
Company_NN
received_VBD
a_DT
second_JJ
Paragraph_NN
IV_NN
notice_NN
in_PIN
March_NN
2003_CD
from_PIN
another_DT
generic_JJ
alleging_VBG [PUBV] [THATD]
that_DEMP
this_DEMO
patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
is_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
its_PIT
products_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
the_DT
subject_NN
of_PIN
a_DT
pending_VBG
ANDA_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
taken_VBN
no_SYNE
action_NOMZ
and_CC
this_DEMO
company_NN
will_PRMD
be_VB [BEMA]
able_PRED
to_TO
market_VB
its_PIT
product_NN
upon_PIN
FDA_NN
approval_NN
of_PIN
its_PIT
ANDA_NN
application_NOMZ
,_,
subject_JJ
to_PIN
Barrs_NN
exclusivity_NOMZ
period_NN
for_PIN
the_DT
above_PLACE
doses_NN
._.
The_DT
sales_NN
of_PIN
any_QUAN
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
may_POMD
have_VB
a_DT
material_NN
adverse_JJ
impact_NN
on_PIN
the_DT
Companys_NN
results_NN
and_CC
financial_JJ
position_NOMZ
._.
Shire_NN
filed_VBD
a_DT
Complaint_NN
against_PIN
Barr_NN
on_PIN
30_CD
April_NN
2002_CD
in_PIN
the_DT
District_NN
Court_NN
of_PIN
New_NN
Jersey_NN
._.
In_PIN
the_DT
Complaint_NN
,_,
Shire_NN
requested_VBD [SUAV]
a_DT
preliminary_JJ
and_PHC
permanent_JJ
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
marketing_VBG
a_DT
mixed_JJ
amphetamine_NN
salt_NN
product_NN
in_PIN
a_DT
trade_NN
dress_NN
similar_JJ
to_PIN
that_DEMO
of_PIN
ADDERALL_NN
._.
Shire_NN
requested_VBD [SUAV]
that_THVC
Barr_NN
recall_VPRT [PRIV]
all_QUAN
such_JJ
products_NN
and_CC
also_RB
asked_VBD [SUAV]
for_PIN
damages_NN
._.
An_DT
order_NN
denying_VBG [PUBV] [THATD] [WZPRES]
the_DT
preliminary_JJ
injunction_NOMZ
was_VBD [PASS]
issued_VBN
on_PIN
26_CD
August_NN
2002_CD
._.
Shire_NN
filed_VBD
a_DT
Notice_NN
of_PIN
Appeal_NN
to_PIN
the_DT
United_NN
States_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Third_NN
Circuit_NN
on_PIN
16_CD
September_NN
2002_CD
appealing_VBG
the_DT
denial_NN
of_PIN
Shires_NN
motion_NOMZ
for_PIN
a_DT
preliminary_JJ
injunction_NOMZ
._.
iii_FW
Emory_NN
Shire_NN
BioChem_NN
was_VBD [PASS]
involved_VBN
in_PIN
worldwide_JJ
patent_NN
disputes_NN
with_PIN
Emory_NN
University_NOMZ
Emory_NN
relating_VBG [WZPRES]
to_PIN
lamivudine_JJ
wherein_NN
Shire_NN
BioChem_NN
opposed_VBD
certain_JJ
patents_NN
and_PHC
patent_NN
applications_NOMZ
of_PIN
Emory_NN
and_CC
wherein_JJ
Emory_NN
opposed_VBD
certain_JJ
patents_NN
and_PHC
patent_NN
applications_NOMZ
of_PIN
Shire_NN
BioChem_NN
._.
Pursuant_JJ
to_PIN
a_DT
global_JJ
Settlement_NOMZ
Agreement_NOMZ
,_,
finalized_VBN [PASTP]
in_PIN
May_POMD
2002_CD
,_,
Emory_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
Shire_NN
and_PHC
GSK_NN
an_DT
exclusive_JJ
licence_NN
under_IN
Emorys_NN
patent_NN
rights_NN
for_PIN
lamivudine_NN
._.
The_DT
Settlement_NOMZ
Agreement_NOMZ
provides_VPRT
for_PIN
the_DT
resolution_NOMZ
of_PIN
all_QUAN
worldwide_JJ
patent_NN
disputes_NN
between_PIN
the_DT
parties_NN
relating_VBG [WZPRES]
to_PIN
lamivudine_NN
and_PHC
FTC_NN
,_,
including_VBG
pending_VBG
opposition_NOMZ
and_PHC
revocation_NOMZ
proceedings_GER
in_PIN
Europe_NN
,_,
South_NN
Korea_NN
and_PHC
Australia_NN
._.
The_DT
settlement_NOMZ
involves_VPRT
a_DT
small_JJ
royalty_NN
payment_NOMZ
on_PIN
worldwide_JJ
sales_NN
of_PIN
lamivudine_NN
and_CC
a_DT
licence_NN
under_IN
Shires_NN
FTC_NN
patent_NN
rights_NN
,_,
in_PIN
consideration_NOMZ
for_PIN
the_DT
settlement_NOMZ
of_PIN
all_QUAN
claims_NN
against_PIN
Shire_NN
and_PHC
GSK_NN
relating_VBG [WZPRES]
to_PIN
lamivudine_NN
._.
Shire_NN
BioChem_NN
was_VBD [SPAU] [PASS]
also_RB
involved_VBN
in_PIN
worldwide_JJ
patent_NN
disputes_NN
with_PIN
Emory_NN
and_CC
the_DT
University_NOMZ
of_PIN
Georgia_NN
Research_NN
Foundation_NOMZ
Georgia_NN
relating_VBG [WZPRES]
to_PIN
certain_JJ
dioxolane_NN
nucleoside_NN
analogs_NN
._.
Shire_NN
BioChem_NN
opposed_VBD
certain_JJ
patents_NN
and_PHC
patent_NN
applications_NOMZ
of_PIN
Emory_NN
and_PHC
Georgia_NN
and_PHC
Emory_NN
opposed_VBD
a_DT
European_JJ
patent_NN
of_PIN
Shire_NN
BioChem_NN
._.
Pursuant_JJ
to_PIN
global_JJ
Settlement_NOMZ
and_PHC
License_NN
Agreements_NOMZ
finalized_VBD
in_PIN
August_NN
2002_CD
by_PIN
Shire_NN
BioChem_NN
,_,
Shire_NN
Pharmaceuticals_NN
Group_NN
,_,
Georgia_NN
and_PHC
Triangle_NN
Pharmaceuticals_NN
Inc._NN
._.
Triangle_NN
,_,
Shire_NN
will_PRMD
grant_VB [SUAV]
an_DT
exclusive_JJ
royalty_NN
bearing_GER
licence_NN
to_PIN
Emory_NN
,_,
sub_NN
licensable_JJ
to_PIN
Triangle_NN
,_,
for_PIN
certain_JJ
dioxolane_NN
nucleoside_NN
analogs_NN
,_,
including_VBG
diamino_NN
purine_NN
dioxolane_NN
DAPD_NN
._.
Emory_NN
,_,
Georgia_NN
and_PHC
Triangle_NN
will_PRMD
grant_VB [SUAV]
an_DT
exclusive_JJ
royalty_NN
bearing_GER
licence_NN
to_PIN
Shire_NN
for_PIN
certain_JJ
dioxolane_NN
nucleosides_NN
,_,
including_VBG
SPD756_NN
._.
The_DT
compounds_NN
the_DT
subject_NN
of_PIN
these_DEMO
licenses_NN
are_VPRT [BEMA]
in_PIN
development_NOMZ
._.
A_DT
royalty_NN
will_PRMD
be_VB [BEMA]
payable_PRED
by_PIN
Shire_NN
upon_PIN
commercialisation_NOMZ
of_PIN
SPD756_NN
._.
The_DT
Settlement_NOMZ
and_PHC
License_NN
Agreements_NOMZ
provide_VB
for_PIN
the_DT
resolution_NOMZ
of_PIN
all_QUAN
worldwide_JJ
patent_NN
disputes_NN
relating_VBG [WZPRES]
to_PIN
the_DT
licensed_JJ
patents_NN
._.
iv_VB
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
is_VPRT [PASS]
involved_VBN
in_PIN
other_JJ
claims_NN
and_PHC
lawsuits_NN
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
._.
27_CD
Pension_NN
arrangements_NOMZ
The_DT
Group_NN
has_VPRT
a_DT
number_NN
of_PIN
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
that_TSUB
together_RB
cover_VPRT
substantially_RB
all_QUAN
employees_NN
._.
The_DT
Company_NN
contribution_NOMZ
is_VPRT [PASS]
fixed_VBN
as_IN
a_DT
set_VBN
percentage_NN
of_PIN
employees_NN
pay_VPRT
._.
The_DT
pension_NN
cost_NN
charge_NN
for_PIN
the_DT
defined_VBN
contribution_NOMZ
schemes_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
4,702,000_CD
2001_CD
:_:
3,123,000_CD
._.
The_DT
closing_GER
creditor_NN
in_PIN
respect_NN
of_PIN
pension_NN
premiums_NN
at_PIN
31_CD
December_NN
2002_CD
is_VPRT [BEMA]
306,000_CD
31_CD
December_NN
2001_CD
:_:
521,000_CD
._.
The_DT
defined_VBN
benefit_NN
plan_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
was_VBD [BEMA]
a_DT
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
for_PIN
certain_JJ
US_FPP1
employees_NN
of_PIN
the_DT
acquired_VBN
company_NN
,_,
Roberts_NN
,_,
who_WP
met_VBD
certain_JJ
age_NN
and_PHC
service_NN
requirements_NOMZ
._.
The_DT
plan_NN
was_VBD [PASS]
discontinued_VBN
in_PIN
2000_CD
and_CC
there_EX
were_VBD
no_SYNE
contributions_NOMZ
payable_JJ
in_PIN
respect_NN
of_PIN
the_DT
years_NN
2002_CD
and_CC
2001_CD
._.
The_DT
Group_NN
paid_VBD
a_DT
lump_NN
sum_NN
of_PIN
11.3_CD
million_CD
$_$
18_CD
million_CD
into_PIN
the_DT
SERP_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
fair_JJ
value_NN
adjustment_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
to_TO
make_VB
good_JJ
the_DT
deficit_NN
on_PIN
this_DEMO
scheme_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
lump_NN
sum_NN
payment_NOMZ
has_VPRT [PEAS]
led_VBN
to_PIN
the_DT
Group_NN
having_VBG [WZPRES]
no_SYNE
future_JJ
liability_NOMZ
under_IN
the_DT
SERP_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
with_PIN
contributions_NOMZ
no_RB
longer_RB
payable_JJ
by_PIN
existing_VBG
members_NN
._.
The_DT
asset_NN
and_PHC
liability_NOMZ
of_PIN
7.5_CD
million_CD
and_CC
5.2_CD
million_CD
respectively_RB
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
notes_NN
18_CD
and_CC
21_CD
respectively_RB
._.
52_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
28_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
a_DT
Reconciliation_NOMZ
of_PIN
operating_GER
profit_NN
to_PIN
net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
2002 2001 000 000_CD
Group_NN
operating_GER
loss_NN
profit_NN
533,145_CD
76,422_CD
Exchange_NN
gains_NN
962_CD
4,315_CD
Depreciation_NOMZ
9,073_CD
7,092_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
fixed_JJ
assets_NN
153,979_CD
111,254_CD
Profit_NN
on_PIN
sale_NN
of_PIN
discontinued_VBN
operations_NOMZ
2,006_CD
Loss_NN
on_PIN
sale_NN
of_PIN
fixed_JJ
assets_NN
854_CD
7,646_CD
Write-off_PIN
of_PIN
fixed_JJ
asset_NN
investments_NOMZ
5,809_CD
500_CD
Write-off_PIN
of_PIN
intangible_JJ
fixed_JJ
assets_NN
631,447_CD
3,092_CD
Increase_VPRT
decrease_NN
in_PIN
stocks_NN
1,485_CD
2,836_CD
Decrease_NN
increase_NN
in_PIN
debtors_NN
51,832_CD
44,695_CD
Decrease_NN
increase_NN
in_PIN
creditors_NN
14,999_CD
43,044_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
302,321_CD
202,876_CD
The_DT
company_NN
acquired_VBN [WZPAST]
during_PIN
2002_CD
contributed_VBD
3.6_CD
million_CD
US$_$
5.8_CD
million_CD
outflow_NN
to_PIN
the_DT
Groups_NN
net_JJ
operating_GER
cash_NN
flows_NN
and_CC
utilised_JJ
3.5_CD
million_CD
US$_$
5.7_CD
million_CD
for_PIN
capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
._.
Companies_NN
acquired_VBN [WZPAST]
during_PIN
2001_CD
contributed_VBD
6.3_CD
million_CD
CAN$_NN
14.1_CD
million_CD
outflow_NN
to_PIN
the_DT
Groups_NN
net_JJ
operating_GER
cash_NN
flows_VPRT
,_,
contributed_VBD
4.6_CD
million_CD
CAN$_NN
10.3_CD
million_CD
inflow_NN
in_PIN
respect_NN
of_PIN
net_JJ
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
,_,
paid_VBD
11.4_CD
million_CD
CAN$_NN
25.5_CD
million_CD
in_PIN
respect_NN
of_PIN
taxation_NOMZ
and_CC
utilised_JJ
12.1_CD
million_CD
CAN$_NN
27.0_CD
million_CD
for_PIN
capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
._.
b_NN
Analysis_NN
and_PHC
reconciliation_NOMZ
of_PIN
net_JJ
debt_NN
Acquired_VBN [WZPAST]
in_PIN
year_NN
Other_JJ
Start_NN
excluding_VBG [WZPRES]
non-cash_JJ
Exchange_NN
End_NN
of_PIN
of_PIN
year_NN
cash_NN
Cash_NN
flow_NN
changes_NN
movement_NOMZ
year_NN
Year_NN
ended_VBD
31_CD
December_NN
2002 000 000 000_CD
000 000 000_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
81,434_CD
493,102_CD
16,104_CD
558,432_CD
Debt_NN
due_JJ
within_PIN
one_CD
year_NN
3,008_CD
2,005_CD
565_CD
49_CD
389_CD
Finance_NN
leases_NN
243_CD
74_CD
7_CD
162_CD
78,426_CD
243_CD
495,181_CD
565_CD
16,048_CD
557,881_CD
Debt_NN
due_JJ
after_IN
one_CD
year_NN
269,883_CD
1,173_CD
389_CD
26,342_CD
244,325_CD
Finance_NN
leases_NN
3,926_CD
169_CD
3,757_CD
191,457_CD
4,169_CD
494,008_CD
954_CD
10,463_CD
309,799_CD
Current_JJ
assets_NN
investments_NOMZ
497,397_CD
254,561_CD
87_CD
46,385_CD
196,364_CD
Net_JJ
funds_NN
305,940_CD
4,169_CD
239,447_CD
867_CD
35,922_CD
506,163_CD
Acquired_VBN
in_PIN
year_NN
Other_JJ
Start_NN
excluding_VBG [WZPRES]
non-cash_JJ
Exchange_NN
End_NN
of_PIN
of_PIN
year_NN
cash_NN
Cash_NN
flow_NN
changes_NN
movement_NOMZ
year_NN
Year_NN
ended_VBD
31_CD
December_NN
2001 000 000 000_CD
000 000 000_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
31,194_CD
51,029_CD
789_CD
81,434_CD
Debt_NN
due_JJ
within_PIN
one_CD
year_NN
1,004_CD
2,089_CD
32_CD
1,004_CD
1,057_CD
3,008_CD
30,190_CD
2,089_CD
51,061_CD
1,004_CD
268_CD
78,426_CD
Debt_NN
due_JJ
after_IN
one_CD
year_NN
84,683_CD
2,075_CD
182,840_CD
1,004_CD
1,289_CD
269,883_CD
54,493_CD
4,164_CD
131,779_CD
1,021_CD
191,457_CD
Current_JJ
assets_NN
investments_NOMZ
93,550_CD
81,995_CD
325,479_CD
3,627_CD
497,397_CD
Net_JJ
funds_NN
39,057_CD
77,831_CD
193,700_CD
4,648_CD
305,940_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
53_CD
Notes_NN
to_PIN
the_DT
accounts_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
28_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
continued_VBD
b_NN
Analysis_NN
and_PHC
reconciliation_NOMZ
of_PIN
net_JJ
debt_NN
2002 2001 000 000_CD
Increase_VPRT
in_PIN
cash_NN
in_PIN
the_DT
year_NN
493,102_CD
51,029_CD
Cash_NN
outflow_NN
inflow_NN
from_PIN
decrease_NN
increase_NN
in_PIN
debt_NN
and_PHC
lease_NN
financing_GER
906_CD
182,808_CD
Cash_NN
inflow_NN
outflow_NN
from_PIN
decrease_NN
increase_NN
in_PIN
liquid_JJ
resources_NN
254,561_CD
325,479_CD
Change_NN
in_PIN
net_JJ
debt_NN
resulting_VBG [WZPRES]
from_PIN
cash_NN
flows_NN
239,447_CD
193,700_CD
Leases_NN
and_CC
current_JJ
asset_NN
investments_NOMZ
acquired_VBN [WZPAST]
with_PIN
subsidiary_NN
undertakings_GER
4,169_CD
77,831_CD
Arenol_NN
loan_NN
note_NN
conversion_NN
954_CD
Qualia_NN
Computing_GER
Inc._NN
joint_JJ
venture_NN
87_CD
Translation_NOMZ
difference_NN
35,922_CD
4,648_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
in_PIN
year_NN
200,223_CD
266,883_CD
Net_JJ
funds_NN
at_PIN
beginning_GER
of_PIN
year_NN
305,940_CD
39,057_CD
Net_JJ
funds_NN
at_PIN
end_NN
of_PIN
year_NN
506,163_CD
305,940_CD
c_NN
Major_JJ
non-cash_JJ
transactions_NOMZ
i_FPP1
Arenol_FW
loan_NN
note_NN
conversion_NN
In_PIN
1999_CD
the_DT
Group_NN
financed_VBD
the_DT
purchase_NN
of_PIN
intellectual_JJ
property_NN
relating_VBG [WZPRES]
to_PIN
the_DT
manufacture_NN
of_PIN
ADDERALL_NN
from_PIN
Arenol_NN
Corporation_NOMZ
by_PIN
a_DT
total_NN
of_PIN
7.9_CD
million_CD
$_$
11.8_CD
million_CD
in_PIN
unsecured_JJ
convertible_JJ
zero_CD
coupon_NN
loan_NN
notes_NN
._.
On_PIN
6_CD
August_NN
2002_CD
,_,
the_DT
Company_NN
issued_VBD
the_DT
final_JJ
instalment_NOMZ
of_PIN
267,572_CD
ordinary_JJ
shares_NN
to_PIN
Arenol_NN
Corporation_NOMZ
or_CC
its_PIT
nominee_NN
broker_NN
in_PIN
consideration_NOMZ
of_PIN
the_DT
conversion_NN
of_PIN
the_DT
loan_NN
notes_NN
in_PIN
the_DT
Company_NN
._.
ii_FW
Qualia_FW
Computing_GER
Inc._NN
joint_JJ
venture_NN
In_PIN
September_NN
2002_CD
,_,
the_DT
Group_NN
sold_VBD
the_DT
net_JJ
assets_NN
of_PIN
its_PIT
CADx_NN
group_NN
of_PIN
companies_NN
,_,
to_PIN
Qualia_NN
Computing_GER
Inc_NN
,_,
in_PIN
exchange_NN
for_PIN
50_CD
%_NN
of_PIN
the_DT
common_JJ
stock_NN
in_PIN
the_DT
joint_JJ
venture_NN
._.
The_DT
value_NN
of_PIN
the_DT
assets_NN
in_PIN
the_DT
CADx_NN
group_NN
of_PIN
companies_NN
at_PIN
the_DT
time_NN
of_PIN
transfer_NN
was_VBD [BEMA]
5.9_CD
million_CD
$_$
9.3_CD
million_CD
._.
29_CD
Related_VBN
party_NN
transactions_NOMZ
Transactions_NOMZ
with_PIN
directors_NN
of_PIN
the_DT
company_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
the_DT
remuneration_NOMZ
report_NN
on_PIN
page_NN
13_CD
and_CC
in_PIN
the_DT
directors_NN
report_VPRT [PUBV]
on_PIN
page_NN
7_CD
._.
During_PIN
the_DT
year_NN
the_DT
Group_NN
incurred_VBN
costs_NN
on_PIN
behalf_NN
of_PIN
Qualia_NN
,_,
a_DT
joint_JJ
venture_NN
,_,
of_PIN
2.3_CD
million_CD
._.
Amounts_NN
owed_VBN [WZPAST]
by_PIN
Qualia_NN
to_PIN
the_DT
Group_NN
at_PIN
31_CD
December_NN
2002_CD
were_VBD [BEMA]
12,975_CD
._.
In_PIN
accordance_NN
with_PIN
FRS_NN
8_CD
,_,
Related_NN
Party_NN
Disclosures_NN
,_,
transactions_NOMZ
with_PIN
other_JJ
companies_NN
in_PIN [STPR]
,_,
and_ANDC
investee_NN
related_VBN
parties_NN
of_PIN [STPR]
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
disclosed_VBN [PUBV]
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
._.
30_CD
Post_NN
balance_NN
events_NN
i_FPP1
Resignationation_NOMZ
of_PIN
Chief_NN
Executive_NN
On_PIN
19_CD
March_NN
2003_CD
,_,
Mr_NN
Rolf_NN
Stahel_NN
stepped_VBD
down_RP
as_IN
Chief_NN
Executive_NN
and_CC
as_IN
a_DT
director_NN
of_PIN
the_DT
Company_NN
._.
Details_NN
of_PIN
payments_NOMZ
made_VBN [WZPAST]
to_PIN
Mr_NN
Stahel_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
remuneration_NOMZ
report_NN
on_PIN
page_NN
14_CD
._.
ii_FW
New_NN
product_NN
acquisition_NOMZ
In_PIN
February_NN
2003_CD
,_,
Shire_NN
agreed_VBD [SUAV] [PUBV]
to_TO
acquire_VB
,_,
from_PIN
Noven_NN
Pharmaceuticals_NN
Inc._NN
._.
Noven_NN
,_,
for_PIN
15.8_CD
million_CD
,_,
the_DT
worldwide_JJ
sales_NN
and_PHC
marketing_GER
rights_NN
to_PIN
METHYPATCH_NN
,_,
a_DT
methylphenidate_NN
transdermal_JJ
delivery_NN
system_NN
for_PIN
the_DT
once-daily_JJ
treatment_NOMZ
of_PIN
ADHD_NN
._.
On_PIN
28_CD
April_NN
2003_CD
,_,
Shire_NN
announced_VBD [PUBV]
that_THVC
Noven_NN
had_VBD [PEAS]
received_VBN
a_DT
not_XX0
approvable_JJ
letter_NN
from_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
in_PIN
response_NN
to_PIN
its_PIT
New_NN
Drug_NN
Application_NOMZ
for_PIN
METHYPATCH_NN
._.
54_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Designed_VBN
and_PHC
produced_VBN
by_PIN
C&FD_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Chineham_NN
Basingstoke_NN
Hampshire_NN
RG24_NN
8EP_NN
Tel_NN
44_CD
0_CD
1256 894 000_CD
Fax_NN
44_CD
0_CD
1256 894 708_CD
www_NN
._.
com_NN
Registered_NN
number_NN
:_:
2883758_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2002_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2002_CD
Contents_NN
20_CD
Advanced_NN
drug_NN
delivery_NN
51_CD
Consolidated_NN
balance_NN
sheets_NN
87_CD
Summary_NN
financial_JJ
statement_NOMZ
22_CD
Biologics_NN
52_CD
Consolidated_NN
statements_NOMZ
88_CD
Auditors_NN
statement_NOMZ
2_CD
2002_CD
at_PIN
a_DT
glance_NN
24_CD
Corporate_NN
social_JJ
responsibility_NOMZ
of_PIN
operations_NOMZ
88_CD
Summary_NN
directors_NN
report_VPRT [PUBV]
3_CD
Chairmans_NN
statement_NOMZ
report_NN
53_CD
Consolidated_NN
statements_NOMZ
89_CD
Consolidated_NN
profit_NN
and_CC
4_CD
Chief_NN
Executives_NN
review_VPRT
30_CD
Financial_JJ
review_NN
of_PIN
changes_NN
in_PIN
shareholders_NN
loss_NN
account_NN
6_CD
Development_NOMZ
pipeline_NN
34_CD
Board_NN
of_PIN
Directors_NN
equity_NOMZ
90_CD
Consolidated_NN
balance_NN
sheet_NN
7Product_NN
portfolio_NN
36_CD
Executive_NN
Committee_NN
54_CD
Consolidated_NN
statements_NOMZ
91_CD
Consolidated_NN
cash_NN
flow_NN
8_CD
Operating_GER
review_NN
38_CD
Directors_NN
remuneration_JJ
report_NN
of_PIN
comprehensive_JJ
income_NN
statement_NOMZ
8_CD
Central_NN
nervous_JJ
system_NN
48_CD
Corporate_JJ
governance_NN
losses_NN
92_CD
Notes_NN
to_PIN
the_DT
summary_NN
12_CD
Anti-infectives_NN
statement_NOMZ
54_CD
Consolidated_NN
statements_NOMZ
financial_JJ
statement_NOMZ
14_CD
Oncology_NN
and_CC
hematology_JJ
50_CD
Statement_NOMZ
of_PIN
directors_NN
of_PIN
cash_NN
flows_VPRT
94_CD
Shire_NN
head_NN
office_NN
and_CC
main_JJ
disorders_NN
responsibilities_NOMZ
56_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
operating_GER
locations_NOMZ
16_CD
Additional_JJ
Shire_NN
portfolio_NN
50_CD
Report_NN
of_PIN
independent_JJ
financial_JJ
statements_NOMZ
95_CD
Shareholder_NN
information_NOMZ
18_CD
Gastrointestinal_NN
auditors_NN
86_CD
Five-year_JJ
review_NN
96_CD
Glossary_NN
Winning_VBG [WZPRES]
in_PIN
a_DT
competitive_JJ
world_NN
Advances_NN
in_PIN
medical_JJ
science_NN
and_PHC
technologies_NN
allow_VPRT [SUAV]
a_DT
greater_JJ
understanding_GER
of_PIN
disease_NN
and_PHC
treatment_NOMZ
possibilities_NOMZ
,_,
with_PIN
the_DT
pharmaceutical_JJ
industry_NN
constantly_RB
evolving_VBG
to_TO
take_VB
advantage_NN
of_PIN
these_DEMO
changes_NN
._.
Equally_RB
challenging_JJ
is_VPRT [BEMA]
the_DT
increased_JJ
level_NN
of_PIN
competition_NOMZ
,_,
including_VBG
that_DEMP
which_WDT
comes_VPRT
from_PIN
new_JJ
products_NN
that_TSUB
are_VPRT [PASS]
not_XX0
based_VBN
on_PIN
innovative_JJ
research_NN
and_PHC
development_NOMZ
._.
A_DT
constant_JJ
element_NOMZ
in_PIN
this_DEMP
changing_VBG
and_PHC
challenging_VBG
environment_NOMZ
is_VPRT
Shires_NN
determination_NOMZ
to_TO
succeed_VB
._.
This_DEMP
has_VPRT [PEAS]
been_VBN [BEMA]
evident_PRED
from_PIN
the_DT
very_AMP
early_TIME
days_NN
of_PIN
Shire_NN
,_,
when_RB
it_PIT
set_VBD
its_PIT
sights_NN
on_PIN
becoming_VBG
one_CD
of_PIN
the_DT
leading_VBG
pharmaceutical_JJ
companies_NN
in_PIN
the_DT
specialist_NN
marketplace_NN
._.
By_PIN
focusing_VBG
on_PIN
and_CC
leveraging_VBG
areas_NN
of_PIN
key_JJ
strength_NN
,_,
Shire_NN
is_VPRT [SPAU] [PASS]
well_RB
positioned_VBN
to_TO
build_VB
on_PIN
its_PIT
success_NN
in_PIN
the_DT
face_NN
of_PIN
ever-present_JJ
challenges_NN
,_,
bringing_VBG
important_JJ
new_JJ
medicines_NN
to_PIN
patients_NN
in_PIN
key_JJ
markets_NN
worldwide_JJ
and_CC
continuing_VBG
to_TO
grow_VB
its_PIT
business_NOMZ
._.
Shire_NN
has_VPRT [PEAS]
built_VBN
franchises_NN
in_PIN
the_DT
therapeutic_JJ
areas_NN
of_PIN
central_JJ
nervous_JJ
system_NN
disorders_NN
,_,
gastrointestinal_JJ
,_,
oncology_JJ
and_CC
anti-infectives_NN
._.
These_DEMP
are_VPRT
areas_NN
where_RB
significant_JJ
medical_JJ
needs_NN
remain_VPRT
unmet_JJ
,_,
and_ANDC
where_RB
Shire_NN
has_VPRT [PEAS]
developed_VBN
important_JJ
expertise_NN
both_DT
in_PIN
the_DT
market_NN
and_CC
in_PIN
research_NN
and_PHC
development_NOMZ
._.
The_DT
strength_NN
and_PHC
effectiveness_NOMZ
of_PIN
Shires_NN
sales_NN
and_PHC
marketing_GER
organization_NOMZ
is_VPRT [SPAU] [PASS]
well_RB
recognized_VBN [PRIV]
and_PHC
has_VPRT [PEAS]
been_VBN [BEMA]
an_DT
important_JJ
component_NN
of_PIN
the_DT
Companys_NN
growth_NN
._.
Relationships_NN
with_PIN
Shires_NN
target_NN
group_NN
of_PIN
specialist_NN
physicians_NN
will_PRMD
continue_VB
to_TO
be_VB [PASS]
strengthened_VBN
as_IN
the_DT
Company_NN
launches_VPRT
additional_JJ
new_JJ
products_NN
over_IN
the_DT
coming_JJ
months_NN
and_PHC
years_NN
._.
Targeting_VBG [PRESP]
an_DT
R&D_NN
investment_NOMZ
of_PIN
18-20_CD
%_NN
of_PIN
revenues_NN
,_,
Shire_NN
now_TIME
has_VPRT
one_CD
of_PIN
the_DT
largest_JJ
R&D_NN
portfolios_NN
among_PIN
pharmaceutical_JJ
companies_NN
of_PIN
a_DT
similar_JJ
size_NN
._.
Efforts_NN
to_TO
broaden_VB
this_DEMO
portfolio_NN
further_RB
are_VPRT
constantly_RB
underway_RB
through_PIN
two_CD
avenues_NN
:_:
internally_RB
via_PIN
lead_NN
optimisation_NOMZ
,_,
biologics_NN
research_NN
and_PHC
drug_NN
delivery_NN
:_:
externally_RB
via_PIN
in-licensing_JJ
and_PHC
targeted_JJ
mergers_NN
&_CC
acquisitions_NOMZ
._.
Each_QUAN
of_PIN
these_DEMO
elements_NOMZ
allows_VPRT [SUAV]
Shire_NN
to_TO
overcome_VB
challenges_NN
in_PIN
the_DT
changing_VBG
pharmaceutical_JJ
industry_NN
while_OSUB
capitalising_VBG
on_PIN
the_DT
many_QUAN
opportunities_NOMZ
._.
With_PIN
a_DT
sales_NN
and_PHC
marketing_GER
focus_NN
,_,
supported_VBN [PASTP]
by_PIN
broad_JJ
R&D_NN
capabilities_NOMZ
and_CC
a_DT
promising_JJ
project_NN
portfolio_NN
,_,
Shire_NN
is_VPRT [SPAU] [PASS]
very_AMP
well_RB
positioned_VBN
for_PIN
its_PIT
emergence_NN
as_IN
a_DT
strong_JJ
global_JJ
pharmaceutical_JJ
company_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
1_CD
2002_CD
at_PIN
a_DT
glance_NN
Financial_NN
highlights_VPRT
Revenues_NN
$_$
m_CD
R&D_NN
spend_VB
$_$
m_CD
Operating_GER
income_NN
$_$
m_CD
Diluted_NN
EPS_NN
:_:
Diluted_NN
EPS_NN
:_:
ADS_NN
ordinary_JJ
shares_NN
2002_CD
1,037.3_CD
2002_CD
189.2_CD
2002_CD
327.0_CD
2002_CD
49.0_CD
2002_CD
147.1_CD
2001_CD
853.0_CD
2001_CD
171.0_CD
2001_CD
143.1_CD
2001_CD
7.7_CD
2001_CD
23.0_CD
22_CD
%_NN
11_CD
%_NN
01_CD
02_CD
01_CD
02_CD
01_CD
02_CD
01_CD
02_CD
01_CD
02_CD
Revenues_NN
by_PIN
product_NN
royalties_NN
Revenues_NN
by_PIN
therapeutic_JJ
area_NN
Revenues_NN
by_PIN
geographic_JJ
area_NN
1_CD
ADDERALL_NN
41_CD
%_NN
1_CD
Central_NN
nervous_JJ
system_NN
48_CD
%_NN
1_CD
US_FPP1
69_CD
%_NN
2_CD
AGRYLIN_NN
11_CD
%_NN
2_CD
Gastrointestinal_NN
8_CD
%_NN
2_CD
International_NN
31_CD
%_NN
3_CD
PENTASA_NN
8_CD
%_NN
3_CD
Oncology_NN
12_CD
%_NN
4_CD
CARBATROL_NN
4_CD
%_NN
4_CD
Anti-infectives_NN
15_CD
%_NN
5_CD
PROAMATINE_NN
5_CD
%_NN
5_CD
Others_NN
14_CD
%_NN
6_CD
CALCICHEW_NN
2_CD
%_NN
5_CD
8_CD
2_CD
7_CD
Others_NN
12_CD
%_NN
1_CD
4_CD
7_CD
1_CD
8_CD
Royalties_NN
17_CD
%_NN
6_CD
5_CD
3_CD
1_CD
4_CD
3_CD
2_CD
2_CD
In_PIN
2002_CD
Shires_NN
revenues_NN
exceeded_VBD
$_$
1_CD
billion_CD
for_PIN
the_DT
first_JJ
time_NN
in_PIN
its_PIT
history_NN
Revenue_NN
growth_NN
over_IN
the_DT
past_JJ
five_CD
years_NN
$_$
1,037.3_CD
million_CD
$_$
853.0_CD
million_CD
$_$
647.7_CD
million_CD
$_$
515.4_CD
million_CD
$_$
411.0_CD
million_CD
98_CD
99_CD
00_CD
01_CD
02_CD
2_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chairmans_NN
statement_NOMZ
2002_CD
was_VBD [BEMA]
a_DT
challenging_JJ
year_NN
for_PIN
Shire_NN
and_CC
our_FPP1
industry_NN
._.
Pressure_NN
on_PIN
the_DT
global_JJ
pharmaceutical_JJ
industry_NN
was_VBD [BYPA]
increased_VBN
by_PIN
several_QUAN
aggressive_JJ
launches_NN
of_PIN
generic_JJ
drugs_NN
._.
In_CONJ
addition_NULL
,_,
an_DT
ever-increasing_JJ
population_NOMZ
of_PIN
ageing_NN
patients_NN
and_CC
inadequate_JJ
third-party_JJ
reimbursement_NOMZ
schedules_NN
continued_VBD
to_TO
exert_VB
price_NN
pressure_NN
on_PIN
healthcare_NN
providers_NN
._.
Maximising_VBG
returns_NN
in_PIN
the_DT
face_NN
of_PIN
these_DEMO
pressures_NN
will_PRMD
require_VB [SUAV]
pharmaceutical_JJ
companies_NN
to_TO
deploy_VB
resources_NN
effectively_RB
to_TO
drive_VB
the_DT
discovery_NN
,_,
development_NOMZ
and_PHC
marketing_GER
of_PIN
novel_NN
drugs_NN
._.
Shire_NN
is_VPRT [SPAU] [PASS]
particularly_RB
well_RB
placed_VBN
to_TO
deal_VB
with_PIN
such_JJ
challenges_NN
._.
The_DT
Executive_NN
,_,
Rolf_NN
drove_VBD
Shires_NN
formidable_JJ
success_NN
and_PHC
growth_NN
._.
He_TPP3
Company_NN
has_VPRT [SPAU] [PEAS]
always_RB
maintained_VBN [PUBV]
a_DT
substantial_JJ
research_NN
and_PHC
development_NOMZ
presided_VBD
over_IN
the_DT
listing_GER
of_PIN
the_DT
Companys_NN
shares_NN
in_PIN
1996_CD
,_,
over_IN
six_CD
R&D_NN
program_NN
to_TO
create_VB
a_DT
sizeable_JJ
portfolio_NN
of_PIN
new_JJ
therapies_NN
._.
significant_JJ
mergers_NN
and_PHC
acquisitions_NOMZ
,_,
the_DT
broadening_VBG
of_PIN
the_DT
Companys_NN
Building_GER
from_PIN
its_PIT
position_NOMZ
as_IN
an_DT
international_JJ
pharmaceutical_JJ
company_NN
sales_NN
and_PHC
marketing_GER
infrastructure_NN
,_,
and_ANDC
the_DT
development_NOMZ
of_PIN
a_DT
number_NN
targeting_VBG [WZPRES]
specialist_NN
doctors_NN
,_,
Shire_NN
is_VPRT
emerging_VBG
as_IN
a_DT
global_JJ
pharmaceutical_NN
of_PIN
successful_JJ
products_NN
through_PIN
the_DT
Companys_NN
extensive_JJ
R&D_NN
pipeline_NN
._.
Today_TIME
the_DT
Company_NN
not_XX0
only_DWNT
in-licenses_JJ
projects_NN
for_PIN
internal_JJ
Today_TIME
Shire_NN
is_VPRT [BEMA]
the_DT
third_JJ
largest_JJ
pharmaceutical_JJ
company_NN
in_PIN
the_DT
UK_NN
and_PHC
development_NOMZ
,_,
but_CC
also_RB
has_VPRT
the_DT
technological_JJ
capabilities_NOMZ
to_TO
discover_VB [PRIV]
and_PHC
is_VPRT [BEMA]
the_DT
US_FPP1
market_NN
leader_NN
in_PIN
the_DT
ADHD_NN
field_NN
._.
I_FPP1
would_PRMD
like_VB
to_TO
take_VB
this_DEMP
develop_VB
its_PIT
own_JJ
molecules_NN
._.
Our_FPP1
R&D_NN
approach_NN
is_VPRT [PASS]
risk_NN
balanced_VBN [WZPAST]
with_PIN
opportunity_NOMZ
to_TO
thank_VB
Rolf_NN
for_PIN
his_TPP3
outstanding_JJ
contribution_NOMZ
to_PIN
the_DT
success_NN
a_DT
careful_JJ
and_PHC
objective_JJ
discipline_NN
that_TSUB
focuses_VPRT
the_DT
portfolio_NN
on_PIN
low_JJ
to_PIN
of_PIN
the_DT
Company_NN
._.
In_PIN
March_NN
2003_CD
,_,
Shire_NN
took_VBD
a_DT
major_JJ
step_NN
towards_PIN
the_DT
next_JJ
stage_NN
of_PIN
its_PIT
In_PIN
2002_CD
,_,
following_VBG [PRESP]
six_CD
major_JJ
mergers_NN
and_PHC
acquisitions_NOMZ
during_PIN
the_DT
growth_NN
by_PIN
choosing_VBG
Matthew_NN
Emmens_NN
as_IN
Chief_NN
Executive_NN
._.
Matthew_NN
has_VPRT
past_JJ
eight_CD
years_NN
,_,
Shire_NN
acquired_VBD
the_DT
US_FPP1
specialty_NN
pharmaceutical_NN
a_DT
strong_JJ
track_NN
record_NN
of_PIN
success_NN
over_IN
a_DT
pharmaceutical_JJ
career_NN
spanning_VBG [WZPRES]
manufacturing_GER
facility_NOMZ
of_PIN
Atlantic_NN
Pharmaceutical_NN
Services_NN
Inc._NN
._.
APS_NN
,_,
nearly_DWNT
30_CD
years_NN
._.
He_TPP3
was_VBD [BEMA]
a_DT
founder_NN
of_PIN
the_DT
Astra_NN
Merck_NN
Inc._NN
joint_JJ
venture_NN
,_,
and_ANDC
more_EMPH
recently_TIME
,_,
the_DT
rights_NN
to_PIN
METHYPATCH_NN
methylphenidate_NN
and_CC
later_TIME
its_PIT
President_NN
and_PHC
Chief_NN
Executive_NN
._.
Most_EMPH
recently_TIME
,_,
Matthew_NN
a_DT
transdermal_JJ
delivery_NN
system_NN
,_,
an_DT
important_JJ
new_JJ
ADHD_NN
attention_NOMZ
was_VBD
President_NN
of_PIN
the_DT
global_JJ
pharmaceutical_JJ
business_NOMZ
of_PIN
Merck_NN
KGaA_NN
deficit_NN
and_PHC
hyperactivity_NOMZ
disorder_NN
product_NN
under_IN
registration_NOMZ
._.
He_TPP3
had_VBD [PEAS]
established_VBN [PRIV]
its_PIT
US_FPP1
prescription_NOMZ
pharmaceutical_JJ
business_NOMZ
,_,
EMD_NN
Pharmaceuticals_NN
,_,
before_IN
moving_VBG [SUAV]
to_PIN
Germany_NN
._.
Matthews_NN
2002_CD
results_NN
extensive_JJ
experience_NN
and_PHC
leadership_NN
should_NEMD
prove_VB [PRIV]
crucial_JJ
drivers_NN
as_IN
the_DT
Shire_NN
achieved_VBD
strong_JJ
financial_JJ
results_NN
in_PIN
2002_CD
which_WDT
saw_VBD [PRIV]
revenues_NN
business_NOMZ
moves_VPRT [SUAV]
ahead_PLACE
._.
exceed_VB
$_$
1_CD
billion_CD
for_PIN
the_DT
first_JJ
time_NN
in_PIN
its_PIT
history_NN
._.
Group_NN
revenues_NN
increased_VBN [WZPAST]
by_PIN
22_CD
%_NN
and_PHC
income_NN
from_PIN
continuing_VBG
operations_NOMZ
,_,
before_IN
People_NN
income_NN
taxes_NN
and_PHC
equity_NOMZ
method_NN
investees_NN
,_,
increased_VBD
to_TO
$_$
329.1_CD
million_CD
._.
Shire_NN
had_VBD
1,847_CD
employees_NN
worldwide_JJ
as_IN
of_PIN
31_CD
December_NN
2002_CD
._.
The_DT
Diluted_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
was_VBD [BEMA]
49.0_CD
._.
Group_NN
believes_VPRT [PRIV]
in_PIN
the_DT
importance_NN
of_PIN
hiring_VBG
well-qualified_JJ
,_,
experienced_JJ
staff_NN
with_PIN
proven_JJ
records_NN
of_PIN
success_NN
._.
The_DT
Groups_NN
future_JJ
success_NN
depends_VPRT
The_DT
US_FPP1
product_NN
portfolio_NN
,_,
which_WDT [SERE]
includes_VPRT
ADDERALL_NN
XR_NN
mixed_JJ
upon_PIN
its_PIT
ability_NOMZ
to_TO
attract_VB
and_PHC
retain_VB
such_JJ
individuals_NN
._.
Shire_NN
will_PRMD
continue_VB
amphetamine_JJ
salts_NN
,_,
ADDERALL_NN
mixed_JJ
amphetamine_NN
salts_NN
,_,
AGRYLIN_NN
to_TO
apply_VB
and_PHC
develop_VB
a_DT
strong_JJ
focus_NN
on_PIN
staff_NN
development_NOMZ
at_PIN
all_QUAN
levels_NN
._.
anagrelide_NN
hydrochloride_NN
,_,
CARBATROL_NN
carbamazepine_NN
,_,
PENTASA_NN
mesalamine_NN
and_PHC
PROAMATINE_NN
midodrine_NN
hydrochloride_NN
has_VPRT
,_,
once_TIME
Future_JJ
prospects_NN
again_TIME
,_,
delivered_VBN
strong_JJ
revenue_NN
growth_NN
._.
Notwithstanding_CONJ
aggressive_JJ
ADDERALL_NN
XR_NN
is_VPRT [SPAU] [PASS]
now_TIME
well_RB
established_VBN [PRIV]
as_IN
a_DT
leading_VBG
once-daily_RB
ADHD_NN
generic_JJ
competition_NOMZ
,_,
our_FPP1
US_FPP1
sales_NN
and_PHC
marketing_GER
team_NN
delivered_VBN
22_CD
%_NN
treatment_NOMZ
and_CC
,_,
in_PIN
its_PIT
first_JJ
year_NN
of_PIN
launch_NN
,_,
has_VPRT [PEAS]
become_VBN
the_DT
preferred_JJ
revenue_NN
growth_NN
in_PIN
our_FPP1
US_FPP1
business_NOMZ
,_,
including_VBG [PRESP]
22_CD
%_NN
growth_NN
in_PIN
the_DT
choice_NN
of_PIN
top-prescribing_JJ
physicians_NN
for_PIN
their_TPP3
patients_NN
in_PIN
the_DT
US_FPP1
._.
ADDERALL_NN
franchise_NN
during_PIN
the_DT
year_NN
._.
In_PIN
conjunction_NOMZ
with_PIN
continued_JJ
growth_NN
of_PIN
our_FPP1
key_JJ
revenue_NN
streams_NN
,_,
including_VBG [PRESP]
the_DT
relaunch_VPRT
of_PIN
CARBATROL_NN
,_,
and_ANDC
three_CD
pending_VBG
product_NN
Augmenting_VBG [WZPRES]
its_PIT
strong_JJ
US_FPP1
business_NOMZ
,_,
Shire_NN
continued_VBD
to_TO
develop_VB
its_PIT
registrations_NOMZ
ADDERALL_NN
XR_NN
adults_NN
in_PIN
the_DT
US_FPP1
,_,
FOSRENOL_NN
international_JJ
strategy_NN
,_,
launching_VBG [PRESP]
two_CD
specialty_NN
pharmaceutical_JJ
products_NN
lanthanum_VPRT
carbonate_JJ
US_FPP1
EU_NN
,_,
XAGRID_NN
EU_NN
,_,
our_FPP1
sales_NN
and_PHC
marketing_GER
in_PIN
Europe_NN
,_,
SOLARAZE_NN
diclofenac_NN
sodium_NN
3_CD
%_NN
and_CC
ADEPT_JJ
4_CD
%_NN
organization_NOMZ
is_VPRT [PASS]
poised_VBN
to_TO
continue_VB
driving_VBG
the_DT
performance_NN
of_PIN
Shires_NN
icodextrin_NN
solution_NOMZ
._.
Total_JJ
revenues_NN
in_PIN
the_DT
international_JJ
pharmaceutical_JJ
revenues_NN
._.
segment_NOMZ
grew_VBD
by_PIN
29_CD
%_NN
in_PIN
2002_CD
,_,
with_PIN
a_DT
meaningful_JJ
contribution_NOMZ
from_PIN
XAGRID_NN
anagrelide_NN
hydrochloride_NN
._.
The_DT
Board_NN
is_VPRT [PASS]
committed_VBN
to_TO
continuing_VBG
to_TO
develop_VB
the_DT
Companys_NN
global_JJ
strategy_NN
and_PHC
growth_NN
._.
Shires_NN
strong_JJ
investment_NOMZ
in_PIN
R&D_NN
will_PRMD
continue_VB
to_PIN
The_DT
Board_NN
support_NN
the_DT
future_JJ
growth_NN
of_PIN
Shire_NN
,_,
with_PIN
a_DT
total_NN
of_PIN
four_CD
further_JJ
projects_NN
It_PIT
is_VPRT [BEMA]
with_PIN
much_QUAN
regret_NN
that_TOBJ
we_FPP1
report_VPRT [PUBV]
the_DT
passing_GER
of_PIN
Dr_NN
Bernard_NN
Canavan_NN
,_,
scheduled_VBN
to_TO
move_VB [SUAV]
into_PIN
phase_NN
III_NN
development_NOMZ
this_DEMO
year_NN
._.
We_FPP1
have_VPRT
all_QUAN
the_DT
former_JJ
President_NN
of_PIN
Wyeth_NN
Pharmaceuticals_NN
Inc._NN
a_DT
member_NN
of_PIN
Shires_NN
witnessed_VBD
the_DT
dramatic_JJ
growth_NN
of_PIN
Shire_NN
over_IN
the_DT
last_JJ
few_QUAN
years_NN
and_CC
I_FPP1
believe_VPRT [PRIV]
Board_NN
of_PIN
Directors_NN
and_PHC
Chairman_NN
of_PIN
our_FPP1
Audit_NN
Committee_NN
._.
Dr_NN
Canavan_NN
we_FPP1
can_POMD
look_VB
forward_RB
to_TO
even_RB
more_EMPH
opportunities_NOMZ
in_PIN
the_DT
years_NN
ahead_PLACE
._.
His_TPP3
guidance_NN
and_PHC
dedication_NOMZ
to_PIN
the_DT
Shire_NN
Board_NN
will_PRMD
be_VB [SPAU] [PASS]
greatly_AMP
missed_VBN
._.
In_PIN
October_NN
2002_CD
,_,
we_FPP1
announced_VBD [PUBV]
that_THVC
Rolf_NN
Stahel_NN
,_,
our_FPP1
Chief_NN
Executive_NN
,_,
Dr_NN
James_NN
Cavanaugh_NN
Chairman_NN
would_PRMD
be_VB
stepping_VBG
down_RB
in_PIN
2003_CD
._.
During_PIN
his_TPP3
nine_CD
years_NN
as_IN
Chief_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
3_CD
Chief_NN
Executives_NN
review_NN
During_PIN
2002_CD
,_,
for_PIN
the_DT
first_JJ
time_NN
in_PIN
Shires_NN
history_NN
,_,
the_DT
Company_NN
faced_VBD
generic_JJ
competition_NOMZ
to_PIN
one_CD
of_PIN
its_PIT
key_JJ
products_NN
,_,
ADDERALL_NN
,_,
an_DT
immediate-release_NN
ADHD_NN
drug_NN
._.
For_PIN
many_QUAN
successful_JJ
pharmaceutical_JJ
companies_NN
,_,
it_PIT
is_VPRT [PASS]
accepted_VBN [PRIV]
that_THVC
such_PDT
an_DT
event_NN
can_POMD
have_VB
a_DT
significant_JJ
negative_JJ
impact_NN
on_PIN
a_DT
companys_NN
financial_JJ
performance_NN
._.
I_FPP1
am_VPRT [BEMA]
pleased_PRED
to_TO
say_VB [PUBV]
that_THVC
Shires_NN
ADDERALL_NN
franchise_NN
remained_VBD
the_DT
US_FPP1
ADHD_NN
market_NN
leader_NN
and_CC
our_FPP1
US_FPP1
sales_NN
and_PHC
marketing_GER
team_NN
was_VBD [BEMA]
able_PRED
to_TO
grow_VB
our_FPP1
ADHD_NN
franchise_NN
by_PIN
22_CD
%_NN
despite_PIN
this_DEMO
challenge_NN
._.
The_DT
conversion_NN
of_PIN
patients_NN
from_PIN
immediate-release_JJ
ADDERALL_NN
to_TO
to_PIN
R&D_NN
risk_NN
management_NOMZ
by_PIN
weighting_GER
our_FPP1
portfolio_NN
of_PIN
projects_NN
towards_PIN
our_FPP1
new_JJ
product_NN
,_,
ADDERALL_NN
XR_NN
,_,
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
great_JJ
success_NN
,_,
with_PIN
those_DEMO
projects_NN
viewed_VBN [WZPAST]
as_RB
low_JJ
to_PIN
medium_JJ
risk_NN
._.
Part_NN
of_PIN
this_DEMO
strategy_NN
is_VPRT
ADDERALL_NN
XR_NN
being_VBG [WZPRES] [PASS]
welcomed_VBN
as_IN
a_DT
substantially_RB
improved_VBN
oral_JJ
,_,
the_DT
acquisition_NOMZ
of_PIN
projects_NN
at_PIN
a_DT
given_VBN
stage_NN
of_PIN
development_NOMZ
._.
Its_PIT
recognition_NOMZ
as_IN
a_DT
preferred_JJ
treatment_NOMZ
opportunities_NOMZ
typically_RB
reduce_VB
exposure_NN
to_PIN
the_DT
high_JJ
risks_NN
associated_VBN [WZPAST]
with_PIN
combined_VBN
with_PIN
a_DT
very_AMP
successful_JJ
sales_NN
and_PHC
marketing_GER
campaign_NN
gave_VBD
the_DT
early_TIME
stages_NN
of_PIN
R&D_NN
._.
Shire_NN
believes_VPRT [PRIV]
,_,
as_CONJ
a_NULL
consequence_NULL
,_,
that_THVC
the_DT
ADDERALL_NN
XR_NN
a_DT
23.8_CD
%_NN
share_NN
of_PIN
the_DT
US_FPP1
ADHD_NN
prescription_NOMZ
market_NN
average_JJ
risk_NN
profile_NN
of_PIN
projects_NN
in_PIN
our_FPP1
R&D_NN
portfolio_NN
is_VPRT [BEMA]
lower_PRED
than_PIN
the_DT
in_PIN
December_NN
2002_CD
._.
Shires_NN
combined_VBN
ADHD_NN
franchise_NN
prescription_NOMZ
industry_NN
average_NN
._.
Going_VBG [PRESP]
forward_RB
we_FPP1
will_PRMD
focus_VB
our_FPP1
R&D_NN
resources_NN
to_TO
share_VB
in_PIN
December_NN
2002_CD
was_VBD [BEMA]
28.8_CD
%_NN
,_,
which_WDT [SERE]
includes_VPRT
both_DT
ADDERALL_NN
ensure_VB [SUAV] [PRIV] [THATD]
we_FPP1
foster_VPRT
depth_NN
in_PIN
a_DT
few_QUAN
areas_NN
rather_RB
than_PIN
spreading_VBG
thinly_RB
in_PIN
the_DT
and_CC
ADDERALL_NN
XR_NN
._.
pursuit_NN
of_PIN
breadth_NN
in_PIN
many_QUAN
._.
The_DT
year_NN
2002_CD
also_RB
highlighted_VBD
the_DT
growing_VBG
value_NN
of_PIN
our_FPP1
international_JJ
Shires_NN
sales_NN
and_PHC
marketing_GER
function_NOMZ
is_VPRT [BEMA]
another_DT
essential_JJ
factor_NN
operations_NOMZ
,_,
with_PIN
29_CD
%_NN
revenue_NN
growth_NN
._.
Two_CD
new_JJ
specialty_NN
pharmaceutical_JJ
contributing_VBG
to_PIN
its_PIT
success_NN
._.
Shire_NN
takes_VPRT
pride_NN
in_PIN
its_PIT
well-trained_JJ
and_CC
products_NN
,_,
SOLARAZE_NN
and_PHC
ADEPT_NN
,_,
were_VBD [PASS]
launched_VBN
in_PIN
several_QUAN
European_JJ
highly_AMP
motivated_JJ
sales_NN
forces_NN
which_WDT [WHSUB]
have_VPRT
,_,
through_PIN
the_DT
success_NN
countries_NN
,_,
leveraging_VBG [PRESP]
the_DT
existing_VBG
European_JJ
infrastructure_NN
._.
of_PIN
Shires_NN
key_JJ
marketed_VBN
products_NN
,_,
demonstrated_VBD [PRIV]
outstanding_JJ
professionalism_NN
and_PHC
performance_NN
._.
Shire_NN
has_VPRT
a_DT
risk-balanced_JJ
R&D_NN
portfolio_NN
with_PIN
a_DT
clear_JJ
focus_NN
on_PIN
future_JJ
product_NN
needs_NN
._.
To_TO
enhance_VB
the_DT
potential_NN
for_PIN
future_JJ
growth_NN
,_,
Shire_NN
follows_VPRT
Customer_NN
focus_NN
two_CD
main_JJ
approaches_NN
:_:
to_TO
start_VB
projects_NN
in-house_RB
through_PIN
research_NN
and_PHC
Shire_NN
has_VPRT
a_DT
particular_JJ
interest_NN
in_PIN
innovative_JJ
therapies_NN
that_TSUB
are_VPRT [PASS]
advanced_VBN
drug_NN
delivery_NN
:_:
and_ANDC
to_PIN
in-license_JJ
projects_NN
and_PHC
products_NN
on_PIN
prescribed_VBN
by_PIN
specialist_NN
doctors_NN
,_,
as_IN
opposed_VBN
to_PIN
those_DEMP
prescribed_VBN
reasonable_JJ
commercial_JJ
terms_NN
,_,
and_ANDC
then_RB
to_TO
develop_VB
and_PHC
launch_VB
them_TPP3
._.
by_PIN
primary_JJ
care_NN
or_CC
general_JJ
practitioners_NN
._.
Shire_NN
targets_VPRT
specialists_NN
This_DEMO
broad_JJ
approach_NN
strengthens_VPRT
Shires_NN
strategy_NN
._.
because_CAUS
they_TPP3
usually_RB
lead_VPRT
innovations_NOMZ
in_PIN
prescribing_VBG
as_RB
well_RB
as_IN
being_VBG [BEMA]
smaller_PRED
in_PIN
number_NN
and_CC
easier_JJ
for_PIN
a_DT
company_NN
of_PIN
Shires_NN
size_NN
Shire_NN
remains_VPRT
an_DT
acquisitive_JJ
company_NN
and_CC
in_PIN
the_DT
past_JJ
eight_CD
years_NN
has_VPRT
to_TO
target_VB
effectively_RB
._.
completed_VBN
six_CD
major_JJ
mergers_NN
and_PHC
acquisitions_NOMZ
,_,
each_QUAN
one_CD
providing_VBG
or_CC
building_VBG
on_PIN
our_FPP1
internal_JJ
platforms_NN
for_PIN
growth_NN
._.
Shire_NN
will_PRMD
continue_VB
to_PIN
Therapeutic_JJ
focus_NN
evaluate_VPRT
companies_NN
,_,
products_NN
and_PHC
project_NN
opportunities_NOMZ
that_TSUB
offer_VPRT
a_DT
Shires_NN
main_JJ
areas_NN
of_PIN
therapeutic_JJ
focus_NN
are_VPRT
:_:
central_JJ
nervous_JJ
system_NN
good_JJ
strategic_JJ
fit_NN
and_CC
enhance_VB
shareholder_NN
value_NN
._.
disorders_NN
,_,
gastrointestinal_JJ
,_,
oncology_JJ
and_CC
anti-infectives_NN
._.
Functional_JJ
focus_NN
In_PIN
December_NN
2002_CD
,_,
Shire_NN
completed_VBD
the_DT
sale_NN
of_PIN
its_PIT
US_FPP1
over-the-counter_JJ
Shire_NN
focuses_VPRT
on_PIN
specific_JJ
functional_JJ
areas_NN
of_PIN
the_DT
business_NOMZ
that_TSUB
are_VPRT
OTC_NN
product_NN
portfolio_NN
to_PIN
Purdue_NN
Pharmaceuticals_NN
Inc._NN
._.
This_DEMO
divestment_NOMZ
identified_VBN
as_IN
key_JJ
drivers_NN
for_PIN
success_NN
,_,
such_JJ
as_IN
R&D_NN
and_PHC
sales_NN
and_PHC
marks_NN
Shires_NN
complete_JJ
exit_NN
from_PIN
OTC_NN
operations_NOMZ
and_CC
will_PRMD
allow_VB [SUAV]
the_DT
marketing_GER
._.
Company_NN
to_TO
focus_VB
resources_NN
on_PIN
its_PIT
core_NN
strategy_NN
of_PIN
providing_VBG
prescription_NOMZ
pharmaceuticals_NN
to_PIN
specialist_JJ
doctors_NN
._.
Shires_NN
current_JJ
R&D_NN
pipeline_NN
includes_VPRT
13_CD
projects_NN
that_TSUB
are_VPRT [BEMA]
either_RB
in_PIN
or_CC
post_IN
phase_NN
II_NN
development_NOMZ
._.
In_PIN
order_NN
to_TO
reduce_VB
financial_JJ
and_CC
business_NOMZ
Geographic_JJ
focus_NN
risk_NN
,_,
Shire_NN
maintains_VPRT [PUBV]
a_DT
careful_JJ
and_PHC
objective_JJ
discipline_NN
in_PIN
its_PIT
approach_NN
Shire_NN
currently_RB
markets_VPRT
its_PIT
products_NN
using_VBG [WZPRES]
its_PIT
sales_NN
forces_NN
in_PIN
seven_CD
major_JJ
pharmaceutical_JJ
markets_NN
of_PIN
the_DT
world_NN
._.
Shire_NN
covers_VPRT
other_JJ
significant_JJ
pharmaceutical_JJ
markets_NN
indirectly_RB
through_PIN
distributors_NN
._.
4_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chief_NN
Executives_NN
review_NN
Technology_NN
focus_NN
Shires_VPRT
current_JJ
business_NOMZ
model_NN
has_VPRT
five_CD
levels_NN
Shires_NN
three_CD
platform_NN
technologies_NN
lead_VPRT
optimisation_NOMZ
for_PIN
small_JJ
of_PIN
focus_NN
:_:
functional_JJ
,_,
customer_NN
,_,
therapeutic_JJ
,_,
molecules_NN
,_,
biologics_NN
research_NN
and_CC
advanced_VBN
drug_NN
delivery_NN
are_VPRT [BEMA]
an_DT
technology_NN
and_CC
geographic_JJ
._.
important_JJ
part_NN
of_PIN
its_PIT
risk-balanced_JJ
approach_NN
._.
Importantly_RB
these_DEMO
three_CD
platform_NN
technologies_NN
also_RB
widen_VPRT
our_FPP1
ability_NOMZ
to_PIN
in-license_JJ
research_NN
programs_NN
,_,
development_NOMZ
projects_NN
and_PHC
products_NN
._.
These_DEMO
technologies_NN
Therapeutic_NN
Customer_NN
focus_NN
focus_NN
can_POMD [SPAU]
also_RB
be_VB [PASS]
used_VBN
to_TO
manage_VB
the_DT
lifecycle_NN
of_PIN
existing_VBG
products_NN
._.
CNS_NN
,_,
GI_NN
,_,
Specialty_NN
Moving_VBG [SUAV] [WZPRES]
forward_RB
Oncology_NN
,_,
doctors_NN
AntiShire_NN
is_VPRT
moving_VBG [SUAV]
forward_RB
with_PIN
confidence_NN
as_IN
a_DT
strong_JJ
,_,
independent_JJ
infectives_NN
company_NN
well_RB
positioned_VBD
for_PIN
continued_JJ
growth_NN
._.
We_FPP1
have_VPRT
a_DT
strong_JJ
track_NN
record_NN
of_PIN
successful_JJ
mergers_NN
and_PHC
acquisitions_NOMZ
and_CC
this_DEMP
will_PRMD
continue_VB
to_PIN
Functional_NN
Geographic_NN
be_VB [BEMA]
a_DT
major_JJ
focus_NN
for_PIN
our_FPP1
future_JJ
expansion_NN
._.
Shire_NN
has_VPRT [SPAU] [PEAS]
recently_TIME
launched_VBN
focus_NN
focus_NN
a_DT
number_NN
of_PIN
new_JJ
products_NN
,_,
both_DT
in_PIN
the_DT
US_FPP1
and_CC
in_PIN
its_PIT
international_JJ
USA_NN
,_,
Search_NN
Germany_NN
,_,
Research_NN
,_,
markets_NN
,_,
and_ANDC
it_PIT
continues_VPRT
to_TO
invest_VB
in_PIN
focused_JJ
R&D_NN
capabilities_NOMZ
to_TO
sustain_VB
UK_NN
,_,
France_NN
,_,
Development_NOMZ
,_,
Technology_NN
Italy_NN
,_,
Spain_NN
,_,
growth_NN
in_PIN
future_JJ
years_NN
._.
Marketing_GER
Canada_NN
focus_NN
Small_JJ
molecules_NN
,_,
I_FPP1
would_PRMD
like_VB
to_TO
thank_VB
all_QUAN
employees_NN
for_PIN
their_TPP3
diligence_NN
and_PHC
dedication_NOMZ
,_,
Biologics_NN
,_,
which_WDT [SERE]
were_VBD [BEMA]
the_DT
key_JJ
drivers_NN
of_PIN
our_FPP1
success_NN
in_PIN
2002_CD
,_,
probably_RB
Advanced_NN
drug_NN
one_CD
of_PIN
the_DT
most_EMPH
challenging_JJ
and_CC
equally_RB
most_EMPH
successful_JJ
in_PIN
Shires_NN
delivery_NN
16-year_JJ
history_NN
._.
Their_TPP3
hard_JJ
work_NN
and_CC
innovative_JJ
ideas_NN
will_PRMD
help_VB
Shire_VB
to_TO
achieve_VB
even_RB
greater_JJ
results_NN
in_PIN
the_DT
years_NN
ahead_PLACE
._.
Matthew_NN
Emmens_NN
Chief_NN
Executive_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
5_CD
Development_NOMZ
pipeline_NN
One_CD
of_PIN
the_DT
largest_JJ
R&D_NN
portfolios_NN
for_PIN
a_DT
company_NN
of_PIN
its_PIT
size_NN
Shire_NN
has_VPRT
a_DT
long-term_JJ
commitment_NOMZ
to_PIN
annual_JJ
R&D_NN
investment_NOMZ
In_PIN
2003_CD
Shire_NN
expects_VPRT [PRIV]
the_DT
following_VBG
late-stage_JJ
milestones_NN
to_TO
occur_VB
:_:
of_PIN
18-20_CD
%_NN
of_PIN
its_PIT
revenues_NN
._.
The_DT
benefit_NN
of_PIN
this_DEMO
level_NN
of_PIN
spending_GER
is_VPRT
gaining_VBG
visibility_NOMZ
as_IN
the_DT
late_TIME
stage_NN
pipeline_NN
emerges_VPRT
._.
The_DT
Approval_NN
regulatory_JJ
action_NOMZ
:_:
Progress_NN
into_PIN
phase_NN
III_NN
clinical_JJ
trials_NN
:_:
Company_NN
has_VPRT
a_DT
total_NN
of_PIN
22_CD
projects_NN
in_PIN
full_JJ
development_NOMZ
of_PIN
FOSRENOL_NN
hyperphosphatemia_NN
US_FPP1
EU_NN
SPD503_NN
ADHD_NN
already_RB
occurred_VBD
which_WDT
13_CD
are_VPRT [BEMA]
in_PIN
phase_NN
II_NN
or_CC
beyond_IN
._.
XAGRID_NN
essential_JJ
thombocythemia_NN
EU_NN
SPD476_NN
ulcerative_JJ
colitis_NN
ADDERALL_NN
XR_NN
adult_NN
ADHD_NN
US_FPP1
TROXATYL_NN
troxacitabine_NN
acute_JJ
myelogenous_JJ
leukemia_NN
TROXATYL_NN
pancreatic_JJ
cancer_NN
Indication_NOMZ
Product_NN
Preclinical_NN
Phase_NN
I_FPP1
Phase_NN
II_NN
Phase_NN
III_NN
Registration_NOMZ
CNS_NN
Bipolar_NN
disorder_NN
SPD417_NN
Attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
ADHD_NN
SPD465_CD
ADHD_NN
SPD483_CD
ADHD_NN
SPD503_CD
ADHD_NN
SPD473_CD
ADHD_NN
METHYPATCH_NN
Parkinsons_NN
disease_NN
SPD451_NN
Gastrointestinal_NN
Inflammatory_NN
bowel_NN
disease_NN
IBD_NN
PENTASA_NN
IBD_NN
COLAZIDE_NN
IBD_NN
SPD476_NN
IBD_NN
SPD480_NN
Oncology_NN
Essential_NN
thrombocythemia_NN
AGRYLIN_NN
Acute_NN
myeloid_VBD
leukemia_NN
TROXATYL_NN
Pancreatic_NN
cancer_NN
TROXATYL_NN
Anti-infectives_NN
Influenza_NN
SPD701_NN
Influenza_NN
SPD707_NN
Meningitis_NN
,_,
septicemia_NN
SPD704_NN
Opportunistic_NN
infections_NOMZ
SPD705_NN
HIV_NN
SPD754_NN
HIV_NN
SPD756_NN
Pneumonia_NN
,_,
meningitis_VPRT
SPD703_NN
Other_JJ
disease_NN
areas_NN
Hyperphosphatemia_NN
FOSRENOL_NN
6_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Product_NN
portfolio_NN
A_DT
strong_JJ
range_NN
of_PIN
effective_JJ
marketed_VBN
products_NN
Shire_NN
has_VPRT
a_DT
strategic_JJ
focus_NN
on_PIN
four_CD
therapeutic_JJ
areas_NN
central_JJ
nervous_JJ
system_NN
disorders_NN
,_,
gastrointestinal_JJ
disorders_NN
,_,
oncology_NN
and_PHC
anti-infectives_NN
._.
The_DT
wide_JJ
ranging_VBG
portfolio_NN
of_PIN
products_NN
that_TOBJ
Shire_NN
sells_VPRT
in_PIN
countries_NN
worldwide_JJ
includes_VPRT
some_QUAN
key_JJ
products_NN
featured_VBN [WZPAST]
here_RB
._.
ADDERALL_NN
mixed_JJ
amphetamine_NN
ADDERALL_NN
XR_NN
mixed_JJ
ADEPT_NN
4_CD
%_NN
icodextrin_NN
solution_NOMZ
._.
ADDERALL_NN
is_VPRT [BEMA]
an_DT
amphetamine_JJ
salts_NN
._.
ADDERALL_NN
XR_NN
ADEPT_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
use_NN
as_IN
hydrochloride_NN
._.
AGRYLIN_NN
is_VPRT [BEMA]
immediate-release_JJ
product_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
an_DT
intraperitoneal_JJ
instillate_NN
for_PIN
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
and_CC
is_VPRT [BEMA]
a_DT
once-daily_JJ
formulation_NOMZ
of_PIN
reduction_NOMZ
of_PIN
adhesions_NN
following_VBG [WZPRES]
thrombocythemia_NN
._.
Research_NN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
ADDERALL_NN
._.
It_PIT
offers_VPRT
convenience_NN
abdominal_NN
surgery_NN
._.
It_PIT
acts_VPRT
by_PIN
indicates_VPRT [PRIV]
that_THVC
a_DT
key_JJ
benefit_NN
of_PIN
disorder_NN
ADHD_NN
._.
to_PIN
patients_NN
and_PHC
caregivers_NN
,_,
and_ANDC
the_DT
providing_VBG
a_DT
temporary_JJ
separation_NOMZ
AGRYLIN_NN
is_VPRT [BEMA]
its_PIT
platelet_NN
selectivity_NOMZ
,_,
potential_NN
for_PIN
improved_VBN
compliance_NN
._.
of_PIN
peritoneal_JJ
surfaces_NN
by_PIN
targeting_VBG
only_DWNT
those_DEMO
cells_NN
that_DEMO
hydroflotation_NOMZ
._.
CALCICHEW_NN
range_NN
calcium_NN
FLUVIRAL_NN
S_NN
F_NN
split-virion_NN
PENTASA_NN
mesalamine_NN
._.
CARBATROL_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
use_NN
carbonate_NN
._.
FLUVIRAL_NN
is_VPRT
PENTASA_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
as_IN
an_DT
anticonvulsant_JJ
drug_NN
and_CC
is_VPRT
range_NN
of_PIN
products_NN
are_VPRT
calcium_NN
a_DT
vaccine_NN
indicated_VBD [PRIV]
for_PIN
active_JJ
induction_NOMZ
of_PIN
remission_NN
and_CC
marketed_VBN
for_PIN
the_DT
treatment_NOMZ
of_PIN
supplements_NOMZ
with_PIN
or_CC
without_PIN
immunisation_NOMZ
against_PIN
the_DT
treatment_NOMZ
of_PIN
patients_NN
with_PIN
mildly_DWNT
to_PIN
epilepsy_NN
,_,
combining_VBG
proven_JJ
vitamin_NN
D_NN
used_VBD
as_IN
adjunctive_JJ
influenza_NN
virus_NN
._.
moderately_RB
active_JJ
ulcerative_JJ
colitis_NN
,_,
medication_NOMZ
with_PIN
drug_NN
delivery_NN
treatments_NOMZ
for_PIN
osteoporosis_NN
._.
technology_NN
to_TO
enable_VB
a_DT
convenient_JJ
twice-daily_JJ
treatment_NOMZ
._.
PROAMATINE_NN
midodrine_NN
REMINYL_NN
galantamine_NN
SOLARAZE_NN
diclofenac_JJ
sodium_NN
ZEFFIX_NN
lamivudine_NN
._.
SOLARAZE_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
the_DT
only_DWNT
FDA_NN
approved_VBD
product_NN
indicated_VBD [PRIV]
for_PIN
the_DT
symptomatic_JJ
the_DT
treatment_NOMZ
of_PIN
actinic_JJ
keratosis_NN
,_,
of_PIN
chronic_JJ
hepatitis_NN
B_NN
infection_NOMZ
indicated_VBD [PRIV]
for_PIN
the_DT
treatment_NOMZ
treatment_NOMZ
of_PIN
mild_JJ
to_TO
moderately_RB
a_DT
precancerous_JJ
skin_NN
condition_NOMZ
._.
associated_VBN [PASTP]
with_PIN
evidence_NN
of_PIN
of_PIN
symptomatic_JJ
orthostatic_JJ
severe_JJ
dementia_NN
of_PIN
the_DT
Alzheimer_NN
hepatitis_NN
B_NN
viral_JJ
replication_NOMZ
and_PHC
hypotension_NN
._.
REMINYL_NN
differs_VPRT
from_PIN
other_JJ
acute_JJ
liver_NN
inflammation_NOMZ
._.
compounds_NN
in_PIN
its_PIT
class_NN
in_PIN
that_DEMO
it_PIT
has_VPRT
a_DT
dual_JJ
mechanism_NN
of_PIN
action_NOMZ
._.
3TC_CD
,_,
in_PIN
combination_NOMZ
with_PIN
other_JJ
antiretroviral_JJ
agents_NN
,_,
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
human_JJ
Trade_NN
mark_NN
of_PIN
ML_NN
Laboratories_NN
plc._NN
._.
Trade_NN
mark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
._.
Lamivudine_NN
is_VPRT [BEMA]
a_DT
component_NN
of_PIN
the_DT
Trade_NN
mark_NN
of_PIN
GSK_NN
._.
GSK_NN
is_VPRT [BEMA]
the_DT
owner_NN
combination_NOMZ
HIV_NN
treatments_NOMZ
,_,
licensor_NN
of_PIN
some_QUAN
rights_NN
in_PIN
these_DEMO
products_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
7_CD
ADHD_NN
Patients_NN
with_PIN
ADHD_NN
can_POMD
present_VB
with_PIN
symptoms_NN
of_PIN
inattention_NOMZ
,_,
impulsivity_NOMZ
hyperactivity_NOMZ
or_CC
both_DT
._.
This_DEMP
can_POMD
lead_VB
to_TO
impaired_VBN
functioning_VBG
in_PIN
social_JJ
and_PHC
educational_JJ
settings_GER
with_PIN
resultant_JJ
educational_JJ
and_CC
family_NN
disruption_NOMZ
._.
8_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Central_NN
nervous_JJ
system_NN
Experience_NN
and_PHC
innovation_NOMZ
With_PIN
a_DT
central_JJ
nervous_JJ
system_NN
CNS_NN
franchise_NN
founded_VBN [WZPAST]
on_PIN
established_VBN [PRIV]
,_,
tried_VBD
and_PHC
tested_VBD
therapies_NN
,_,
Shire_NN
is_VPRT [PASS]
committed_VBN
to_TO
developing_VBG
products_NN
to_TO
meet_VB
the_DT
current_JJ
and_PHC
future_JJ
needs_NN
of_PIN
CNS_NN
patients_NN
._.
Attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
584_CD
children_NN
,_,
concluded_VBD [PRIV]
that_THVC
one_CD
morning_GER
Adult_NN
ADHD_NN
ADHD_NN
dose_NN
of_PIN
ADDERALL_NN
XR_NN
was_VBD [BEMA]
well-tolerated_PRED
and_CC
At_PIN
the_DT
end_NN
of_PIN
2002_CD
Shire_NN
filed_VBD
a_DT
supplemental_JJ
ADHD_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
between_PIN
3_CD
%_NN
and_CC
effective_JJ
at_PIN
controlling_VBG
symptoms_NN
of_PIN
ADHD_NN
New_NN
Drug_NN
Application_NOMZ
sNDA_NN
with_PIN
the_DT
Food_NN
7_CD
%_NN
of_PIN
children_NN
in_PIN
the_DT
US_FPP1
._.
Often_RB
presenting_VBG
throughout_PIN
the_DT
day_NN
._.
A_DT
second_JJ
study_NN
,_,
the_DT
and_CC
Drug_NN
Administration_NOMZ
FDA_NN
for_PIN
use_NN
of_PIN
with_PIN
symptoms_NN
of_PIN
inattention_NOMZ
,_,
impulsivity_NOMZ
largest-ever_JJ
ADHD_NN
clinical_JJ
trial_NN
the_DT
Long_NN
ADDERALL_NN
XR_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
adult_NN
ADHD_NN
._.
hyperactivity_NOMZ
,_,
or_CC
both_DT
,_,
the_DT
sufferer_NN
can_POMD
Acting_GER
Adderall_NN
Community_NOMZ
Assessment_NOMZ
Trial_NN
It_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
up_RB
to_PIN
8_CD
million_CD
adults_NN
in_PIN
the_DT
experience_NN
impaired_VBN
functioning_VBG
in_PIN
social_JJ
and_CC
or_CC
LADD_NN
._.
CAT_NN
study_NN
,_,
was_VBD [PASS]
presented_VBN
at_PIN
the_DT
US_FPP1
have_VPRT [PEAS]
ADHD_VBN
._.
However_CONJ
,_,
this_DEMP
is_VPRT [BEMA]
a_DT
relatively_RB
educational_JJ
settings_GER
with_PIN
resultant_JJ
educational_JJ
American_JJ
Psychiatric_NN
Association_NOMZ
Annual_JJ
underdeveloped_JJ
market_NN
with_PIN
only_DWNT
approximately_RB
and_CC
family_NN
disruption_NOMZ
._.
In_PIN
approximately_RB
66_CD
%_NN
of_PIN
Meeting_VBG
in_PIN
Philadelphia_NN
,_,
in_PIN
2002_CD
._.
Involving_VBG [PRESP]
5_CD
%_NN
of_PIN
those_DEMO
affected_JJ
receiving_VBG
treatment_NOMZ
._.
children_NN
,_,
symptoms_NN
will_PRMD
persist_VB
into_PIN
adulthood_NN
nearly_DWNT
3,000_CD
children_NN
,_,
the_DT
study_NN
demonstrated_VBD [PRIV] [THATD]
This_DEMP
may_POMD
result_VB
from_PIN
limited_JJ
awareness_NOMZ
and_CC
with_PIN
estimates_NN
of_PIN
up_RB
to_PIN
8_CD
million_CD
adults_NN
in_PIN
the_DT
that_DEMO
ADDERALL_NN
XR_NN
significantly_RB
improves_VPRT
the_DT
diagnosis_NN
of_PIN
ADHD_NN
in_PIN
the_DT
adult_NN
population_NOMZ
._.
hallmark_NN
symptoms_NN
of_PIN
ADHD_NN
and_CC
the_DT
quality_NOMZ
of_PIN
life_NN
of_PIN
children_NN
living_VBG [WZPRES]
with_PIN
the_DT
condition_NOMZ
._.
ADHD_NN
pipeline_NN
Since_OSUB
the_DT
launch_NN
of_PIN
its_PIT
first_JJ
products_NN
for_PIN
the_DT
SPD503_NN
,_,
a_DT
novel_NN
formulation_NOMZ
of_PIN
a_DT
nonmanagement_NOMZ
of_PIN
ADHD_NN
DEXTROSTAT_NN
The_DT
most_EMPH
successful_JJ
switch_NN
scheduled_VBN
compound_NN
,_,
entered_VBD
phase_NN
III_NN
of_PIN
dextroamphetamine_NN
salt_NN
and_PHC
ADDERALL_NN
,_,
Launched_VBN [PASTP]
in_PIN
November_NN
2001_CD
,_,
ADDERALL_NN
XR_NN
clinical_JJ
development_NOMZ
in_PIN
children_NN
in_PIN
early_TIME
2003_CD
._.
Shire_NN
has_VPRT [PEAS]
remained_VBN
committed_JJ
to_PIN
the_DT
has_VPRT [PEAS]
become_VBN
one_CD
of_PIN
the_DT
most_EMPH
widely_RB
prescribed_VBN
Studies_NN
to_TO
assess_VB
its_PIT
potential_NN
in_PIN
adult_NN
ADHD_NN
development_NOMZ
of_PIN
products_NN
for_PIN
ADHD_NN
._.
The_DT
ADHD_NN
treatments_NOMZ
in_PIN
the_DT
US_FPP1
._.
Over_IN
4.5_CD
million_CD
patients_NN
are_VPRT
being_VBG [PASS]
designed_VBN
._.
latest_JJ
addition_NOMZ
to_PIN
the_DT
marketed_VBN
ADHD_NN
portfolio_NN
prescriptions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
,_,
and_ANDC
by_PIN
the_DT
is_VPRT
ADDERALL_NN
XR_NN
,_,
a_DT
patented_JJ
once-daily_JJ
end_NN
of_PIN
2002_CD
the_DT
product_NN
claimed_VBD [PUBV]
23.8_CD
%_NN
of_PIN
SPD473_CD
is_VPRT [BEMA]
a_DT
mixed_JJ
monoamine_NN
reuptake_NN
dosing_VBG [WZPRES]
formulation_NOMZ
of_PIN
ADDERALL_NN
that_TSUB
uses_VPRT
the_DT
ADHD_NN
market_NN
in_PIN
the_DT
US_FPP1
._.
Its_PIT
unique_JJ
mode_NN
of_PIN
action_NOMZ
,_,
affecting_VBG
Shire_NN
Laboratories_NN
MICROTROL_NN
drug_NN
success_NN
in_PIN
switching_VBG
patients_NN
from_PIN
the_DT
original_JJ
three_CD
neurotransmitters_NN
that_TSUB
may_POMD
be_VB [PASS]
implicated_VBN
delivery_NN
technology_NN
._.
Once-daily_RB
dosing_VBG
offers_NN
immediate-release_JJ
product_NN
to_PIN
the_DT
once-daily_JJ
in_PIN
ADHD_NN
noradrenaline_NN
,_,
serotonin_NN
and_CC
a_DT
significant_JJ
convenience_NN
to_PIN
patients_NN
and_PHC
brand_NN
._.
Underpinning_VBG [PRESP]
the_DT
successful_JJ
launch_NN
of_PIN
dopamine_NN
makes_VPRT
this_DEMO
an_DT
interesting_JJ
candidate_NN
caregivers_NN
,_,
removing_VBG [PRESP]
the_DT
need_NN
for_PIN
duringADDERALL_NN
XR_NN
Shire_NN
continues_VPRT
to_TO
promote_VB
for_PIN
ADHD_NN
treatment_NOMZ
._.
A_DT
phase_NN
II_NN
proof-ofschool_NN
or_CC
after-school_JJ
treatment_NOMZ
,_,
and_ANDC
provides_VPRT
awareness_NOMZ
and_PHC
understanding_GER
of_PIN
ADHD_NN
to_PIN
the_DT
concept_NN
study_NN
in_PIN
ADHD_NN
is_VPRT [PASS]
planned_VBN
for_PIN
2003_CD
._.
the_DT
potential_NN
for_PIN
improved_VBN
compliance_NN
._.
METHYPATCH_NN
is_VPRT [BEMA]
a_DT
recent_JJ
acquisition_NOMZ
to_PIN
the_DT
Largest-ever_JJ
ADHD_NN
clinical_JJ
trial_NN
New_NN
strengths_NN
Shire_NN
portfolio_NN
,_,
and_ANDC
was_VBD [PASS]
filed_VBN
with_PIN
the_DT
FDA_NN
on_PIN
Results_NN
from_PIN
two_CD
key_JJ
trials_NN
have_VPRT [PEAS]
contributed_VBN
The_DT
addition_NOMZ
of_PIN
three_CD
new_JJ
strengths_NN
of_PIN
27_CD
June_NN
2002_CD
._.
Subject_JJ
to_PIN
regulatory_JJ
approval_NN
it_PIT
to_PIN
the_DT
strong_JJ
demand_NN
for_PIN
ADDERALL_NN
XR_NN
._.
ADDERALL_NN
XR_NN
5mg_CD
,_,
15mg_CD
,_,
25mg_CD
to_PIN
the_DT
will_PRMD
be_VB [BEMA]
the_DT
first_JJ
transdermal_JJ
drug_NN
delivery_NN
based_VBN
A_DT
multi-centre_JJ
,_,
randomised_JJ
,_,
double-blind_JJ
,_,
product_NN
range_NN
complements_VPRT
the_DT
existing_VBG
product_NN
offered_VBN [WZPAST]
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
._.
placebo_NN
controlled_VBD
study_NN
published_VBN [WZPAST]
in_PIN
the_DT
strengths_NN
10mg_VPRT
,_,
20mg_JJ
and_PHC
30mg_JJ
providing_VBG
journal_NN
Pediatrics_NN
August_NN
2002_CD
,_,
involving_VBG
patients_NN
and_PHC
clinicians_NN
with_PIN
additional_JJ
flexibility_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
9_CD
Operating_GER
review_NN
:_:
Central_NN
nervous_JJ
system_NN
Alzheimers_NN
disease_NN
dementia_NN
Epilepsy_NN
phase_NN
III_NN
demonstrated_VBD [PRIV]
the_DT
potential_NN
of_PIN
Alzheimers_NN
disease_NN
AD_NN
affects_VPRT
over_IN
12_CD
million_CD
Epilepsy_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
most_EMPH
common_JJ
CARBATROL_NN
SPD417_NN
in_PIN
treating_VBG
bipolar_JJ
mood_NN
people_NN
worldwide_JJ
._.
It_PIT
is_VPRT [BEMA]
a_DT
progressive_JJ
,_,
neuroneurological_JJ
disorders_NN
and_CC
is_VPRT [PASS]
estimated_VBN [PRIV]
to_PIN
disorder_NN
in_PIN
adults_NN
._.
Shire_NN
has_VPRT [PEAS]
initiated_VBN
a_DT
further_JJ
degenerative_JJ
disorder_NN
characterised_VBN [WZPAST]
by_PIN
a_DT
loss_NN
affect_VB
approximately_RB
2.5_CD
million_CD
people_NN
in_PIN
phase_NN
III_NN
study_NN
to_TO
support_VB
these_DEMO
findings_GER
._.
of_PIN
memory_NN
and_PHC
cognition_NOMZ
,_,
ability_NOMZ
to_TO
perform_VB
the_DT
US_FPP1
._.
Characterised_VBN [PASTP]
by_PIN
a_DT
propensity_NOMZ
for_PIN
activities_NOMZ
of_PIN
daily_JJ
living_NN
,_,
and_ANDC
changes_NN
in_PIN
personality_NOMZ
recurrent_NN
seizures_NN
,_,
it_PIT
is_VPRT [BYPA]
defined_VBN
by_PIN
two_CD
or_CC
Discontinued_VBN
research_NN
projects_NN
and_PHC
behavior_NN
._.
REMINYL_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
more_EMPH
unprovoked_JJ
seizures_NN
._.
In_PIN
2002_CD
following_VBG
poor_JJ
pre-clinical_JJ
results_NN
,_,
work_NN
symptomatic_JJ
treatment_NOMZ
of_PIN
mild_JJ
to_TO
moderately_RB
on_PIN
SPD474_CD
,_,
a_DT
potential_JJ
Parkinsons_NN
disease_NN
severe_JJ
dementia_NN
of_PIN
the_DT
Alzheimer_NN
type_NN
._.
CARBATROL_NN
,_,
a_DT
twice-daily_JJ
extended-release_NN
treatment_NOMZ
,_,
was_VBD [PASS]
discontinued_VBN
._.
The_DT
option_NOMZ
to_PIN
formulation_NOMZ
of_PIN
carbamazepine_NN
,_,
is_VPRT [PASS]
marketed_VBN
for_PIN
develop_VB
SPD420_NN
for_PIN
ADHD_NN
was_VBD [SPAU] [PASS]
also_RB
stopped_VBN
An_DT
acetylcholinesterase_NN
inhibitor_NN
,_,
REMINYL_NN
epilepsy_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
2002_CD
it_PIT
attained_VBD
36.3_CD
%_NN
following_VBG [WZPRES]
poor_JJ
phase_NN
II_NN
trial_NN
results_NN
._.
Following_VBG
differs_VPRT
from_PIN
other_JJ
compounds_NN
in_PIN
this_DEMO
class_NN
of_PIN
the_DT
US_FPP1
extended-release_NN
carbamezapine_NN
a_DT
portfolio_NN
review_NN
,_,
development_NOMZ
of_PIN
DIRAME_NN
in_PIN
that_DEMO
it_PIT
has_VPRT
a_DT
dual_JJ
mechanism_NN
of_PIN
action_NOMZ
:_:
market_NN
._.
ceased_VBN
and_CC
the_DT
project_NN
was_VBD [PASS]
made_VBN
available_JJ
for_PIN
inhibiting_VBG
acetylcholinesterase_NN
and_CC
,_,
uniquely_RB
,_,
potential_JJ
outsourcing_GER
._.
enhancing_VBG [PRESP]
the_DT
effect_NN
of_PIN
acetylcholine_NN
on_PIN
Epilepsy_NN
projects_NN
nicotinic_JJ
receptors_NN
which_WDT [WHSUB]
are_VPRT [PASS]
known_VBN [PRIV]
to_PIN
Shire_NN
is_VPRT [SPAU]
actively_RB
pursuing_VBG
epilepsy_NN
projects_NN
be_VB [BEMA]
important_PRED
in_PIN
maintaining_VBG [PUBV]
attention_NOMZ
and_CC
for_PIN
in-licensing_JJ
._.
Initial_JJ
results_NN
from_PIN
a_DT
comparator_NN
study_NN
demonstrated_VBD [PRIV]
a_DT
superior_JJ
treatment_NOMZ
During_PIN
the_DT
year_NN
Shire_NN
reviewed_VBD
results_NN
from_PIN
profile_NN
for_PIN
REMINYL_NN
on_PIN
measures_NN
of_PIN
attention_NOMZ
studies_NN
on_PIN
its_PIT
epilepsy_NN
projects_NN
SPD421_NN
,_,
and_ANDC
cognition_NOMZ
compared_VBN [WZPAST]
to_PIN
the_DT
market_NN
leader_NN
SPD452_NN
and_PHC
SPD453_NN
._.
Recent_JJ
data_NN
published_VBN [WZPAST]
in_PIN
The_DT
that_DEMO
results_NN
from_PIN
studies_NN
on_PIN
SPD421_CD
did_VBD
not_XX0
Lancet_NN
April_NN
2002_CD
suggest_VPRT [SUAV] [PUBV]
that_THVC
it_PIT
is_VPRT [BEMA]
effective_PRED
meet_VPRT
the_DT
Companys_NN
criteria_NN
to_TO
warrant_VB
in_PIN
treating_VBG
a_DT
broad_JJ
range_NN
of_PIN
symptoms_NN
in_PIN
investment_NOMZ
in_PIN
phase_NN
III_NN
studies_NN
._.
The_DT
licensor_NN
,_,
AD_NN
patients_NN
with_PIN
additional_JJ
cerebrovascular_JJ
D-Pharm_NN
Ltd._NN
has_VPRT [PEAS]
indicated_VBN [PRIV]
its_PIT
intent_NN
to_PIN
disease_NN
CVD_NN
which_WDT [WHSUB]
represents_VPRT
another_DT
continue_VPRT
development_NOMZ
._.
Shire_NN
also_RB
decided_VBD [SUAV] [PRIV]
important_JJ
market_NN
._.
not_XX0
to_TO
pursue_VB
the_DT
two_CD
reformulation_NOMZ
projects_NN
SPD452_NN
and_PHC
SPD453_NN
._.
Shire_NN
receives_VPRT
royalties_NN
on_PIN
sales_NN
of_PIN
REMINYL_NN
from_PIN
Janssen_NN
Pharmaceutica_NN
NV_NN
worldwide_NN
,_,
Bipolar_NN
disorder_NN
except_PIN
in_PIN
the_DT
UK_NN
and_PHC
Ireland_NN
where_RB
Shire_NN
Bipolar_NN
disorder_NN
,_,
a_DT
life-long_JJ
illness_NOMZ
,_,
is_VPRT [PASS]
associated_VBN
co-promotes_NN
REMINYL_NN
with_PIN
Janssen_NN
._.
with_PIN
a_DT
high_JJ
incidence_NN
of_PIN
comorbidity_NOMZ
._.
There_EX
are_VPRT
an_DT
estimated_VBN [PRIV]
1.5_CD
million_CD
adults_NN
with_PIN
bipolar_JJ
disorder_NN
in_PIN
the_DT
US_FPP1
alone_RB
._.
Initial_JJ
results_NN
from_PIN
Alzheimers_NN
disease_NN
affects_VPRT
over_IN
12_CD
million_CD
people_NN
worldwide_JJ
._.
Initial_JJ
results_NN
from_PIN
a_DT
comparator_NN
study_NN
demonstrated_VBD [PRIV]
a_DT
superior_JJ
treatment_NOMZ
profile_NN
for_PIN
REMINYL_NN
on_PIN
measures_NN
of_PIN
attention_NOMZ
and_PHC
cognition_NOMZ
._.
REMINYL_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
symptomatic_JJ
treatment_NOMZ
of_PIN
mild_JJ
to_TO
moderately_RB
severe_JJ
dementia_NN
of_PIN
the_DT
Alzheimer_NN
type_NN
._.
10_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Epilepsy_NN
Epilepsy_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
most_EMPH
common_JJ
neurological_JJ
disorders_NN
and_CC
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
approximately_RB
2.5_CD
million_CD
people_NN
in_PIN
the_DT
US_FPP1
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
11_CD
HIV_NN
HIV_NN
has_VPRT [PEAS]
established_VBN [PRIV]
itself_PIT
as_IN
one_CD
of_PIN
the_DT
most_EMPH
serious_JJ
epidemics_NN
of_PIN
modern_JJ
time_NN
and_CC
a_DT
significant_JJ
source_NN
of_PIN
morbidity_NOMZ
,_,
mortality_NOMZ
and_PHC
cost_NN
to_PIN
society_NN
._.
12_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Anti-infectives_NN
According_VBG [WZPRES]
to_PIN
UNAIDS_NN
,_,
in_PIN
December_NN
2002_CD
there_EX
were_VBD
42_CD
million_CD
adults_NN
and_PHC
children_NN
living_VBG [WZPRES]
with_PIN
the_DT
HIV_NN
infection_NOMZ
worldwide_NN
._.
Reducing_VBG
Estimates_NN
suggest_VPRT [SUAV] [PUBV]
that_THVC
there_EX
are_VPRT
16,000_CD
new_JJ
infections_NOMZ
each_QUAN
day_NN
._.
Over_IN
2_CD
billion_CD
people_NN
alive_JJ
today_TIME
have_VPRT [PEAS]
been_VBN [PASS]
infected_VBN
with_PIN
hepatitis_NN
B_NN
virus_NN
HBV_NN
at_PIN
some_QUAN
time_NN
in_PIN
their_TPP3
lives_NN
._.
the_DT
load_NN
There_EX
is_VPRT
an_DT
ever-increasing_JJ
need_NN
for_PIN
anti-infective_JJ
treatments_NOMZ
,_,
as_IN
new_JJ
diseases_NN
and_PHC
treatment_NOMZ
resistance_NN
continues_VPRT
to_TO
emerge_VB
._.
With_PIN
a_DT
strong_JJ
track_NN
record_NN
in_PIN
this_DEMO
field_NN
,_,
Shire_NN
continues_VPRT
to_TO
develop_VB
innovative_JJ
products_NN
for_PIN
the_DT
prevention_NOMZ
and_PHC
treatment_NOMZ
of_PIN
infectious_JJ
diseases_NN
._.
HIV_NN
that_TSUB
contain_VPRT
lamivudine_JJ
COMBIVIR_NN
and_PHC
cirrhosis_NN
and_CC
hepatocellular_JJ
carcinoma_NN
HCC_NN
._.
Since_OSUB
the_DT
early_TIME
1980s_CD
when_RB
the_DT
human_JJ
TRIZIVIR_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
Canada_NN
In_CONJ
addition_NULL
HBV_NN
carriers_NN
can_POMD
transmit_VB
the_DT
disease_NN
immunodeficiency_NN
virus_NN
HIV_NN
was_VBD [BEMA]
first_PRED
identified_VBN
where_RB
there_EX
is_VPRT
a_DT
marketing_GER
partnership_NN
with_PIN
for_PIN
many_QUAN
years_NN
._.
Although_CONC
vaccines_NN
to_TO
prevent_VB
it_PIT
has_VPRT [PEAS]
established_VBN [PRIV]
itself_PIT
as_IN
one_CD
of_PIN
the_DT
most_EMPH
GSK_NN
._.
COMBIVIR_NN
and_PHC
TRIZIVIR_NN
combine_VPRT
HBV_NN
are_VPRT [BEMA]
currently_RB
available_PRED
,_,
they_TPP3
have_VPRT [PEAS]
not_XX0
been_VBN [BEMA]
serious_JJ
epidemics_NN
of_PIN
modern_JJ
time_NN
and_CC
a_DT
lamivudine_NN
with_PIN
one_CD
or_CC
two_CD
other_JJ
agents_NN
shown_VBN [PRIV]
to_TO
be_VB [BEMA]
effective_PRED
in_PIN
people_NN
who_WP [WHSUB]
are_VPRT [BEMA]
significant_JJ
source_NN
of_PIN
morbidity_NOMZ
,_,
mortality_NOMZ
and_CC
respectively_RB
,_,
in_PIN
a_DT
single_JJ
tablet_NN
._.
Compliance_NN
already_RB
infected_VBN
with_PIN
HBV_NN
._.
HIV_NN
is_VPRT [BEMA]
a_DT
retrovirus_NN
recognized_VBN [PRIV] [WZPAST]
to_PIN
multi-drug_JJ
regimes_NN
has_VPRT [PEAS]
been_VBN
greatly_AMP
as_IN
the_DT
causative_JJ
agent_NN
of_PIN
acquired_VBN
immunoimproved_VBN
by_PIN
these_DEMO
advancements_NOMZ
and_CC
further_JJ
Lamivudine_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
deficiency_NN
syndrome_NN
AIDS_NN
._.
There_EX
are_VPRT
many_QUAN
investigations_NOMZ
of_PIN
new_JJ
combinations_NOMZ
and_CC
chronic_JJ
hepatitis_NN
B_NN
associated_VBN [WZPAST]
with_PIN
evidence_NN
of_PIN
strains_NN
of_PIN
HIV_NN
throughout_PIN
the_DT
world_NN
,_,
although_CONC
formulations_NOMZ
involving_VBG [WZPRES]
lamivudine_NN
are_VPRT
underway_NN
._.
hepatitis_NN
B_NN
viral_JJ
replication_NOMZ
,_,
and_ANDC
is_VPRT [PASS]
marketed_VBN
as_IN
they_TPP3
all_QUAN
exhibit_VPRT
the_DT
same_JJ
disease_NN
mechanism_NN
._.
ZEFFIX_NN
and_CC
various_JJ
other_JJ
trademarks_NN
around_PLACE
The_DT
RNA_NN
of_PIN
the_DT
virus_NN
is_VPRT [PASS]
converted_VBN
to_PIN
DNA_NN
Shire_NN
holds_VPRT [PRIV]
the_DT
worldwide_NN
rights_NN
to_PIN
SPD754_CD
,_,
the_DT
world_NN
._.
In_PIN
an_DT
agreement_NOMZ
similar_JJ
to_PIN
that_DEMO
for_PIN
using_VBG
the_DT
reverse_NN
transcriptase_NN
enzyme_NN
and_CC
a_DT
nucleoside_NN
analog_NN
reverse_VB
transcriptase_NN
lamivudine_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
,_,
Shire_NN
the_DT
DNA_NN
is_VPRT [PASS]
integrated_VBN
into_PIN
the_DT
host_NN
organisms_NN
inhibitor_VPRT
NRTI_NN
that_DEMO
selectively_RB
blocks_NN
HIV-1_JJ
receives_VPRT
royalties_NN
on_PIN
sales_NN
of_PIN
lamivudine_NN
by_PIN
genome_NN
where_RB
it_PIT
is_VPRT [PASS]
replicated_VBN
._.
Granted_VBN [SUAV]
fast_JJ
track_NN
review_NN
status_NN
GSK_NN
for_PIN
HBV_NN
,_,
except_PIN
in_PIN
Canada_NN
where_RB
Shire_NN
by_PIN
the_DT
US_FPP1
FDA_NN
it_PIT
has_VPRT [PEAS]
demonstrated_VBN [PRIV] [THATD]
activity_NOMZ
has_VPRT
a_DT
commercialisation_NOMZ
partnership_NN
with_PIN
GSK_NN
._.
According_VBG [PRESP]
to_PIN
UNAIDS_NN
,_,
in_PIN
December_NN
2002_CD
there_EX
against_PIN
HIV_NN
strains_NN
resistant_JJ
to_PIN
other_JJ
were_VBD [BEMA]
42_CD
million_CD
adults_NN
and_PHC
children_NN
living_VBG [WZPRES]
with_PIN
nucleoside_NN
analogs_NN
,_,
including_VBG
AZT_NN
and_PHC
3TC_NN
._.
Estimates_NN
suggest_VPRT [SUAV] [PUBV]
Resistance_NN
to_PIN
SPD754_CD
appears_VPRT [SMP]
to_TO
develop_VB
that_DEMO
there_EX
are_VPRT
16,000_CD
new_JJ
infections_NOMZ
each_QUAN
day_NN
._.
Currently_RB
under_IN
development_NOMZ
,_,
phase_NN
I_FPP1
trials_NN
have_VPRT [PEAS]
shown_VBN [PRIV]
it_PIT
to_TO
be_VB [BEMA]
well_RB
tolerated_PRED
and_CC
Treatment_NOMZ
guidelines_NN
now_TIME
specify_VPRT
that_DEMO
people_NN
rapidly_RB
absorbed_VBN
,_,
and_ANDC
the_DT
first_JJ
phase_NN
II_NN
trial_NN
receive_VPRT
combination_NOMZ
therapy_NN
._.
was_VBD [PASS]
initiated_VBN
in_PIN
the_DT
fourth_JJ
quarter_NN
of_PIN
2002_CD
._.
Lamivudine_NN
forms_NN
a_DT
key_JJ
component_NN
in_PIN
most_EMPH
of_PIN
SPD756_NN
,_,
a_DT
guanosine_NN
analog_NN
reverse_VB
the_DT
combination_NOMZ
regimes_VPRT
._.
Discovered_VBN [PRIV] [PASTP]
by_PIN
Shire_NN
transcriptase_NN
inhibitor_NN
,_,
is_VPRT
Shires_NN
second_JJ
BioChem_NN
,_,
lamivudine_NN
was_VBD [PASS]
licensed_VBN
to_PIN
Glaxo_NN
antiretroviral_JJ
compound_NN
._.
An_DT
internal_JJ
review_NN
now_TIME
GlaxoSmithKline_NN
plc_NN
or_CC
GSK_NN
in_PIN
1990_CD
._.
of_PIN
preclinical_JJ
data_NN
is_VPRT
currently_RB
underway_NN
._.
Available_JJ
in_PIN
more_EMPH
than_PIN
100_CD
countries_NN
worldwide_VPRT
it_PIT
is_VPRT [PASS]
sold_VBN
in_PIN
most_EMPH
markets_NN
as_IN
3TC_NN
or_CC
EPIVIR_NN
._.
Hepatitis_NN
B_NN
A_NN
once-daily_RB
formulation_NOMZ
of_PIN
3TC_NN
is_VPRT
also_RB
Over_IN
2_CD
billion_CD
people_NN
alive_JJ
today_TIME
have_VPRT [PEAS]
been_VBN [BEMA]
available_PRED
in_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
._.
infected_VBN [PASTP]
with_PIN
the_DT
hepatitis_NN
B_NN
virus_NN
HBV_NN
at_PIN
some_QUAN
time_NN
in_PIN
their_TPP3
lives_NN
._.
The_DT
consequence_NN
Shire_NN
receives_VPRT
royalties_NN
from_PIN
GSK_NN
on_PIN
the_DT
of_PIN
persistent_JJ
HBV_NN
infections_NOMZ
includes_VPRT
the_DT
3TC_NN
,_,
EPIVIR_NN
,_,
COMBIVIR_NN
,_,
TRIZIVIR_NN
,_,
AZT_NN
and_PHC
ZEFFIX_NN
worldwide_JJ
sales_NN
of_PIN
lamivudine_NN
and_PHC
products_NN
development_NOMZ
of_PIN
chronic_JJ
hepatic_JJ
insufficiency_NN
,_,
are_VPRT [PASS]
registered_VBN
trade_NN
marks_NN
of_PIN
GSK_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
13_CD
Operating_GER
review_NN
:_:
Oncology_NN
and_CC
hematology_JJ
disorders_NN
In_PIN
2002_CD
the_DT
estimated_VBN [PRIV]
number_NN
of_PIN
new_JJ
cases_NN
of_PIN
AML_NN
in_PIN
the_DT
US_FPP1
alone_RB
was_VBD [BEMA]
10,600_CD
with_PIN
mortality_NOMZ
of_PIN
approximately_RB
7,400_CD
._.
Managing_VBG
Cancer_NN
of_PIN
the_DT
pancreas_NN
ranks_VPRT
as_IN
the_DT
fifth_JJ
leading_VBG
cause_NN
of_PIN
cancer_NN
in_PIN
the_DT
US_FPP1
with_PIN
30,300_CD
new_JJ
cases_NN
reported_VBN [PUBV] [WZPAST]
in_PIN
2002_CD
._.
In_PIN
December_NN
2002_CD
at_PIN
the_DT
American_JJ
challenges_NN
Society_NN
of_PIN
Hematology_NN
meeting_GER
,_,
positive_JJ
results_NN
from_PIN
a_DT
long-term_JJ
efficacy_NN
and_PHC
safety_NN
trial_NN
were_VBD [PASS]
reported_VBN [PUBV]
._.
These_DEMO
data_NN
will_PRMD
support_VB
the_DT
continued_VBN
strong_JJ
prescription_NOMZ
growth_NN
An_DT
estimated_VBN [PRIV]
one_CD
in_PIN
three_CD
people_NN
will_PRMD
be_VB [PASS]
diagnosed_VBN
with_PIN
of_PIN
AGRYLIN_NN
in_PIN
the_DT
US_FPP1
,_,
which_WDT [SERE]
was_VBD [BEMA]
21.8_CD
%_NN
in_PIN
the_DT
US_FPP1
during_PIN
2002_CD
._.
cancer_NN
during_PIN
their_TPP3
lifetime_NN
and_CC
one_CD
in_PIN
four_CD
people_NN
will_PRMD
die_VB
from_PIN
cancer_NN
._.
The_DT
risk_NN
of_PIN
getting_VBG
the_DT
disease_NN
rises_VPRT
significantly_RB
with_PIN
age_NN
and_ANDC
as_CONJ
a_NULL
result_NULL
of_PIN
improved_JJ
life_NN
expectancy_NN
the_DT
population_NOMZ
at_PIN
risk_NN
of_PIN
cancer_NN
is_VPRT
increasing_VBG
._.
Shire_NN
is_VPRT [PASS]
committed_VBN
to_PIN
the_DT
development_NOMZ
of_PIN
products_NN
for_PIN
oncology_NN
and_CC
hematological_JJ
disorders_NN
that_TSUB
may_POMD
provide_VB
patients_NN
with_PIN
more_EMPH
effective_JJ
treatment_NOMZ
options_NOMZ
than_PIN
those_DEMO
currently_RB
available_JJ
._.
Haematology_NN
disorders_NN
number_NN
of_PIN
new_JJ
cases_NN
of_PIN
AML_NN
in_PIN
the_DT
US_FPP1
gemcitabine_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
pancreatic_JJ
AGRYLIN_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
marketed_VBN
by_PIN
Shire_NN
in_PIN
the_DT
alone_JJ
was_VBD [BEMA]
10,600_CD
with_PIN
a_DT
mortality_NOMZ
rate_NN
of_PIN
cancer_NN
is_VPRT [PASS]
planned_VBN
for_PIN
the_DT
second_JJ
half_NN
of_PIN
2003_CD
._.
US_FPP1
and_PHC
Canada_NN
and_CC
filed_VBD
as_IN
XAGRID_NN
in_PIN
Europe_NN
,_,
approximately_RB
7,400_CD
._.
is_VPRT [PASS]
used_VBN
as_IN
an_DT
effective_JJ
treatment_NOMZ
for_PIN
patients_NN
In_PIN
the_DT
US_FPP1
,_,
Shire_NN
markets_NN
FARESTON_NN
suffering_VBG [WZPRES]
from_PIN
this_DEMO
chronic_JJ
disorder_NN
._.
AGRYLIN_NN
Shires_NN
TROXATYL_NN
,_,
a_DT
dioxolane_NN
nucleoside_NN
toremifene_NN
,_,
an_DT
anti-oestrogen_NN
for_PIN
metastatic_JJ
XAGRID_NN
reduces_VPRT
elevated_JJ
platelet_NN
count_NN
._.
analog_NN
,_,
is_VPRT [PASS]
scheduled_VBN
to_TO
enter_VB
phase_NN
III_NN
trials_NN
breast_NN
cancer_NN
._.
FARESTON_NN
offers_VPRT
a_DT
treatment_NOMZ
Platelet_NN
reduction_NOMZ
is_VPRT [PASS]
associated_VBN
with_PIN
a_DT
reduced_VBN
in_PIN
2003_CD
in_PIN
combination_NOMZ
with_PIN
cytarabine_NN
for_PIN
the_DT
alternative_NN
in_PIN
this_DEMO
rapidly_RB
changing_VBG
environment_NOMZ
._.
risk_NN
of_PIN
blood_NN
clots_NN
and_CC
other_JJ
bleeding_VBG
events_NN
._.
TROXATYL_NN
is_VPRT [BEMA]
a_DT
complete_JJ
Other_JJ
treatments_NOMZ
used_VBN [WZPAST]
in_PIN
the_DT
management_NOMZ
of_PIN
DNA_NN
chain_NN
terminator_NN
and_PHC
DNA_NN
polymerase_NN
Actinic_NN
keratosis_NN
essential_JJ
thrombocythemia_NN
ET_NN
can_POMD
cause_VB
inhibitor_NN
._.
This_DEMO
mechanism_NN
of_PIN
action_NOMZ
interferes_VPRT
Actinic_NN
keratosis_NN
AK_NN
is_VPRT [BEMA]
a_DT
skin_NN
condition_NOMZ
serious_JJ
side-effects_NN
by_PIN
decreasing_VBG
white_JJ
or_CC
red_JJ
with_PIN
the_DT
ability_NOMZ
of_PIN
cancer_NN
cells_NN
to_TO
replicate_VB
._.
associated_VBN [PASTP]
with_PIN
prolonged_JJ
exposure_NN
to_PIN
the_DT
sun_NN
blood_NN
cell_NN
counts_NN
._.
Research_NN
indicates_VPRT [PRIV]
that_THVC
a_DT
In_CONJ
addition_NULL
,_,
data_NN
suggests_VPRT [SUAV] [PUBV]
that_THVC
unlike_IN
other_JJ
and_CC
it_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
up_RP
to_PIN
10_CD
million_CD
key_JJ
benefit_NN
of_PIN
AGRYLIN_NN
XAGRID_NN
is_VPRT [BEMA]
its_PIT
platelet_NN
cytidine_NN
analogs_NN
used_VBN [WZPAST]
in_PIN
oncology_NN
,_,
TROXATYL_NN
people_NN
across_PLACE
Europe_NN
._.
If_COND
left_VBN
untreated_JJ
it_PIT
can_POMD
selectivity_NOMZ
,_,
targeting_VBG [PRESP]
only_DWNT
those_DEMO
cells_NN
that_DEMP
is_VPRT [BEMA]
not_XX0
degraded_PRED
by_PIN
cytidine_JJ
deaminase_NN
,_,
lead_NN
to_PIN
squamous_JJ
cell_NN
carcinoma_NN
,_,
a_DT
form_NN
of_PIN
develop_VB
into_PIN
platelets_NN
._.
an_DT
enzyme_NN
used_VBN [WZPAST]
by_PIN
cancer_NN
cells_NN
to_TO
resist_VB
skin_NN
cancer_NN
,_,
in_PIN
up_RB
to_PIN
16_CD
%_NN
of_PIN
sufferers_NN
._.
Skin_NN
a_DT
number_NN
of_PIN
other_JJ
cancer_NN
treatments_NOMZ
._.
cancers_NN
are_VPRT [BEMA]
the_DT
most_EMPH
common_JJ
cancer_NN
in_PIN
In_PIN
March_NN
2002_CD
,_,
Shire_NN
submitted_VBD [PUBV]
its_PIT
marketing_GER
white_JJ
populations_NOMZ
._.
In_PIN
2002_CD
Shire_NN
in-licensed_JJ
authorisation_NOMZ
application_NOMZ
for_PIN
XAGRID_NN
through_PIN
Solid_JJ
tumors_NN
SOLARAZE_NN
,_,
a_DT
novel_NN
gel_NN
preparation_NOMZ
for_PIN
the_DT
treatthe_NN
European_JJ
Medicines_NN
Evaluation_NOMZ
Agency_NN
._.
Shire_NN
is_VPRT [SPAU]
also_RB
developing_VBG
TROXATYL_NN
for_PIN
the_DT
ment_NOMZ
of_PIN
AK_NN
._.
SOLARAZE_NN
gel_NN
offers_VPRT
an_DT
alternative_JJ
Granted_NN
orphan_JJ
drug_NN
OD_NN
designation_NOMZ
by_PIN
treatment_NOMZ
of_PIN
pancreatic_JJ
cancer_NN
._.
Symptoms_NN
to_TO
existing_VBG
treatment_NOMZ
options_NOMZ
,_,
which_WDT [SERE]
may_POMD
burn_VB
the_DT
European_JJ
Commission_NN
and_CC
the_DT
Japanese_NN
of_PIN
pancreatic_JJ
cancer_NN
are_VPRT
not_XX0
usually_RB
obvious_PRED
or_CC
peel_JJ
during_PIN
the_DT
treatment_NOMZ
of_PIN
AK_NN
lesions_NN
._.
Authorities_NOMZ
,_,
it_PIT
will_PRMD
have_VB
up_RP
to_TO
ten_VB
years_NN
during_PIN
the_DT
initial_JJ
stages_NN
of_PIN
the_DT
disease_NN
and_CC
this_DEMO
market_NN
exclusivity_NOMZ
upon_PIN
approval_NN
._.
AGRYLIN_NN
makes_VPRT
early_TIME
diagnosis_NN
difficult_JJ
._.
When_RB
obvious_JJ
,_,
Shire_NN
initially_TIME
acquired_VBD
the_DT
rights_NN
for_PIN
SOLARAZE_NN
has_VPRT [PEAS]
OD_VBN
exclusivity_NOMZ
status_NN
in_PIN
the_DT
US_FPP1
that_TSUB
will_PRMD
symptoms_NN
can_POMD
include_VB
abdominal_JJ
pain_NN
,_,
for_PIN
Europe_NN
from_PIN
SkyePharma_NN
plc_NN
and_CC
the_DT
expire_VPRT
in_PIN
2004_CD
._.
unexpected_JJ
weight_NN
loss_NN
,_,
digestive_JJ
problems_NN
administrators_NN
of_PIN
Bioglan_NN
Pharma_NN
plc_NN
in_PIN
May_POMD
and_PHC
jaundice_NN
._.
Cancer_NN
of_PIN
the_DT
pancreas_NN
ranks_VPRT
2002_CD
and_CC
relaunched_VBD
the_DT
product_NN
within_PIN
two_CD
Development_NOMZ
work_NN
on_PIN
SPD427_NN
,_,
a_DT
reformulation_NOMZ
as_IN
the_DT
fifth_JJ
leading_VBG
cause_NN
of_PIN
cancer_NN
in_PIN
the_DT
US_FPP1
months_NN
in_PIN
the_DT
UK_NN
and_PHC
Germany_NN
._.
Further_JJ
work_NN
of_PIN
an_DT
existing_VBG
hematology_NN
product_NN
,_,
was_VBD [BEMA]
with_PIN
30,300_CD
estimated_VBD [PRIV] [THATD]
new_JJ
cases_NN
reported_VBD [PUBV]
has_VPRT [PEAS]
seen_VBN [PRIV] [THATD]
SOLARAZE_NN
launched_VBN [WZPAST]
by_PIN
Shire_NN
in_PIN
terminated_VBN
during_PIN
the_DT
year_NN
as_IN
it_PIT
failed_VBD
to_TO
meet_VB
in_PIN
2002_CD
._.
Prognosis_NN
is_VPRT [BEMA]
poor_PRED
and_PHC
typical_PRED
patient_NN
Italy_NN
and_PHC
Sweden_NN
and_CC
additional_JJ
regulatory_JJ
the_DT
required_VBN [SUAV]
target_NN
profile_NN
._.
survival_NN
post-diagnosis_NN
is_VPRT [BEMA]
short_PRED
,_,
with_PIN
US_FPP1
submissions_NN
were_VBD [PASS]
completed_VBN
for_PIN
approval_NN
of_PIN
mortality_NOMZ
figures_NN
reaching_VBG [WZPRES]
29,700_CD
in_PIN
2002_CD
._.
SOLARAZE_NN
for_PIN
other_JJ
countries_NN
in_PIN
the_DT
European_JJ
Haematology_NN
malignancies_NN
Union_NN
in_PIN
December_NN
2002_CD
._.
Additionally_RB
,_,
Acute_JJ
myeloid_JJ
leukemia_NN
AML_NN
is_VPRT [BEMA]
a_DT
form_NN
of_PIN
TROXATYL_NN
has_VPRT [PEAS]
shown_VBN [PRIV]
equivalent_JJ
activity_NOMZ
to_PIN
Shire_NN
acquired_VBD
the_DT
rights_NN
to_PIN
SOLARAZE_NN
for_PIN
cancer_NN
that_TSUB
affects_VPRT
the_DT
proliferation_NOMZ
of_PIN
white_JJ
gemcitabine_NN
,_,
another_DT
widely_RB
used_VBN
chemoAustralia_NN
,_,
New_NN
Zealand_NN
and_PHC
South_NN
Africa_NN
as_IN
blood_NN
cells_NN
._.
Uncontrolled_JJ
production_NOMZ
of_PIN
white_JJ
therapeutic_JJ
agent_NN
,_,
when_RB
used_VBN
as_IN
monotherapy_JJ
well_RB
as_IN
access_NN
to_PIN
future_JJ
data_NN
from_PIN
studies_NN
blood_NN
cells_NN
can_POMD
lead_VB
to_PIN
anemia_NN
,_,
infection_NOMZ
for_PIN
pancreatic_JJ
cancer_NN
._.
A_DT
phase_NN
III_NN
clinical_JJ
trial_NN
being_VBG [WZPRES] [PASS]
conducted_VBN
in_PIN
Australia_NN
where_RB
up_RB
to_PIN
60_CD
%_NN
and_CC
severe_JJ
bleeding_GER
._.
In_PIN
2002_CD
the_DT
estimated_VBN [PRIV]
investigating_VBG
TROXATYL_NN
in_PIN
combination_NOMZ
with_PIN
of_PIN
the_DT
population_NOMZ
may_POMD
have_VB
AK_NN
._.
14_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Essential_NN
thrombocythemia_NN
Essential_NN
thrombocythemia_NN
is_VPRT [BEMA]
a_DT
chronic_JJ
disorder_NN
of_PIN
the_DT
bone_NN
marrow_NN
associated_VBN [WZPAST]
with_PIN
increased_JJ
production_NOMZ
of_PIN
blood_NN
platelets_NN
._.
Excessive_JJ
platelet_NN
production_NOMZ
can_POMD
result_VB
in_PIN
abnormal_JJ
blood_NN
clot_NN
formation_NOMZ
and_PHC
bleeding_GER
,_,
thereby_RB
increasing_VBG
the_DT
risk_NN
of_PIN
stroke_NN
,_,
heart_NN
attack_NN
and_CC
gastrointestinal_JJ
bleeding_GER
._.
AGRYLIN_NN
is_VPRT [PASS]
used_VBN
as_IN
an_DT
effective_JJ
treatment_NOMZ
for_PIN
patients_NN
suffering_VBG [WZPRES]
from_PIN
this_DEMO
chronic_JJ
disorder_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
15_CD
Additional_JJ
Shire_NN
portfolio_NN
In_PIN
end-stage_JJ
renal_JJ
disease_NN
ESRD_NN
poor_JJ
control_NN
of_PIN
phosphate_NN
levels_NN
can_POMD
result_VB
in_PIN
hyperphosphatemia_NN
which_WDT [WHSUB]
can_POMD
lead_VB
to_PIN
bone_NN
disorders_NN
and_CC
is_VPRT [PASS]
associated_VBN
with_PIN
the_DT
development_NOMZ
of_PIN
cardiovascular_JJ
disease_NN
._.
FOSRENOL_NN
has_VPRT [PEAS]
been_VBN [PASS]
shown_VBN [PRIV]
to_TO [SPIN]
effectively_RB
reduce_VB
phosphate_NN
levels_NN
and_PHC
control_NN
hyperphosphatemia_NN
._.
16_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Additional_JJ
Shire_NN
portfolio_NN
It_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
nearly_DWNT
1_CD
million_CD
patients_NN
worldwide_JJ
have_VPRT
end-stage_JJ
renal_JJ
disease_NN
._.
Looking_VBG [PRESP]
to_PIN
Recent_JJ
research_NN
also_RB
suggests_VPRT [SUAV] [PUBV]
that_THVC
hyperphosphatemia_NN
is_VPRT [PASS]
associated_VBN
with_PIN
the_DT
development_NOMZ
of_PIN
cardiovascular_JJ
disease_NN
which_WDT [WHSUB]
accounts_VPRT
for_PIN
nearly_DWNT
50_CD
%_NN
of_PIN
all_QUAN
deaths_NN
in_PIN
dialysis_NN
patients_NN
._.
the_DT
future_JJ
FOSRENOL_NN
lanthanum_NN
carbonate_NN
,_,
previously_TIME
known_VBN [PRIV]
as_IN
LAMBDA_NN
and_PHC
FOZNOL_NN
,_,
a_DT
phosphate_NN
binder_NN
,_,
will_PRMD
be_VB [BEMA]
the_DT
first_JJ
global_JJ
product_NN
launched_VBN [WZPAST]
by_PIN
Shire_NN
._.
Hyperphosphatemia_NN
two_CD
phase_NN
III_NN
studies_NN
that_TSUB
demonstrated_VBD [PRIV]
unconsciousness_NOMZ
._.
Shire_JJ
markets_NN
midodrine_VB
It_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
there_EX
are_VPRT
nearly_DWNT
one_CD
million_CD
FOSRENOL_NN
to_TO
be_VB [BEMA]
an_DT
effective_JJ
binder_NN
of_PIN
dietary_JJ
hydrochloride_NN
in_PIN
the_DT
US_FPP1
as_IN
PROAMATINE_NN
patients_NN
worldwide_VPRT
with_PIN
end-stage_JJ
renal_JJ
phosphate_NN
,_,
reducing_VBG
high_JJ
phosphate_NN
levels_NN
and_CC
in_PIN
Canada_NN
as_IN
AMATINE_NN
for_PIN
the_DT
treatment_NOMZ
disease_NN
._.
In_PIN
this_DEMO
condition_NOMZ
the_DT
kidneys_NN
are_VPRT [BEMA]
unable_PRED
and_CC
,_,
in_PIN
long-term_JJ
use_NN
,_,
controlling_VBG [PRESP]
the_DT
of_PIN
OH_NN
._.
The_DT
product_NN
demonstrated_VBD [PRIV]
good_JJ
to_TO
regulate_VB
the_DT
balance_NN
of_PIN
phosphate_NN
in_PIN
the_DT
hyperphosphatemia_NN
of_PIN
chronic_JJ
renal_JJ
failure_NN
._.
underlying_VBG
prescription_NOMZ
growth_NN
and_CC
increased_VBD
body_NN
._.
If_COND
untreated_JJ
the_DT
resultant_JJ
retention_NOMZ
FOSRENOL_NN
also_RB
has_VPRT
the_DT
notable_JJ
advantage_NN
market_NN
share_NN
during_PIN
2002_CD
._.
and_ANDC
elevated_JJ
blood_NN
phosphate_NN
levels_NN
that_DEMO
hypercalcemia_NN
is_VPRT [BEMA]
much_QUAN
less_JJ
common_JJ
hyperphosphatemia_NN
can_POMD
combine_VB
with_PIN
other_JJ
than_PIN
with_PIN
calcium-based_JJ
treatments_NOMZ
._.
PROAMATINE_NN
currently_RB
has_VPRT
orphan_JJ
drug_NN
status_NN
biochemical_JJ
disturbances_NN
and_PHC
result_NN
in_PIN
bone_NN
in_PIN
the_DT
US_FPP1
:_:
the_DT
term_NN
of_PIN
this_DEMO
market_NN
exclusivity_NOMZ
disorders_NN
described_VBD
as_IN
renal_JJ
osteodystrophy_NN
._.
Following_VBG
comprehensive_JJ
regulatory_JJ
will_PRMD
expire_VB
in_PIN
September_NN
2003_CD
._.
Recent_JJ
research_NN
also_RB
suggests_VPRT [SUAV] [PUBV]
that_THVC
submissions_NN
for_PIN
FOSRENOL_NN
containing_VBG [WZPRES]
data_NN
hyperphosphatemia_NN
is_VPRT [PASS]
associated_VBN
with_PIN
the_DT
on_PIN
over_IN
2,400_CD
patients_NN
,_,
Shire_NN
has_VPRT [PEAS]
received_VBN
an_DT
Surgical_NN
adhesions_NN
development_NOMZ
of_PIN
cardiovascular_JJ
disease_NN
which_WDT [WHOBJ]
Approvable_JJ
letter_NN
from_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Adhesions_NN
occur_VPRT
in_PIN
up_RB
to_PIN
95_CD
%_NN
of_PIN
patients_NN
accounts_NN
for_PIN
nearly_DWNT
50_CD
%_NN
of_PIN
all_QUAN
deaths_NN
in_PIN
dialysis_NN
Administration_NOMZ
FDA_NN
and_PHC
submissions_NN
remain_VPRT
undergoing_VBG
abdominal_JJ
surgery_NN
._.
under_IN
review_NN
in_PIN
Europe_NN
and_PHC
Canada_NN
._.
internal_JJ
scars_NN
formed_VBN
post_NN
trauma_NN
from_PIN
complex_JJ
processes_NN
involving_VBG [WZPRES]
tissues_NN
that_TSUB
have_VPRT
FOSRENOL_NN
is_VPRT
Shires_NN
phosphate_NN
binder_NN
for_PIN
use_NN
Other_JJ
specialist_NN
products_NN
been_VBN [PASS]
damaged_VBN
during_PIN
surgery_NN
._.
They_TPP3
are_VPRT [BEMA]
a_DT
in_PIN
end-stage_JJ
renal_JJ
failure_NN
patients_NN
receiving_VBG [WZPRES]
major_JJ
cause_NN
of_PIN
pain_NN
,_,
infertility_NOMZ
,_,
small_JJ
bowel_NN
dialysis_NN
._.
Binding_VBG
dietary_JJ
phosphate_NN
in_PIN
the_DT
Osteoporosis_NN
obstruction_NOMZ
,_,
and_ANDC
are_VPRT [BEMA]
a_DT
potentially_RB
fatal_JJ
stomach_NN
to_TO
prevent_VB
it_PIT
passing_VBG
through_PIN
the_DT
Osteoporosis_NN
is_VPRT [BYPA]
characterised_VBN
by_PIN
a_DT
progressive_JJ
complication_NOMZ
of_PIN
abdominal_JJ
surgery_NN
._.
Up_IN
to_PIN
gut_NN
lining_NN
,_,
FOSRENOL_NN
is_VPRT [PASS]
formulated_VBN
as_IN
a_DT
loss_NN
of_PIN
bone_NN
mass_NN
that_TSUB
renders_VPRT
bone_NN
fragile_JJ
10_CD
%_NN
of_PIN
patients_NN
are_VPRT [BEMA]
re-admitted_PRED
to_PIN
hospital_NN
convenient_JJ
chewable_JJ
tablet_NN
to_PIN
aid_NN
in_PIN
patient_NN
and_CC
liable_JJ
to_PIN
fracture_NN
._.
More_EMPH
than_PIN
3_CD
million_CD
within_PIN
12_CD
months_NN
of_PIN
colon_NN
surgery_NN
with_PIN
an_DT
compliance_NN
and_CC
,_,
importantly_RB
in_PIN
this_DEMO
population_NOMZ
,_,
people_NN
in_PIN
the_DT
UK_NN
are_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
suffer_VB
with_PIN
adhesion-related_JJ
problem_NN
making_VBG [WZPRES]
adhesions_NN
it_PIT
requires_VPRT [SUAV]
reduced_JJ
levels_NN
of_PIN
fluid_NN
to_TO
ingest_VB
._.
Osteoporosis_NN
affects_VPRT
both_DT
sexes_NN
a_DT
significant_JJ
cost_NN
burden_NN
to_PIN
health_NN
services_NN
._.
but_CC
is_VPRT [BEMA]
more_EMPH
rapid_PRED
and_PHC
profound_PRED
in_PIN
women_NN
,_,
In_PIN
2002_CD
Shire_NN
made_VBD
a_DT
series_NN
of_PIN
detailed_VBN
largely_RB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
decline_NN
in_PIN
estrogen_NN
In_PIN
2002_CD
Shire_NN
completed_VBD
the_DT
European_JJ
launch_NN
research_NN
presentations_NOMZ
that_TSUB
highlighted_VBD
the_DT
production_NOMZ
following_VBG [WZPRES]
the_DT
menopause_NN
._.
Our_FPP1
of_PIN
ADEPT_NN
,_,
a_DT
novel_NN
solution_NOMZ
for_PIN
the_DT
prevention_NOMZ
efficacy_NN
and_PHC
safety_NN
of_PIN
FOSRENOL_NN
._.
The_DT
principal_JJ
products_NN
for_PIN
the_DT
adjunctive_JJ
treatment_NOMZ
of_PIN
adhesions_NN
following_VBG [WZPRES]
abdominal_JJ
surgery_NN
._.
outcome_NN
of_PIN
a_DT
phase_NN
III_NN
study_NN
was_VBD
that_DEMP
,_,
following_VBG [PRESP]
of_PIN
osteoporosis_NN
are_VPRT [BEMA]
the_DT
CALCICHEW_NN
range_NN
of_PIN
ADEPT_NN
is_VPRT [SPAU] [PASS]
now_TIME
marketed_VBN
in_PIN
19_CD
countries_NN
across_PLACE
12_CD
months_NN
of_PIN
treatment_NOMZ
with_PIN
FOSRENOL_NN
,_,
no_SYNE
calcium_NN
and_PHC
calcium_NN
vitamin_NN
D_NN
supplements_NOMZ
._.
adverse_JJ
effects_NN
on_PIN
bone_NN
were_VBD [PASS]
observed_VBN [PRIV]
._.
Symptomatic_JJ
orthostatic_JJ
hypotension_NN
During_PIN
the_DT
American_NN
Society_NN
of_PIN
Nephrologys_NN
Symptomatic_NN
orthostatic_JJ
hypotension_NN
OH_NN
,_,
35th_JJ
Annual_JJ
Meeting_VBG
and_CC
Scientific_NN
Exposition_NOMZ
,_,
which_WDT [SERE]
is_VPRT [BEMA]
due_PRED
to_PIN
a_DT
marked_JJ
fall_NN
in_PIN
blood_NN
pressure_NN
November_NN
2002_CD
,_,
Shire_NN
reported_VBD [PUBV]
the_DT
results_NN
of_PIN
on_PIN
standing_GER
,_,
causes_VPRT
dizziness_NOMZ
,_,
weakness_NOMZ
and_PHC
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
17_CD
Operating_GER
review_NN
:_:
Gastrointestinal_NN
Ulcerative_NN
colitis_VPRT
UC_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
upwards_NN
of_PIN
1.12_CD
million_CD
people_NN
worldwide_JJ
A_DT
new_JJ
Shire_NN
markets_NN
COLAZIDE_NN
and_PHC
PENTASA_NN
for_PIN
UC_NN
._.
emphasis_NN
An_DT
increasingly_RB
important_JJ
strategic_JJ
focus_NN
for_PIN
Shire_NN
is_VPRT [BEMA]
the_DT
gastrointestinal_JJ
GI_NN
therapeutic_JJ
area_NN
._.
With_PIN
the_DT
addition_NOMZ
of_PIN
two_CD
new_JJ
development_NOMZ
projects_NN
in_PIN
2002_CD
,_,
the_DT
GI_NN
portfolio_NN
continues_VPRT
to_TO
evolve_VB
._.
Ulcerative_JJ
colitis_NN
New_JJ
projects_NN
Ulcerative_JJ
colitis_NN
UC_NN
,_,
a_DT
serious_JJ
chronic_NN
Shire_NN
introduced_VBD
two_CD
new_JJ
products_NN
for_PIN
UC_NN
and_CC
inflammatory_JJ
disease_NN
of_PIN
the_DT
colon_NN
and_PHC
rectum_NN
,_,
potentially_RB
other_JJ
forms_NN
of_PIN
inflammatory_JJ
bowel_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
affect_VB
upwards_NN
of_PIN
1.12_CD
million_CD
disease_NN
IBD_NN
to_PIN
its_PIT
development_NOMZ
pipeline_NN
in_PIN
people_NN
worldwide_JJ
._.
The_DT
key_JJ
worldwide_NN
rights_NN
to_TO
project_VB
intermittent_JJ
attacks_NN
separated_VBN [WZPAST]
by_PIN
periods_NN
of_PIN
SPD476_CD
were_VBD [PASS]
acquired_VBN
from_PIN
Giuliani_NN
S._NN
p._NN
A._NN
remission_NN
._.
Clinical_JJ
features_NN
include_VPRT
diarrhea_NN
,_,
Based_VBN [PASTP]
on_PIN
a_DT
novel_NN
proprietary_NN
system_NN
for_PIN
bleeding_VBG
and_CC
abdominal_JJ
pain_NN
and_CC
within_PIN
ten_NN
targeting_VBG [WZPRES]
the_DT
release_NN
of_PIN
high_JJ
concentrations_NOMZ
years_NN
of_PIN
diagnosis_NN
approximately_RB
25_CD
%_NN
of_PIN
of_PIN
mesalamine_NN
to_PIN
the_DT
bowel_NN
,_,
the_DT
formulation_NOMZ
sufferers_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
undergo_VB
surgery_NN
._.
enables_VPRT
even_RB
delivery_NN
of_PIN
the_DT
highest_JJ
available_JJ
market_NN
dose_NN
of_PIN
mesalamine_NN
to_PIN
the_DT
colon_NN
._.
This_DEMO
Shire_JJ
markets_NN
COLAZIDE_NN
balsalazide_NN
for_PIN
includes_VPRT
the_DT
descending_VBG
colon_NN
,_,
which_WDT [SERE]
can_POMD
be_VB
UC_NN
in_PIN
the_DT
UK_NN
and_CC
other_JJ
European_JJ
markets_NN
._.
With_PIN
this_DEMO
profile_NN
SPD476_NN
COLAZIDE_NN
is_VPRT [BEMA]
a_DT
pro-drug_NN
of_PIN
5-ASA_JJ
mesalamine_NN
may_POMD
offer_VB
a_DT
reduced_VBN
tablet_NN
burden_NN
for_PIN
UC_NN
that_DEMP
is_VPRT [PASS]
joined_VBN
to_PIN
an_DT
inert_JJ
carrier_NN
molecule_NN
._.
patients_NN
,_,
promote_VB
greater_JJ
patient_NN
compliance_NN
COLAZIDE_NN
is_VPRT [PASS]
swallowed_VBN
in_PIN
capsule_NN
form_NN
and_CC
and_CC
a_DT
better_JJ
quality_NOMZ
of_PIN
life_NN
._.
SPD476_CD
is_VPRT [SPAU] [PASS]
currently_RB
activated_VBN
in_PIN
the_DT
colon_NN
at_PIN
the_DT
site_NN
of_PIN
UC_NN
by_PIN
the_DT
in_PIN
phase_NN
II_NN
trials_NN
and_PHC
phase_NN
III_NN
trials_NN
are_VPRT [PASS]
planned_VBN
action_NOMZ
of_PIN
gut_NN
bacteria_NN
whose_WPS [WHOBJ]
enzymes_NN
cleave_VPRT
for_PIN
the_DT
second_JJ
half_NN
of_PIN
2003_CD
._.
the_DT
inert_JJ
molecule_NN
and_PHC
release_NN
5-ASA_NN
._.
In_PIN
an_DT
agreement_NOMZ
that_TSUB
gives_VPRT
Shire_NN
rights_NN
to_PIN
PENTASA_NN
is_VPRT [PASS]
marketed_VBN
for_PIN
UC_NN
in_PIN
the_DT
US_FPP1
._.
develop_VB
,_,
manufacture_NN
and_PHC
market_NN
in_PIN
key_JJ
A_DT
sustained-release_NN
formulation_NOMZ
,_,
it_PIT
enables_VPRT
territories_NN
worldwide_JJ
,_,
a_DT
second_JJ
product_NN
drug_NN
delivery_NN
not_XX0
only_DWNT
in_PIN
the_DT
colon_NN
but_CC
also_RB
SPD480_CD
for_PIN
the_DT
treatment_NOMZ
of_PIN
UC_NN
was_VBD
inthroughout_VBG
the_DT
small_JJ
and_PHC
large_JJ
intestine_JJ
._.
licensed_VBN [PASTP]
from_PIN
Giuliani_NN
S._NN
p._NN
A._NN
A_NN
single-dose_JJ
,_,
Development_NOMZ
of_PIN
a_DT
double_JJ
strength_NN
500mg_CD
2g_CD
or_CC
4g_CD
mesalamine_JJ
rectally_RB
administered_VBN
version_NN
of_PIN
the_DT
product_NN
,_,
which_WDT [SERE]
should_NEMD
support_VB
foam_NN
,_,
it_PIT
is_VPRT [PASS]
considered_VBN [PRIV]
more_EMPH
acceptable_JJ
and_PHC
greater_JJ
convenience_NN
and_PHC
patient_NN
compliance_NN
,_,
easier_JJ
to_TO
use_VB
than_PIN
conventional_JJ
liquid_JJ
enema_NN
is_VPRT
currently_RB
underway_NN
._.
treatments_NOMZ
,_,
thereby_RB
offering_VBG
better_JJ
compliance_NN
._.
SPD480_CD
is_VPRT [BEMA]
currently_RB
in_PIN
phase_NN
II_NN
of_PIN
development_NOMZ
._.
18_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Ulcerative_NN
colitis_VPRT
Shires_NN
portfolio_NN
contains_VPRT
a_DT
number_NN
of_PIN
products_NN
that_TSUB
can_POMD
offer_VB
different_JJ
treatment_NOMZ
options_NOMZ
in_PIN
the_DT
management_NOMZ
of_PIN
ulcerative_JJ
colitis_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
19_CD
Shire_NN
Laboratories_NN
,_,
Inc._NN
._.
Utilising_VBG [PRESP]
its_PIT
proven_VBN
proprietary_JJ
technologies_NN
,_,
SLI_NN
works_VPRT
with_PIN
Shire_NN
and_CC
the_DT
pharmaceutical_JJ
industry_NN
to_TO
solve_VB
drug_NN
delivery_NN
problems_NN
._.
20_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Advanced_NN
drug_NN
delivery_NN
Building_GER
business_NOMZ
on_PIN
proven_JJ
technologies_NN
Innovative_JJ
drug_NN
delivery_NN
provides_VPRT
a_DT
strategic_JJ
advantage_NN
for_PIN
product_NN
enhancement_NOMZ
._.
Oral_JJ
drug_NN
delivery_NN
applied_VBD
alone_RB
or_CC
in_PIN
combination_NOMZ
with_PIN
SLIs_NN
Shire_NN
Laboratories_NN
,_,
Inc._NN
._.
SLI_NN
,_,
a_DT
subsidiary_NN
of_PIN
bioavailability_NOMZ
enhancement_NOMZ
systems_NN
._.
MICROTROL_NN
is_VPRT [BEMA]
a_DT
proven_JJ
and_CC
the_DT
Shire_NN
Group_NN
,_,
is_VPRT [BEMA]
a_DT
specialist_NN
provider_NN
of_PIN
commercialised_JJ
family_NN
of_PIN
drug_NN
delivery_NN
innovative_JJ
oral_JJ
drug_NN
delivery_NN
technologies_NN
._.
SLIs_NN
bioavailability_NOMZ
enhancement_NOMZ
technologies_NN
technologies_NN
based_VBN [WZPAST]
on_PIN
the_DT
use_NN
of_PIN
beadlets_NN
Adaptations_NOMZ
to_PIN
the_DT
delivery_NN
profile_NN
of_PIN
a_DT
product_NN
include_VPRT
PROSCREEN_NN
,_,
OPTISCREEN_NN
,_,
that_DEMP
can_POMD
be_VB [PASS]
customised_VBN
based_VBN
on_PIN
API_NN
involve_VPRT
modification_NOMZ
of_PIN
its_PIT
release_NN
characteristics_NN
RAPITROL_NN
and_PHC
EMUTROL_NN
._.
A_DT
bioavailability_NOMZ
characteristics_NN
,_,
targeted_VBN
release_NN
profile_NN
either_RB
by_PIN
increasing_VBG
its_PIT
absorption_NOMZ
bioavailability_NOMZ
enhancement_NOMZ
program_NN
typically_RB
starts_VPRT
with_PIN
and_CC
desired_VBN [SUAV]
dosage_NN
form_NN
._.
enhancement_NOMZ
or_CC
controlling_VBG
the_DT
rate_NN
of_PIN
its_PIT
the_DT
application_NOMZ
of_PIN
PROSCREEN_NN
in_PIN
conjunction_NOMZ
absorption_NOMZ
into_PIN
the_DT
bloodstream_NN
controlled_VBN [WZPAST]
with_PIN
in-silico_JJ
modelling_GER
to_TO
characterise_VB
the_DT
drug_NN
SOLUTROL_NN
is_VPRT [BEMA]
a_DT
patented_JJ
matrix_NN
tablet_NN
release_NN
._.
By_PIN
such_PDT
an_DT
approach_NN
the_DT
effectiveness_NOMZ
and_CC
identify_VB
its_PIT
barriers_NN
to_PIN
oral_JJ
absorption_NOMZ
._.
This_DEMO
formulation_NOMZ
that_DEMP
is_VPRT [PASS]
designed_VBN
to_TO
provide_VB
and_CC
convenience_NN
of_PIN
the_DT
original_JJ
product_NN
can_POMD
be_VB
work_NN
will_PRMD [SPAU]
then_RB
be_VB [BYPA]
followed_VBN
by_PIN
OPTISCREEN_NN
,_,
an_DT
extended-release_JJ
drug_NN
delivery_NN
profile_NN
._.
which_WDT [SERE]
aims_VPRT
at_PIN
designing_VBG
and_PHC
screening_VBG
several_QUAN
It_PIT
is_VPRT [SPAU] [PASS]
well_RB
suited_VBN
for_PIN
highly_AMP
soluble_JJ
formulations_NOMZ
to_TO
address_VB
those_DEMO
absorption_NOMZ
compounds_VPRT
._.
Utilising_VBG [PRESP]
its_PIT
proven_VBN
proprietary_JJ
technologies_NN
,_,
barriers_NN
and_CC
optimise_JJ
bioavailability_NOMZ
._.
The_DT
final_JJ
SLI_NN
works_VPRT
with_PIN
Shire_NN
and_CC
the_DT
pharmaceutical_JJ
selected_VBN
formulation_NOMZ
could_POMD
incorporate_VB
one_CD
or_CC
ENSOTROL_NN
is_VPRT [BEMA]
a_DT
patented_JJ
osmotic_JJ
drug_NN
industry_NN
to_TO
solve_VB
drug_NN
delivery_NN
problems_NN
._.
SLI_NN
a_DT
combination_NOMZ
of_PIN
solubility_NOMZ
and_PHC
permeability_NOMZ
delivery_NN
system_NN
designed_VBN [WZPAST]
to_PIN
solubilise_NN
has_VPRT [SPAU] [PEAS]
successfully_RB
collaborated_VBN
with_PIN
Shire_NN
in_PIN
the_DT
enhancers_NN
as_RB
well_RB
as_IN
delivery_NN
systems_NN
._.
drugs_NN
and_CC
provide_VB
extended_VBN
drug_NN
release_NN
development_NOMZ
of_PIN
CARBATROL_NN
,_,
the_DT
twice-daily_JJ
properties_NN
._.
formulation_NOMZ
of_PIN
carbamazepine_NN
,_,
and_ANDC
ADDERALL_NN
SLI_NN
screens_NN
new_JJ
formulations_NOMZ
using_VBG [WZPRES]
a_DT
range_NN
XR_NN
,_,
both_DT
of_PIN
which_WDT [PIRE]
are_VPRT [PASS]
based_VBN
on_PIN
the_DT
SLI_NN
of_PIN
cell_NN
lines_NN
that_TSUB
can_POMD
predict_VB [PUBV]
absorption_NOMZ
of_PIN
PROSCREEN_NN
is_VPRT [BEMA]
a_DT
family_NN
of_PIN
technologies_NN
MICROTROL_NN
technology_NN
._.
drugs_NN
in_PIN
the_DT
gastrointestinal_JJ
tract_NN
._.
In_PIN
2002_CD
,_,
that_DEMP
identify_VB
barriers_NN
and_PHC
mechanisms_NN
SLI_NN
developed_VBD
a_DT
new_JJ
buccal_JJ
cell_NN
line_NN
model_NN
to_PIN
oral_JJ
delivery_NN
and_CC
select_VB
best_JJ
drug_NN
SLIs_NN
oral_JJ
controlled-release_NN
technologies_NN
that_TSUB
expresses_VPRT
similar_JJ
characteristics_NN
to_PIN
those_DEMO
candidates_NN
for_PIN
development_NOMZ
._.
It_PIT
consists_VPRT
include_VPRT
MICROTROL_NN
,_,
which_WDT [SERE]
consists_VPRT
of_PIN
of_PIN
real_EMPH
human_JJ
buccal_JJ
tissue_NN
._.
This_DEMO
novel_NN
cell_NN
of_PIN
in-silico_NN
,_,
solubility_NOMZ
and_PHC
permeability_NOMZ
beadlets_NN
that_TSUB
can_POMD
be_VB [PASS]
coated_VBN
to_TO
provide_VB
line_NN
allows_VPRT [SUAV]
SLI_NN
to_TO
study_VB
the_DT
barriers_NN
to_TO
delivering_VBG
models_NN
,_,
physico-chemical_JJ
property_NN
customised_VBN
release_NN
profiles_NN
such_JJ
as_IN
extended_JJ
drugs_NN
in_PIN
the_DT
buccal_JJ
cavity_NOMZ
,_,
to_TO
screen_VB
formulations_NOMZ
prediction_NOMZ
and_PHC
PK_NN
profiling_GER
and_PHC
prediction_NOMZ
._.
delivery_NN
MICROTROL_NN
XR_NN
,_,
pulsed_VBD
delivery_NN
to_TO
address_VB
such_JJ
barriers_NN
,_,
and_ANDC
to_TO
select_VB
MICROTROL_NN
PR_NN
or_CC
delayed_VBN
delivery_NN
those_DEMO
formulations_NOMZ
that_TSUB
are_VPRT [BEMA]
most_EMPH
effective_JJ
OPTISCREEN_NN
is_VPRT [BEMA]
a_DT
family_NN
of_PIN
technologies_NN
MICROTROL_NN
DR_NN
:_:
SOLUTROL_NN
,_,
a_DT
in_PIN
enhancing_VBG
absorption_NOMZ
._.
SLI_NN
is_VPRT
establishing_VBG [PRIV] [THATD]
that_DEMP
enhance_VB
bioavailability_NOMZ
of_PIN
drugs_NN
proprietary_JJ
matrix_NN
tablet_NN
which_WDT [WHSUB]
can_POMD
provide_VB
the_DT
capability_NOMZ
of_PIN
this_DEMO
cell_NN
line_NN
in_PIN
predicting_VBG [PUBV]
the_DT
through_PIN
the_DT
use_NN
of_PIN
solubility_NOMZ
and_CC
extended_VBD
release_NN
of_PIN
highly_AMP
soluble_JJ
and_PHC
pH_JJ
impact_NN
of_PIN
various_JJ
enhancers_NN
and_PHC
formulation_NOMZ
permeability_NOMZ
enhancers_NN
,_,
efflux_NN
and_CC
dependent_JJ
compounds_NN
:_:
and_ANDC
ENSOTROL_NN
systems_NN
on_PIN
bioavailability_NOMZ
._.
Also_RB
in_PIN
2002_CD
,_,
SLI_NN
enzyme_NN
inhibitors_NN
,_,
and_ANDC
a_DT
wide_JJ
range_NN
osmotic_JJ
tablet_NN
technology_NN
which_WDT [WHSUB]
can_POMD
facilitate_VB
identified_VBN
four_CD
new_JJ
bioavailability_NOMZ
enhancers_NN
of_PIN
formulation_NOMZ
systems_NN
._.
absorption_NOMZ
of_PIN
poorly_RB
soluble_JJ
and_PHC
soluble_JJ
that_THAC
can_POMD
be_VB [PASS]
used_VBN
to_TO
enhance_VB
the_DT
absorption_NOMZ
compounds_VPRT
._.
These_DEMO
technologies_NN
can_POMD
be_VB [BEMA]
of_PIN
drugs_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
21_CD
Operating_GER
review_NN
:_:
Biologics_NN
Apart_RB
from_PIN
epidemics_NN
,_,
at_PIN
least_JJ
1.2_CD
million_CD
cases_NN
of_PIN
bacterial_JJ
meningitis_NN
are_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
occur_VB
every_QUAN
year_NN
,_,
135,000_CD
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
Future_JJ
fatal_JJ
according_VBG
to_PIN
WHO_WP
statistics_NN
._.
Some_QUAN
500,000_CD
of_PIN
these_DEMO
cases_NN
and_CC
50,000_CD
of_PIN
the_DT
deaths_NN
are_VPRT [BEMA]
attributable_PRED
to_PIN
N._NN
meningitidis_NN
._.
protection_NOMZ
Use_NN
of_PIN
modern_JJ
vaccines_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
one_CD
of_PIN
the_DT
most_EMPH
cost-effective_JJ
health_NN
interventions_NOMZ
available_JJ
._.
As_CONJ
a_NULL
result_NULL
the_DT
global_JJ
vaccine_NN
market_NN
is_VPRT
expanding_VBG
,_,
and_ANDC
it_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
it_PIT
will_PRMD
be_VB [BEMA]
a_DT
US$_$
10_CD
billion_CD
market_NN
by_PIN
2007_CD
._.
Shire_NN
has_VPRT
a_DT
strong_JJ
vaccine_NN
capability_NOMZ
and_CC
aims_VPRT
to_TO
safeguard_VB
future_JJ
health_NN
by_PIN
developing_VBG
vaccines_NN
that_TSUB
provide_VPRT
greater_JJ
protection_NOMZ
against_PIN
illnesses_NOMZ
such_JJ
as_IN
influenza_NN
,_,
meningitis_NN
,_,
pneumonia_NN
and_PHC
hepatitis_NN
._.
In_PIN
2002_CD
Shire_NN
invested_VBN [WZPAST]
in_PIN
a_DT
new_JJ
vaccine_NN
research_NN
facility_NOMZ
that_TSUB
will_PRMD
be_VB [BEMA]
operational_PRED
in_PIN
2004_CD
._.
Influenza_NN
vaccines_NN
primarily_RB
the_DT
US_FPP1
and_PHC
Europe_NN
:_:
this_DEMO
project_NN
is_VPRT
Streptococcus_NN
pneumoniae_NN
vaccine_NN
For_PIN
most_EMPH
healthy_JJ
people_NN
influenza_JJ
amounts_NN
now_TIME
at_PIN
the_DT
end_NN
of_PIN
phase_NN
II_NN
._.
Phase_NN
III_NN
data_NN
will_PRMD
Streptococcus_NN
pneumoniae_NN
can_POMD
cause_VB
a_DT
variety_NN
to_PIN
a_DT
high_JJ
fever_NN
,_,
headaches_NN
and_CC
coughing_VBG
be_VB [PASS]
needed_VBN
to_TO
support_VB
the_DT
marketing_GER
approval_NN
of_PIN
infections_NOMZ
including_VBG [WZPRES]
meningitis_NN
,_,
pneumonia_NN
followed_VBN [WZPAST]
by_PIN
a_DT
complete_JJ
recovery_NN
._.
For_PIN
the_DT
elderly_JJ
applications_NOMZ
in_PIN
the_DT
major_JJ
markets_NN
._.
and_ANDC
acute_JJ
otitis_NN
media_NN
ear_NN
infection_NOMZ
._.
The_DT
US_FPP1
and_CC
chronically_RB
ill_JJ
influenza_NN
often_RB
leads_VPRT
to_PIN
Centers_NN
for_PIN
Disease_NN
Control_NN
and_PHC
Protection_NOMZ
hospitalisation_NOMZ
or_CC
death_NN
._.
According_VBG [PRESP]
to_PIN
the_DT
World_NN
As_IN
part_NN
of_PIN
the_DT
commercial_JJ
agreement_NOMZ
with_PIN
estimate_NN
that_TOBJ
each_QUAN
year_NN
in_PIN
the_DT
US_FPP1
S._NN
pneumoniae_NN
Health_NN
Organisation_NOMZ
WHO_WP [WHOBJ]
,_,
during_PIN
the_DT
annual_JJ
Berna_NN
Biotech_NN
,_,
Shire_NN
gains_VPRT
exclusive_JJ
rights_NN
to_PIN
infections_NOMZ
cause_VB
up_RP
to_PIN
135,000_CD
hospitalisations_NOMZ
influenza_JJ
epidemics_NN
the_DT
disease_NN
infects_VPRT
as_IN
sell_NN
Bernas_NN
hepatitis_NN
B_NN
vaccines_NN
,_,
HEPAVAX_NN
for_PIN
pneumonia_NN
,_,
6_CD
million_CD
cases_NN
of_PIN
otitis_NN
media_NN
,_,
many_QUAN
as_IN
100_CD
million_CD
people_NN
in_PIN
the_DT
northern_JJ
GENE_NN
and_PHC
BIO-HEP_NN
B_NN
in_PIN
Europe_NN
._.
and_ANDC
approximately_RB
3,300_CD
cases_NN
of_PIN
meningitis_NN
._.
hemisphere_NN
and_CC
causes_VPRT
approximately_RB
20,000_CD
There_EX
are_VPRT
over_IN
90_CD
different_JJ
serogroups_NN
or_CC
deaths_NN
in_PIN
the_DT
US_FPP1
alone_RB
._.
In_CONJ
addition_NULL
to_PIN
the_DT
In_CONJ
addition_NULL
to_PIN
FLUVIRAL_NN
S_NN
F_NN
,_,
SPD701_NN
,_,
a_DT
variants_NN
of_PIN
the_DT
bacteria_NN
,_,
but_CC
the_DT
currently_RB
annual_JJ
epidemic_JJ
there_EX
is_VPRT
also_RB
the_DT
continued_VBN
cell-based_JJ
influenza_NN
vaccine_NN
,_,
is_VPRT [BEMA]
in_PIN
early-stage_JJ
available_JJ
paediatric_JJ
vaccine_NN
elicits_VPRT
an_DT
immune_JJ
threat_NN
of_PIN
an_DT
influenza_NN
pandemic_NN
._.
development_NOMZ
awaiting_VBG [WZPRES]
a_DT
partner_NN
prior_RB
to_PIN
response_NN
to_TO
only_DWNT
seven_CD
of_PIN
these_DEMP
._.
existing_VBG
polysaccharide_NN
vaccines_NN
fail_VPRT
to_TO
elicit_VB
Shires_NN
commercial_JJ
biologics_NN
portfolio_NN
contains_VPRT
much_QUAN
of_PIN
a_DT
response_NN
in_PIN
the_DT
elderly_JJ
or_CC
in_PIN
healthy_JJ
FLUVIRAL_NN
S_NN
F_NN
,_,
a_DT
split-virion_JJ
influenza_NN
vaccine_NN
Neisseria_NN
meningitidis_VPRT
vaccine_NN
children_NN
under_IN
the_DT
age_NN
of_PIN
two_CD
years_NN
._.
for_PIN
the_DT
prevention_NOMZ
of_PIN
influenza_NN
infection_NOMZ
._.
Shire_NN
Two_CD
of_PIN
the_DT
most_EMPH
common_JJ
outcomes_NN
of_PIN
infection_NOMZ
signed_VBD
a_DT
ten-year_JJ
contract_NN
with_PIN
the_DT
Government_NOMZ
by_PIN
Neisseria_NN
meningitidis_NN
are_VPRT [BEMA]
meningococcal_JJ
SPD703_NN
is_VPRT [BEMA]
a_DT
vaccine_NN
designed_VBN
to_TO
prevent_VB
of_PIN
Canada_NN
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
state_NN
of_PIN
readiness_NOMZ
in_PIN
the_DT
meningitis_NN
,_,
a_DT
bacterial_JJ
infection_NOMZ
which_WDT [WHSUB]
causes_VPRT
S._NN
pneumoniae_NN
infections_NOMZ
._.
This_DEMO
vaccine_NN
should_NEMD
event_NN
of_PIN
an_DT
influenza_NN
pandemic_NN
and_CC
to_TO
provide_VB
inflammation_NOMZ
of_PIN
the_DT
membranes_NN
covering_VBG [WZPRES]
the_DT
stimulate_VB
the_DT
immune_JJ
system_NN
more_EMPH
effectively_RB
influenza_JJ
vaccine_NN
for_PIN
all_QUAN
Canadian_JJ
citizens_NN
in_PIN
brain_NN
and_CC
spinal_JJ
cord_NN
,_,
and_ANDC
septicemia_NN
,_,
an_DT
than_PIN
existing_VBG
vaccines_NN
and_CC
has_VPRT
the_DT
potential_JJ
to_PIN
such_PDT
an_DT
event_NN
._.
Under_IN
the_DT
contract_NN
Shire_NN
will_PRMD
infection_NOMZ
of_PIN
the_DT
blood_NN
stream_NN
giving_VBG [WZPRES]
rise_NN
to_PIN
fever_NN
,_,
provide_VPRT
improved_JJ
protection_NOMZ
for_PIN
children_NN
and_CC
also_RB
supply_VB
the_DT
Government_NOMZ
of_PIN
Canada_NN
with_PIN
hypotension_NN
and_PHC
infection_NOMZ
of_PIN
secondary_JJ
sites_NN
such_JJ
old_JJ
people_NN
alike_RB
across_PLACE
all_QUAN
S._NN
pneumoniae_NN
a_DT
substantial_JJ
proportion_NOMZ
of_PIN
its_PIT
annual_JJ
influenza_NN
as_IN
lungs_NN
,_,
urinary_JJ
tract_NN
and_CC
gastrointestinal_JJ
tract_NN
._.
Phase_NN
I_FPP1
clinical_JJ
trials_NN
are_VPRT [BEMA]
underway_PRED
._.
vaccine_NN
requirements_NOMZ
over_IN
the_DT
ten-year_JJ
period_NN
._.
NEISVAC-C_NN
vaccine_NN
is_VPRT [PASS]
used_VBN
in_PIN
the_DT
prevention_NOMZ
of_PIN
meningitis_NN
caused_VBN [WZPAST]
by_PIN
N._NN
meningitidis_NN
serogroup_VPRT
Other_JJ
activities_NOMZ
To_TO
expand_VB
its_PIT
position_NOMZ
in_PIN
the_DT
influenza_NN
vaccines_NN
C._NN
Shire_NN
acquired_VBD
Canadian_JJ
rights_NN
to_TO
sell_VB
the_DT
Pseudomonas_NN
aeruginosa_NN
is_VPRT [BEMA]
a_DT
bacterium_NN
market_NN
,_,
Shire_NN
entered_VBD
a_DT
commercial_JJ
agreement_NOMZ
vaccine_NN
from_PIN
Baxter_NN
International_NN
,_,
and_ANDC
Health_NN
responsible_JJ
for_PIN
severe_JJ
hospital_NN
acquired_VBN [WZPAST]
with_PIN
Berna_NN
Biotech_NN
AG_NN
of_PIN
Switzerland_NN
in_PIN
which_WDT [PIRE]
Canada_NN
approved_VBD
the_DT
vaccine_NN
in_PIN
January_NN
2002_CD
._.
infections_NOMZ
,_,
life-threatening_JJ
infections_NOMZ
in_PIN
Shire_NN
will_PRMD
manufacture_VB
and_PHC
supply_VB
FLUVIRAL_NN
immunocompromised_JJ
individuals_NN
and_CC
chronic_JJ
S_NN
F_NN
for_PIN
sale_NN
by_PIN
Berna_NN
Biotech_NN
in_PIN
international_JJ
Building_GER
on_PIN
the_DT
success_NN
of_PIN
NEISVAC-C_NN
Shire_NN
infections_NOMZ
in_PIN
cystic_JJ
fibrosis_NN
patients_NN
._.
Shire_NN
is_VPRT
territories_NN
excluding_VBG [WZPRES]
Europe_NN
and_PHC
North_NN
Biologics_NN
is_VPRT [SPAU]
also_RB
developing_VBG
SPD704_CD
that_DEMP
collaborating_VBG
with_PIN
Cytovax_NN
Biotechnologies_NN
Inc._NN
._.
America_NN
._.
Shire_NN
also_RB
continues_VPRT
to_TO
capitalize_VB
appears_VPRT [SMP]
to_TO
protect_VB
against_PIN
all_QUAN
serogroups_NN
of_PIN
in_PIN
the_DT
development_NOMZ
of_PIN
SPD705_CD
,_,
a_DT
vaccine_NN
on_PIN
the_DT
global_JJ
rights_NN
to_PIN
FLUVIRAL_NN
S_NN
F_NN
by_PIN
N._NN
meningitidis_NN
infections_NOMZ
including_VBG [WZPRES]
serogroup_NN
against_PIN
P._NN
aeruginosa_NN
._.
investigating_VBG [PRESP]
its_PIT
potential_NN
for_PIN
other_JJ
markets_NN
,_,
B_NN
for_PIN
which_WDT [PIRE]
no_SYNE
vaccine_NN
is_VPRT [BEMA]
available_PRED
._.
HEPAVAX_NN
GENE_NN
and_PHC
BIO-HEP_NN
B_NN
are_VPRT
trade_NN
marks_NN
of_PIN
Berna_NN
Biotech_NN
AG_NN
._.
22_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
NEISVAC-C_NN
is_VPRT [BEMA]
a_DT
trade_NN
mark_NN
of_PIN
Baxter_NN
International_NN
Inc._NN
._.
Shire_NN
Biologics_NN
Existing_VBG [WZPRES]
polysaccharide-based_JJ
vaccines_NN
offer_VPRT
protection_NOMZ
against_PIN
a_DT
limited_JJ
range_NN
of_PIN
bacterial_JJ
strains_NN
serogroups_NN
._.
Shires_NN
research_NN
focuses_VPRT
on_PIN
the_DT
identification_NOMZ
and_PHC
development_NOMZ
of_PIN
vaccines_NN
based_VBN [WZPAST]
on_PIN
universal_JJ
surface_NN
protein_NN
antigens_NN
._.
Universal_NN
products_NN
elicit_VPRT
an_DT
immune_JJ
response_NN
to_PIN
all_QUAN
different_JJ
serogroups_NN
or_CC
variants_NN
of_PIN
pathogenic_JJ
organisms_NN
,_,
while_OSUB
proteins_NN
are_VPRT [BEMA]
the_DT
antigen_NN
of_PIN
choice_NN
in_PIN
many_QUAN
vaccines_NN
._.
This_DEMO
approach_NN
could_POMD [SPAU]
eventually_TIME
render_VB
some_QUAN
existing_VBG
vaccines_NN
obsolete_JJ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
23_CD
Corporate_NN
social_JJ
responsibility_NOMZ
report_NN
Shire_NN
commitment_NOMZ
Shire_NN
takes_VPRT
its_PIT
corporate_JJ
social_JJ
responsibility_NOMZ
CSR_NN
seriously_RB
._.
We_FPP1
believe_VPRT [PRIV]
that_THVC
sound_JJ
social_JJ
,_,
ethical_JJ
and_PHC
environmental_JJ
practices_NN
make_VPRT
good_JJ
business_NOMZ
sense_NN
and_CC
we_FPP1
consider_VPRT [PRIV]
these_DEMO
issues_NN
as_IN
implicit_JJ
to_PIN
the_DT
success_NN
of_PIN
our_FPP1
Company_NN
,_,
as_RB
well_RB
as_IN
to_PIN
the_DT
recruitment_NOMZ
,_,
motivation_NOMZ
and_PHC
retention_NOMZ
of_PIN
talented_JJ
people_NN
._.
During_PIN
the_DT
reporting_GER
year_NN
we_FPP1
have_VPRT [PEAS]
continued_VBN
to_TO
develop_VB
and_PHC
improve_VB
the_DT
way_NN
in_PIN
which_WDT [PIRE]
we_FPP1
manage_VPRT
,_,
measure_NN
and_PHC
report_NN
on_PIN
this_DEMO
important_JJ
aspect_NN
of_PIN
our_FPP1
business_NOMZ
._.
Shire_NN
conducts_VPRT
its_PIT
business_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
department_NOMZ
._.
This_DEMO
document_NOMZ
is_VPRT [PASS]
presented_VBN
to_PIN
the_DT
Shire_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
constituent_NN
of_PIN
the_DT
values_NN
it_PIT
considers_VPRT [PRIV]
important_JJ
It_PIT
is_VPRT [BEMA]
our_FPP1
aim_NN
Board_NN
and_CC
the_DT
Executive_NN
Committee_NN
annually_RB
FTSE4Good_CD
index_NN
and_CC
has_VPRT [PEAS]
participated_VBN
in_PIN
the_DT
to_TO
be_VB [BEMA]
innovative_PRED
and_PHC
dynamic_PRED
:_:
we_FPP1
apply_VPRT
for_PIN
discussion_NN
._.
Business_NOMZ
in_PIN
the_DT
Community_NOMZ
Environmental_NN
BiE_NN
high_JJ
standards_NN
of_PIN
integrity_NOMZ
and_CC
we_FPP1
care_VPRT
for_PIN
Index_NN
since_OSUB
2001_CD
._.
the_DT
interests_NN
of_PIN
those_DEMO
with_PIN
whom_WP [PIRE]
we_FPP1
have_VPRT
During_PIN
2002_CD
,_,
Shire_NN
used_VBD
independent_JJ
expert_JJ
relationships_NN
our_FPP1
patients_NN
,_,
our_FPP1
customers_NN
,_,
consultants_NN
to_TO
conduct_VB
a_DT
comprehensive_JJ
CSR_NN
We_FPP1
were_VBD [BEMA]
also_RB
one_CD
of_PIN
53_CD
FTSE_NN
100_CD
companies_NN
our_FPP1
suppliers_NN
,_,
our_FPP1
shareholders_NN
,_,
our_FPP1
employees_NN
assessment_NOMZ
._.
The_DT
findings_GER
of_PIN
the_DT
review_NN
were_VBD
that_DEMP
completed_VBD
the_DT
1st_CD
Corporate_JJ
Responsibility_NOMZ
and_CC
the_DT
communities_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
conduct_VPRT
our_FPP1
shared_VBN
with_PIN
the_DT
Executive_NN
Committee_NN
and_CC
the_DT
Index_NN
CRI_NN
2002_CD
,_,
run_VBN [PASTP]
by_PIN
Business_NOMZ
in_PIN
the_DT
activities_NOMZ
._.
Shire_NN
is_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
implementing_VBG
Community_NOMZ
._.
The_DT
Company_NN
was_VBD [PASS]
pleased_VBN
with_PIN
several_QUAN
key_JJ
recommendations_NOMZ
._.
These_DEMP
include_VPRT
its_PIT
above-sector_NN
and_CC
overall_JJ
index_NN
rating_NN
for_PIN
The_DT
CSR_NN
policy_NN
is_VPRT [BEMA]
the_DT
cornerstone_NN
of_PIN
the_DT
the_DT
establishment_NOMZ
of_PIN
a_DT
CSR_NN
Committee_NN
,_,
corporate_JJ
strategy_NN
,_,
integration_NOMZ
and_PHC
assurance_NN
Companys_NN
CSR_NN
management_NOMZ
framework_NN
._.
chaired_VBN [PASTP]
by_PIN
Angus_NN
Russell_NN
,_,
the_DT
Group_NN
Finance_NN
as_RB
well_RB
as_IN
for_PIN
its_PIT
profile_NN
gradings_GER
,_,
which_WDT [SERE]
were_VBD [BEMA]
This_DEMO
policy_NN
identifies_VPRT
and_PHC
assesses_VPRT
the_DT
Director_NN
,_,
and_ANDC
the_DT
formation_NOMZ
of_PIN
specific_JJ
work_NN
As_IN
and_CC
Bs_NN
._.
significant_JJ
issues_NN
and_PHC
stakeholder_NN
groups_NN
that_TOBJ
groups_NN
to_TO
examine_VB
the_DT
specialist_NN
areas_NN
of_PIN
the_DT
Shire_NN
Board_NN
of_PIN
Directors_NN
believes_VPRT [PRIV]
should_NEMD
be_VB
environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
,_,
and_ANDC
contractor_NN
In_PIN
the_DT
national_JJ
UK_NN
newspaper_NN
The_DT
Guardians_NN
managed_VBD
as_IN
part_NN
of_PIN
the_DT
Companys_NN
approach_NN
and_PHC
supplier_NN
relationships_NN
._.
survey_NN
The_DT
Giving_GER
List_NN
25_CD
November_NN
2002_CD
,_,
to_PIN
day-to-day_TIME
business_NOMZ
activities_NOMZ
._.
The_DT
policy_NN
Shire_NN
appeared_VBD [SMP]
in_PIN
17th_JJ
position_NOMZ
in_PIN
a_DT
ranking_GER
of_PIN
is_VPRT [BEMA]
available_JJ
internally_RB
to_PIN
our_FPP1
staff_NN
through_PIN
its_PIT
External_NN
surveys_NN
and_PHC
indexes_NN
FTSE_VPRT
100_CD
giving_VBG
companies_NN
,_,
compared_VBN [PASTP]
with_PIN
intranet_NN
,_,
and_ANDC
publicly_RB
accessible_JJ
on_PIN
the_DT
During_PIN
the_DT
reporting_GER
year_NN
,_,
Shire_NN
responded_VBD
86th_CD
in_PIN
the_DT
previous_JJ
year_NN
._.
The_DT
result_NN
highlights_VPRT
Company_NN
website_NN
._.
constructively_RB
to_PIN
numerous_JJ
external_JJ
requests_NN
our_FPP1
continual_JJ
support_NN
for_PIN
charitable_JJ
activities_NOMZ
for_PIN
information_NOMZ
on_PIN
its_PIT
CSR_NN
and_CC
related_JJ
activities_NOMZ
and_CC
the_DT
significant_JJ
improvements_NOMZ
that_TOBJ
the_DT
Angus_NN
Russell_NN
,_,
Group_NN
Finance_NN
Director_NN
,_,
has_VPRT
from_PIN
a_DT
range_NN
of_PIN
research_NN
bodies_NN
including_VBG [WZPRES]
PIRC_NN
Company_NN
has_VPRT [PEAS]
made_VBN
tracking_GER
and_CC
measuring_VBG
assumed_JJ
responsibility_NOMZ
for_PIN
CSR_NN
on_PIN
the_DT
Shire_NN
Pensions_NN
Investment_NOMZ
Research_NN
Consultants_NN
,_,
time_NN
and_PHC
resource_NN
allocation_NOMZ
in_PIN
this_DEMO
type_NN
of_PIN
Board_NN
and_CC
led_VBD
activities_NOMZ
in_PIN
this_DEMO
field_NN
during_PIN
2002_CD
EIRIS_NN
Ethical_NN
Investment_NOMZ
Research_NN
Service_NN
activity_NOMZ
and_CC
reflecting_VBG [PRIV]
it_PIT
more_EMPH
accurately_RB
in_PIN
the_DT
in_PIN
co-ordination_NOMZ
with_PIN
the_DT
Chief_NN
Executive_NN
and_CC
and_CC
the_DT
ABI_NN
Association_NOMZ
of_PIN
British_NN
Insurers_NN
._.
The_DT
Board_NN
is_VPRT [PASS]
kept_VBN
We_FPP1
recognize_VPRT [PRIV]
the_DT
value_NN
in_PIN
participating_VBG
in_PIN
informed_VBN
of_PIN
significant_JJ
developments_NOMZ
and_CC
independent_JJ
voluntary_JJ
benchmarking_VBG
surveys_NN
consulted_VBN [WZPAST]
on_PIN
major_JJ
CSR_NN
initiatives_NN
and_PHC
policy_NN
and_CC
welcome_VB
their_TPP3
outcome_NN
as_IN
a_DT
driver_NN
to_PIN
approvals_NN
._.
further_JJ
improvement_NOMZ
in_PIN
our_FPP1
management_NOMZ
systems_NN
helping_VBG [WZPRES]
to_TO
identify_VB
priority_NOMZ
areas_NN
for_PIN
The_DT
Board_NN
uses_VPRT
the_DT
corporate_JJ
risk_NN
management_NOMZ
development_NOMZ
and_CC
contribute_VPRT
to_PIN
our_FPP1
thinking_GER
process_NN
to_TO
monitor_VB
risks_NN
and_PHC
opportunities_NOMZ
around_PLACE
how_RB
to_TO
define_VB
targets_NN
and_PHC
objectives_NN
arising_VBG [WZPRES]
from_PIN
social_JJ
,_,
ethical_JJ
and_PHC
environmental_JJ
for_PIN
the_DT
future_NN
._.
A_DT
summary_NN
risk_NN
schedule_NN
is_VPRT [PASS]
reviewed_VBN
regularly_RB
by_PIN
the_DT
Companys_NN
risk_NN
management_NOMZ
www_NN
._.
com_NN
24_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
social_JJ
responsibility_NOMZ
report_NN
CSR_NN
policy_NN
Shire_NN
CSR_NN
policy_NN
addresses_VPRT
the_DT
following_VBG
issues_NN
to_TO
support_VB
managing_VBG
risks_NN
and_CC
maintaining_VBG [PUBV]
and_PHC
improving_VBG
Shires_NN
position_NOMZ
as_IN
a_DT
good_JJ
corporate_JJ
citizen_NN
in_PIN
its_PIT
dealings_GER
with_PIN
its_PIT
patients_NN
,_,
customers_NN
,_,
suppliers_NN
,_,
shareholders_NN
,_,
employees_NN
and_CC
the_DT
communities_NOMZ
where_RB
it_PIT
conducts_VPRT
its_PIT
activities_NOMZ
:_:
Ethics_NN
Employee_NN
practices_NN
Health_NN
and_PHC
safety_NN
Environment_NOMZ
Animal_NN
welfare_NN
Community_NOMZ
relations_NOMZ
._.
The_DT
policy_NN
itself_PIT
has_VPRT [PEAS]
spawned_VBN
additional_JJ
specific_JJ
policies_NN
for_CONJ
example_NULL
,_,
during_PIN
2002_CD
the_DT
Board_NN
www_NN
._.
com_NN
agreed_VBD [SUAV] [PUBV]
a_DT
new_JJ
charity_NOMZ
policy_NN
that_TSUB
governs_VPRT
community_NOMZ
affairs_NN
and_CC
charitable_JJ
giving_VBG
during_PIN
the_DT
year_NN
,_,
as_RB
well_RB
as_IN
a_DT
whistle_VPRT
blowing_VBG
policy_NN
which_WDT [WHSUB]
enables_VPRT
concerns_NN
to_TO
be_VB [PASS]
raised_VBN
confidentially_RB
inside_PLACE
,_,
and_ANDC
if_COND
necessary_JJ
,_,
outside_PLACE
the_DT
organization_NOMZ
._.
Shire_NN
values_VPRT
The_DT
Shire_NN
values_NN
innovation_NOMZ
,_,
dynamism_NN
,_,
integrity_NOMZ
At_PIN
Shire_NN
,_,
we_FPP1
demonstrate_VPRT [PRIV]
our_FPP1
caring_NN
by_PIN
constantly_RB
displaying_VBG
respect_NN
and_CC
and_CC
caring_NN
govern_VPRT
daily_JJ
behavior_NN
and_PHC
actions_NOMZ
consideration_NOMZ
to_PIN
each_QUAN
other_JJ
,_,
by_PIN
recognizing_VBG [PRIV]
contribution_NOMZ
and_PHC
efforts_NN
and_CC
by_PIN
within_PIN
Shire_NN
._.
A_DT
set_NN
of_PIN
values_NN
first_RB
identified_VBN
by_PIN
listening_VBG
to_PIN
others_NN
views_NN
._.
We_FPP1
care_VPRT
for_PIN
the_DT
patients_NN
through_PIN
our_FPP1
commitment_NOMZ
Shire_NN
senior_JJ
management_NOMZ
was_VBD [PASS]
presented_VBN
,_,
to_PIN
health_NN
and_CC
we_FPP1
care_VPRT
for_PIN
our_FPP1
shareholders_NN
by_PIN
our_FPP1
commitment_NOMZ
to_PIN
the_DT
Companys_NN
goals_NN
and_PHC
objectives_NN
._.
challenged_VBN
and_PHC
enhanced_VBN
by_PIN
employees_NN
through_PIN
a_DT
major_JJ
consultative_JJ
exercise_NN
across_PLACE
all_QUAN
geographic_JJ
areas_NN
and_PHC
levels_NN
of_PIN
responsibility_NOMZ
._.
At_PIN
Shire_NN
we_FPP1
strongly_AMP
believe_VPRT [PRIV]
in_PIN
integrity_NOMZ
as_IN
evidenced_VBN
by_PIN
the_DT
creation_NOMZ
Employees_NN
represent_VPRT
a_DT
key_JJ
stakeholder_NN
group_NN
._.
of_PIN
an_DT
environment_NOMZ
characterised_VBN [WZPAST]
by_PIN
trust_NN
and_PHC
openness_NOMZ
,_,
quality_NOMZ
and_CC
The_DT
values_NN
identification_NOMZ
and_CC
daily_JJ
implementation_NOMZ
professionalism_NN
,_,
honesty_NN
,_,
high_JJ
ethical_JJ
standards_NN
and_PHC
reliability_NOMZ
._.
demonstrate_VB [PRIV]
that_THVC
the_DT
Shire_NN
commitment_NOMZ
to_PIN
CSR_NN
runs_VPRT
throughout_PIN
the_DT
Company_NN
._.
The_DT
Companys_NN
people_NN
policies_NN
and_PHC
practices_NN
,_,
including_VBG
objective_JJ
setting_GER
and_PHC
appraisals_NN
,_,
all_QUAN
now_TIME
include_VPRT
At_PIN
Shire_NN
we_FPP1
strive_VPRT
to_TO
maintain_VB [PUBV]
our_FPP1
dynamism_NN
by_PIN
keeping_VBG
an_DT
the_DT
assessment_NOMZ
of_PIN
individual_JJ
and_CC
team_NN
entrepreneurial_JJ
spirit_NN
,_,
by_PIN
being_VBG [PASS]
result_NN
oriented_VBN
,_,
focused_VBN [PASTP]
on_PIN
value-creating_JJ
implementation_NOMZ
of_PIN
the_DT
values_NN
._.
activities_NOMZ
and_CC
by_PIN
being_VBG [BEMA]
flexible_JJ
adaptable_JJ
._.
Our_FPP1
dynamism_NN
will_PRMD
be_VB [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
passion_NN
we_FPP1
have_VPRT
for_PIN
health_NN
and_CC
for_PIN
reaching_VBG
our_FPP1
objectives_NN
._.
At_PIN
Shire_NN
we_FPP1
are_VPRT [BEMA]
innovative_PRED
because_CAUS
we_FPP1
dare_VPRT
to_TO
challenge_VB
the_DT
usual_JJ
practices_NN
in_PIN
an_DT
effort_NN
to_TO [SPIN]
constantly_RB
improve_VB
the_DT
way_NN
we_FPP1
do_VPRT [PROD]
things_NN
._.
We_FPP1
value_VPRT
creativity_NOMZ
and_PHC
initiative_NN
._.
We_FPP1
accept_VPRT [PRIV]
mistakes_NN
as_IN
they_TPP3
create_VPRT
opportunities_NOMZ
for_PIN
learning_VBG [PRIV]
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
25_CD
Innovation_NOMZ
Dynamism_NN
Integrity_NOMZ
Caring_GER
Corporate_NN
social_JJ
responsibility_NOMZ
report_NN
Our_FPP1
people_NN
Shire_VPRT
people_NN
comment_VB [PUBV]
on_PIN
the_DT
values_NN
Shire_NN
employs_VPRT
over_IN
1,800_CD
people_NN
globally_RB
Our_FPP1
job_NN
in_PIN
the_DT
Professional_NN
Education_NOMZ
throughout_PIN
its_PIT
operations_NOMZ
._.
Shires_NN
goal_NN
is_VPRT
to_TO
manage_VB
department_NOMZ
is_VPRT
to_TO
make_VB
sure_JJ
that_THAC
the_DT
correct_JJ
its_PIT
human_JJ
resources_NN
actively_RB
with_PIN
a_DT
decentralised_JJ
messages_NN
about_IN
all_QUAN
our_FPP1
products_NN
are_VPRT
being_VBG
approach_NN
._.
A_DT
small-scale_JJ
global_JJ
HR_NN
function_NOMZ
aims_VPRT
conveyed_VBN [PUBV]
._.
The_DT
integrity_NOMZ
of_PIN
our_FPP1
team_NN
is_VPRT [PASS]
proven_VBN
to_TO
create_VB
common_JJ
HR_NN
strategies_NN
and_PHC
initiatives_NN
by_PIN
the_DT
messages_NN
we_FPP1
are_VPRT
presenting_VBG
on_PIN
a_DT
daily_JJ
to_TO
support_VB
the_DT
growth_NN
and_CC
the_DT
success_NN
of_PIN
the_DT
basis_NN
._.
Caring_NN
was_VBD [PASS]
demonstrated_VBN [PRIV]
when_RB [WHCL]
our_FPP1
Company_NN
._.
The_DT
global_JJ
function_NOMZ
interacts_VPRT
regularly_RB
whole_JJ
team_NN
was_VBD [PASS]
included_VBN
to_TO
develop_VB
our_FPP1
own_JJ
with_PIN
local_JJ
HR_NN
managers_NN
within_PIN
the_DT
operational_JJ
units_NN
departmental_JJ
values_NN
which_WDT [WHSUB]
spin_VPRT
out_PIN
from_PIN
to_TO
ensure_VB [SUAV] [PRIV]
consistency_NN
and_CC
the_DT
sharing_GER
of_PIN
best_JJ
Shires_NN
core_NN
values_NN
._.
Our_FPP1
particular_JJ
values_NN
for_PIN
practice_NN
across_PLACE
Shire_NN
._.
Professional_NN
Education_NOMZ
Marketing_GER
are_VPRT
Excellence_NN
,_,
Work-Family_NN
Balance_NN
,_,
Integrity_NOMZ
,_,
In_PIN
2002_CD
,_,
new_JJ
Company-wide_JJ
human_JJ
resources_NN
Communication_NOMZ
,_,
Synergy_NN
and_PHC
No_SYNE
Surprises_NN
initiatives_NN
included_VBD
the_DT
following_GER
:_:
Kathy_NN
Driscoll_NN
,_,
Administrative_NN
and_CC
are_VPRT [PASS]
framed_VBN
in_PIN
all_QUAN
our_FPP1
offices_NN
!_.
My_FPP1
favorite_JJ
Assistant_NN
Professional_NN
Education_NOMZ
value_NN
is_VPRT
Caring_VBG
._.
All_QUAN
of_PIN
the_DT
support_NN
staff_NN
in_PIN
myShire_NN
introduced_VBD
a_DT
global_JJ
framework_NN
for_PIN
Marketing_GER
,_,
Shire_NN
US_FPP1
._.
department_NOMZ
consider_VB [PRIV]
each_QUAN
other_JJ
an_DT
equal_JJ
performance_NN
assessment_NOMZ
,_,
which_WDT [SERE]
includes_VPRT
and_CC
we_FPP1
go_VPRT
out_PIN
of_PIN
our_FPP1
way_NN
to_TO
make_VB
sure_JJ
that_THAC
feedback_JJ
sessions_NN
between_PIN
employees_NN
and_CC
we_FPP1
are_VPRT [BEMA]
all_QUAN
supported_VBN
in_PIN
our_FPP1
daily_JJ
activities_NOMZ
their_TPP3
managers_NN
._.
The_DT
assessment_NOMZ
includes_VPRT
our_FPP1
own_JJ
Shire_NN
band_NN
of_PIN
brothers_NN
._.
We_FPP1
are_VPRT [BEMA]
corporate_JJ
criteria_NN
and_PHC
implementation_NOMZ
of_PIN
values_NN
,_,
committed_VBN
to_TO
making_VBG
our_FPP1
work_NN
environment_NOMZ
a_DT
objective_JJ
setting_GER
and_CC
professional_JJ
development_NOMZ
rewarding_JJ
and_CC
preferably_RB
enjoyable_JJ
experience_NN
._.
We_FPP1
respect_VPRT
and_PHC
value_VPRT
each_QUAN
other_JJ
and_CC
revel_VB
in_PIN
each_QUAN
and_CC
everyones_NN
unique_JJ
talents_NN
._.
Shire_NN
expanded_VBD
its_PIT
Stock_NN
Purchase_NN
Plan_NN
for_PIN
all_QUAN
employees_NN
worldwide_VPRT
with_PIN
the_DT
aim_NN
of_PIN
developing_VBG
a_DT
sense_NN
of_PIN
ownership_NN
amongst_PIN
staff_NN
._.
More_EMPH
than_PIN
70_CD
%_NN
of_PIN
employees_NN
are_VPRT [SPAU]
already_RB
participating_VBG
worldwide_NN
._.
In_CONJ
addition_NULL
,_,
all_QUAN
employees_NN
have_VPRT
share_NN
options_NOMZ
and_CC
can_POMD [SPAU]
therefore_CONJ
benefit_VB
from_PIN
the_DT
future_JJ
growth_NN
of_PIN
Global_JJ
assignments_NOMZ
often_RB
present_JJ
unique_JJ
the_DT
Company_NN
._.
challenges_NN
,_,
but_CC
invariably_RB
employees_NN
come_VPRT
away_PLACE
enriched_VBN
and_CC
with_PIN
a_DT
deeper_JJ
A_DT
Code_NN
of_PIN
Ethics_NN
was_VBD [PASS]
introduced_VBN
and_CC
understanding_GER
of_PIN
Shires_NN
global_JJ
operations_NOMZ
:_:
communicated_VBN [PASTP]
to_PIN
all_QUAN
employees_NN
:_:
it_PIT
is_VPRT [BEMA]
also_RB
a_DT
key_JJ
part_NN
of_PIN
the_DT
Companys_NN
induction_NOMZ
process_NN
._.
I_FPP1
am_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Health_NN
Care_NN
The_NN
Code_NN
includes_VPRT
the_DT
Companys_NN
policy_NN
on_PIN
business_NOMZ
units_NN
marketing_GER
and_PHC
sales_NN
force_NN
._.
equal_JJ
opportunities_NOMZ
and_CC
a_DT
discrimination-free_JJ
Being_VBG [SPAU] [PASS]
physically_RB
located_VBN
in_PIN
the_DT
UK_NN
is_VPRT [BEMA]
vital_JJ
environment_NOMZ
:_:
it_PIT
also_RB
includes_VPRT
a_DT
specific_JJ
because_CAUS
you_SPP2
can_POMD
not_XX0
be_VB [BEMA]
successful_PRED
without_PIN
statement_NOMZ
on_PIN
sexual_JJ
harassment_NOMZ
._.
being_VBG [BEMA]
close_PRED
to_PIN
your_SPP2
team_NN
and_CC
your_SPP2
market_NN
._.
Working_VBG [PRESP]
in_PIN
another_DT
country_NN
has_VPRT
always_RB
Internal_NN
communications_NOMZ
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
been_VBN [BEMA]
one_CD
of_PIN
my_FPP1
dreams_NN
and_CC
I_FPP1
am_VPRT [BEMA]
grateful_PRED
a_DT
priority_NOMZ
in_PIN
2002_CD
._.
Shire_NN
makes_VPRT
a_DT
significant_JJ
to_TO
Shire_VB
for_PIN
making_VBG
it_PIT
possible_JJ
and_CC
for_PIN
helping_VBG
effort_NN
to_TO
share_VB
and_PHC
provide_VB
all_QUAN
of_PIN
its_PIT
people_NN
Natascha_NN
Sellschopp_NN
transferred_VBD
from_PIN
with_PIN
the_DT
logistics_NN
._.
with_PIN
information_NOMZ
about_IN
the_DT
Company_NN
and_CC
its_PIT
Germany_NN
to_PIN
the_DT
UK_NN
in_PIN
January_NN
2002_CD
._.
activities_NOMZ
._.
The_DT
new_JJ
intranet_NN
,_,
Orbit_NN
,_,
was_VBD [BEMA]
Current_JJ
position_NOMZ
:_:
Business_NOMZ
Unit_NN
Director_NN
,_,
I_FPP1
believe_VPRT [PRIV]
that_THVC
a_DT
global_JJ
assignment_NOMZ
broadens_VPRT
introduced_VBN
this_DEMO
year_NN
:_:
an_DT
electronic_JJ
news_NN
letter_NN
is_VPRT
Health_NN
Care_NN
Business_NOMZ
Unit_NN
,_,
Shire_NN
UK_NN
._.
your_SPP2
experience_NN
immensely_RB
,_,
makes_VPRT
you_SPP2
more_EMPH
issued_VBN
globally_RB
every_QUAN
six_CD
weeks_NN
and_CC
a_DT
Company_NN
open_JJ
and_PHC
flexible_JJ
and_CC
teaches_VPRT
you_SPP2
to_TO
look_VB
at_PIN
magazine_NN
is_VPRT [PASS]
sent_VBN
to_PIN
all_QUAN
staff_NN
three_CD
times_NN
a_DT
year_NN
._.
In_PIN
Dynamic_NN
people_NN
things_NN
from_PIN
different_JJ
perspectives_NN
._.
I_FPP1
love_VPRT
addition_NOMZ
,_,
senior_JJ
management_NOMZ
hosts_NN
regular_JJ
staff_NN
One_CD
of_PIN
Shires_NN
greatest_JJ
strengths_NN
is_VPRT
changes_NN
and_PHC
challenges_NN
and_CC
this_DEMP
makes_VPRT
you_SPP2
meetings_GER
in_PIN
all_QUAN
the_DT
major_JJ
Company_NN
locations_NOMZ
._.
the_DT
ability_NOMZ
of_PIN
its_PIT
employees_NN
to_TO
work_VB
break_NN
with_PIN
old_JJ
habits_NN
,_,
giving_VBG [PRESP]
you_SPP2
a_DT
start_NN
all_QUAN
seamlessly_RB
across_PLACE
national_JJ
borders_NN
,_,
new_JJ
again_TIME
feeling_GER
._.
Shire_NN
offers_VPRT
career_NN
development_NOMZ
expertly_RB
navigate_VPRT
through_PIN
a_DT
variety_NN
of_PIN
opportunities_NOMZ
and_CC
leverages_VPRT
its_PIT
global_JJ
status_NN
economic_JJ
,_,
social_JJ
and_PHC
political_JJ
systems_NN
,_,
The_DT
most_EMPH
challenging_JJ
aspect_NN
has_VPRT [PEAS]
been_VBN [BEMA]
through_PIN
making_VBG
these_DEMO
available_JJ
throughout_PIN
and_CC
successfully_RB
adapt_VB
to_PIN
different_JJ
language_NN
I_FPP1
still_RB
have_VPRT
a_DT
long_JJ
way_NN
to_TO
go_VB
to_TO
be_VB [BEMA]
the_DT
organization_NOMZ
._.
as_IN
spontaneous_JJ
in_PIN
English_NN
as_IN
I_FPP1
am_VPRT [BEMA]
in_PIN
German_JJ
!_.
transfers_NN
and_PHC
secondments_NOMZ
at_PIN
a_DT
range_NN
of_PIN
levels_NN
But_CC
overall_JJ
,_,
this_DEMP
is_VPRT [BEMA]
a_DT
perfect_JJ
opportunity_NOMZ
to_TO
have_VB [PEAS]
taken_VBN
place_NN
during_PIN
the_DT
year_NN
._.
improve_VB
your_SPP2
career_NN
and_CC
help_VB
you_SPP2
with_PIN
your_SPP2
personal_JJ
development_NOMZ
._.
My_FPP1
advice_NN
is_VPRT
:_:
overcome_VB
Shire_NN
has_VPRT
a_DT
proactive_JJ
people_NN
management_NOMZ
any_QUAN
concerns_NN
you_SPP2
might_POMD
have_VB
this_DEMP
is_VPRT [BEMA]
an_DT
strategy_NN
which_WDT [WHSUB]
aims_VPRT
to_TO
attract_VB
and_PHC
retain_VB
the_DT
experience_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
really_EMPH
worth_PRED
having_VBG
and_CC
most_EMPH
talented_JJ
employees_NN
._.
Global_JJ
turnover_NN
of_PIN
which_WDT [PIRE]
you_SPP2
will_PRMD
remember_VB [PRIV]
all_QUAN
your_SPP2
life_NN
._.
staff_NN
for_PIN
2002_CD
was_VBD [BEMA]
around_PLACE
10_CD
%_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
low_PRED
by_PIN
industry_NN
standards_NN
._.
26_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
social_JJ
responsibility_NOMZ
report_NN
2001_CD
and_CC
2002_CD
environmental_JJ
data_NN
Transport_VPRT
Water_NN
usage_NN
Effluent_JJ
3_CD
km_NN
m_NN
discharge_VB
3_CD
m_NN
Energy_NN
Solid_JJ
waste_NN
consumption_NOMZ
metric_JJ
kWh_NN
tonnes_NN
2002_CD
52,770,000_CD
70,118,500_CD
2,800_CD
226,500_CD
56,000_CD
2001_CD
41,022,500_CD
48,430,000_CD
2,000_CD
215,000_CD
43,500_CD
The_DT
2001_CD
data_NN
covers_VPRT
figures_NN
of_PIN
Shire_NN
Biologics_NN
starting_VBG [WZPRES]
from_PIN
the_DT
date_NN
of_PIN
merger_NN
between_PIN
BioChem_NN
Pharma_NN
and_PHC
Shire_NN
in_PIN
May_POMD
2001_CD
._.
The_DT
data_NN
covers_VPRT
8085_CD
%_NN
of_PIN
Shires_NN
activity_NOMZ
,_,
based_VBN [PASTP]
on_PIN
the_DT
number_NN
of_PIN
employees_NN
located_VBN [WZPAST]
at_PIN
the_DT
sites_NN
,_,
which_WDT [SERE]
were_VBD [PASS]
included_VBN
in_PIN
the_DT
data_NN
collection_NOMZ
process_NN
._.
The_DT
2002_CD
figures_NN
do_VPRT
not_XX0
include_VB
data_NN
from_PIN
the_DT
newly_RB
acquired_VBN
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
._.
SUMI_NN
,_,
formerly_TIME
APS_NN
Inc._NN
._.
Numbers_NN
given_VBN [WZPAST]
for_PIN
2001_CD
do_VPRT
not_XX0
always_RB
correspond_VB
exactly_RB
to_PIN
numbers_NN
reported_VBN [PUBV] [WZPAST]
previously_TIME
due_JJ
to_PIN
improvements_NOMZ
made_VBN [WZPAST]
in_PIN
our_FPP1
measurement_NOMZ
and_PHC
data_NN
gathering_GER
process_NN
._.
Health_NN
and_PHC
safety_NN
we_FPP1
are_VPRT
endeavoring_VBG
to_TO
manage_VB
these_DEMO
supply_NN
2003_CD
these_DEMP
working_VBG
groups_NN
intend_VPRT [SUAV]
to_TO
make_VB
Shire_NN
developed_VBD
a_DT
global_JJ
health_NN
and_PHC
safety_NN
chain_NN
issues_NN
in_PIN
a_DT
responsible_JJ
manner_NN
._.
recommendations_NOMZ
to_PIN
the_DT
CSR_NN
Committee_NN
for_PIN
policy_NN
during_PIN
the_DT
year_NN
which_WDT [WHSUB]
was_VBD [PASS]
published_VBN
on_PIN
actions_NOMZ
to_TO
be_VB [PASS]
undertaken_VBN
to_TO
deliver_VB
improved_VBN
the_DT
staff_NN
intranet_NN
._.
This_DEMP
is_VPRT [BEMA]
the_DT
template_NN
for_PIN
the_DT
With_PIN
the_DT
acquisition_NOMZ
of_PIN
Shire_NN
US_FPP1
Manufacturing_GER
environmental_JJ
performance_NN
._.
way_NN
health_NN
and_PHC
safety_NN
issues_NN
are_VPRT [PASS]
managed_VBN
in_PIN
Owings_NN
Mills_NN
,_,
Maryland_NN
,_,
USA_NN
,_,
our_FPP1
commitment_NOMZ
throughout_PIN
the_DT
organization_NOMZ
._.
Depending_VBG [PRESP]
on_PIN
the_DT
to_PIN
environmental_JJ
concerns_NN
remains_VPRT
at_PIN
the_DT
During_PIN
2002_CD
we_FPP1
introduced_VBD
new_JJ
Group_NN
nature_NN
of_PIN
the_DT
particular_JJ
site_NN
,_,
the_DT
amount_NN
of_PIN
highest_JJ
level_NN
._.
Shire_NN
works_VPRT
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
compliance_NN
reporting_VBG [PUBV] [WZPRES]
processes_NN
for_PIN
regularly_RB
measuring_VBG
our_FPP1
additional_JJ
attention_NOMZ
and_CC
detailed_JJ
local_JJ
policy_NN
with_PIN
local_JJ
,_,
state_NN
and_CC
national_JJ
regulations_NOMZ
._.
We_FPP1
seek_VPRT
further_RB
,_,
through_PIN
our_FPP1
environmental_JJ
of_PIN
our_FPP1
2001_CD
and_CC
2002_CD
data-gathering_JJ
exercises_NN
and_PHC
safety_NN
officer_NN
and_CC
outside_PLACE
consultants_NN
,_,
to_TO
are_VPRT [PASS]
reported_VBN [PUBV]
above_PLACE
._.
Current_JJ
indicators_NN
are_VPRT
Health_NN
and_PHC
safety_NN
committees_NN
operate_VPRT
in_PIN
most_EMPH
remain_VPRT
abreast_NN
of_PIN
current_JJ
scientific_JJ
thinking_GER
and_CC
related_VBN
to_PIN
energy_NN
consumption_NOMZ
,_,
transport_NN
,_,
of_PIN
the_DT
major_JJ
Shire_NN
sites_NN
and_CC
the_DT
Company_NN
is_VPRT [PASS]
programs_NN
aimed_VBN [WZPAST]
at_PIN
improving_VBG
environmental_JJ
water_NN
use_NN
,_,
effluent_JJ
discharge_VB
and_CC
solid_JJ
waste_NN
._.
examining_VBG [PRESP]
the_DT
introduction_NOMZ
of_PIN
central_JJ
data_NN
quality_NOMZ
for_PIN
the_DT
next_JJ
generation_NOMZ
._.
Based_VBN [PASTP]
on_PIN
an_DT
analysis_NN
of_PIN
current_JJ
performance_NN
,_,
collection_NOMZ
and_PHC
measurement_NOMZ
._.
a_DT
key_JJ
task_NN
for_PIN
the_DT
EHS_NN
work_NN
group_NN
during_PIN
During_PIN
2002_CD
we_FPP1
established_VBD [PRIV]
a_DT
corporate_JJ
2003_CD
will_PRMD
be_VB
to_TO
evaluate_VB
and_PHC
provide_VB
Dr_NN
Wilson_NN
Totten_NN
,_,
Group_NN
R&D_NN
Director_NN
,_,
is_VPRT [BEMA]
the_DT
framework_NN
within_PIN
which_WDT [PIRE]
to_TO
manage_VB
on_PIN
respective_JJ
targets_NN
for_PIN
Board_NN
member_NN
responsible_JJ
for_PIN
Shires_NN
approach_NN
mental_JJ
issues_NN
._.
Jeff_NN
Devlin_NN
,_,
Corporate_NN
Affairs_NN
performance_NN
improvement_NOMZ
on_PIN
these_DEMO
direct_JJ
to_PIN
health_NN
and_PHC
safety_NN
._.
Director_NN
and_PHC
member_NN
of_PIN
the_DT
Companys_NN
environmental_JJ
impacts_NN
identified_VBN [WZPAST]
for_PIN
Shire_NN
Executive_NN
Committee_NN
,_,
leads_VPRT
Shires_NN
environmental_JJ
at_PIN
Group_NN
and_PHC
site_NN
levels_NN
._.
Environment_NOMZ
issues_NN
at_PIN
Group_NN
level_NN
._.
Operational_JJ
responsibility_NOMZ
Shire_NN
recognizes_VPRT [PRIV] [THATD]
its_PIT
corporate_JJ
responsibility_NOMZ
rests_VPRT
with_PIN
senior_JJ
management_NOMZ
in_PIN
each_QUAN
of_PIN
the_DT
towards_PIN
the_DT
environment_NOMZ
and_CC
believes_VPRT [PRIV]
in_PIN
business_NOMZ
units_NN
,_,
supported_VBN [PASTP]
through_PIN
a_DT
network_NN
the_DT
importance_NN
of_PIN
environmental_JJ
protection_NOMZ
of_PIN
environmental_JJ
and_CC
facility_NOMZ
managers_NN
at_PIN
site_NN
and_PHC
improvement_NOMZ
._.
Our_FPP1
environmental_JJ
policy_NN
,_,
available_JJ
on_PIN
our_FPP1
relevant_JJ
environmental_JJ
laws_NN
and_PHC
regulations_NOMZ
website_NN
,_,
www_NN
._.
com_NN
,_,
guides_NN
our_FPP1
activities_NOMZ
is_VPRT [BEMA]
a_DT
minimum_JJ
standard_JJ
across_PLACE
the_DT
business_NOMZ
,_,
in_PIN
this_DEMO
field_NN
._.
It_PIT
identifies_VPRT
objectives_NN
such_JJ
as_IN
and_CC
we_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
achieving_VBG
minimizing_VBG
resource_NN
consumption_NOMZ
,_,
improving_VBG
improvements_NOMZ
in_PIN
environmental_JJ
performance_NN
pollution_NOMZ
control_NN
and_PHC
waste_NN
management_NOMZ
,_,
continually_RB
._.
and_ANDC
promoting_VBG
good_JJ
practices_NN
amongst_PIN
our_FPP1
employees_NN
and_CC
in_PIN
our_FPP1
supply_NN
chain_NN
._.
With_PIN
our_FPP1
activities_NOMZ
focused_VBD
on_PIN
research_NN
and_PHC
development_NOMZ
of_PIN
new_JJ
drugs_NN
and_PHC
marketing_GER
to_PIN
We_FPP1
are_VPRT
establishing_VBG [PRIV]
two_CD
CSR_NN
work_NN
groups_NN
,_,
specialist_NN
doctors_NN
,_,
our_FPP1
direct_JJ
impact_NN
on_PIN
the_DT
one_CD
to_TO
manage_VB
our_FPP1
direct_JJ
environmental_JJ
,_,
health_NN
environment_NOMZ
is_VPRT [SPAU] [PASS]
relatively_RB
limited_VBN
._.
Our_FPP1
indirect_JJ
and_CC
safety_NN
EHS_NN
issues_NN
and_CC
another_DT
dedicated_VBN
impacts_NN
are_VPRT
potentially_RB
more_EMPH
significant_JJ
,_,
and_ANDC
to_PIN
contractor_NN
and_PHC
supplier_NN
relationships_NN
._.
During_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
27_CD
Corporate_NN
social_JJ
responsibility_NOMZ
report_NN
Shire_NN
in_PIN
the_DT
community_NOMZ
Six_CD
Shire_NN
employees_NN
are_VPRT
volunteering_VBG
their_TPP3
time_NN
every_QUAN
week_NN
to_TO
listen_VB
to_PIN
young_JJ
children_NN
read_VPRT
at_PIN
a_DT
local_JJ
elementary_JJ
school_NN
as_IN
part_NN
of_PIN
the_DT
UKs_NN
Business_NOMZ
in_PIN
the_DT
Community_NOMZ
Reading_VBG [WZPRES]
Volunteers_NN
program_NN
._.
Heres_VPRT
what_WP
some_QUAN
of_PIN
the_DT
volunteers_NN
said_VBD [PUBV]
:_:
I_FPP1
had_VBD
one_CD
girl_NN
this_DEMO
term_NN
who_WP [WHSUB]
could_POMD [SPAU]
barely_DWNT
read_VB
:_:
I_FPP1
thought_VBD [PRIV] [THATD]
she_TPP3
was_VBD [BEMA]
dyslexic_PRED
._.
Now_DPAR
seven_CD
weeks_NN
on_PIN [STPR]
,_,
you_SPP2
would_PRMD
not_XX0
think_VB [PRIV] [THATD]
it_PIT
was_VBD [BEMA]
the_DT
same_JJ
child_NN
._.
She_TPP3
doesnt_JJ
mind_NN
missing_VBG [WZPRES]
the_DT
start_NN
of_PIN
her_TPP3
PE_NN
-LRB-_-LRB-
physical_JJ
education_NOMZ
-RRB-_-RRB-
class_NN
just_EMPH
to_TO
sit_VB
and_PHC
do_VB [PROD]
extra_JJ
words_NN
with_PIN
me_FPP1
._.
I_FPP1
think_VPRT [PRIV]
the_DT
process_NN
of_PIN
interaction_NOMZ
with_PIN
the_DT
children_NN
puts_VPRT
a_DT
different_JJ
perspective_NN
on_PIN
your_SPP2
working_VBG
life_NN
._.
The_DT
process_NN
of_PIN
coming_VBG
down_RB
to_PIN
the_DT
childs_NN
level_NN
helps_VPRT
to_TO
focus_VB
ones_NN
own_JJ
daily_JJ
activities_NOMZ
,_,
especially_RB
in_PIN
communication_NOMZ
._.
It_PIT
improves_VPRT
the_DT
patience_NN
levels_NN
and_PHC
replenishes_NN
you_SPP2
spiritually_RB
after_IN
a_DT
hectic_JJ
day_NN
in_PIN
the_DT
office_NN
._.
I_FPP1
certainly_RB
feel_VPRT [PRIV]
refreshed_VBN
when_RB
I_FPP1
return_VPRT
from_PIN
a_DT
session_NN
and_CC
invariably_RB
leave_VPRT
the_DT
school_NN
with_PIN
a_DT
smile_NN
on_PIN
my_FPP1
face_NN
._.
Shire_NN
in_PIN
the_DT
communityFinancial_JJ
support_NN
for_PIN
the_DT
2002_CD
BritishFunding_GER
for_PIN
the_DT
Epilepsy_NN
Foundation_NOMZ
of_PIN
Shire_NN
is_VPRT [PASS]
committed_VBN
to_PIN
its_PIT
role_NN
as_IN
a_DT
socially_RB
Transplant_NN
Games_NN
America_NN
,_,
at_PIN
both_DT
the_DT
national_JJ
level_NN
,_,
responsible_JJ
company_NN
and_CC
has_VPRT
the_DT
aim_NN
that_DEMP
and_CC
locally_PLACE
to_PIN
the_DT
Epilepsy_NN
Foundation_NOMZ
communities_NOMZ
in_PIN
which_WDT [PIRE]
it_PIT
operates_VPRT
should_NEMD
benefitFinancial_NN
support_NN
for_PIN
the_DT
National_NN
of_PIN
Cincinnati_NN
,_,
where_RB
Shire_NN
US_FPP1
has_VPRT
its_PIT
directly_RB
from_PIN
the_DT
wealth_NN
and_PHC
jobs_NN
created_VBN
and_CC
Association_NOMZ
of_PIN
Crohns_NN
and_PHC
Colitis_NN
headquarters_NN
from_PIN
the_DT
investment_NOMZ
of_PIN
time_NN
and_PHC
money_NN
in_PIN
the_DT
community_NOMZ
._.
As_IN
part_NN
of_PIN
its_PIT
marketing_GER
support_NN
activity_NOMZ
,_,
In_PIN
partnership_NN
with_PIN
GlaxoSmithKline_NN
,_,
jointly_RB
with_PIN
marketing_GER
partner_NN
J&J_NN
funding_GER
sponsorship_NN
to_TO
support_VB
the_DT
AIDS_NN
Walks_VPRT
A_DT
charity_NOMZ
policy_NN
was_VBD [PASS]
established_VBN [PRIV]
during_PIN
2002_CD
for_PIN
educational_JJ
meetings_GER
for_PIN
doctors_NN
,_,
the_DT
across_PLACE
Canada_NN
three_CD
major_JJ
walks_VPRT
in_PIN
outlining_VBG
the_DT
approach_NN
that_TOBJ
the_DT
Company_NN
memoryclinic_NN
._.
com_NN
website_NN
,_,
provision_NN
Montreal_NN
,_,
Toronto_NN
,_,
Vancouver_NN
and_CC
100_CD
takes_VPRT
to_PIN
corporate_JJ
sponsorships_NN
,_,
bursaries_NN
,_,
of_PIN
educational_JJ
materials_NN
and_PHC
funding_GER
of_PIN
walks_VPRT
in_PIN
smaller_JJ
cities_NOMZ
fundraising_VBG [WZPRES]
and_CC
charitable_JJ
contributions_NOMZ
._.
It_PIT
memory_NN
clinic_NN
nurses_NN
and_CC
a_DT
hospital_NN
registrar_NN
sets_VPRT
clear_JJ
parameters_NN
as_IN
to_PIN
the_DT
charities_NOMZ
and_CC
to_TO
assist_VB
with_PIN
the_DT
support_NN
of_PIN
AlzheimersA_NN
donation_NOMZ
to_PIN
The_DT
Teresa_NN
Group_NN
to_TO
assist_VB
causes_NN
that_TOBJ
we_FPP1
choose_VPRT
to_TO
support_VB
at_PIN
both_DT
treatment_NOMZ
publication_NOMZ
of_PIN
Bye_NN
Bye_NN
Secrets_NN
,_,
a_DT
book_NN
a_DT
local_JJ
and_PHC
corporate_JJ
level_NN
._.
The_DT
overarching_JJ
about_IN
children_NN
living_VBG [WZPRES]
with_PIN
HIV_NN
or_CC
AIDS_NN
in_PIN
principle_NN
behind_PLACE
this_DEMO
policy_NN
is_VPRT
to_TO
allow_VB [SUAV]
localFinancial_JJ
contribution_NOMZ
to_PIN
the_DT
Crohns_NN
and_CC
their_TPP3
family_NN
flexibility_NOMZ
to_TO
make_VB
decisions_NN
that_TSUB
are_VPRT [BEMA]
appropriate_JJ
Colitis_NN
Foundation_NOMZ
of_PIN
America_NN
CCFA_NN
and_CC
to_TO
support_VB
both_DT
Group_NN
and_CC
local_JJ
objectives_NN
._.
membership_NN
of_PIN
its_PIT
Presidents_NN
CircleDonation_NOMZ
of_PIN
FLUVIRAL_NN
vaccine_NN
to_PIN
the_DT
Columbian_NN
Ministry_NN
of_PIN
Healths_NN
national_JJ
During_PIN
the_DT
year_NN
,_,
Shire_NN
supported_VBD
a_DT
wide_JJ
rangeFinancial_JJ
support_NN
for_PIN
CHADD_NN
Children_NN
and_PHC
immunisation_NOMZ
program_NN
for_PIN
the_DT
of_PIN
charities_NOMZ
and_PHC
causes_NN
:_:
Adults_NN
with_PIN
Attention_NOMZ
Deficit_NN
Hyperactivity_NOMZ
disadvantaged_JJ
Disorder_NN
,_,
the_DT
leading_VBG
non-profit_JJ
organization_NOMZ
The_DT
Basingstoke_NN
Alzheimers_NN
Society_NN
serving_VBG [WZPRES]
individuals_NN
with_PIN
ADHD_NN
in_PIN
the_DT
United_NN
providing_VBG [WZPRES]
funding_GER
to_TO
enable_VB
increased_VBN
States_NN
support_NN
for_PIN
carers_NN
in_PIN
the_DT
area_NN
where_RB
the_DT
Companys_NN
head_VPRT
office_NN
is_VPRT [BEMA]
basedFinancial_JJ
support_NN
for_PIN
the_DT
American_NN
Academy_NN
of_PIN
Child_NN
and_PHC
Adolescent_NN
Child_NN
Victims_NN
of_PIN
Crime_NN
making_VBG [WZPRES]
a_DT
donation_NOMZ
Psychiatry_NN
AACAP_NN
,_,
the_DT
leading_JJ
national_JJ
instead_CONJ
of_NULL
sending_VBG [WZPRES]
Company_NN
Christmas_NN
cards_NN
professional_JJ
medical_JJ
association_NOMZ
dedicated_VBN
to_TO
treating_VBG
and_PHC
improving_VBG
the_DT
quality_NOMZ
of_PIN
Provision_NN
of_PIN
Maxolon_NN
product_NN
for_PIN
the_DT
life_NN
for_PIN
children_NN
,_,
adolescents_NN
and_PHC
families_NN
pharmacy_VPRT
supporting_VBG
the_DT
athletes_NN
at_PIN
the_DT
affected_VBN
by_PIN
mental_JJ
,_,
behavioural_JJ
or_CC
Commonwealth_NN
Games_NN
in_PIN
Manchester_NN
developmental_JJ
disorders_NN
28_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
social_JJ
responsibility_NOMZ
report_NN
Marking_VBG [WZPRES]
Breast_NN
Awareness_NOMZ
Month_NN
the_DT
Shire_NN
matched_VBD
funds_NN
raised_VBN [WZPAST]
by_PIN
head_NN
office_NN
Human_NN
Resources_NN
and_PHC
Marketing_GER
Departments_NOMZ
employees_NN
in_PIN
a_DT
sponsored_VBN
run_NN
to_TO
support_VB
at_PIN
Shire_NN
in_PIN
the_DT
US_FPP1
hosted_VBD
an_DT
educational_JJ
meeting_GER
Cancer_NN
Research_NN
._.
The_DT
American_NN
Cancer_NN
Society_NN
presented_VBD
information_NOMZ
on_PIN
its_PIT
research_NN
,_,
early_TIME
detection_NOMZ
and_PHC
treatment_NOMZ
of_PIN
breast_NN
cancer_NN
and_CC
had_VBD
a_DT
breast_NN
cancer_NN
survivor_NN
give_VB
her_TPP3
testimonial_NN
._.
Several_QUAN
employees_NN
also_RB
showed_VBD [PRIV]
their_TPP3
support_NN
by_PIN
participating_VBG
in_PIN
the_DT
walk_NN
Making_VBG [WZPRES]
Strides_NN
Against_PIN
Breast_NN
Cancer_NN
in_PIN
Cincinnati_NN
and_CC
more_EMPH
than_PIN
US$_$
3,000_CD
was_VBD [PASS]
raised_VBN
._.
Sponsorship_NN
of_PIN
the_DT
sixth_JJ
Organic_NN
Workshop_NN
for_PIN
Leading_VBG
Young_JJ
Canadian_JJ
Chemists_NN
Actions_NOMZ
on_PIN
CSR_NN
planned_VBD
for_PIN
2003_CD
organised_VBN
by_PIN
the_DT
Simon_NN
Fraser_NN
University_NOMZ
in_PIN
In_PIN
2003_CD
,_,
the_DT
Group_NN
intends_VPRT [SUAV]
to_TO
continue_VB
British_JJ
Columbia_NN
,_,
Canada_NN
to_TO
embed_VB
CSR_NN
issues_NN
into_PIN
its_PIT
corporate_JJ
governance_NN
framework_NN
._.
A_DT
number_NN
of_PIN
Support_NN
of_PIN
the_DT
Daffodil_NN
Ball_NN
,_,
a_DT
fundraising_VBG
specific_JJ
projects_NN
are_VPRT [BEMA]
underway_PRED
,_,
including_VBG
:_:
event_NN
of_PIN
the_DT
Canadian_JJ
Cancer_NN
Society_NN
Strengthening_GER
our_FPP1
engagement_NOMZ
with_PIN
Employee_NN
involvement_NOMZ
and_CC
fundraising_VBG
to_PIN
stakeholders_NN
support_VPRT
Centraide_NN
,_,
a_DT
Canadian_JJ
organization_NOMZ
that_TSUB
encourages_VPRT
community_NOMZ
volunteering_GER
._.
Setting_VBG
up_RP
Group_NN
and_PHC
site_NN
Its_PIT
mission_NN
is_VPRT
to_TO
help_VB
build_VB
caring_VBG
environmental_JJ
objectives_NN
and_PHC
targets_NN
communities_NOMZ
and_CC
provide_VB
direct_JJ
financial_JJ
support_NN
to_PIN
people_NN
in_PIN
needSetting_VBG
up_RP
Group_NN
and_PHC
site_NN
health_NN
and_PHC
safety_NN
objectives_NN
and_PHC
targets_NN
Support_NN
for_PIN
the_DT
Worcester_NN
Regional_NN
Science_NN
and_PHC
Engineering_GER
Fair_NN
inIntegrating_GER
CSR_NN
topics_NN
into_PIN
the_DT
Northborough_NN
Massachussets_NN
,_,
US_FPP1
,_,
and_ANDC
management_NOMZ
of_PIN
our_FPP1
contractors_NN
and_PHC
sponsorship_NN
of_PIN
a_DT
scholarship_NN
program_NN
suppliers_NN
for_PIN
community_NOMZ
schools_NN
._.
Improving_GER
our_FPP1
CSR_NN
data_NN
gathering_GER
and_PHC
reporting_GER
Building_GER
up_IN
employee_NN
awareness_NOMZ
and_PHC
commitment_NOMZ
to_PIN
CSR_NN
Improving_GER
Shire_NN
ranking_GER
in_PIN
key_JJ
CSR_NN
indices_NN
._.
Over_IN
time_NN
,_,
additional_JJ
information_NOMZ
will_PRMD
be_VB [PASS]
made_VBN
available_JJ
regarding_VBG
our_FPP1
policies_NN
and_PHC
practices_NN
in_PIN
this_DEMO
area_NN
both_DT
on_PIN
our_FPP1
website_NN
,_,
www_NN
._.
com_NN
,_,
and_ANDC
in_PIN
future_JJ
Annual_JJ
Reviews_NN
._.
We_FPP1
welcome_VPRT
any_QUAN
comments_NOMZ
and_PHC
ideas_NN
for_PIN
improvement_NOMZ
in_PIN
our_FPP1
practices_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
29_CD
Financial_NN
review_NN
The_DT
following_VBG
review_NN
should_NEMD
be_VB [PASS]
read_VBN
in_PIN
conjunction_NOMZ
with_PIN
the_DT
Groups_NN
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
related_JJ
notes_NN
appearing_VBG [SMP] [WZPRES]
elsewhere_RB
in_PIN
this_DEMO
report_NN
._.
Material_NN
acquisitions_NOMZ
and_PHC
disposals_NN
Sales_NN
of_PIN
ADDERALL_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
were_VBD [BEMA]
On_PIN
27_CD
September_NN
2002_CD
,_,
Shire_NN
completed_VBD
its_PIT
acquisition_NOMZ
of_PIN
Atlantic_NN
$_$
109.8_CD
million_CD
compared_VBN
to_TO
$_$
317.7_CD
million_CD
in_PIN
the_DT
comparative_JJ
period_NN
._.
Pharmaceutical_NN
Services_NN
Inc._NN
._.
APS_NN
from_PIN
Niro_NN
Inc._NN
for_PIN
cash_NN
consideration_NOMZ
This_DEMO
decline_NN
in_PIN
ADDERALL_NN
sales_NN
is_VPRT [BEMA]
largely_RB
due_PRED
to_PIN
the_DT
success_NN
in_PIN
of_PIN
$_$
17.3_CD
million_CD
,_,
including_VBG
$_$
0.3_CD
million_CD
costs_NN
of_PIN
acquisition_NOMZ
._.
This_DEMP
converting_VBG
patients_NN
to_PIN
the_DT
new_JJ
,_,
once-a-day_JJ
formulation_NOMZ
of_PIN
the_DT
drug_NN
,_,
transaction_NOMZ
provides_VPRT
an_DT
in-house_JJ
facility_NOMZ
in_PIN
which_WDT [PIRE]
to_TO
manufacture_VB
several_QUAN
ADDERALL_NN
XR_NN
._.
key_JJ
US_FPP1
products_NN
,_,
thus_CONJ
ensuring_VBG [SUAV] [PRIV]
dual_JJ
sourcing_VBG
of_PIN
major_JJ
growth_NN
drivers_NN
for_PIN
the_DT
Company_NN
and_CC
attendant_JJ
cost_NN
benefits_NN
._.
The_DT
acquisition_NOMZ
was_VBD [BEMA]
On_PIN
a_DT
combined_VBN
basis_NN
,_,
product_NN
sales_NN
from_PIN
the_DT
ADHD_NN
franchise_NN
in_PIN
2002_CD
accounted_VBD
for_PIN
using_VBG
the_DT
purchase_NN
method_NN
and_PHC
goodwill_NN
of_PIN
$_$
10.2_CD
million_CD
were_VBD
up_RB
$_$
77.4_CD
million_CD
,_,
a_DT
22_CD
%_NN
increase_NN
compared_VBN [WZPAST]
to_PIN
the_DT
prior_JJ
year_NN
._.
Over_IN
the_DT
same_JJ
period_NN
,_,
the_DT
number_NN
of_PIN
prescriptions_NOMZ
written_VBN [PUBV] [WZPAST]
for_PIN
ADDERALL_NN
XR_NN
and_PHC
ADDERALL_NN
was_VBD [BEMA]
marginally_RB
higher_PRED
,_,
by_PIN
0.6_CD
%_NN
._.
On_PIN
27_CD
December_NN
2002_CD
,_,
Shire_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
a_DT
group_NN
of_PIN
In_PIN
December_NN
2002_CD
,_,
these_DEMO
products_NN
achieved_VBD
a_DT
28.8_CD
%_NN
share_NN
of_PIN
the_DT
non-strategic_JJ
US_FPP1
products_NN
,_,
known_VBN [PRIV] [PASTP]
collectively_RB
as_IN
the_DT
over-the-counter_JJ
US_FPP1
ADHD_NN
prescription_NOMZ
market_NN
December_NN
2001_CD
:_:
34.4_CD
%_NN
._.
Shire_NN
received_VBD
sale_NN
proceeds_NN
of_PIN
$_$
72_CD
million_CD
ADHD_NN
market_NN
grew_VBD
by_PIN
14_CD
%_NN
during_PIN
2002_CD
and_ANDC
thus_CONJ
provided_VBN
further_RB
around_PLACE
three_CD
times_NN
annual_JJ
sales_NN
and_CC
recorded_VBD
a_DT
gain_NN
on_PIN
disposal_NN
support_NN
to_PIN
the_DT
excellent_JJ
result_NN
in_PIN
switching_VBG
patients_NN
to_PIN
ADDERALL_NN
XR_NN
._.
Our_FPP1
extended-release_JJ
product_NN
ADDERALL_NN
XR_NN
is_VPRT [BYPA]
covered_VBN
by_PIN
a_DT
US_FPP1
patent_NN
._.
Results_NN
of_PIN
operations_NOMZ
In_PIN
January_NN
2003_CD
we_FPP1
received_VBD
a_DT
Paragraph_NN
IV_NN
notice_NN
from_PIN
Barr_NN
alleging_VBG [PUBV] [WZPRES]
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
that_DEMP
this_DEMO
patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
not_XX0
infringed_VBN
by_PIN
Barrs_NN
extended-release_NN
method_NN
investees_NN
,_,
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
was_VBD [BEMA]
mixed_JJ
amphetamine_NN
salt_NN
product_NN
._.
In_PIN
February_NN
2003_CD
,_,
Shire_NN
Laboratories_NN
$_$
329.1_CD
million_CD
compared_VBN
to_TO
$_$
101.5_CD
million_CD
in_PIN
2001_CD
._.
Included_VBN [PASTP]
in_PIN
the_DT
Inc._NN
filed_VBD
suit_NN
against_PIN
Barr_NN
for_PIN
infringement_NOMZ
of_PIN
this_DEMO
US_FPP1
patent_NN
._.
For_PIN
more_EMPH
results_NN
for_PIN
2001_CD
were_VBD
charges_NN
of_PIN
$_$
177.0_CD
million_CD
relating_VBG
to_PIN
the_DT
merger_NN
details_NN
see_VPRT [PRIV]
note_NN
19_CD
to_PIN
this_DEMO
report_NN
and_CC
financial_JJ
statements_NOMZ
._.
There_EX
can_POMD
be_VB
with_PIN
BioChem_NN
Pharma_NN
Inc._NN
._.
Diluted_JJ
earnings_GER
per_PIN
share_NN
,_,
for_PIN
the_DT
year_NN
no_SYNE
assurance_NN
that_TOBJ
the_DT
Group_NN
will_PRMD
prevail_VB
in_PIN
the_DT
suit_NN
and_CC
in_PIN
the_DT
event_NN
it_PIT
ended_VBD
31_CD
December_NN
2002_CD
was_VBD [BEMA]
49.0_CD
compared_VBN
to_PIN
7.7_CD
in_PIN
2001_CD
._.
does_VPRT
not_XX0
this_DEMP
may_POMD
have_VB
a_DT
material_NN
adverse_JJ
impact_NN
on_PIN
the_DT
Groups_NN
results_NN
and_CC
financial_JJ
position_NOMZ
._.
The_DT
current_JJ
year_NN
results_NN
include_VPRT
the_DT
results_NN
of_PIN
APS_NN
from_PIN
the_DT
acquisition_NOMZ
date_NN
._.
The_DT
results_NN
,_,
for_PIN
all_QUAN
periods_NN
other_JJ
than_PIN
2002_CD
,_,
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_PIN
AGRYLIN_NN
reflect_VPRT [PRIV]
the_DT
disposal_NN
of_PIN
our_FPP1
OTC_NN
business_NOMZ
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
Total_JJ
AGRYLIN_NN
sales_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2002_CD
were_VBD
as_IN
a_DT
discontinued_VBN
operation_NOMZ
._.
$_$
119.2_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
39_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
prior_JJ
year_NN
2001_CD
:_:
$_$
85.5_CD
million_CD
._.
Turnover_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
total_JJ
revenues_NN
increased_VBN [WZPAST]
by_PIN
Underlying_JJ
prescriptions_NOMZ
for_PIN
AGRYLIN_NN
in_PIN
the_DT
US_FPP1
,_,
where_RB
it_PIT
is_VPRT [BEMA]
the_DT
only_DWNT
22_CD
%_NN
to_TO
$_$
1,037.3_CD
million_CD
,_,
compared_VBN
to_TO
$_$
853.0_CD
million_CD
in_PIN
2001_CD
._.
product_NN
licensed_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
essential_JJ
thrombocythemia_NN
,_,
increased_VBN [PASTP]
by_PIN
22_CD
%_NN
._.
Shire_NN
achieved_VBD
26.5_CD
%_NN
of_PIN
the_DT
total_JJ
US_FPP1
AGRYLIN_NN
,_,
Turnover_NN
is_VPRT [SPAU] [PASS]
primarily_RB
derived_VBN
from_PIN
sales_NN
of_PIN
pharmaceutical_JJ
products_NN
with_PIN
hydrea_NN
and_CC
generic_JJ
hydroxyurea_NN
prescription_NOMZ
market_NN
in_PIN
December_NN
2002_CD
,_,
the_DT
balance_NN
coming_VBG [WZPRES]
from_PIN
royalties_NN
earned_VBN [WZPAST]
on_PIN
products_NN
out-licensed_JJ
to_TO
compared_VBN
to_PIN
24.4_CD
%_NN
in_PIN
December_NN
2001_CD
._.
third_JJ
parties_NN
._.
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
83_CD
%_NN
of_PIN
turnover_NN
was_VBD [BEMA]
in_PIN
respect_NN
of_PIN
product_NN
sales_NN
2001_CD
:_:
82_CD
%_NN
._.
PENTASA_NN
Sales_NN
of_PIN
PENTASA_NN
,_,
for_PIN
the_DT
treatment_NOMZ
of_PIN
ulcerative_JJ
colitis_NN
,_,
were_VBD [BEMA]
up_RB
15_CD
%_NN
Product_NN
sales_NN
at_PIN
$_$
87.2_CD
million_CD
2001_CD
:_:
$_$
75.5_CD
million_CD
._.
PENTASA_NN
had_VBD
a_DT
prescription_NOMZ
share_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
product_NN
sales_NN
increased_VBN [WZPAST]
by_PIN
23_CD
%_NN
of_PIN
17.6_CD
%_NN
of_PIN
the_DT
US_FPP1
oral_JJ
mesalamine_NN
olsalazine_NN
market_NN
in_PIN
December_NN
to_TO
$_$
859.4_CD
million_CD
,_,
compared_VBN
to_TO
$_$
699.4_CD
million_CD
in_PIN
the_DT
prior_JJ
year_NN
._.
ADDERALL_NN
franchise_NN
PROAMATINE_NN
At_PIN
the_DT
outset_NN
,_,
2002_CD
was_VBD
to_TO
be_VB [BEMA]
a_DT
challenging_JJ
year_NN
for_PIN
the_DT
ADDERALL_NN
Sales_NN
of_PIN
PROAMATINE_NN
,_,
for_PIN
the_DT
treatment_NOMZ
of_PIN
postural_JJ
hypotension_NN
,_,
were_VBD
franchise_NN
,_,
as_IN
it_PIT
was_VBD [PASS]
expected_VBN [PRIV]
to_TO
face_VB
strong_JJ
competition_NOMZ
from_PIN
generic_JJ
$_$
50.9_CD
million_CD
,_,
34_CD
%_NN
higher_JJ
than_PIN
2001_CD
sales_NN
of_PIN
$_$
38.0_CD
million_CD
._.
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
sales_NN
of_PIN
ADDERALL_NN
prescription_NOMZ
market_NN
for_PIN
PROAMATINE_NN
and_CC
fludrocortisone_JJ
acetate_NN
XR_NN
were_VBD
$_$
317.9_CD
million_CD
compared_VBN
to_TO
$_$
32.6_CD
million_CD
in_PIN
the_DT
last_JJ
two_CD
prescriptions_NOMZ
indicated_VBD [PRIV]
that_THVC
PROAMATINE_NN
had_VBD
a_DT
25.3_CD
%_NN
market_NN
share_NN
for_PIN
months_NN
of_PIN
2001_CD
the_DT
year_NN
of_PIN
launch_NN
._.
the_DT
month_NN
of_PIN
December_NN
2002_CD
,_,
an_DT
increase_NN
from_PIN
23.6_CD
%_NN
in_PIN
December_NN
2001_CD
._.
30_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
CARBATROL_NN
$_$
31.4_CD
million_CD
._.
The_DT
underlying_VBG
charge_NN
for_PIN
the_DT
year_NN
decreased_VBD
because_CAUS
Sales_NN
of_PIN
CARBATROL_NN
,_,
for_PIN
the_DT
treatment_NOMZ
of_PIN
epilepsy_NN
,_,
were_VBD
$_$
45.3_CD
million_CD
in_PIN
accordance_NN
with_PIN
US_FPP1
Accounting_GER
Standards_NN
goodwill_NN
is_VPRT
no_RB
longer_RB
in_PIN
2002_CD
,_,
an_DT
increase_NN
of_PIN
23_CD
%_NN
over_IN
prior_JJ
year_NN
sales_NN
of_PIN
$_$
36.8_CD
million_CD
._.
amortised_JJ
and_CC
is_VPRT [SPAU] [PASS]
instead_CONJ
tested_VBN
at_PIN
least_JJ
annually_RB
for_PIN
impairment_NOMZ
._.
Goodwill_NN
CARBATROL_NN
achieved_VBD
36.3_CD
%_NN
of_PIN
the_DT
US_FPP1
extended-release_NN
amortisation_NOMZ
was_VBD
$_$
10.8_CD
million_CD
in_PIN
2001_CD
._.
The_DT
depreciation_NOMZ
charge_NN
for_PIN
carbamazepine_NN
prescription_NOMZ
market_NN
in_PIN
December_NN
2002_CD
,_,
compared_VBN [PASTP]
with_PIN
2002_CD
was_VBD
$_$
12.9_CD
million_CD
,_,
a_DT
decrease_NN
of_PIN
$_$
1.5_CD
million_CD
compared_VBN
to_PIN
2001_CD
._.
Capital_NN
structure_NN
Royalties_NN
The_DT
Group_NN
has_VPRT [PEAS]
financed_VBN
its_PIT
operations_NOMZ
since_OSUB
inception_NOMZ
through_PIN
private_JJ
Royalty_NN
revenue_NN
increased_VBD
20_CD
%_NN
to_TO
$_$
174.8_CD
million_CD
for_PIN
the_DT
year_NN
ended_VBD
and_CC
public_JJ
offerings_GER
of_PIN
equity_NOMZ
securities_NOMZ
,_,
the_DT
issuance_NN
of_PIN
loan_NN
notes_NN
and_CC
31_CD
December_NN
2002_CD
compared_VBN
to_TO
$_$
145.2_CD
million_CD
in_PIN
2001_CD
._.
Shire_NN
receives_VPRT
convertible_JJ
notes_NN
,_,
collaborative_JJ
licensing_GER
and_PHC
development_NOMZ
fees_NN
,_,
product_NN
royalties_NN
from_PIN
GSK_NN
on_PIN
the_DT
worldwide_JJ
sales_NN
of_PIN
3TC_NN
and_PHC
ZEFFIX_NN
,_,
with_PIN
the_DT
sales_NN
and_PHC
investment_NOMZ
income_NN
._.
exception_NOMZ
of_PIN
Canada_NN
,_,
where_RB
a_DT
partnership_NN
with_PIN
GSK_NN
exists_VPRT
._.
The_DT
Groups_NN
funding_GER
requirements_NOMZ
depend_VPRT
on_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
Other_JJ
royalties_NN
are_VPRT [PASS]
received_VBN
in_PIN
respect_NN
of_PIN
REMINYL_NN
from_PIN
Johnson_NN
&_CC
including_VBG
the_DT
Groups_NN
product_NN
development_NOMZ
programs_NN
,_,
business_NOMZ
and_PHC
Johnson_NN
,_,
and_ANDC
in_CONJ
addition_NULL
a_DT
number_NN
of_PIN
hormone-replacement_NOMZ
therapy_NN
product_NN
acquisitions_NOMZ
,_,
the_DT
level_NN
of_PIN
resources_NN
required_VBN [SUAV] [WZPAST]
for_PIN
the_DT
expansion_NN
HRT_NN
products_NN
from_PIN
various_JJ
licensees_NN
._.
of_PIN
marketing_GER
capabilities_NOMZ
as_IN
the_DT
product_NN
base_NN
expands_VPRT
,_,
increased_VBD
investment_NOMZ
in_PIN
trade_NN
debtors_NN
and_PHC
stock_NN
levels_NN
which_WDT [WHSUB]
may_POMD
arise_VB
as_IN
sales_NN
Cost_NN
of_PIN
sales_NN
levels_NN
increase_NN
,_,
competitive_JJ
and_PHC
technological_JJ
developments_NOMZ
,_,
the_DT
timing_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
cost_NN
of_PIN
sales_NN
amounted_VBD
to_PIN
16_CD
%_NN
and_PHC
cost_NN
of_PIN
obtaining_VBG
required_JJ
regulatory_JJ
approvals_NN
for_PIN
new_JJ
products_NN
,_,
of_PIN
product_NN
sales_NN
,_,
consistent_JJ
with_PIN
2001_CD
._.
A_DT
slight_JJ
favourable_JJ
mix_NN
of_PIN
higherand_NN
the_DT
continuing_VBG
revenues_NN
generated_VBD
from_PIN
sales_NN
of_PIN
key_JJ
products_NN
._.
margin_NN
products_NN
largely_RB
offset_VPRT
costs_NN
associated_VBN [WZPAST]
with_PIN
enhancing_VBG
internal_JJ
and_PHC
external_JJ
production_NOMZ
facility_NOMZ
capabilities_NOMZ
._.
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
had_VBD
cash_NN
,_,
cash_NN
equivalents_NN
and_CC
marketable_JJ
securities_NOMZ
of_PIN
$_$
1,213.8_CD
million_CD
31_CD
December_NN
2001_CD
:_:
Research_NN
and_PHC
development_NOMZ
expenses_NN
$_$
842.0_CD
million_CD
,_,
which_WDT [SERE]
consisted_VBD
of_PIN
immediately_TIME
available_JJ
money_NN
market_NN
R&D_NN
expenditure_NN
increased_VBD
to_TO
$_$
189.2_CD
million_CD
in_PIN
2002_CD
,_,
from_PIN
$_$
171.0_CD
million_CD
fund_NN
balances_NN
and_PHC
investment_NOMZ
grade_NN
securities_NOMZ
._.
Total_JJ
long-term_JJ
debt_NN
,_,
in_PIN
2001_CD
,_,
representing_VBG [PRESP]
an_DT
overall_JJ
increase_NN
of_PIN
11_CD
%_NN
._.
As_IN
a_DT
percentage_NN
of_PIN
excluding_VBG
capital_NN
leases_NN
,_,
as_IN
of_PIN
31_CD
December_NN
2002_CD
was_VBD
$_$
401.9_CD
million_CD
turnover_NN
,_,
research_NN
and_PHC
development_NOMZ
costs_NN
were_VBD [BEMA]
18_CD
%_NN
2001_CD
:_:
20_CD
%_NN
._.
31_CD
December_NN
2001_CD
:_:
$_$
406.8_CD
million_CD
of_PIN
which_WDT [PIRE]
$_$
400_CD
million_CD
was_VBD [BEMA]
in_PIN
Shire_NN
aims_VPRT
to_TO
invest_VB
between_PIN
18_CD
%_NN
and_CC
20_CD
%_NN
of_PIN
total_JJ
turnover_NN
in_PIN
R&D_NN
,_,
respect_NN
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
which_WDT [WHSUB]
were_VBD [PASS]
issued_VBN
on_PIN
although_CONC
the_DT
actual_JJ
level_NN
of_PIN
expenditure_NN
required_VBN [SUAV] [THATD]
each_QUAN
year_NN
is_VPRT [PASS]
driven_VBN
15_CD
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly_RB
owned_VBN
by_PIN
the_DT
progress_NN
and_PHC
development_NOMZ
phase_NN
of_PIN
existing_VBG
and_CC
new_JJ
projects_NN
._.
These_DEMO
convertible_JJ
notes_NN
due_JJ
2011_CD
were_VBD [PASS]
issued_VBN
to_PIN
international_JJ
institutional_JJ
investors_NN
and_PHC
bear_NN
interest_NN
at_PIN
a_DT
rate_NN
of_PIN
2_CD
%_NN
per_PIN
annum_NN
._.
Selling_VBG
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
Selling_VBG [WZPRES]
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
increased_VBD
from_PIN
The_DT
convertible_JJ
notes_NN
are_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
Shire_NN
and_CC
are_VPRT [BEMA]
convertible_PRED
into_PIN
$_$
303.5_CD
million_CD
in_PIN
2001_CD
to_TO
$_$
386.0_CD
million_CD
in_PIN
2002_CD
,_,
an_DT
increase_NN
of_PIN
27_CD
%_NN
._.
redeemable_JJ
preference_NN
shares_NN
of_PIN
the_DT
Issuer_NN
which_WDT [WHOBJ]
upon_PIN
issuance_NN
will_PRMD
be_VB
As_IN
a_DT
percentage_NN
of_PIN
product_NN
sales_NN
,_,
these_DEMO
expenses_NN
were_VBD [BEMA]
45_CD
%_NN
immediately_TIME
exchanged_VBD
for_PIN
either_DT
i_FPP1
Shire_FW
common_JJ
shares_NN
or_CC
ii_FW
Shire_FW
2001_CD
:_:
43_CD
%_NN
._.
American_JJ
Depository_NN
Shares_NN
ADSs_NN
,_,
or_CC
iii_NN
at_PIN
the_DT
Issuers_NN
option_NOMZ
,_,
a_DT
cash_NN
amount_NN
based_VBN [WZPAST]
upon_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
volume-weighted_JJ
Higher_JJ
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
were_VBD [BEMA]
primarily_RB
average_JJ
prices_NN
of_PIN
common_JJ
shares_NN
on_PIN
the_DT
fourth_JJ
through_PIN
eighth_JJ
business_NOMZ
due_JJ
to_TO
increased_VBN
selling_GER
and_PHC
marketing_GER
expenses_NN
supporting_VBG [WZPRES]
higher_JJ
days_NN
following_VBG [WZPRES]
conversion_NN
._.
See_VB [PRIV]
note_NN
16_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
field_NN
headcount_NN
and_CC
promotional_JJ
efforts_NN
for_PIN
recent_JJ
product_NN
launches_NN
,_,
statements_NOMZ
for_PIN
further_JJ
information_NOMZ
._.
The_DT
only_DWNT
other_JJ
long-term_JJ
debt_NN
outstanding_JJ
at_PIN
31_CD
December_NN
2002_CD
was_VBD [BEMA]
A_DT
component_NN
of_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
is_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
a_DT
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
of_PIN
depreciation_NOMZ
and_PHC
amortisation_NOMZ
,_,
which_WDT [SERE]
increased_VBD
from_PIN
$_$
45.8_CD
million_CD
in_PIN
$_$
1.9_CD
million_CD
CAN$_NN
3.0_CD
million_CD
._.
This_DEMO
facility_NOMZ
is_VPRT [BEMA]
non-interest-bearing_PRED
and_CC
2001_CD
to_TO
$_$
55.2_CD
million_CD
in_PIN
2002_CD
._.
For_PIN
2002_CD
,_,
the_DT
amortisation_NOMZ
expense_NN
of_PIN
is_VPRT [BEMA]
repayable_PRED
in_PIN
annual_JJ
instalments_NOMZ
of_PIN
$_$
0.6_CD
million_CD
CAN$_NN
1.0_CD
million_CD
._.
$_$
42.3_CD
million_CD
included_VBD
amortisation_NOMZ
charged_VBN [WZPAST]
for_PIN
the_DT
year_NN
of_PIN
$_$
23.5_CD
million_CD
and_CC
$_$
18.8_CD
million_CD
in_PIN
respect_NN
of_PIN
impairments_NOMZ
recorded_VBN [WZPAST]
on_PIN
tail-end_JJ
products_NN
Treasury_NN
policies_NN
and_CC
financial_JJ
risk_NN
management_NOMZ
in_PIN
Europe_NN
and_CC
the_DT
US_FPP1
._.
In_PIN
the_DT
prior_JJ
year_NN
the_DT
annual_JJ
charge_NN
was_VBD
Shires_NN
principal_JJ
treasury_NN
operations_NOMZ
are_VPRT [BYPA]
managed_VBN
by_PIN
the_DT
corporate_JJ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
31_CD
Financial_NN
review_NN
treasury_NN
function_NOMZ
based_VBN [WZPAST]
in_PIN
the_DT
UK_NN
._.
All_QUAN
treasury_NN
operations_NOMZ
are_VPRT [PASS]
conducted_VBN
was_VBD
$_$
92.19_CD
,_,
compared_VBN [PASTP]
with_PIN
an_DT
issue_NN
price_NN
of_PIN
$_$
100_CD
._.
If_COND
the_DT
loan_NN
is_VPRT [BEMA]
not_XX0
within_PIN
a_DT
framework_NN
of_PIN
policies_NN
and_PHC
procedures_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
._.
converted_VBN [PASTP]
into_PIN
equity_NOMZ
,_,
it_PIT
would_PRMD
be_VB [BEMA]
repayable_PRED
at_PIN
$_$
100_CD
per_PIN
note_NN
._.
The_DT
total_JJ
As_IN
a_DT
matter_NN
of_PIN
policy_NN
,_,
the_DT
Company_NN
does_VPRT
not_XX0
undertake_VB
speculative_JJ
fair_JJ
value_NN
of_PIN
the_DT
debt_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
above_PLACE
transactions_NOMZ
which_WDT [WHSUB]
would_PRMD
increase_VB
currency_NN
or_CC
interest_NN
rate_NN
exposure_NN
._.
There_EX
is_VPRT
no_SYNE
material_NN
difference_NN
between_PIN
The_DT
Board_NN
reviews_NN
and_CC
agrees_VPRT [SUAV] [PUBV]
policies_NN
for_PIN
managing_VBG
these_DEMO
risks_NN
and_CC
the_DT
book_NN
and_CC
fair_JJ
value_NN
of_PIN
the_DT
remainder_NN
of_PIN
the_DT
Companys_NN
debt_NN
._.
These_DEMO
convertible_JJ
notes_NN
are_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
Shire_NN
and_CC
are_VPRT [BEMA]
convertible_PRED
into_PIN
Foreign_JJ
currency_NN
risk_NN
redeemable_JJ
preference_NN
shares_NN
of_PIN
the_DT
Issuer_NN
which_WDT [WHOBJ]
upon_PIN
issuance_NN
will_PRMD
be_VB [BEMA]
The_DT
Company_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
movements_NOMZ
in_PIN
foreign_JJ
exchange_NN
rates_NN
immediately_TIME
exchanged_VBD
for_PIN
either_DT
Shire_NN
i_FPP1
common_JJ
shares_NN
or_CC
ii_FW
ADSs_FW
,_,
against_PIN
US_FPP1
dollars_NN
for_PIN
trading_GER
transactions_NOMZ
and_CC
the_DT
translation_NOMZ
of_PIN
net_JJ
or_CC
,_,
iii_FW
at_PIN
the_DT
Issuers_NN
option_NOMZ
,_,
cash_NN
._.
The_DT
convertible_JJ
notes_NN
bear_VPRT
interest_NN
of_PIN
assets_NN
and_PHC
earnings_GER
of_PIN
non-US_FPP1
subsidiaries_NN
._.
The_DT
main_JJ
trading_GER
currencies_NN
2_CD
%_NN
per_PIN
annum_NN
,_,
payable_JJ
semi-annually_RB
._.
This_DEMO
interest_NN
rate_NN
is_VPRT [PASS]
fixed_VBN
over_IN
of_PIN
the_DT
Company_NN
are_VPRT [BEMA]
the_DT
US_FPP1
dollar_NN
,_,
the_DT
Canadian_JJ
dollar_NN
,_,
pounds_NN
sterling_GER
the_DT
period_NN
of_PIN
the_DT
debt_NN
,_,
thus_CONJ
reducing_VBG
any_QUAN
cash_NN
flow_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
and_CC
the_DT
euro_NN
._.
The_DT
financial_JJ
statements_NOMZ
of_PIN
foreign_JJ
entities_NOMZ
are_VPRT [PASS]
translated_VBN
movements_NOMZ
in_PIN
interest_NN
rates_NN
._.
using_VBG [PRESP]
the_DT
accounting_GER
policies_NN
described_VBN [WZPAST]
in_PIN
note_NN
2_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
The_DT
interest_NN
rate_NN
risk_NN
that_TSUB
has_VPRT [PEAS]
been_VBN [BYPA]
mitigated_VBN
by_PIN
obtaining_VBG
a_DT
fixed_JJ
rate_NN
debt_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
a_DT
$_$
4.0_CD
million_CD
saving_NN
per_PIN
1_CD
%_NN
rise_NN
in_PIN
interest_NN
rates_NN
A_DT
small_JJ
proportion_NOMZ
of_PIN
debt_NN
is_VPRT [PASS]
denominated_VBN
in_PIN
foreign_JJ
currencies_NN
._.
Conversely_CONJ
a_DT
fall_NN
in_PIN
interest_NN
rates_NN
by_PIN
1_CD
%_NN
would_PRMD
effectively_RB
31_CD
December_NN
2002_CD
,_,
a_DT
total_NN
of_PIN
$_$
1.9_CD
million_CD
was_VBD [BEMA]
outstanding_PRED
31_CD
December_NN
cost_NN
the_DT
Company_NN
$_$
4.0_CD
million_CD
._.
Investors_NN
have_VPRT
the_DT
right_NN
to_TO
require_VB [SUAV]
the_DT
2001_CD
:_:
$_$
5.4_CD
million_CD
in_PIN
respect_NN
of_PIN
loans_NN
denominated_VBN [WZPAST]
in_PIN
Canadian_JJ
dollars_NN
._.
Issuer_NN
to_TO
redeem_VB
the_DT
notes_NN
at_PIN
par_NN
on_PIN
21_CD
August_NN
2004_CD
,_,
2006_CD
or_CC
2008_CD
._.
Subject_JJ
to_PIN
certain_JJ
conditions_NOMZ
,_,
the_DT
convertible_JJ
notes_NN
will_PRMD
be_VB [BEMA]
callable_PRED
after_IN
The_DT
exposure_NN
to_PIN
foreign_JJ
exchange_NN
market_NN
risk_NN
is_VPRT [PASS]
managed_VBN
and_CC
21_CD
August_NN
2004_CD
._.
monitored_VBN [PASTP]
by_PIN
the_DT
treasury_NN
function_NOMZ
,_,
using_VBG
forecasts_NN
provided_VBN [WZPAST]
by_PIN
the_DT
operating_VBG
units_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
not_XX0
undertaken_VBN
any_QUAN
foreign_JJ
currency_NN
In_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
the_DT
average_JJ
interest_NN
rate_NN
received_VBD
hedges_NN
through_PIN
the_DT
use_NN
of_PIN
spot_NN
or_CC
forward_RB
foreign_JJ
exchange_NN
contracts_NN
on_PIN
cash_NN
and_CC
liquid_JJ
investments_NOMZ
was_VBD [BEMA]
approximately_RB
1.8_CD
%_NN
per_PIN
annum_NN
._.
during_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2002_CD
._.
Instead_CONJ
,_,
exposures_NN
have_VPRT [PEAS]
been_VBN [BEMA]
The_DT
largest_JJ
proportion_NOMZ
of_PIN
investments_NOMZ
was_VBD [BEMA]
in_PIN
US_FPP1
dollar_NN
deposits_NN
._.
managed_VBN [PASTP]
through_PIN
natural_JJ
hedging_GER
via_PIN
the_DT
currency_NN
denomination_NOMZ
of_PIN
cash_NN
balances_NN
._.
Taxation_NOMZ
The_NN
effective_JJ
tax_NN
rate_NN
for_PIN
2002_CD
was_VBD [BEMA]
27_CD
%_NN
2001_CD
:_:
68_CD
%_NN
._.
The_DT
effective_JJ
The_DT
Company_NN
has_VPRT
subsidiaries_NN
in_PIN
European_JJ
countries_NN
that_TSUB
have_VPRT
tax_NN
rate_NN
for_PIN
2001_CD
was_VBD [BYPA]
affected_VBN
by_PIN
the_DT
$_$
177.0_CD
million_CD
of_PIN
charges_NN
in_PIN
converted_VBN
to_PIN
the_DT
euro_NN
._.
All_QUAN
such_JJ
subsidiaries_NN
successfully_RB
converted_VBD
to_PIN
connection_NOMZ
with_PIN
the_DT
BioChem_NN
merger_NN
._.
Income_NN
taxes_NN
in_PIN
respect_NN
of_PIN
the_DT
euro_NN
in_PIN
a_DT
timely_JJ
and_PHC
efficient_JJ
manner_NN
._.
continuing_VBG
operations_NOMZ
increased_VBN [WZPAST]
by_PIN
$_$
19.5_CD
million_CD
to_TO
$_$
88.4_CD
million_CD
2001_CD
:_:
$_$
68.9_CD
million_CD
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
net_JJ
deferred_VBN
tax_NN
assets_NN
Market_NN
risk_NN
of_PIN
investments_NOMZ
of_PIN
$_$
41.1_CD
million_CD
were_VBD [PASS]
recognized_VBN [PRIV]
31_CD
December_NN
2001_CD
:_:
$_$
39.7_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
has_VPRT
$_$
72.0_CD
million_CD
of_PIN
investments_NOMZ
on_PIN
its_PIT
books_NN
comprising_VBG [WZPRES]
equity_NOMZ
investment_NOMZ
funds_NN
,_,
private_JJ
companies_NN
and_CC
A_DT
reconciliation_NOMZ
of_PIN
the_DT
current_JJ
tax_NN
charge_NN
for_PIN
2002_CD
and_CC
2001_CD
to_PIN
the_DT
profit_NN
public_JJ
quoted_VBN
equities_NOMZ
31_CD
December_NN
2001_CD
:_:
$_$
68.7_CD
million_CD
._.
The_DT
public_NN
before_IN
tax_NN
for_PIN
those_DEMO
years_NN
at_PIN
the_DT
statutory_JJ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
is_VPRT [PASS]
given_VBN
in_PIN
quoted_VBN
equities_NOMZ
are_VPRT [PASS]
exposed_VBN
to_PIN
market_NN
risk_NN
._.
No_SYNE
financial_JJ
instruments_NOMZ
or_CC
note_NN
26_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
derivatives_NN
have_VPRT [PEAS]
been_VBN [PASS]
employed_VBN
to_TO
hedge_VB
this_DEMO
risk_NN
._.
Cash_NN
flows_VPRT
Interest_NN
rate_NN
risk_NN
As_IN
of_PIN
31_CD
December_NN
2002_CD
cash_NN
,_,
cash_NN
equivalents_NN
and_CC
marketable_JJ
Due_JJ
to_PIN
the_DT
proportion_NOMZ
of_PIN
fixed_JJ
rate_NN
debt_NN
,_,
the_DT
Companys_NN
interest_NN
charge_NN
securities_NOMZ
totalled_VBD
$_$
1,213.8_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
$_$
371.8_CD
million_CD
from_PIN
has_VPRT [PEAS]
limited_VBN
exposure_NN
to_PIN
interest_NN
rate_NN
movements_NOMZ
._.
Marketable_JJ
securities_NOMZ
consisted_VBD
of_PIN
money_NN
market_NN
fund_NN
balances_NN
and_PHC
investment_NOMZ
grade_NN
securities_NOMZ
._.
Total_JJ
debt_NN
as_IN
of_PIN
31_CD
December_NN
2002_CD
was_VBD
$_$
408.2_CD
million_CD
31_CD
December_NN
2001_CD
:_:
$_$
406.8_CD
million_CD
._.
The_DT
main_JJ
component_NN
was_VBD
$_$
400_CD
million_CD
in_PIN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
._.
These_DEMP
were_VBD [PASS]
issued_VBN
in_PIN
August_NN
activities_NOMZ
amounted_VBD
to_TO
$_$
356.5_CD
million_CD
compared_VBN
to_TO
$_$
196.8_CD
million_CD
in_PIN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
._.
Net_JJ
income_NN
of_PIN
$_$
250.6_CD
million_CD
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
accounting_VBG
for_PIN
nonThe_JJ
market_NN
price_NN
of_PIN
the_DT
convertible_JJ
notes_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
cash_NN
depreciation_NOMZ
and_PHC
amortisation_NOMZ
of_PIN
$_$
55.2_CD
million_CD
and_CC
other_JJ
non-cash_JJ
32_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
items_NN
totalling_VBG [WZPRES]
$_$
9.4_CD
million_CD
._.
There_EX
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [BEMA]
an_DT
overall_JJ
inflow_NN
of_PIN
The_DT
Company_NN
has_VPRT
a_DT
ten-year_JJ
contract_NN
with_PIN
the_DT
Canadian_JJ
government_NOMZ
$_$
41.3_CD
million_CD
from_PIN
working_VBG
capital_NN
items_NN
due_JJ
to_PIN
changes_NN
in_PIN
receivables_NN
,_,
to_TO
assure_VB
a_DT
state_NN
of_PIN
readiness_NOMZ
in_PIN
the_DT
case_NN
of_PIN
an_DT
influenza_NN
pandemic_JJ
inventories_NN
and_PHC
payables_NN
._.
worldwide_JJ
epidemic_JJ
and_CC
to_TO
manufacture_VB
influenza_NN
vaccine_NN
for_PIN
all_QUAN
Canadian_JJ
citizens_NN
in_PIN
such_JJ
an_DT
event_NN
._.
Under_IN
the_DT
contract_NN
,_,
Shire_NN
Biologics_NN
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
cash_NN
generated_VBD
from_PIN
will_PRMD [SPAU]
also_RB
supply_VB
the_DT
Government_NOMZ
of_PIN
Canada_NN
with_PIN
a_DT
substantial_JJ
proportion_NOMZ
operations_NOMZ
was_VBD [PASS]
used_VBN
primarily_RB
to_TO
fund_VB
capital_NN
expenditures_NN
,_,
including_VBG [PRESP]
of_PIN
its_PIT
annual_JJ
influenza_NN
vaccine_NN
requirements_NOMZ
over_IN
the_DT
ten-year_JJ
period_NN
._.
the_DT
purchase_NN
of_PIN
the_DT
APS_NN
manufacturing_GER
facility_NOMZ
for_PIN
$_$
17.0_CD
million_CD
,_,
Subject_NN
to_PIN
mutual_JJ
agreement_NOMZ
,_,
the_DT
contract_NN
can_POMD
be_VB [PASS]
renewed_VBN
for_PIN
a_DT
further_JJ
the_DT
purchase_NN
of_PIN
SOLARAZE_NN
for_PIN
$_$
20.1_CD
million_CD
and_CC
various_JJ
capital_NN
period_NN
of_PIN
between_PIN
one_CD
and_CC
ten_CD
years_NN
from_PIN
2011_CD
._.
expenditures_NN
on_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
._.
The_DT
sale_NN
of_PIN
the_DT
US_FPP1
OTC_NN
business_NOMZ
generated_VBD
a_DT
cash_NN
inflow_NN
of_PIN
$_$
71.0_CD
million_CD
._.
The_DT
concept_NN
of_PIN
a_DT
state_NN
of_PIN
readiness_NOMZ
against_PIN
an_DT
influenza_NN
pandemic_JJ
requires_VPRT [SUAV]
the_DT
development_NOMZ
of_PIN
sufficient_JJ
infrastructure_NN
and_PHC
capacity_NOMZ
in_PIN
Balance_NN
sheet_NN
value_NN
Canada_NN
to_TO
provide_VB
100_CD
%_NN
of_PIN
domestic_JJ
vaccine_NN
needs_NN
in_PIN
the_DT
event_NN
of_PIN
an_DT
The_DT
consolidated_JJ
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
increased_VBN [WZPAST]
by_PIN
$_$
310.2_CD
million_CD
influenza_NN
pandemic_NN
._.
Canada_NN
would_PRMD
require_VB [SUAV]
32_CD
million_CD
doses_NN
of_PIN
singleto_JJ
$_$
1,573.2_CD
million_CD
at_PIN
31_CD
December_NN
2002_CD
._.
The_DT
increase_NN
reflects_VPRT [PRIV]
mainly_RB
strain_NN
monovalent_JJ
flu_NN
vaccine_NN
within_PIN
a_DT
production_NOMZ
period_NN
of_PIN
16_CD
weeks_NN
._.
net_JJ
income_NN
of_PIN
$_$
250.6_CD
million_CD
generated_VBN
in_PIN
the_DT
year_NN
._.
Gross_NN
cash_NN
and_PHC
cash_NN
Shire_NN
Biologics_NN
has_VPRT [SPAU] [PEAS]
therefore_CONJ
begun_VBN
to_TO
expand_VB
its_PIT
current_JJ
production_NOMZ
equivalents_NN
,_,
inclusive_NN
of_PIN
marketable_JJ
securities_NOMZ
and_PHC
debt_NN
,_,
have_VPRT [PEAS]
increased_VBN
capacity_NOMZ
in_PIN
order_NN
to_TO
meet_VB
this_DEMO
objective_NN
within_PIN
a_DT
five-year_JJ
period_NN
._.
The_DT
Arenol_NN
loan_NN
conversion_NN
of_PIN
$_$
1.5_CD
million_CD
was_VBD [BEMA]
the_DT
performance_NN
bond_NN
equal_JJ
to_PIN
10_CD
%_NN
of_PIN
the_DT
minimum_NN
estimated_VBN [PRIV]
contract_NN
only_DWNT
significant_JJ
debt_NN
movement_NOMZ
during_PIN
the_DT
year_NN
._.
value_NN
in_PIN
any_QUAN
year_NN
would_PRMD
become_VB
payable_JJ
to_PIN
the_DT
Canadian_JJ
government_NOMZ
if_COND
contracted_VBN
penalty_NN
clauses_NN
were_VBD [PASS]
triggered_VBN
._.
Accounts_NN
receivable_JJ
decreased_VBN
by_PIN
$_$
55.5_CD
million_CD
,_,
from_PIN
$_$
193.9_CD
million_CD
at_PIN
31_CD
December_NN
2001_CD
to_TO
$_$
138.4_CD
million_CD
at_PIN
31_CD
December_NN
2002_CD
._.
There_EX
Shire_NN
Biologics_NN
is_VPRT [PASS]
committed_VBN
to_TO
investing_VBG
$_$
18.5_CD
million_CD
in_PIN
the_DT
were_VBD [BEMA]
no_SYNE
other_JJ
net_JJ
significant_JJ
movements_NOMZ
in_PIN
working_VBG
capital_NN
._.
construction_NOMZ
of_PIN
a_DT
new_JJ
global_JJ
vaccine_NN
research_NN
center_NN
in_PIN
Laval_NN
,_,
Canada_NN
._.
Under_IN
the_DT
The_DT
book_NN
value_NN
of_PIN
long-term_JJ
assets_NN
has_VPRT [PEAS]
decreased_VBN
by_PIN
$_$
28.6_CD
million_CD
._.
Technology_NN
Partnerships_NN
Canada_NN
TPC_NN
agreement_NOMZ
,_,
Shire_NN
could_POMD
be_VB [BEMA]
This_DEMP
is_VPRT [BEMA]
due_PRED
to_PIN
an_DT
increase_NN
of_PIN
$_$
29.3_CD
million_CD
to_PIN
assets_NN
used_VBN [WZPAST]
in_PIN
continuing_VBG
eligible_JJ
for_PIN
a_DT
government_NOMZ
investment_NOMZ
of_PIN
approximately_RB
$_$
3.5_CD
million_CD
._.
operations_NOMZ
,_,
offset_VBN [PASTP]
by_PIN
$_$
57.9_CD
million_CD
book_NN
value_NN
of_PIN
assets_NN
included_VBN [WZPAST]
in_PIN
the_DT
OTC_NN
disposal_NN
._.
Capital_NN
expenditure_NN
and_PHC
commitments_NOMZ
Capital_NN
expenditure_NN
on_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
was_VBD
$_$
22.6_CD
million_CD
._.
This_DEMO
expenditure_NN
included_VBD
Angus_NN
Russell_NN
Group_NN
Finance_NN
Director_NN
$_$
5.7_CD
million_CD
within_PIN
Shire_NN
US_FPP1
and_CC
$_$
4.8_CD
million_CD
on_PIN
leasehold_NN
improvements_NOMZ
at_PIN
Shire_NN
Laboratories_NN
Inc._NN
._.
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
we_FPP1
acquired_VBD
exclusive_JJ
rights_NN
to_TO
manufacture_VB
,_,
distribute_VB
and_PHC
sell_VB
SOLARAZE_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
actinic_JJ
keratosis_NN
from_PIN
SkyePharma_NN
plc._NN
._.
In_PIN
May_POMD
2002_CD
,_,
we_FPP1
paid_VBD
$_$
18.9_CD
million_CD
12.9_CD
million_CD
in_PIN
respect_NN
of_PIN
SOLARAZE_NN
rights_NN
for_PIN
certain_JJ
European_JJ
territories_NN
,_,
followed_VBD
in_PIN
December_NN
2002_CD
by_PIN
a_DT
further_JJ
$_$
1.2_CD
million_CD
0.7_CD
million_CD
in_PIN
respect_NN
of_PIN
the_DT
rights_NN
for_PIN
Australia_NN
,_,
New_NN
Zealand_NN
,_,
South_NN
Africa_NN
and_CC
certain_JJ
other_JJ
countries_NN
in_PIN
the_DT
Pacific_NN
Rim_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
subscribe_VB
to_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totalling_VBG [WZPRES]
$_$
38.1_CD
million_CD
2001_CD
:_:
$_$
37.7_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
an_DT
amount_NN
of_PIN
$_$
20.3_CD
million_CD
2001_CD
:_:
$_$
20.1_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
subscribed_VBN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
33_CD
Board_NN
of_PIN
Directors_NN
1_CD
2_CD
3_CD
4_CD
5_CD
6_CD
7_CD
8_CD
9_CD
10_CD
The_DT
Board_NN
meets_VPRT
at_PIN
least_JJ
four_CD
times_NN
a_DT
year_NN
and_CC
the_DT
meetings_GER
are_VPRT [SPAU] [PASS]
well_RB
attended_VBN
._.
The_DT
Board_NN
seeks_VPRT
to_TO
provide_VB
effective_JJ
leadership_NN
and_CC
the_DT
control_NN
required_VBN [SUAV] [WZPAST]
for_PIN
a_DT
listed_VBN
company_NN
._.
Specific_JJ
powers_NN
and_PHC
authorities_NOMZ
are_VPRT [PASS]
delegated_VBN
to_PIN
the_DT
Executive_NN
Committee_NN
and_CC
to_PIN
various_JJ
other_JJ
Board_NN
committees_NN
:_:
the_DT
Audit_NN
Committee_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
,_,
and_ANDC
the_DT
Nomination_NOMZ
Committee_NN
._.
Each_QUAN
committee_NN
has_VPRT
its_PIT
own_JJ
written_VBN [PUBV]
terms_NN
of_PIN
reference_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
._.
Details_NN
of_PIN
each_QUAN
committee_NN
are_VPRT [BEMA]
on_PIN
page_NN
48_CD
._.
34_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Board_NN
of_PIN
Directors_NN
1_CD
Dr_NN
James_NN
Cavanaugh_NN
66_CD
Mr_NN
Stahel_NN
received_VBD
the_DT
Chief_NN
Executive_NN
7_CD
The_DT
Hon_NN
James_NN
Grant_NN
65_CD
Chairman_NN
and_CC
Non-executive_JJ
Director_NN
Officer_NN
of_PIN
the_DT
Year_NN
Award_NN
2001_CD
for_PIN
the_DT
global_JJ
Non-executive_JJ
Director_NN
Joined_VBD
the_DT
Board_NN
on_PIN
24_CD
March_NN
1997_CD
and_CC
was_VBD [BEMA]
pharmaceutical_JJ
industry_NN
._.
On_PIN
19_CD
March_NN
2003_CD
Joined_VBD
the_DT
Board_NN
on_PIN
11_CD
May_POMD
2001_CD
as_IN
a_DT
nonappointed_JJ
as_IN
non-executive_JJ
Chairman_NN
with_PIN
effect_NN
Mr_NN
Stahel_NN
stepped_VBD
down_RP
as_IN
Chief_NN
Executive_NN
executive_NN
director_NN
._.
He_TPP3
was_VBD [BEMA]
formerly_TIME
a_DT
director_NN
from_PIN
11_CD
May_POMD
1999_CD
._.
Dr_NN
Cavanaugh_NN
is_VPRT
President_NN
and_CC
as_IN
a_DT
director_NN
of_PIN
the_DT
Company_NN
._.
of_PIN
BioChem_NN
since_OSUB
1986_CD
,_,
and_ANDC
is_VPRT [BEMA]
a_DT
partner_NN
with_PIN
of_PIN
HealthCare_NN
Ventures_NN
LLC_NN
._.
Formerly_TIME
he_TPP3
was_VBD [BEMA]
the_DT
law_NN
firm_NN
of_PIN
Stikeman_NN
Elliot_NN
in_PIN
Montreal_NN
._.
President_NN
of_PIN
SmithKline_NN
&_CC
French_NN
Laboratories_NN
,_,
4_CD
Mr_NN
Angus_NN
Russell_NN
46_CD
Mr_NN
Grant_NN
sits_VPRT
on_PIN
the_DT
boards_NN
of_PIN
two_CD
other_JJ
the_DT
US_FPP1
pharmaceutical_JJ
division_NN
of_PIN
SmithKline_NN
Group_NN
Finance_NN
Director_NN
Canadian_NN
corporations_NOMZ
,_,
in_CONJ
addition_NULL
to_PIN
other_JJ
Beecham_NN
Corporation_NOMZ
._.
Prior_RB
to_PIN
that_DEMP
,_,
he_TPP3
was_VBD [PASS]
Joined_VBN
Shire_NN
on_PIN
13_CD
December_NN
1999_CD
as_IN
Group_NN
foundations_NOMZ
and_PHC
councils_NN
that_TSUB
are_VPRT [BEMA]
not-for-profit_JJ
President_NN
of_PIN
SmithKline_NN
Beecham_NN
Corporations_NOMZ
Finance_NN
Director_NN
._.
Mr_NN
Russell_NN
worked_VBD
for_PIN
ICI_NN
,_,
organizations_NOMZ
._.
He_TPP3
attended_VBD
McGill_NN
University_NOMZ
,_,
clinical_JJ
laboratory_NN
business_NOMZ
and_CC
,_,
before_IN
that_DEMP
,_,
Zeneca_NN
and_PHC
AstraZeneca_NN
for_PIN
a_DT
total_NN
of_PIN
19_CD
receiving_VBG
a_DT
BA_NN
in_PIN
Arts_NN
in_PIN
1958_CD
and_CC
a_DT
BCL_NN
in_PIN
President_NN
of_PIN
Allergan_NN
International_NN
._.
His_TPP3
last_JJ
position_NOMZ
was_VBD
Vice_NN
President_NN
Law_NN
in_PIN
1961_CD
._.
Mr_NN
Grant_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
industry_NN
experience_NN
,_,
Dr_NN
Cavanaugh_NN
served_VBD
as_IN
Corporate_JJ
Finance_NN
at_PIN
AstraZeneca_NN
PLC_NN
,_,
where_RB
Nomination_NOMZ
Committee_NN
._.
Deputy_NN
Assistant_NN
to_PIN
the_DT
President_NN
of_PIN
the_DT
US_FPP1
he_TPP3
was_VBD [BEMA]
responsible_PRED
for_PIN
financial_JJ
input_NN
into_PIN
for_PIN
Health_NN
Affairs_NN
on_PIN
the_DT
White_NN
House_NN
Staff_NN
M&A_NN
activities_NOMZ
,_,
management_NOMZ
of_PIN
tax_NN
,_,
legal_JJ
and_CC
8_CD
Mr_NN
Ronald_NN
Nordmann_NN
61_CD
in_PIN
Washington_NN
,_,
DC_NN
._.
He_TPP3
is_VPRT [BEMA]
Non-executive_JJ
finance_NN
structure_NN
,_,
investor_NN
relations_NOMZ
activities_NOMZ
Non-executive_JJ
Director_NN
Chairman_NN
of_PIN
Diversa_NN
Corporation_NOMZ
and_PHC
Vicuron_NN
,_,
and_ANDC
the_DT
management_NOMZ
of_PIN
various_JJ
financial_JJ
risks_NN
._.
Joined_VBN
the_DT
Board_NN
on_PIN
23_CD
December_NN
1999_CD
Inc._NN
and_CC
a_DT
non-executive_JJ
director_NN
of_PIN
Prior_RB
to_PIN
this_DEMP
,_,
he_TPP3
held_VBD [PRIV]
a_DT
number_NN
of_PIN
positions_NOMZ
having_VBG [WZPRES] [SPAU] [PEAS]
previously_TIME
served_VBN
as_IN
a_DT
non-executive_JJ
MedImmune_NN
Inc._NN
._.
Dr_NN
Cavanaugh_NN
is_VPRT [BEMA]
a_DT
member_NN
within_PIN
Zeneca_NN
Group_NN
PLC_NN
from_PIN
1993_CD
until_IN
director_NN
of_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
the_DT
Audit_NN
1999_CD
,_,
including_VBG
Group_NN
Treasurer_NN
,_,
and_ANDC
before_IN
since_OSUB
May_POMD
1999_CD
and_CC
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
financial_JJ
Committee_NN
and_CC
the_DT
Nomination_NOMZ
Committee_NN
._.
Mr_NN
Russell_NN
analyst_NN
in_PIN
healthcare_NN
equities_NOMZ
since_OSUB
1971_CD
._.
From_PIN
is_VPRT [BEMA]
a_DT
chartered_JJ
accountant_NN
,_,
having_VBG [PEAS]
qualified_VBN
September_NN
1994_CD
to_PIN
January_NN
2000_CD
he_TPP3
was_VBD [BEMA]
an_DT
2_CD
Mr_NN
Matthew_NN
Emmens_NN
51_CD
with_PIN
Coopers_NN
&_CC
Lybrand_NN
,_,
and_ANDC
is_VPRT [BEMA]
a_DT
fellow_NN
of_PIN
analyst_NN
and_PHC
partner_NN
at_PIN
Deerfield_NN
Management_NOMZ
._.
Chief_NN
Executive_NN
the_DT
Association_NOMZ
of_PIN
Corporate_NN
Treasurers_NN
._.
He_TPP3
has_VPRT [PEAS]
held_VBN [PRIV]
senior_JJ
positions_NOMZ
with_PIN
PaineWebber_NN
,_,
Joined_VBN
Shire_NN
as_IN
Chief_NN
Executive_NN
and_PHC
member_NN
Mr_NN
Russell_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Executive_NN
Oppenheimer_NN
&_CC
Co._NN
._.
F_NN
Eberstadt_NN
&_CC
Co._NN
and_CC
of_PIN
the_DT
Board_NN
on_PIN
12_CD
March_NN
2003_CD
._.
Warner-Chilcott_NN
Laboratories_NN
,_,
a_DT
division_NN
of_PIN
began_VBD
his_TPP3
career_NN
in_PIN
international_JJ
pharmaceuticals_NN
Warner-Lambert_NN
._.
Mr_NN
Nordmann_NN
received_VBD
his_TPP3
in_PIN
1974_CD
when_RB
he_TPP3
joined_VBD
Merck_NN
&_CC
Co._NN
._.
He_TPP3
held_VBD [PRIV]
5_CD
Dr_NN
Wilson_NN
Totten_NN
47_CD
undergraduate_NN
degree_NN
from_PIN
The_DT
John_NN
Hopkins_NN
a_DT
wide_JJ
range_NN
of_PIN
sales_NN
,_,
marketing_GER
and_PHC
training_GER
Group_NN
R&D_NN
Director_NN
University_NOMZ
and_CC
an_DT
MBA_NN
from_PIN
Fairleigh_NN
Dickinson_NN
positions_NOMZ
with_PIN
Merck_NN
&_CC
Co_NN
before_IN
moving_VBG [SUAV]
to_TO
Joined_VBN
Shire_NN
on_PIN
17_CD
January_NN
1998_CD
as_IN
Group_NN
University_NOMZ
._.
Mr_NN
Nordmann_NN
is_VPRT [BEMA]
also_RB
a_DT
director_NN
of_PIN
help_NN
establish_VB [PRIV]
Astra_NN
Merck_NN
,_,
the_DT
joint_JJ
venture_NN
Research_NN
and_PHC
Development_NOMZ
Director_NN
._.
Dr_NN
Totten_NN
Guilford_NN
Pharmaceuticals_NN
Inc._NN
._.
Neurochem_NN
Inc._NN
with_PIN
Astra_NN
Pharmaceuticals_NN
._.
He_TPP3
later_TIME
became_VBD
is_VPRT [BEMA]
a_DT
medical_JJ
doctor_NN
and_CC
has_VPRT
wide_JJ
experience_NN
in_PIN
and_CC
Pharmaceutical_NN
Resources_NN
Inc._NN
._.
Mr_NN
its_PIT
President_NN
and_PHC
Chief_NN
Executive_NN
._.
Astra_NN
Merck_NN
the_DT
pharmaceutical_JJ
industry_NN
covering_VBG [WZPRES]
all_QUAN
phases_NN
Nordmann_NN
is_VPRT
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
Inc._NN
became_VBD
an_DT
independent_JJ
,_,
top_JJ
20_CD
US_FPP1
of_PIN
drug_NN
development_NOMZ
._.
He_TPP3
has_VPRT
substantial_JJ
and_CC
a_DT
member_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
._.
pharmaceutical_JJ
company_NN
with_PIN
annualised_JJ
sales_NN
experience_NN
in_PIN
the_DT
field_NN
of_PIN
central_JJ
nervous_JJ
in_PIN
excess_NN
of_PIN
$_$
4_CD
billion_CD
and_CC
4,000_CD
employees_NN
._.
His_TPP3
last_JJ
position_NOMZ
was_VBD
Vice_NN
9_CD
Dr_NN
Barry_NN
Price_NN
59_CD
In_PIN
1999_CD
he_TPP3
joined_VBD
Merck_NN
KGaA_NN
and_CC
established_VBN [PRIV]
President_NN
of_PIN
Clinical_NN
Research_NN
&_CC
Development_NOMZ
Senior_NN
Non-executive_JJ
Director_NN
EMD_NN
Pharmaceuticals_NN
,_,
the_DT
companys_NN
US_FPP1
with_PIN
Astra_NN
Charnwood_NN
where_RB
he_TPP3
served_VBD
from_PIN
Joined_VBN
the_DT
Board_NN
on_PIN
24_CD
January_NN
1996_CD
having_VBG
prescription_NOMZ
pharmaceutical_JJ
business_NOMZ
._.
Until_IN
1995_CD
to_PIN
1997_CD
,_,
having_VBG [PRESP] [SPAU] [PEAS]
previously_TIME
worked_VBN
for_PIN
spent_VBN
28_CD
years_NN
with_PIN
Glaxo_NN
holding_VBG [PRIV] [WZPRES]
a_DT
succession_NN
Mr_NN
Emmens_NN
joined_VBD
Shire_NN
he_TPP3
was_VBD [PASS]
based_VBN
in_PIN
Fisons_NN
Pharmaceuticals_NN
from_PIN
1989_CD
to_PIN
1995_CD
,_,
of_PIN
key_JJ
executive_NN
positions_NOMZ
with_PIN
Glaxo_NN
Group_NN
Darmstadt_NN
,_,
Germany_NN
,_,
as_IN
President_NN
of_PIN
Mercks_NN
and_CC
prior_RB
to_PIN
that_DEMO
with_PIN
3M_NN
Health_NN
Care_NN
and_PHC
Research_NN
._.
He_TPP3
is_VPRT
Chairman_NN
of_PIN
Antisoma_NN
plc_NN
global_JJ
prescription_NOMZ
pharmaceuticals_NN
business_NOMZ
,_,
Eli_NN
Lilly_NN
._.
Dr_NN
Totten_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Executive_NN
and_CC
also_RB
Biowisdom_NN
Ltd._NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
on_PIN
the_DT
which_WDT
in_PIN
the_DT
year_NN
2002_CD
achieved_VBD
sales_NN
of_PIN
Committee_NN
._.
board_NN
of_PIN
directors_NN
of_PIN
Pharmagene_NN
plc._NN
._.
Mr_NN
Emmens_NN
graduated_VBD
from_PIN
is_VPRT
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Fairleigh_NN
Dickenson_NN
University_NOMZ
in_PIN
Rutherford_NN
,_,
6_CD
Dr_NN
Francesco_NN
Bellini_NN
55_CD
and_CC
a_DT
member_NN
of_PIN
both_DT
the_DT
Audit_NN
Committee_NN
New_NN
Jersey_NN
,_,
US_FPP1
,_,
with_PIN
a_DT
BS_NN
in_PIN
Business_NOMZ
Non-executive_JJ
Director_NN
and_CC
the_DT
Nomination_NOMZ
Committee_NN
._.
Mr_NN
Emmens_NN
is_VPRT [BEMA]
a_DT
member_NN
Joined_VBD
the_DT
Board_NN
on_PIN
11_CD
May_POMD
2001_CD
as_IN
a_DT
nonof_JJ
the_DT
Executive_NN
Committee_NN
._.
Dr_NN
Bellini_NN
is_VPRT
Chairman_NN
of_PIN
10_CD
Mr_NN
Grard_NN
Veilleux_NN
60_CD
Picchio_NN
International_NN
Inc._NN
and_PHC
Neurochem_NN
Inc._NN
._.
Non-executive_JJ
Director_NN
3_CD
Mr_NN
Rolf_NN
Stahel_NN
58_CD
and_CC
is_VPRT [BEMA]
also_RB
on_PIN
the_DT
board_NN
of_PIN
several_QUAN
companies_NN
Joined_VBD
the_DT
Board_NN
on_PIN
11_CD
May_POMD
2001_CD
as_IN
a_DT
nonFormer_NN
Chief_NN
Executive_NN
and_PHC
organizations_NOMZ
such_JJ
as_IN
Molson_NN
Inc._NN
and_CC
executive_JJ
director_NN
._.
He_TPP3
was_VBD [BEMA]
formerly_TIME
a_DT
director_NN
Joined_VBN
Shire_NN
in_PIN
March_NN
1994_CD
as_IN
Chief_NN
Executive_NN
Industrial-Alliance_NN
Life_NN
Insurance_NN
Co._NN
._.
He_TPP3
is_VPRT
President_NN
of_PIN
from_PIN
Wellcome_NN
plc_NN
where_RB
he_TPP3
worked_VBD
for_PIN
27_CD
he_TPP3
was_VBD
Chairman_NN
and_PHC
CEO_NN
of_PIN
BioChem_NN
Power_NN
Communications_NOMZ
Inc._NN
and_PHC
Vice_NN
years_NN
in_PIN
Switzerland_NN
,_,
Italy_NN
,_,
Thailand_NN
,_,
Singapore_NN
Pharma_NN
which_WDT [WHOBJ]
he_TPP3
co-founded_VBD
in_PIN
1986_CD
._.
President_NN
of_PIN
Power_NN
Corporation_NOMZ
,_,
a_DT
diversified_JJ
and_CC
the_DT
UK_NN
._.
As_IN
Regional_NN
Director_NN
of_PIN
Wellcome_NN
management_NOMZ
and_CC
holding_VBG [PRIV]
company_NN
._.
Mr_NN
Veilleux_NN
based_VBN [WZPAST]
in_PIN
Singapore_NN
,_,
Mr_NN
Stahel_NN
was_VBD [BEMA]
responsible_PRED
is_VPRT [BEMA]
a_DT
director_NN
of_PIN
several_QUAN
public_JJ
and_PHC
private_JJ
for_PIN
18_CD
Pacific_NN
Rim_NN
countries_NN
._.
From_PIN
April_NN
1990_CD
companies_NN
as_RB
well_RB
as_IN
a_DT
member_NN
of_PIN
the_DT
Board_NN
until_IN
February_NN
1994_CD
,_,
he_TPP3
served_VBD
as_IN
Director_NN
of_PIN
Governors_NN
of_PIN
McGill_NN
University_NOMZ
._.
He_TPP3
has_VPRT
a_DT
of_PIN
Group_NN
Marketing_GER
reporting_VBG [PUBV] [WZPRES]
to_PIN
the_DT
Chief_NN
Masters_NN
degree_NN
in_PIN
Public_NN
Administration_NOMZ
from_PIN
Executive_NN
._.
A_DT
Business_NOMZ
Studies_NN
graduate_NN
of_PIN
Carleton_NN
University_NOMZ
and_CC
a_DT
Bachelor_NN
of_PIN
KSL_NN
Lucerne_NN
,_,
Switzerland_NN
,_,
he_TPP3
attended_VBD
Commerce_NN
from_PIN
Laval_NN
University_NOMZ
._.
Mr_NN
Veilleux_NN
is_VPRT [BEMA]
the_DT
97th_JJ
Advanced_NN
Managers_NN
Program_NN
at_PIN
a_DT
member_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
On_PIN
15_CD
March_NN
2001_CD
,_,
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
35_CD
Executive_NN
Committee_NN
1_CD
2_CD
3_CD
4_CD
5_CD
6_CD
7_CD
8_CD
9_CD
The_DT
Executive_NN
Committee_NN
meets_VPRT
at_PIN
least_JJ
11_CD
times_NN
a_DT
year_NN
and_CC
has_VPRT
the_DT
day-to-day_TIME
management_NOMZ
of_PIN
the_DT
Company_NN
delegated_VBD
to_PIN
it_PIT
by_PIN
the_DT
Board_NN
and_CC
operates_VPRT
within_PIN
clear_JJ
and_PHC
formal_JJ
parameters_NN
._.
The_DT
Chief_NN
Executive_NN
is_VPRT [BEMA]
the_DT
Chairman_NN
of_PIN
the_DT
Committee_NN
,_,
which_WDT [SERE]
consists_VPRT
of_PIN
nine_CD
senior_JJ
executives_NN
including_VBG [WZPRES]
the_DT
three_CD
executive_NN
directors_NN
._.
The_DT
Executive_NN
Committee_NN
reports_VPRT [PUBV]
to_TO
and_CC
seeks_VPRT
guidance_NN
from_PIN
the_DT
Board_NN
on_PIN
a_DT
regular_JJ
basis_NN
._.
36_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Executive_NN
Committee_NN
Rolf_NN
Stahel_NN
was_VBD
Chief_NN
Executive_NN
and_CC
5_CD
Jack_NN
Khattar_NN
41_CD
8_CD
Richard_NN
fide_NN
Souza_NN
50_CD
Chairman_NN
of_PIN
the_DT
Executive_NN
Committee_NN
until_IN
President_NN
and_PHC
Chief_NN
Executive_NN
,_,
SLI_NN
Director_NN
International_NN
he_TPP3
stepped_VBD
down_RP
on_PIN
19_CD
March_NN
2003_CD
._.
Joined_VBN
Shire_NN
as_IN
President_NN
and_PHC
CEO_NN
of_PIN
Shire_NN
Joined_VBD
Shire_NN
in_PIN
September_NN
2000_CD
as_IN
Director_NN
Biography_NN
and_PHC
photograph_NN
on_PIN
pages_NN
34_CD
and_CC
35_CD
._.
Prior_RB
to_PIN
this_DEMO
he_TPP3
worked_VBD
as_IN
came_VBD
to_TO
Shire_VB
from_PIN
CIMA_NN
,_,
a_DT
drug_NN
delivery_NN
President_NN
,_,
Pharmaceuticals_NN
Europe_NN
and_CC
1_CD
Mr_NN
Matthew_NN
Emmens_NN
51_CD
company_NN
,_,
where_RB
he_TPP3
last_JJ
served_VBD
as_IN
an_DT
executive_NN
Asia_NN
in_PIN
Warner_NN
Lambert_NN
Parke-Davis_NN
._.
He_TPP3
Chief_NN
Executive_NN
and_PHC
Chairman_NN
of_PIN
the_DT
officer_NN
and_CC
the_DT
Chairman_NN
of_PIN
the_DT
Operating_GER
was_VBD [BEMA]
previously_TIME
with_PIN
SmithKline_NN
Beecham_NN
Executive_NN
Committee_NN
Management_NOMZ
Committee_NN
._.
Prior_RB
to_PIN
CIMA_NN
,_,
for_PIN
22_CD
years_NN
,_,
where_RB
he_TPP3
was_VBD
Chairman_NN
,_,
Biography_NN
on_PIN
page_NN
35_CD
._.
Mr_NN
Khattar_NN
held_VBD [PRIV]
several_QUAN
marketing_GER
and_PHC
Pharmaceuticals_NN
Europe_NN
._.
business_NOMZ
development_NOMZ
positions_NOMZ
at_PIN
Merck_NN
&_CC
2_CD
Angus_NN
Russell_NN
46_CD
Co._NN
._.
Novartis_NN
,_,
Playtex_NN
and_PHC
Kodak_NN
in_PIN
the_DT
US_FPP1
,_,
9_CD
Mark_NN
Webster_NN
41_CD
Group_NN
Finance_NN
Director_NN
Europe_NN
and_CC
the_DT
Middle_NN
East_NN
._.
In_PIN
1985_CD
,_,
he_TPP3
Commercial_JJ
Director_NN
Biography_NN
on_PIN
page_NN
35_CD
._.
received_VBD
his_TPP3
MBA_NN
from_PIN
the_DT
Wharton_NN
School_NN
Responsible_JJ
for_PIN
Global_NN
Business_NOMZ
Development_NOMZ
,_,
of_PIN
the_DT
University_NOMZ
of_PIN
Pennsylvania_NN
._.
Mergers_NN
&_CC
Acquisitions_NOMZ
and_PHC
Strategic_NN
Marketing_GER
._.
3_CD
Dr_NN
Wilson_NN
Totten_NN
47_CD
He_TPP3
has_VPRT [PEAS]
worked_VBN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
Group_NN
R&D_NN
Director_NN
6_CD
Tatjana_NN
May_POMD
38_CD
for_PIN
20_CD
years_NN
in_PIN
a_DT
number_NN
of_PIN
general_JJ
management_NOMZ
Biography_NN
on_PIN
page_NN
35_CD
._.
General_NN
Counsel_NN
and_PHC
Company_NN
Secretary_NN
and_CC
senior_JJ
sales_NN
and_PHC
marketing_GER
roles_NN
in_PIN
the_DT
Joined_VBN
Shire_NN
in_PIN
May_POMD
2001_CD
from_PIN
AstraZeneca_NN
UK_NN
,_,
Canada_NN
and_CC
the_DT
US_FPP1
._.
Mr_NN
Webster_NN
worked_VBD
4_CD
Jeff_NN
Devlin_NN
50_CD
PLC_NN
formerly_TIME
Zeneca_NN
Group_NN
where_RB
she_TPP3
for_PIN
Abbott_NN
Laboratories_NN
for_PIN
13_CD
years_NN
,_,
where_RB
Director_NN
Corporate_NN
Affairs_NN
was_VBD
Assistant_NN
General_NN
Counsel_NN
in_PIN
Corporate_NN
immediately_TIME
before_IN
joining_VBG
Shire_NN
he_TPP3
held_VBD [PRIV]
the_DT
Joined_VBN
Shire_NN
in_PIN
January_NN
2000_CD
as_IN
Director_NN
of_PIN
Headquarters_NN
._.
Ms_NN
May_POMD
has_VPRT
substantial_JJ
post_NN
of_PIN
Vice-President_NN
and_PHC
General_NN
Manager_NN
Corporate_NN
Affairs_NN
._.
Prior_RB
to_TO
joining_VBG
Shire_NN
he_TPP3
was_VBD
experience_NN
and_PHC
knowledge_NN
of_PIN
undertaking_VBG
large_JJ
Anti-Virals_NN
,_,
Abbott_NN
Labs_NN
USA_NN
._.
He_TPP3
has_VPRT
a_DT
BSc_NN
a_DT
partner_NN
at_PIN
Ernst_NN
&_CC
Young_NN
and_CC
also_RB
a_DT
member_NN
M&A_NN
transactions_NOMZ
as_RB
well_RB
as_IN
the_DT
negotiation_NOMZ
and_PHC
Hons_NN
in_PIN
Chemistry_NN
from_PIN
Durham_NN
University_NOMZ
._.
of_PIN
its_PIT
Global_NN
Executive_NN
Steering_GER
Group_NN
for_PIN
Life_NN
implementation_NOMZ
of_PIN
a_DT
large_JJ
number_NN
of_PIN
commercial_JJ
Sciences_NN
._.
He_TPP3
was_VBD [BEMA]
previously_TIME
with_PIN
Arthur_NN
D_NN
agreements_NOMZ
._.
Prior_RB
to_TO
joining_VBG
AstraZeneca_NN
she_TPP3
Little_RB
,_,
Management_NOMZ
Consultancy_NN
,_,
where_RB
he_TPP3
was_VBD [PASS]
worked_VBN
at_PIN
Slaughter_NN
and_PHC
May_POMD
._.
a_DT
European_JJ
Director_NN
in_PIN
its_PIT
Healthcare_NN
and_PHC
Pharmaceuticals_NN
practice_NN
._.
7_CD
William_NN
Nuerge_NN
51_CD
President_NN
and_PHC
Chief_NN
Executive_NN
,_,
Shire_NN
US_FPP1
Inc._NN
._.
Joined_VBN
Shire_NN
US_FPP1
in_PIN
1994_CD
as_IN
Chief_NN
Operating_GER
Officer_NN
._.
Mr_NN
Nuerge_NN
has_VPRT
over_IN
25_CD
years_NN
experience_NN
within_PIN
the_DT
industry_NN
and_CC
has_VPRT [PEAS]
held_VBN [PRIV]
several_QUAN
senior_JJ
pharmaceutical_JJ
positions_NOMZ
._.
Mr_NN
Nuerge_NN
holds_VPRT [PRIV]
a_DT
Bachelor_NN
of_PIN
Science_NN
degree_NN
from_PIN
Purdue_NN
University_NOMZ
and_CC
an_DT
MBA_NN
from_PIN
Indiana_NN
Wesleyan_NN
University_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
37_CD
Directors_NN
remuneration_JJ
report_NN
Introduction_NOMZ
There_EX
are_VPRT
six_CD
main_JJ
elements_NOMZ
of_PIN
the_DT
remuneration_NOMZ
package_NN
for_PIN
executive_NN
This_DEMO
Report_NN
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Directors_NN
directors_NN
and_CC
senior_JJ
management_NOMZ
:_:
basic_JJ
annual_JJ
salary_NN
:_:
benefits_NN
:_:
annual_JJ
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
which_WDT
introduced_VBD
new_JJ
statutory_JJ
bonus_NN
payments_NOMZ
:_:
share_NN
options_NOMZ
:_:
long_JJ
term_NN
incentive_NN
awards_NN
:_:
and_ANDC
requirements_NOMZ
for_PIN
the_DT
disclosure_NN
of_PIN
directors_NN
remuneration_NOMZ
in_PIN
respect_NN
of_PIN
pension_NN
arrangements_NOMZ
._.
Executive_NN
directors_NN
contracts_NN
of_PIN
employment_NOMZ
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
after_IN
31_CD
December_NN
2002_CD
._.
This_DEMO
Report_NN
also_RB
meets_VPRT
which_WDT
include_VPRT
details_NN
of_PIN
remuneration_NOMZ
will_PRMD
be_VB [BEMA]
available_PRED
for_PIN
inspection_NOMZ
at_PIN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
._.
Authority_NOMZ
and_CC
describes_VPRT
how_RB
the_DT
Board_NN
has_VPRT [PEAS]
applied_VBN
the_DT
Principles_NN
of_PIN
Basic_JJ
salary_NN
Good_JJ
Governance_NN
relating_VBG [WZPRES]
to_PIN
directors_NN
remuneration_NOMZ
as_IN
set_VBN
out_PIN
in_PIN
the_DT
The_DT
Remuneration_NOMZ
Committee_NN
annually_RB
reviews_VPRT
base_NN
salaries_NN
in_PIN
the_DT
light_JJ
Combined_NN
Code_NN
._.
As_IN
required_VBN [SUAV]
by_PIN
the_DT
Regulations_NOMZ
,_,
a_DT
resolution_NOMZ
to_PIN
of_PIN
a_DT
number_NN
of_PIN
factors_NN
such_JJ
as_IN
competitive_JJ
market_NN
data_NN
provided_VBN [WZPAST]
by_PIN
approve_VB
this_DEMO
Report_NN
will_PRMD
be_VB [PASS]
proposed_VBN [SUAV]
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
independent_JJ
external_JJ
consultants_NN
,_,
local_JJ
market_NN
conditions_NOMZ
and_PHC
individual_NN
of_PIN
the_DT
Company_NN
at_PIN
which_WDT [PIRE]
the_DT
financial_JJ
statements_NOMZ
will_PRMD
be_VB [PASS]
approved_VBN
._.
The_DT
Remuneration_NOMZ
Committees_NN
policy_NN
is_VPRT [BEMA]
for_PIN
base_NN
pay_NN
to_TO
be_VB [PASS]
set_VBN
at_PIN
the_DT
median_NN
of_PIN
the_DT
appropriate_JJ
comparator_NN
group_NN
Unaudited_JJ
information_NOMZ
for_PIN
executive_JJ
directors_NN
this_DEMP
is_VPRT [BEMA]
the_DT
FTSE_NN
100_CD
unless_COND
individual_JJ
performance_NN
The_DT
Remuneration_NOMZ
Committee_NN
and_CC
or_CC
skills_NN
shortages_NN
require_VPRT [SUAV]
a_DT
different_JJ
stance_NN
._.
In_CONJ
addition_NULL
to_PIN
basic_JJ
The_DT
Company_NN
has_VPRT [PEAS]
established_VBN [PRIV]
a_DT
Remuneration_NOMZ
Committee_NN
which_WDT [WHSUB]
is_VPRT
salary_NN
,_,
the_DT
executive_JJ
directors_NN
receive_VPRT
certain_JJ
benefits_NN
in_PIN
kind_NN
,_,
principally_RB
constituted_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Combined_NN
Code_NN
._.
The_DT
members_NN
of_PIN
a_DT
car_NN
or_CC
car_NN
allowance_NN
,_,
participation_NOMZ
in_PIN
the_DT
Shire_NN
defined_VBD
contribution_NOMZ
the_DT
Remuneration_NOMZ
Committee_NN
in_PIN
2002_CD
were_VBD
Dr_NN
Barry_NN
Price_NN
Chairman_NN
,_,
pension_NN
plan_NN
see_VPRT [PRIV]
below_PLACE
,_,
life_NN
insurance_NN
and_CC
private_JJ
medical_JJ
insurance_NN
._.
Dr_NN
James_NN
Cavanaugh_NN
and_PHC
Mr_NN
Grard_NN
Veilleux_NN
._.
Dr_NN
Bernard_NN
Canavan_NN
Annual_JJ
bonus_NN
payments_NOMZ
was_VBD [BEMA]
also_RB
a_DT
member_NN
of_PIN
the_DT
Committee_NN
until_IN
his_TPP3
death_NN
in_PIN
August_NN
2002_CD
._.
Shire_NN
operates_VPRT
an_DT
annual_JJ
bonus_NN
plan_NN
._.
The_DT
structure_NN
of_PIN
this_DEMO
plan_NN
was_VBD [BEMA]
The_DT
Company_NN
views_VPRT
all_QUAN
members_NN
of_PIN
the_DT
Committee_NN
as_IN
independent_JJ
reviewed_VBN
in_PIN
2002_CD
._.
A_DT
key_JJ
objective_NN
of_PIN
the_DT
plan_NN
is_VPRT
to_TO
encourage_VB
and_CC
non-executive_JJ
directors_NN
._.
The_DT
Chief_NN
Executive_NN
attends_VPRT
meetings_GER
of_PIN
the_DT
reward_NN
the_DT
achievement_NOMZ
of_PIN
stretch_JJ
performance_NN
objectives_NN
at_PIN
both_DT
Committee_NN
at_PIN
its_PIT
invitation_NOMZ
,_,
but_CC
is_VPRT [PASS]
not_XX0
involved_VBN
in_PIN
any_QUAN
discussions_NN
on_PIN
his_TPP3
the_DT
Group_NN
level_NN
and_CC
the_DT
individual_JJ
level_NN
._.
objectives_NN
are_VPRT [PASS]
set_VBN
at_PIN
the_DT
start_NN
of_PIN
each_QUAN
financial_JJ
year_NN
by_PIN
the_DT
Remuneration_NOMZ
The_NN
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
materially_RB
assisted_VBN
in_PIN
2002_CD
by_PIN
Committee_NN
and_CC
the_DT
individuals_NN
performance_NN
against_PIN
objectives_NN
is_VPRT
also_RB
Rolf_NN
Stahel_NN
,_,
the_DT
Companys_NN
Chief_NN
Executive_NN
in_PIN
2002_CD
,_,
Jeff_NN
Devlin_NN
,_,
Director_NN
,_,
assessed_VBN [PASTP]
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
The_DT
objectives_NN
are_VPRT [PASS]
tailored_VBN
Corporate_JJ
Affairs_NN
,_,
Christian_NN
Proulx_NN
,_,
Senior_NN
VP_NN
Global_NN
Human_NN
Resources_NN
,_,
to_PIN
the_DT
requirements_NOMZ
of_PIN
the_DT
business_NOMZ
and_CC
in_PIN
2002_CD
included_VBD
objectives_NN
and_CC
by_PIN
the_DT
following_VBG
external_JJ
advisers_NN
:_:
Towers_NN
Perrin_NN
,_,
Slaughter_NN
and_CC
relating_VBG
to_PIN
growth_NN
in_PIN
revenue_NN
and_CC
net_JJ
income_NN
._.
The_DT
annual_JJ
bonus_NN
is_VPRT
May_POMD
and_PHC
Deloitte_NN
&_CC
Touche_NN
._.
Slaughter_NN
and_PHC
May_POMD
also_RB
provided_VBD
general_JJ
payable_JJ
in_PIN
cash_NN
and_CC
is_VPRT [BEMA]
not_XX0
pensionable_PRED
._.
Target_NN
bonus_NN
is_VPRT [PASS]
paid_VBN
pro_PIN
rata_JJ
legal_JJ
advice_NN
to_PIN
the_DT
Company_NN
in_PIN
2002_CD
and_CC
Deloitte_NN
&_CC
Touche_NN
are_VPRT [BEMA]
also_RB
to_PIN
the_DT
objectives_NN
which_WDT [WHSUB]
have_VPRT [PEAS]
been_VBN [PASS]
achieved_VBN
,_,
up_IN
to_PIN
the_DT
maximum_NN
target_NN
the_DT
Companys_NN
auditors_NN
and_CC
provided_VBD
some_QUAN
general_JJ
accountancy_NN
advice_NN
bonus_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
also_RB
has_VPRT
the_DT
discretion_NOMZ
to_TO
make_VB
and_CC
taxation_NOMZ
advice_NN
in_PIN
2002_CD
._.
The_DT
Remuneration_NOMZ
Committee_NN
approved_VBD
further_JJ
awards_NN
under_IN
the_DT
plan_NN
for_PIN
exceptional_JJ
achievement_NOMZ
beyond_IN
the_DT
appointment_NOMZ
of_PIN
Slaughter_NN
and_PHC
May_POMD
and_PHC
Deloitte_NN
&_CC
Touche_NN
Executive_NN
and_CC
or_CC
in_CONJ
addition_NULL
to_PIN
the_DT
objectives_NN
set_VBN [WZPAST]
at_PIN
the_DT
start_NN
of_PIN
the_DT
year_NN
._.
The_DT
Compensation_NOMZ
Consulting_GER
Practice_NN
as_IN
advisers_NN
to_PIN
the_DT
Remuneration_NOMZ
maximum_NN
bonus_NN
is_VPRT [PASS]
capped_VBN
at_PIN
100_CD
%_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Executive_NN
Committee_NN
._.
and_ANDC
75_CD
%_NN
of_PIN
salary_NN
for_PIN
other_JJ
executive_JJ
directors_NN
._.
Details_NN
of_PIN
the_DT
bonus_NN
structure_NN
and_CC
the_DT
relative_JJ
weighting_GER
of_PIN
objectives_NN
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
Remuneration_NOMZ
policy_NN
table_NN
below_PLACE
._.
To_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
Company_NN
can_POMD
compete_VB
effectively_RB
for_PIN
high_JJ
calibre_NN
Target_NN
Maximum_NN
individuals_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
adopted_VBN
a_DT
durable_JJ
bonus_NN
bonus_NN
Weighting_GER
of_PIN
target_NN
compensation_NOMZ
and_PHC
benefits_NN
policy_NN
based_VBN [WZPAST]
on_PIN
the_DT
following_VBG
principles_NN
:_:
up_RB
to_PIN
%_NN
up_RP
to_PIN
%_NN
bonus_NN
objectives_NN
of_PIN
salary_NN
of_PIN
salary_NN
Group_NN
Personal_NN
compensation_NOMZ
should_NEMD
,_,
as_IN
far_PLACE
as_IN
possible_JJ
,_,
be_VB [BEMA]
market-driven_PRED
:_:
Mr_NN
R_NN
Stahel_NN
compensation_NOMZ
should_NEMD
be_VB [BEMA]
performance-related_PRED
and_CC
reflect_VPRT [PRIV]
an_DT
Former_JJ
Chief_NN
Executive_NN
55_CD
%_NN
100_CD
%_NN
80_CD
%_NN
20_CD
%_NN
appropriate_JJ
mix_NN
of_PIN
corporate_JJ
and_PHC
individual_JJ
performance_NN
:_:
Mr_NN
A_NN
Russell_NN
share-based_JJ
remuneration_NOMZ
is_VPRT [BEMA]
a_DT
key_JJ
element_NOMZ
of_PIN
pay_NN
which_WDT [WHOBJ]
the_DT
Finance_NN
Director_NN
50_CD
%_NN
75_CD
%_NN
60_CD
%_NN
40_CD
%_NN
Committee_NN
believes_VPRT [PRIV]
aligns_IN
the_DT
interests_NN
of_PIN
the_DT
Companys_NN
executives_NN
Dr_VPRT
W_NN
Totten_NN
with_PIN
the_DT
interests_NN
of_PIN
its_PIT
shareholders_NN
:_:
and_ANDC
Group_NN
R&D_NN
Director_NN
50_CD
%_NN
75_CD
%_NN
60_CD
%_NN
40_CD
%_NN
compensation_NOMZ
and_PHC
benefits_NN
arrangements_NOMZ
should_NEMD
be_VB [BEMA]
clear_PRED
and_CC
well_RB
understood_VBN [PRIV]
._.
Deferred_JJ
bonus_NN
plan_NN
To_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
approach_NN
to_TO
remuneration_VB
at_PIN
senior_JJ
levels_NN
is_VPRT [PASS]
aligned_VBN
Consistent_JJ
with_PIN
the_DT
desired_VBN [SUAV]
emphasis_NN
on_PIN
share-based_JJ
remuneration_NOMZ
,_,
to_TO
market_VB
practice_NN
,_,
whilst_OSUB
being_VBG [BEMA]
consistent_PRED
with_PIN
the_DT
principles_NN
of_PIN
the_DT
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
been_VBN
considering_VBG [PRIV]
the_DT
implementation_NOMZ
Companys_NN
compensation_NOMZ
and_PHC
benefits_NN
policy_NN
described_VBN
above_PLACE
,_,
the_DT
of_PIN
a_DT
deferred_VBN
bonus_NN
plan_NN
for_PIN
senior_JJ
management_NOMZ
,_,
including_VBG [PRESP]
the_DT
executive_NN
Remuneration_NOMZ
Committee_NN
reviewed_VBD
and_PHC
made_VBD
a_DT
number_NN
of_PIN
changes_NN
to_PIN
directors_NN
,_,
under_IN
which_WDT
they_TPP3
can_POMD
elect_VB
to_TO
defer_VB
a_DT
portion_NOMZ
of_PIN
their_TPP3
annual_JJ
executive_NN
remuneration_NOMZ
during_PIN
the_DT
course_NN
of_PIN
2002_CD
._.
These_DEMP
are_VPRT [PASS]
described_VBN
bonus_NN
to_TO
buy_VB
shares_NN
in_PIN
the_DT
Company_NN
,_,
with_PIN
the_DT
Company_NN
matching_VBG [WZPRES]
the_DT
below_PLACE
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
the_DT
remuneration_NOMZ
policy_NN
as_IN
described_VBN
will_PRMD
be_VB
shares_NN
so_RB
acquired_VBN
._.
The_DT
Company_NN
will_PRMD
seek_VB
shareholder_NN
approval_NN
for_PIN
appropriate_JJ
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
The_DT
plan_NN
will_PRMD
be_VB [PASS]
designed_VBN
to_TO
balance_VB
the_DT
need_NN
for_PIN
the_DT
delivery_NN
of_PIN
and_CC
reward_VB
for_PIN
short-term_JJ
operating_GER
targets_NN
with_PIN
the_DT
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
performance_NN
longer-term_JJ
interests_NN
of_PIN
the_DT
Company_NN
and_CC
its_PIT
shareholders_NN
._.
The_DT
management_NOMZ
of_PIN
the_DT
executive_JJ
directors_NN
and_CC
of_PIN
key_JJ
members_NN
of_PIN
Remuneration_NOMZ
Committee_NN
believes_VPRT [PRIV]
that_THVC
share-based_JJ
remuneration_NOMZ
for_PIN
senior_JJ
management_NOMZ
and_CC
for_PIN
the_DT
determination_NOMZ
of_PIN
the_DT
elements_NOMZ
of_PIN
their_TPP3
executives_NN
and_CC
encouraging_JJ
share_NN
ownership_NN
are_VPRT [BEMA]
critical_PRED
for_PIN
maximizing_VBG
remuneration_NOMZ
package_NN
._.
No_SYNE
director_NN
is_VPRT [BEMA]
present_PRED
when_RB
his_TPP3
own_JJ
remuneration_NOMZ
shareholder_NN
value_NN
._.
The_DT
remuneration_NOMZ
of_PIN
the_DT
non-executive_JJ
directors_NN
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Board_NN
within_PIN
limits_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
Companys_NN
Articles_NN
of_PIN
Association_NOMZ
see_VPRT [PRIV]
below_PLACE
._.
38_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Share_NN
options_NOMZ
Number_NN
of_PIN
Exercise_NN
Executive_NN
director_NN
and_PHC
Date_NN
of_PIN
ordinary_JJ
price_NN
At_PIN
the_DT
Companys_NN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
June_NN
2001_CD
,_,
shareholders_NN
share_NN
option_NOMZ
scheme_NN
grant_NN
shares_NN
agreed_VBD [SUAV] [PUBV]
that_THVC
the_DT
grant_NN
of_PIN
options_NOMZ
under_IN
the_DT
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Mr_NN
Rolf_NN
Stahel_NN
Scheme_NN
the_DT
Scheme_NN
should_NEMD
be_VB [PASS]
made_VBN
subject_JJ
to_PIN
a_DT
performance_NN
2000_CD
Executive_NN
Scheme_NN
04.03.02_CD
209,211_CD
5.065_CD
condition_NOMZ
on_PIN
grant_NN
._.
If_COND
Shires_NN
share_NN
price_NN
increased_VBN [WZPAST]
by_PIN
an_DT
annualised_JJ
compound_NN
rate_NN
of_PIN
20.5_CD
%_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
period_NN
options_NOMZ
Dr_NN
Wilson_NN
Totten_NN
could_POMD
be_VB [PASS]
granted_VBN [SUAV]
._.
During_PIN
2002_CD
the_DT
performance_NN
condition_NOMZ
was_VBD [PASS]
reviewed_VBN
._.
2000_CD
Executive_NN
Scheme_NN
04.03.02_CD
122,368_CD
5.065_CD
Following_VBG
consultation_NOMZ
with_PIN
major_JJ
institutional_JJ
shareholders_NN
,_,
the_DT
Sharesave_NN
Scheme_NN
23.09.02_CD
1,882_CD
5.02_CD
Remuneration_NOMZ
Committee_NN
decided_VBD [SUAV] [PRIV]
that_THVC
a_DT
performance_NN
condition_NOMZ
based_VBN
Mr_NN
Angus_NN
Russell_NN
on_PIN
real_JJ
growth_NN
in_PIN
earnings_GER
per_PIN
share_NN
EPS_NN
should_NEMD
be_VB [PASS]
attached_VBN
to_PIN
the_DT
2000_CD
Executive_NN
Scheme_NN
04.03.02_CD
114,474_CD
5.065_CD
exercise_NN
of_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Scheme_NN
._.
Diluted_VBN
EPS_NN
will_PRMD
be_VB
Sharesave_NN
Scheme_NN
23.09.02_CD
1,882_CD
5.02_CD
measured_VBN
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
Annual_JJ
Report_NN
and_PHC
Accounts_NN
._.
Earnings_GER
per_PIN
share_NN
provides_VPRT
both_DT
a_DT
direct_JJ
and_PHC
transparent_JJ
link_NN
to_PIN
overall_JJ
corporate_JJ
performance_NN
and_CC
is_VPRT [BYPA]
regarded_VBN
by_PIN
the_DT
Committee_NN
as_IN
the_DT
most_EMPH
appropriate_JJ
During_PIN
2002_CD
,_,
Mr_NN
Angus_NN
Russell_NN
and_PHC
Dr_NN
Wilson_NN
Totten_NN
let_VBD
lapse_NN
options_NOMZ
measure_NN
in_PIN
the_DT
light_NN
of_PIN
Shires_NN
business_NOMZ
strategy_NN
and_CC
the_DT
growth_NN
of_PIN
the_DT
granted_VBN [SUAV]
to_PIN
them_TPP3
in_PIN
April_NN
2000_CD
under_IN
the_DT
Sharesave_NN
Scheme_NN
,_,
over_IN
1,971_CD
Company_NN
in_PIN
the_DT
last_JJ
two_CD
years_NN
._.
To_TO
balance_VB
the_DT
higher_JJ
grants_NN
to_PIN
executive_NN
and_CC
1,139_CD
shares_NN
respectively_RB
,_,
at_PIN
the_DT
option_NOMZ
price_NN
of_PIN
8.56_CD
per_PIN
share_NN
._.
directors_NN
,_,
a_DT
higher_JJ
target_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
as_IN
detailed_JJ
below_PLACE
._.
Share_NN
options_NOMZ
Both_DT
Mr_NN
Russell_NN
and_PHC
Dr_NN
Totten_NN
subsequently_TIME
used_VBD
their_TPP3
maximum_NN
are_VPRT [PASS]
intended_VBN [SUAV]
to_TO
be_VB [BEMA]
long-term_JJ
compensation_NOMZ
and_CC
to_TO
provide_VB
an_DT
incentive_NN
contributions_NOMZ
from_PIN
salary_NN
allowed_VBN [SUAV]
under_IN
the_DT
rules_NN
of_PIN
the_DT
Sharesave_NN
for_PIN
employees_NN
to_TO
deliver_VB
sustained_VBN
long-term_JJ
performance_NN
,_,
whilst_OSUB
Scheme_NN
to_TO
participate_VB
in_PIN
the_DT
Sharesave_NN
offer_NN
made_VBN [WZPAST]
in_PIN
2002_CD
._.
aligning_VBG [PRESP]
the_DT
interests_NN
of_PIN
Shires_NN
executive_NN
directors_NN
and_PHC
employees_NN
with_PIN
Long_NN
Term_NN
Incentive_NN
Plan_NN
those_DEMO
of_PIN
shareholders_NN
._.
The_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
the_DT
Plan_NN
was_VBD [PASS]
adopted_VBN
at_PIN
the_DT
Companys_NN
The_DT
grant_NN
of_PIN
options_NOMZ
is_VPRT [BEMA]
wholly_RB
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
1998_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
and_PHC
amended_VBN
in_PIN
2001_CD
._.
In_PIN
granting_VBG [SUAV]
share_NN
options_NOMZ
,_,
the_DT
Committee_NN
takes_VPRT
into_PIN
account_NN
awards_NN
of_PIN
shares_NN
subject_JJ
to_PIN
a_DT
maximum_NN
of_PIN
100_CD
%_NN
of_PIN
salary_NN
a_DT
year_NN
may_POMD
be_VB [BEMA]
the_DT
advice_NN
and_PHC
recommendations_NOMZ
of_PIN
the_DT
Chief_NN
Executive_NN
and_CC
individual_JJ
made_VBN
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
The_DT
performance_NN
salary_NN
levels_NN
and_PHC
roles_NN
within_PIN
the_DT
Group_NN
._.
The_DT
face_NN
value_NN
of_PIN
options_NOMZ
condition_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
vesting_GER
of_PIN
the_DT
share_NN
awards_NN
made_VBN
under_IN
the_DT
granted_VBN [SUAV]
under_IN
the_DT
Scheme_NN
is_VPRT [SPAU] [PASS]
normally_RB
capped_VBN
at_PIN
three_CD
times_NN
salary_NN
Plan_NN
is_VPRT
Shires_NN
relative_JJ
Total_JJ
Shareholder_NN
Return_NN
TSR_NN
against_PIN
the_DT
FTSE_NN
per_PIN
year_NN
,_,
except_PIN
in_PIN
exceptional_JJ
circumstances_NN
._.
This_DEMO
grant_NN
level_NN
is_VPRT [BEMA]
very_AMP
100_CD
index_NN
._.
Under_IN
the_DT
amended_VBN
Plan_NN
,_,
all_QUAN
the_DT
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
competitive_JJ
in_PIN
the_DT
UK_NN
market_NN
and_CC
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
emphasis_NN
the_DT
is_VPRT [BEMA]
in_PIN
the_DT
top_JJ
10_CD
%_NN
of_PIN
the_DT
FTSE_NN
100_CD
:_:
half_PDT
the_DT
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
Company_NN
places_VPRT
on_PIN
share-based_JJ
remuneration_NOMZ
for_PIN
its_PIT
executives_NN
._.
It_PIT
is_VPRT
performance_NN
is_VPRT [BEMA]
at_PIN
median_NN
:_:
and_ANDC
no_SYNE
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT
below_PLACE
also_RB
in_PIN
accordance_NN
with_PIN
the_DT
Committees_NN
view_VPRT
that_DEMO
well_RB
over_IN
half_NN
of_PIN
each_QUAN
median_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
believes_VPRT [PRIV]
that_THVC
Shires_NN
TSR_NN
relative_JJ
directors_NN
remuneration_NOMZ
should_NEMD
be_VB [PASS]
linked_VBN
to_PIN
Company_NN
performance_NN
._.
to_PIN
the_DT
FTSE_NN
100_CD
is_VPRT [BEMA]
the_DT
most_EMPH
appropriate_JJ
measure_NN
of_PIN
shareholder_NN
value_NN
for_PIN
the_DT
purpose_NN
of_PIN
the_DT
vesting_GER
of_PIN
awards_NN
under_IN
the_DT
Plan_NN
given_VBN
that_DEMO
Shire_NN
The_NN
performance_NN
condition_NOMZ
attaching_VBG [WZPRES]
to_PIN
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
,_,
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
constituent_NN
of_PIN
the_DT
FTSE_NN
100_CD
for_PIN
over_IN
two_CD
years_NN
._.
Moreover_CONJ
,_,
which_WDT [SERE]
is_VPRT [BEMA]
somewhat_DWNT
higher_PRED
for_PIN
executive_JJ
directors_NN
than_PIN
for_PIN
other_JJ
shareholders_NN
are_VPRT [BEMA]
likely_PRED
to_TO
assess_VB
Shires_NN
performance_NN
in_PIN
the_DT
context_NN
employees_NN
,_,
operates_VPRT
as_IN
follows_VPRT
and_PHC
applies_VPRT
to_PIN
all_QUAN
options_NOMZ
granted_VBN [SUAV]
after_IN
of_PIN
this_DEMO
comparator_NN
group_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
will_PRMD
at_PIN
the_DT
August_NN
2002_CD
:_:
appropriate_JJ
time_NN
decide_VB [SUAV] [PRIV]
whether_IN [WHCL]
and_CC
to_TO
what_WP
extent_NN
the_DT
performance_NN
Grant_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
on_PIN
the_DT
basis_NN
of_PIN
data_NN
provided_VBN [WZPAST]
by_PIN
an_DT
%_NN
of_PIN
salary_NN
EPS_NN
growth_NN
independent_JJ
third_JJ
party_NN
._.
To_TO
date_VB
all_QUAN
awards_NN
made_VBN
under_IN
the_DT
Plan_NN
have_VPRT
Up_IN
to_PIN
100_CD
%_NN
Retail_NN
Price_NN
Index_NN
RPI_NN
plus_PIN
3_CD
%_NN
been_VBN [PASS]
made_VBN
as_IN
a_DT
conditional_JJ
allocation_NOMZ
,_,
as_IN
defined_VBN
in_PIN
the_DT
Plan_NN
,_,
thereby_RB
directors_NN
,_,
RPI_NN
plus_PIN
5_CD
%_NN
allowing_VBG [SUAV] [WZPRES]
for_PIN
a_DT
cash_NN
equivalent_NN
to_TO
be_VB [PASS]
paid_VBN
on_PIN
maturity_NOMZ
of_PIN
the_DT
award_NN
._.
101_CD
%_NN
to_PIN
200_CD
%_NN
RPI_NN
plus_PIN
5_CD
%_NN
Directors_NN
were_VBD [PASS]
granted_VBN [SUAV]
an_DT
award_NN
under_IN
the_DT
Plan_NN
in_PIN
2002_CD
as_IN
201_CD
%_NN
to_PIN
300_CD
%_NN
RPI_NN
plus_PIN
7_CD
%_NN
a_DT
conditional_JJ
allocation_NOMZ
,_,
as_IN
defined_VBN
in_PIN
the_DT
Plan_NN
,_,
as_IN
follows_VPRT
:_:
Over_IN
301_CD
%_NN
RPI_NN
plus_PIN
9_CD
%_NN
Earliest_JJ
date_NN
Value_NN
of_PIN
on_PIN
which_WDT [PIRE]
Details_NN
of_PIN
the_DT
share_NN
option_NOMZ
schemes_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
and_CC
in_PIN
note_NN
28_CD
conditional_JJ
Total_NN
an_DT
award_NN
award_NN
at_PIN
number_NN
of_PIN
can_POMD
be_VB [BEMA]
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Except_PIN
as_IN
mentioned_VBN [PUBV]
below_PLACE
,_,
Date_NN
of_PIN
grant_NN
date_NN
ordinary_JJ
made_VBN
to_PIN
none_INPR
of_PIN
the_DT
executive_JJ
directors_NN
who_WP [WHSUB]
served_VBD
during_PIN
the_DT
year_NN
were_VBD [PASS]
granted_VBN [SUAV]
award_NN
000_CD
shares_NN
a_DT
director_NN
additional_JJ
options_NOMZ
under_IN
any_QUAN
of_PIN
the_DT
Companys_NN
share_NN
option_NOMZ
schemes_NN
in_PIN
Mr_NN
Rolf_NN
Stahel_NN
04.03.02_CD
232_CD
34,868_CD
04.03.06_CD
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
._.
Dr_NN
Wilson_NN
Totten_NN
04.03.02_CD
136_CD
20,394_CD
04.03.06_CD
Share_NN
options_NOMZ
under_IN
the_DT
Sharesave_NN
Scheme_NN
see_VPRT [PRIV]
note_NN
iv_NN
on_PIN
page_NN
82_CD
Mr_NN
Angus_NN
Russell_NN
04.03.02_CD
127_CD
19,078_CD
04.03.06_CD
are_VPRT [PASS]
offered_VBN
at_PIN
a_DT
discount_NN
as_IN
permitted_VBN
by_PIN
paragraph_NN
13.31_CD
of_PIN
the_DT
Listing_GER
Rules_NN
._.
Share_NN
options_NOMZ
are_VPRT [PASS]
not_XX0
otherwise_CONJ
offered_VBN
at_PIN
a_DT
discount_NN
._.
For_PIN
awards_NN
made_VBN
under_IN
the_DT
Plan_NN
prior_RB
to_PIN
June_NN
2001_CD
,_,
performance_NN
is_VPRT [BEMA]
The_DT
following_JJ
share_NN
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
to_PIN
executive_JJ
directors_NN
during_PIN
measured_VBN
over_IN
a_DT
three-year_JJ
period_NN
but_CC
the_DT
performance_NN
conditions_NOMZ
are_VPRT [BEMA]
2002_CD
and_CC
were_VBD [PASS]
granted_VBN [SUAV]
prior_RB
to_PIN
the_DT
Companys_NN
review_NN
of_PIN
the_DT
based_VBN
on_PIN
criteria_NN
of_PIN
i_FPP1
50_CD
%_NN
TSR_NN
benchmarked_VBD
against_PIN
the_DT
FTSE_NN
midperformance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
the_DT
grant_NN
of_PIN
options_NOMZ
._.
Accordingly_RB
250_CD
index_NN
and_CC
ii_FW
50_CD
%_NN
subject_NN
to_PIN
an_DT
EPS_NN
condition_NOMZ
measured_VBN [WZPAST]
against_PIN
the_DT
performance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
each_QUAN
option_NOMZ
were_VBD [PASS]
determined_VBN [SUAV] [PRIV]
the_DT
diluted_VBN
EPS_NN
of_PIN
the_DT
Company_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBD
before_IN
the_DT
prior_JJ
to_PIN
the_DT
grant_NN
,_,
namely_CONJ
that_DEMO
the_DT
Companys_NN
share_NN
price_NN
had_VBD [PEAS]
increased_VBN
commencement_NOMZ
of_PIN
the_DT
performance_NN
period_NN
and_CC
the_DT
diluted_VBN
EPS_NN
of_PIN
the_DT
by_PIN
an_DT
annualised_JJ
compound_NN
rate_NN
of_PIN
20.5_CD
%_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
Company_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBN [WZPAST]
on_PIN
or_CC
before_IN
the_DT
end_NN
of_PIN
the_DT
period_NN
._.
Shares_NN
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT
not_XX0
performance_NN
period_NN
._.
Performance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
previous_JJ
executive_NN
option_NOMZ
grants_NN
are_VPRT [PASS]
detailed_VBN
on_PIN
pages_NN
81_CD
and_CC
82_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
39_CD
Directors_NN
remuneration_JJ
report_NN
Pension_NN
arrangements_NOMZ
Mr_NN
Stahels_NN
employment_NOMZ
with_PIN
the_DT
Company_NN
commenced_VBD
on_PIN
28_CD
March_NN
A_NN
defined_VBD
contribution_NOMZ
pension_NN
scheme_NN
operates_VPRT
in_PIN
the_DT
UK_NN
._.
1994_CD
,_,
Mr_NN
Russells_NN
employment_NOMZ
commenced_VBD
on_PIN
13_CD
December_NN
1999_CD
and_CC
Dr_NN
Tottens_NN
employment_NOMZ
commenced_VBD
on_PIN
17_CD
January_NN
1998_CD
._.
The_DT
Companys_NN
policy_NN
is_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
pension_NN
benefits_NN
are_VPRT [BEMA]
competitive_PRED
in_PIN
the_DT
markets_NN
in_PIN
which_WDT [PIRE]
Shire_NN
operates_VPRT
._.
A_DT
review_NN
of_PIN
the_DT
Companys_NN
Non-executive_JJ
directors_NN
pension_NN
arrangements_NOMZ
in_PIN
July_NN
2002_CD
recognized_VBD [PRIV]
a_DT
shortfall_NN
in_PIN
the_DT
level_NN
of_PIN
The_DT
Companys_NN
policy_NN
on_PIN
non-executive_JJ
directors_NN
remuneration_NOMZ
is_VPRT
that_DEMO
pension_NN
benefits_NN
provided_VBN [WZPAST]
to_PIN
our_FPP1
executive_JJ
directors_NN
in_PIN
relation_NOMZ
to_PIN
market_NN
each_QUAN
director_NN
is_VPRT [PASS]
paid_VBN
a_DT
fee_NN
for_PIN
acting_VBG
as_IN
a_DT
non-executive_JJ
director_NN
and_CC
competitive_JJ
practice_NN
._.
additional_JJ
fees_NN
are_VPRT [PASS]
paid_VBN
for_PIN
being_VBG [BEMA]
a_DT
member_NN
of_PIN
the_DT
Audit_NN
,_,
Remuneration_NOMZ
and_CC
or_CC
Nomination_NOMZ
Committee_NN
,_,
as_RB
well_RB
as_IN
for_PIN
being_VBG [BEMA]
the_DT
Chairman_NN
of_PIN
any_QUAN
In_PIN
line_NN
with_PIN
its_PIT
remuneration_NOMZ
principles_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
of_PIN
these_DEMO
Committees_NN
._.
The_DT
Chairman_NN
of_PIN
the_DT
Company_NN
is_VPRT [BEMA]
a_DT
non-executive_JJ
agreed_VBD [SUAV] [PUBV]
that_THVC
the_DT
Companys_NN
contribution_NOMZ
for_PIN
the_DT
Chief_NN
Executive_NN
be_VB
director_NN
and_CC
receives_VPRT
a_DT
separate_JJ
fee_NN
._.
Fees_NN
are_VPRT [PASS]
benchmarked_VBN
against_PIN
increased_VBN
to_PIN
30_CD
%_NN
of_PIN
salary_NN
per_PIN
annum_NN
and_CC
for_PIN
the_DT
Finance_NN
Director_NN
comparable_JJ
companies_NN
in_PIN
the_DT
sector_NN
and_CC
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Board_NN
._.
and_ANDC
the_DT
Group_NN
R&D_NN
Director_NN
to_PIN
25_CD
%_NN
of_PIN
salary_NN
per_PIN
annum_NN
,_,
which_WDT [SERE]
the_DT
Details_NN
of_PIN
fees_NN
paid_VBN [WZPAST]
to_PIN
non-executive_JJ
directors_NN
in_PIN
2002_CD
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
Committee_NN
believes_VPRT [PRIV]
is_VPRT
more_EMPH
appropriately_RB
competitive_JJ
._.
The_DT
Remuneration_NOMZ
the_DT
table_NN
on_PIN
page_NN
42_CD
._.
All_QUAN
fees_NN
paid_VBN [WZPAST]
to_PIN
non-executive_JJ
directors_NN
are_VPRT [PASS]
not_XX0
Committee_NN
agreed_VBD [SUAV] [PUBV]
a_DT
supplemental_JJ
pension_NN
payment_NOMZ
to_PIN
Mr_NN
Stahel_NN
of_PIN
performance_NN
related_VBN
._.
Non-executive_JJ
directors_NN
do_VPRT
not_XX0
participate_VB
in_PIN
any_QUAN
94,333_CD
in_PIN
2002_CD
._.
of_PIN
the_DT
Company_NN
share_NN
schemes_NN
or_CC
other_JJ
employee_NN
benefit_NN
schemes_NN
A_DT
defined_VBN
contribution_NOMZ
pension_NN
arrangement_NOMZ
was_VBD [PASS]
established_VBN [PRIV]
for_PIN
Mr_NN
and_CC
no_SYNE
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
to_PIN
non-executive_JJ
directors_NN
in_PIN
their_TPP3
Stahel_NN
with_PIN
the_DT
intention_NOMZ
that_DEMP
his_TPP3
pension_NN
arrangements_NOMZ
on_PIN
leaving_VBG
Shire_NN
capacity_NOMZ
as_IN
non-executive_JJ
directors_NN
of_PIN
Shire_NN
._.
Non-executive_JJ
directors_NN
were_VBD [BEMA]
commensurate_PRED
with_PIN
his_TPP3
position_NOMZ
as_IN
a_DT
FTSE_NN
100_CD
Chief_NN
Executive_NN
are_VPRT [BEMA]
not_XX0
eligible_PRED
to_TO
join_VB
the_DT
Companys_NN
pension_NN
scheme_NN
._.
Certain_JJ
nonand_NN
reflected_VBD [PRIV]
his_TPP3
past_JJ
contribution_NOMZ
to_PIN
the_DT
Companys_NN
business_NOMZ
._.
A_DT
one-off_PIN
executive_NN
directors_NN
hold_VPRT [PRIV]
share_NN
options_NOMZ
relating_VBG [WZPRES]
to_PIN
their_TPP3
service_NN
with_PIN
payment_NOMZ
of_PIN
4.3_CD
million_CD
to_PIN
this_DEMO
arrangement_NOMZ
has_VPRT [PEAS]
been_VBN [BYPA]
made_VBN
by_PIN
the_DT
companies_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
acquired_VBN
or_CC
merged_VBN
with_PIN
Shire_NN
._.
The_DT
grant_NN
Company_NN
in_PIN
2003_CD
see_VPRT [PRIV]
page_NN
41_CD
._.
of_PIN
these_DEMO
options_NOMZ
was_VBD [PASS]
made_VBN
on_PIN
the_DT
same_JJ
terms_NN
as_IN
applicable_JJ
to_PIN
other_JJ
employees_NN
at_PIN
the_DT
time_NN
and_CC
,_,
by_PIN
the_DT
nature_NN
of_PIN
those_DEMO
plans_NN
,_,
the_DT
exercise_NN
Service_NN
contracts_NN
of_PIN
those_DEMO
options_NOMZ
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
conditions_NOMZ
._.
All_QUAN
nonThe_NN
Remuneration_NOMZ
Committee_NN
reviewed_VBD
the_DT
contracts_NN
of_PIN
employment_NOMZ
executive_NN
directors_NN
have_VPRT
letters_NN
of_PIN
appointment_NOMZ
detailing_VBG [WZPRES]
the_DT
specific_NN
for_PIN
executive_JJ
directors_NN
and_CC
other_JJ
senior_JJ
managers_NN
in_PIN
the_DT
course_NN
of_PIN
2002_CD
terms_NN
of_PIN
engagement_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
for_PIN
a_DT
two-year_JJ
term_NN
and_ANDC
which_WDT
may_POMD
and_CC
a_DT
number_NN
of_PIN
changes_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
to_PIN
the_DT
directors_NN
service_NN
be_VB [PASS]
renewed_VBN
._.
These_DEMP
included_VBD
clarification_NOMZ
of_PIN
current_JJ
provisions_NN
and_PHC
amendments_NOMZ
to_TO
introduce_VB
obligations_NOMZ
on_PIN
the_DT
executive_JJ
directors_NN
in_PIN
Details_NN
of_PIN
the_DT
unexpired_JJ
terms_NN
of_PIN
the_DT
non-executive_JJ
directors_NN
letters_NN
respect_NN
of_PIN
intellectual_JJ
property_NN
and_CC
to_TO
update_VB
and_PHC
introduce_VB
postof_JJ
appointments_NOMZ
and_PHC
notice_NN
periods_NN
are_VPRT
as_IN
follows_VPRT
:_:
termination_NOMZ
restrictions_NOMZ
,_,
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
shareholders_NN
interests_NN
are_VPRT [BEMA]
best_JJ
Date_NN
of_PIN
Notice_NN
met_VBD
in_PIN
the_DT
event_NN
of_PIN
early_TIME
termination_NOMZ
of_PIN
a_DT
director_NN
._.
Each_QUAN
of_PIN
the_DT
executive_NN
Director_NN
term_NN
expiry_NN
period_NN
directors_NN
was_VBD [PASS]
asked_VBN [SUAV]
to_TO
enter_VB
into_PIN
a_DT
new_JJ
contract_NN
of_PIN
employment_NOMZ
Dr_NN
Cavanaugh_NN
23.03.05_CD
3_CD
months_NN
reflecting_VBG [PRIV] [WZPRES]
these_DEMO
changes_NN
._.
The_DT
revised_VBN
contract_NN
of_PIN
employment_NOMZ
for_PIN
Dr_NN
Bellini_NN
10.05.03_CD
3_CD
months_NN
Mr_NN
Russell_NN
is_VPRT [PASS]
dated_VBN
29_CD
November_NN
2002_CD
,_,
for_PIN
Mr_NN
Stahel_NN
28_CD
February_NN
2003_CD
,_,
Dr_NN
Price_NN
24.01.04_CD
3_CD
months_NN
and_CC
for_PIN
Dr_NN
Totten_NN
17_CD
December_NN
2002_CD
._.
The_DT
Hon_NN
James_NN
Grant_NN
10.05.03_CD
3_CD
months_NN
The_DT
Remuneration_NOMZ
Committees_NN
policy_NN
is_VPRT
and_PHC
has_VPRT [PEAS]
been_VBN
that_DEMO
executive_JJ
Mr_NN
Nordmann_NN
22.12.03_CD
3_CD
months_NN
directors_NN
service_NN
contracts_NN
should_NEMD
be_VB [BEMA]
for_PIN
a_DT
rolling_JJ
term_NN
,_,
subject_NN
at_PIN
any_QUAN
Mr_NN
Veilleux_NN
10.05.03_CD
3_CD
months_NN
time_NN
to_PIN
a_DT
12-month_JJ
notice_NN
period_NN
from_PIN
the_DT
Company_NN
._.
In_PIN
the_DT
event_NN
of_PIN
termination_NOMZ
for_PIN
cause_NN
no_SYNE
such_JJ
notice_NN
period_NN
would_PRMD
apply_VB
._.
Related_VBN
party_NN
transactions_NOMZ
The_DT
Committee_NN
also_RB
believes_VPRT [PRIV]
that_THVC
the_DT
Company_NN
should_NEMD
retain_VB
the_DT
right_JJ
Details_NN
relating_VBG [WZPRES]
to_PIN
Mr_NN
John_NN
Spitznagel_NN
,_,
a_DT
former_JJ
director_NN
who_WP [WHSUB]
entered_VBD
to_TO
make_VB
a_DT
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
to_PIN
a_DT
director_NN
,_,
except_PIN
in_PIN
the_DT
event_NN
of_PIN
into_PIN
a_DT
consultancy_NN
agreement_NOMZ
with_PIN
the_DT
Company_NN
,_,
and_ANDC
The_DT
Hon_NN
James_NN
termination_NOMZ
for_PIN
cause_NN
._.
In_PIN
accordance_NN
with_PIN
policy_NN
,_,
the_DT
revised_VBN
contracts_NN
Grant_NN
,_,
who_WP
is_VPRT [BEMA]
a_DT
partner_NN
of_PIN
a_DT
Canadian_JJ
law_NN
firm_NN
with_PIN
which_WDT [PIRE]
the_DT
Group_NN
allow_VPRT [SUAV]
the_DT
Company_NN
,_,
at_PIN
its_PIT
discretion_NOMZ
,_,
to_TO
pay_VB
up_RP
to_PIN
a_DT
maximum_NN
of_PIN
incurred_VBN
professional_JJ
fees_NN
during_PIN
the_DT
year_NN
,_,
are_VPRT [PASS]
given_VBN
in_PIN
note_NN
20_CD
to_PIN
the_DT
12_CD
months_NN
salary_NN
,_,
12_CD
months_NN
maximum_JJ
annual_JJ
bonus_NN
,_,
12_CD
months_NN
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
page_NN
73_CD
._.
pension_NN
contribution_NOMZ
and_CC
up_RB
to_PIN
12_CD
months_NN
of_PIN
the_DT
actual_JJ
cost_NN
to_PIN
the_DT
employee_NN
of_PIN
the_DT
other_JJ
contractual_JJ
benefits_NN
to_PIN
which_WDT [PIRE]
the_DT
director_NN
is_VPRT [PASS]
entitled_VBN
,_,
in_PIN
the_DT
event_NN
of_PIN
termination_NOMZ
,_,
as_IN
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
._.
The_DT
Committee_NN
takes_VPRT
the_DT
view_NN
that_DEMP
this_DEMO
approach_NN
will_PRMD
enable_VB
contractual_JJ
termination_NOMZ
to_TO
be_VB [PASS]
managed_VBN
fairly_RB
and_PHC
appropriately_RB
taking_VBG
into_PIN
account_NN
individual_JJ
circumstances_NN
._.
As_IN
part_NN
of_PIN
its_PIT
review_NN
and_CC
in_PIN
light_NN
of_PIN
growing_VBG
business_NOMZ
uncertainty_NN
in_PIN
the_DT
pharmaceutical_JJ
sector_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
also_RB
decided_VBD [SUAV] [PRIV]
that_THVC
it_PIT
would_PRMD
be_VB [BEMA]
in_PIN
shareholders_NN
interests_NN
to_TO
provide_VB
in_PIN
the_DT
directors_NN
service_NN
contracts_NN
that_DEMP
,_,
in_PIN
the_DT
event_NN
of_PIN
a_DT
change_NN
of_PIN
control_NN
of_PIN
the_DT
Company_NN
and_CC
the_DT
termination_NOMZ
,_,
other_JJ
than_PIN
for_PIN
cause_NN
,_,
by_PIN
the_DT
Company_NN
of_PIN
an_DT
executive_JJ
directors_NN
employment_NOMZ
within_PIN
12_CD
months_NN
thereof_RB
,_,
the_DT
executive_NN
in_PIN
such_JJ
circumstances_NN
would_PRMD
be_VB [PASS]
entitled_VBN
to_TO
receive_VB
24_CD
months_NN
salary_NN
and_CC
24_CD
months_NN
bonus_NN
,_,
inclusive_NN
of_PIN
all_QUAN
other_JJ
benefits_NN
._.
Executive_NN
directors_NN
would_PRMD
not_XX0
be_VB [PASS]
entitled_VBN
,_,
in_CONJ
addition_NULL
,_,
to_PIN
any_QUAN
other_JJ
severance_NN
arrangements_NOMZ
._.
The_DT
Committee_NN
takes_VPRT
the_DT
view_NN
that_DEMP
this_DEMO
level_NN
of_PIN
enhanced_JJ
compensation_NOMZ
is_VPRT [BEMA]
in_PIN
the_DT
interests_NN
of_PIN
shareholders_NN
on_PIN
the_DT
grounds_NN
that_TOBJ
it_PIT
both_DT
reduces_VPRT
the_DT
potential_NN
for_PIN
insecurity_NOMZ
and_CC
enhances_VPRT
levels_NN
of_PIN
commitment_NOMZ
._.
40_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Performance_NN
graph_NN
Rolf_NN
Stahel_NN
The_NN
graph_NN
below_PLACE
sets_NN
out_PIN
the_DT
total_JJ
shareholder_NN
return_NN
for_PIN
the_DT
five_CD
years_NN
It_PIT
was_VBD [PASS]
announced_VBN [PUBV]
on_PIN
29_CD
October_NN
2002_CD
that_DEMO
Mr_NN
Stahel_NN
would_PRMD
be_VB
ending_VBG
31_CD
December_NN
2002_CD
._.
The_DT
graph_NN
sets_VPRT
out_PIN
a_DT
comparison_NN
of_PIN
a_DT
stepping_VBG
down_RP
as_IN
Chief_NN
Executive_NN
once_TIME
a_DT
successor_NN
had_VBD [PEAS]
been_VBN [PASS]
identified_VBN
._.
holding_VBG [PRIV] [PRESP]
of_PIN
the_DT
Companys_NN
shares_NN
over_IN
this_DEMO
period_NN
contrasted_VBN [WZPAST]
with_PIN
a_DT
Mr_NN
Stahels_NN
contract_NN
of_PIN
employment_NOMZ
was_VBD [BYPA]
terminated_VBN
by_PIN
notice_NN
given_VBN [WZPAST]
by_PIN
holding_VBG [PRIV]
of_PIN
shares_NN
of_PIN
UK_NN
pharma_NN
and_CC
biotech_JJ
companies_NN
in_PIN
the_DT
FTSE_NN
the_DT
Company_NN
on_PIN
12_CD
March_NN
2003_CD
and_CC
his_TPP3
employment_NOMZ
terminated_VBN [WZPAST]
on_PIN
over_IN
the_DT
relevant_JJ
periods_NN
,_,
calculated_VBN [PRIV] [PASTP]
in_PIN
accordance_NN
with_PIN
the_DT
Directors_NN
19_CD
March_NN
2003_CD
._.
The_DT
Remuneration_NOMZ
Committee_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
termination_NOMZ
of_PIN
his_TPP3
employment_NOMZ
,_,
the_DT
Company_NN
is_VPRT [BEMA]
of_PIN
the_DT
view_NN
that_DEMP
this_DEMP
is_VPRT [BEMA]
the_DT
most_EMPH
relevant_JJ
broad_JJ
equity_NOMZ
market_NN
index_NN
has_VPRT [PEAS]
made_VBN
a_DT
payment_NOMZ
to_PIN
Mr_NN
Stahel_NN
under_IN
the_DT
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
against_PIN
which_WDT [PIRE]
to_TO
compare_VB
Shires_NN
TSR_NN
performance_NN
for_PIN
this_DEMO
period_NN
._.
To_PIN
provisions_NN
of_PIN
his_TPP3
employment_NOMZ
contract_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Remuneration_NOMZ
note_NN
is_VPRT
that_DEMO
the_DT
methodology_NN
for_PIN
assessing_VBG
Shires_NN
TSR_NN
performance_NN
for_PIN
Committee_NN
awarded_VBD
Mr_NN
Stahel_NN
an_DT
amount_NN
equal_JJ
to_PIN
the_DT
full_JJ
bonus_NN
for_PIN
that_DEMO
the_DT
purposes_NN
of_PIN
establishing_VBG [PRIV]
whether_IN [WHCL]
and_CC
to_TO
what_WP
extent_NN
shares_NN
under_IN
proportion_NOMZ
of_PIN
2003_CD
which_WDT
fell_VBD
prior_RB
to_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
his_TPP3
employment_NOMZ
the_DT
Plan_NN
should_NEMD
vest_NN
is_VPRT [BEMA]
somewhat_DWNT
different_PRED
from_PIN
the_DT
methodology_NN
used_VBN
terminated_VBN
._.
in_PIN
the_DT
compilation_NOMZ
of_PIN
this_DEMO
graph_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
exercise_VB
its_PIT
discretion_NOMZ
to_TO
allow_VB [SUAV]
Mr_NN
Stahel_NN
to_TO
retain_VB
his_TPP3
subsisting_VBG
share_NN
options_NOMZ
._.
However_CONJ
,_,
this_DEMP
is_VPRT [BEMA]
Five-year_JJ
historical_JJ
TSR_NN
performance_NN
Change_NN
in_PIN
the_DT
value_NN
of_PIN
a_DT
hypothetical_JJ
100_CD
holding_GER
over_IN
five_CD
years_NN
subject_JJ
to_PIN
Mr_NN
Stahel_NN
agreeing_VBG [SUAV] [PUBV] [WZPRES]
not_XX0
to_TO
exercise_VB
these_DEMO
options_NOMZ
for_PIN
a_DT
FTSE_NN
UK_NN
Pharma_NN
and_PHC
Biotech_NN
Index_NN
comparison_NN
based_VBN [WZPAST]
on_PIN
spot_NN
values_NN
phased_VBD
period_NN
of_PIN
time_NN
of_PIN
up_RB
to_PIN
two_CD
years_NN
following_VBG [WZPRES]
his_TPP3
termination_NOMZ
date_NN
._.
Mr_NN
Stahels_NN
options_NOMZ
may_POMD
not_XX0
be_VB [PASS]
exercised_VBN
if_COND
he_TPP3
is_VPRT [BEMA]
in_PIN
breach_NN
of_PIN
certain_JJ
400.00_CD
post_NN
termination_NOMZ
restrictive_JJ
covenants_NN
and_CC
or_CC
if_COND
he_TPP3
engages_VPRT
in_PIN
activity_NOMZ
detrimental_JJ
to_PIN
the_DT
Company_NN
over_IN
that_DEMO
period_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
and_CC
the_DT
Board_NN
also_RB
decided_VBD [SUAV] [PRIV]
,_,
in_PIN
350.00_CD
recognition_NOMZ
of_PIN
Mr_NN
Stahels_NN
exceptional_JJ
services_NN
to_PIN
the_DT
Group_NN
over_IN
his_TPP3
period_NN
of_PIN
employment_NOMZ
,_,
to_TO
make_VB
an_DT
additional_JJ
one-off_PIN
payment_NOMZ
,_,
to_PIN
a_DT
defined_VBN
contribution_NOMZ
pension_NN
arrangement_NOMZ
established_VBN [PRIV] [WZPAST]
for_PIN
him_TPP3
,_,
of_PIN
300.00_CD
4.3_CD
million_CD
._.
This_DEMP
is_VPRT [BEMA]
the_DT
amount_NN
that_TOBJ
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
the_DT
Board_NN
considered_VBN [PRIV]
necessary_JJ
,_,
taking_VBG [PRESP]
into_PIN
account_NN
amounts_NN
already_RB
contributed_VBN
by_PIN
the_DT
Company_NN
to_PIN
his_TPP3
personal_JJ
pension_NN
arrangements_NOMZ
and_CC
250.00_CD
his_TPP3
service_NN
with_PIN
and_CC
contribution_NOMZ
to_PIN
the_DT
Company_NN
,_,
to_TO
make_VB
appropriate_JJ
pension_NN
provision_NN
for_PIN
him_TPP3
and_CC
his_TPP3
dependants_NN
._.
200.00_CD
The_DT
Remuneration_NOMZ
Committee_NN
satisfied_VBD
itself_PIT
,_,
on_PIN
the_DT
basis_NN
of_PIN
actuarial_JJ
advice_NN
,_,
that_DEMP
this_DEMP
would_PRMD
provide_VB
Mr_NN
Stahel_NN
with_PIN
an_DT
amount_NN
that_TSUB
broadly_RB
would_PRMD
allow_VB [SUAV]
the_DT
acquisition_NOMZ
of_PIN
an_DT
annuity_NOMZ
capable_JJ
of_PIN
delivering_VBG
a_DT
pension_NN
150.00_CD
equivalent_NN
to_PIN
that_DEMP
which_WDT
he_TPP3
would_PRMD
have_VB [PEAS]
received_VBN
,_,
given_VBN
his_TPP3
years_NN
of_PIN
service_NN
,_,
had_VBD [PEAS]
he_TPP3
been_VBN [BEMA]
in_PIN
a_DT
defined_VBN
benefit_NN
scheme_NN
with_PIN
an_DT
accrual_NN
rate_NN
of_PIN
between_PIN
1_CD
45th_CD
and_CC
1_CD
30th_JJ
of_PIN
his_TPP3
final_JJ
salary_NN
for_PIN
each_QUAN
year_NN
of_PIN
his_TPP3
service_NN
._.
100.00_CD
50.00_CD
Dec_NN
1997_CD
Dec_NN
1998_CD
Dec_NN
1999_CD
Dec_NN
2000_CD
Dec_NN
2001_CD
Dec_NN
2002_CD
FTSE_NN
UK_NN
Pharma_NN
and_PHC
Biotech_NN
Index_NN
Shire_NN
Pharmaceuticals_NN
LON_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
41_CD
Value_NN
of_PIN
hypothetical_JJ
100_CD
holding_VBG [PRIV]
Directors_NN
remuneration_JJ
report_NN
Audited_VBN
information_NOMZ
Aggregate_NN
directors_NN
remuneration_VPRT
The_DT
total_JJ
amounts_NN
for_PIN
directors_NN
remuneration_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
2002 2001 000 000_CD
Emoluments_NOMZ
2,300_CD
2,019_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
2,754_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
2,962_CD
22,005_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
383_CD
103_CD
5,645_CD
26,881_CD
Directors_NN
emoluments_NOMZ
and_PHC
compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
Cash_NN
Non-cash_JJ
Basic_JJ
Annual_JJ
benefits_NN
benefits_NN
Total_JJ
Total_JJ
salary_NN
bonuses_NN
Fees_NN
in_PIN
kind_NN
in_PIN
kind_NN
2002_CD
2001_CD
Director_NN
000 000 000 000_CD
000 000 000_CD
Executive_NN
Mr_NN
Rolf_NN
Stahel_NN
559_CD
559_CD
26_CD
1,144_CD
726_CD
Mr_NN
Angus_NN
Russell_NN
290_CD
128_CD
7_CD
19 444 393_CD
Dr_NN
Wilson_NN
Totten_NN
310_CD
141 30 481 419_CD
1,159_CD
828_CD
7_CD
75_CD
2,069_CD
1,538_CD
Non-executive_JJ
Dr_NN
James_NN
Cavanaugh_NN
45_CD
45_CD
42_CD
Dr_NN
Barry_NN
Price_NN
37_CD
37_CD
31_CD
Dr_NN
Francesco_NN
Bellini_NN
30_CD
30_CD
3,012_CD
The_DT
late_TIME
Dr_NN
Bernard_NN
Canavan_NN
23_CD
23_CD
60_CD
The_DT
Hon_NN
James_NN
Grant_NN
30_CD
30_CD
19_CD
Dr_NN
Zola_NN
Horovitz_NN
7_CD
Mr_NN
Ronald_NN
Nordmann_NN
34_CD
34_CD
29_CD
Mr_NN
Joseph_NN
Smith_NN
7_CD
Mr_NN
John_NN
Spitznagel_NN
7_CD
Mr_NN
Grard_NN
Veilleux_NN
32_CD
32 21 231 231_CD
3,235_CD
Total_JJ
1,159_CD
828_CD
231_CD
7_CD
75_CD
2,300_CD
4,773_CD
These_DEMO
directors_NN
resigned_VBD
on_PIN
11_CD
May_POMD
2001_CD
._.
Cash_NN
benefits_NN
in_PIN
kind_NN
represent_VPRT
expense_NN
allowances_NN
and_CC
non-cash_JJ
benefits_NN
represent_VPRT
emoluments_NOMZ
._.
Non-cash_JJ
benefits_NN
in_PIN
kind_NN
consist_VPRT
of_PIN
a_DT
car_NN
and_CC
private_JJ
medical_JJ
insurance_NN
including_VBG [WZPRES]
dental_JJ
costs_NN
._.
Details_NN
of_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
are_VPRT [PASS]
disclosed_VBN [PUBV]
on_PIN
pages_NN
43_CD
to_PIN
46_CD
._.
Non-executive_JJ
director_NN
remuneration_NOMZ
is_VPRT [BEMA]
to_PIN
from_PIN
the_DT
date_NN
of_PIN
resignation_NOMZ
appointment_NOMZ
._.
42_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Directors_NN
shareholdings_GER
Directors_NN
who_WP [WHSUB]
held_VBD [PRIV]
office_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
had_VBD
interests_NN
in_PIN
the_DT
share_NN
capital_NN
of_PIN
the_DT
Company_NN
as_IN
follows_VPRT
:_:
31_CD
December_NN
31_CD
December_NN
Notes_NN
2002_CD
2001_CD
Dr_NN
James_NN
Cavanaugh_NN
i_FPP1
8,806,368_CD
8,806,368_CD
Mr_NN
Rolf_NN
Stahel_NN
ii_FW
601,779_CD
23,684_CD
Mr_NN
Angus_NN
Russell_NN
Dr_NN
Wilson_NN
Totten_NN
iii_FW
6,061_CD
Dr_NN
Barry_NN
Price_NN
31,350_CD
31,350_CD
Dr_NN
Francesco_NN
Bellini_NN
iv_NN
6,586,708_CD
6,486,708_CD
The_DT
Hon_NN
James_NN
Grant_NN
v_VBD
4,551_CD
4,551_CD
Mr_NN
Ronald_NN
Nordmann_NN
46,968_CD
46,968_CD
Mr_NN
Grard_NN
Veilleux_NN
All_QUAN
interests_NN
are_VPRT [BEMA]
beneficial_PRED
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
Notes_NN
i_FPP1
Dr_NN
Cavanaugh_NN
is_VPRT [BEMA]
the_DT
President_NN
of_PIN
HealthCare_NN
Ventures_NN
LLC_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
management_NOMZ
company_NN
for_PIN
a_DT
number_NN
of_PIN
limited_JJ
partnerships_NN
which_WDT [WHSUB]
have_VPRT
interests_NN
in_PIN
8,690,090_CD
ordinary_JJ
shares_NN
._.
Dr_NN
Cavanaugh_NN
is_VPRT [BEMA]
also_RB
the_DT
beneficial_JJ
owner_NN
of_PIN
116,278_CD
ordinary_JJ
shares_NN
._.
ii_FW
On_PIN
4_CD
March_NN
2002_CD
Mr_NN
Stahel_NN
purchased_VBD
19,000_CD
ordinary_JJ
shares_NN
at_PIN
a_DT
price_NN
of_PIN
5.195_CD
per_PIN
share_NN
._.
On_PIN
16_CD
August_NN
2002_CD
Mr_NN
Stahel_NN
exercised_VBD
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
him_TPP3
under_IN
the_DT
Shire_NN
Holdings_GER
Limited_NN
Share_NN
Option_NOMZ
Scheme_NN
totalling_VBG [WZPRES]
269,520_CD
shares_NN
at_PIN
the_DT
option_NOMZ
price_NN
of_PIN
1.00_CD
per_PIN
share_NN
._.
All_QUAN
269,520_CD
shares_NN
were_VBD [SPAU] [PASS]
subsequently_TIME
sold_VBN
on_PIN
20_CD
December_NN
2002_CD
at_PIN
a_DT
price_NN
of_PIN
3.887_CD
per_PIN
share_NN
._.
Also_RB
on_PIN
20_CD
December_NN
2002_CD
Mr_NN
Stahel_NN
exercised_VBD
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
him_TPP3
under_IN
the_DT
Shire_NN
Holdings_GER
Limited_NN
Share_NN
Option_NOMZ
Scheme_NN
totalling_VBG [WZPRES]
270,480_CD
shares_NN
at_PIN
the_DT
option_NOMZ
price_NN
of_PIN
1.00_CD
per_PIN
share_NN
and_CC
329,095_CD
shares_NN
at_PIN
the_DT
option_NOMZ
price_NN
of_PIN
1.75_CD
per_PIN
share_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
him_TPP3
under_IN
Part_NN
B_NN
of_PIN
the_DT
Shire_NN
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
On_PIN
the_DT
same_JJ
day_NN
40,480_CD
shares_NN
were_VBD [PASS]
sold_VBN
from_PIN
the_DT
Part_NN
B_NN
option_NOMZ
at_PIN
the_DT
price_NN
of_PIN
3.887_CD
per_PIN
share_NN
._.
iii_FW
On_PIN
6_CD
March_NN
2002_CD
Dr_NN
Totten_NN
purchased_VBD
6,061_CD
ordinary_JJ
shares_NN
at_PIN
a_DT
price_NN
of_PIN
4.90_CD
per_PIN
share_NN
._.
iv_VB
On_PIN
1_CD
March_NN
2002_CD
Dr_NN
Bellini_NN
purchased_VBD
100,000_CD
ordinary_JJ
shares_NN
at_PIN
a_DT
price_NN
of_PIN
5.29_CD
per_PIN
share_NN
._.
v_FW
On_PIN
5_CD
June_NN
2002_CD
The_DT
Hon_NN
James_NN
Grant_NN
exercised_VBD
an_DT
option_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
him_TPP3
under_IN
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
for_PIN
31,859_CD
shares_NN
at_PIN
the_DT
option_NOMZ
price_NN
of_PIN
2.08_CD
per_PIN
share_NN
._.
All_QUAN
these_DEMO
shares_NN
were_VBD [PASS]
sold_VBN
on_PIN
the_DT
same_JJ
day_NN
at_PIN
a_DT
price_NN
of_PIN
6.032_CD
per_PIN
share_NN
._.
Directors_NN
share_VPRT
options_NOMZ
Aggregate_JJ
emoluments_NOMZ
disclosed_VBN [PUBV]
above_PLACE
do_VPRT
not_XX0
include_VB
any_QUAN
amounts_NN
for_PIN
the_DT
value_NN
of_PIN
options_NOMZ
to_TO
acquire_VB
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
granted_VBN [SUAV]
to_TO
or_CC
held_VBN [PRIV]
by_PIN
the_DT
directors_NN
._.
Directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
options_NOMZ
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
2000_CD
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Holdings_GER
Limited_NN
Share_NN
Option_NOMZ
Scheme_NN
SHL_NN
Scheme_NN
,_,
the_DT
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
,_,
the_DT
Richwood_NN
1993_CD
and_CC
1995_CD
Stock_NN
Option_NOMZ
Plans_NN
SRI_NN
Plan_NN
,_,
the_DT
Roberts_NN
Stock_NN
Option_NOMZ
Plan_NN
Roberts_NN
Plan_NN
and_CC
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
._.
There_EX
have_VPRT [PEAS]
been_VBN
no_SYNE
variations_NOMZ
to_PIN
the_DT
terms_NN
and_PHC
conditions_NOMZ
or_CC
performance_NN
criteria_NN
for_PIN
share_NN
options_NOMZ
during_PIN
the_DT
financial_JJ
year_NN
except_PIN
as_IN
detailed_VBN
in_PIN
note_NN
vi_FW
below_PLACE
._.
In_CONJ
addition_NULL
to_PIN
the_DT
above_PLACE
disclosures_NN
,_,
the_DT
following_JJ
directors_NN
who_WP [WHSUB]
served_VBD
during_PIN
the_DT
year_NN
under_IN
review_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
,_,
or_CC
have_VPRT [PEAS]
exercised_VBN
the_DT
following_JJ
executive_NN
options_NOMZ
and_CC
long-term_JJ
incentive_NN
awards_NN
during_PIN
the_DT
period_NN
between_PIN
1_CD
January_NN
2003_CD
and_CC
1_CD
May_POMD
2003_CD
._.
Options_NOMZ
granted_VBD [SUAV]
Exercise_NN
Earliest_NN
Latest_JJ
Number_NN
price_NN
Date_NN
of_PIN
exercise_NN
exercise_NN
Director_NN
Scheme_NN
of_PIN
options_NOMZ
grant_NN
date_NN
date_NN
Dr_NN
Wilson_NN
Totten_NN
2000_CD
Executive_NN
Scheme_NN
B_NN
301,775_CD
3.38_CD
04.03.03_CD
04.03.06_CD
03.03.13_CD
Mr_NN
Angus_NN
Russell_NN
2000_CD
Executive_NN
Scheme_NN
B_NN
284,024_CD
3.38_CD
04.03.03_CD
04.03.06_CD
03.03.13_CD
585,799_CD
Options_NOMZ
exercised_VBN
Market_NN
Exercise_NN
price_NN
at_PIN
Number_NN
price_NN
Date_NN
of_PIN
exercise_NN
Gain_NN
on_PIN
Director_NN
Scheme_NN
of_PIN
options_NOMZ
exercise_NN
date_NN
exercise_NN
Mr_NN
Rolf_NN
Stahel_NN
Executive_NN
Scheme_NN
A_NN
13,761_CD
2.18_CD
18.03.03_CD
3.68_CD
20,676_CD
Long_NN
Term_NN
Incentive_NN
Plan_NN
awards_NN
Value_NN
at_PIN
date_NN
of_PIN
Earliest_NN
Award_NN
award_NN
Date_NN
of_PIN
date_NN
of_PIN
Director_NN
Scheme_NN
made_VBD
award_NN
award_NN
Dr_NN
Wilson_NN
Totten_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
47,459_CD
169,998_CD
20.03.03_CD
20.03.07_CD
Mr_NN
Angus_NN
Russell_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
44,667_CD
159,995_CD
20.03.03_CD
20.03.07_CD
92,126_CD
Long_NN
Term_NN
Incentive_NN
Plan_NN
maturities_NOMZ
Actual_NN
Initial_JJ
performance_NN
Value_NN
at_PIN
award_NN
related_VBN
date_NN
of_PIN
Date_NN
of_PIN
Director_NN
Scheme_NN
made_VBD
award_NN
maturity_NOMZ
maturity_NOMZ
Mr_NN
Rolf_NN
Stahel_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
68,015_CD
49,934_CD
183,882_CD
18.03.03_CD
Dr_NN
Wilson_NN
Totten_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
15,255_CD
11,289_CD
46,623_CD
08.03.03_CD
65,189_CD
In_CONJ
addition_NULL
to_PIN
the_DT
above_PLACE
,_,
on_PIN
18_CD
March_NN
2003_CD
,_,
the_DT
remaining_VBG
55,949_CD
of_PIN
Mr_NN
Stahels_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
awards_NN
lapsed_VBD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
45_CD
Dir_NN
Directors_NN
r_SYM
ectors_NN
remuneration_VPRT
r_NN
emuneration_NOMZ
report_NN
eport_NN
Notes_NN
i_FPP1
These_DEMO
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Shire_NN
Holdings_GER
Limited_NN
,_,
a_DT
previous_JJ
holding_VBG [PRIV]
company_NN
of_PIN
the_DT
Group_NN
._.
The_DT
exercise_NN
of_PIN
these_DEMO
options_NOMZ
is_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
criteria_NN
and_PHC
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
._.
ii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
If_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three_CD
years_NN
,_,
they_TPP3
are_VPRT [SPAU] [PASS]
thereafter_RB
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
share_VB
price_NN
growth_NN
over_IN
the_DT
extended_JJ
period_NN
._.
If_COND
the_DT
share_NN
price_NN
does_VPRT
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
of_PIN
the_DT
options_NOMZ
will_PRMD
become_VB
exercisable_JJ
._.
iii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
Employees_NN
may_POMD
enter_VB
into_PIN
three_CD
or_CC
five-year_JJ
savings_GER
contracts_NN
._.
The_DT
exercise_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
Scheme_NN
is_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
criteria_NN
._.
iv_NN
These_DEMO
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Shire_NN
Laboratories_NN
Inc._NN
._.
SLI_NN
,_,
formerly_TIME
Pharmavene_NN
Inc._NN
a_DT
US_FPP1
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
23_CD
March_NN
1997_CD
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SLI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
SLI_NN
Plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
performance_NN
criteria_NN
._.
v_FW
These_DEMO
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
,_,
a_DT
US_FPP1
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
23_CD
December_NN
1999_CD
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
Roberts_NN
Plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
criteria_NN
._.
vi_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
following_VBG [WZPRES]
the_DT
Companys_NN
2000_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
period_NN
._.
If_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
will_PRMD
be_VB [BEMA]
exercisable_PRED
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
they_TPP3
will_PRMD [SPAU]
thereafter_RB
be_VB [PASS]
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
compound_VB
annual_JJ
share_NN
price_NN
growth_NN
over_IN
an_DT
extended_JJ
period_NN
._.
If_COND
the_DT
share_NN
price_NN
does_VPRT
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
of_PIN
these_DEMO
options_NOMZ
will_PRMD
become_VB
exercisable_JJ
._.
At_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
of_PIN
the_DT
Company_NN
,_,
held_VBN [PRIV] [PASTP]
on_PIN
5_CD
June_NN
2001_CD
,_,
a_DT
resolution_NOMZ
was_VBD [PASS]
passed_VBN
to_TO
permit_VB
the_DT
grant_NN
of_PIN
options_NOMZ
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
to_TO
be_VB [PASS]
made_VBN
subject_JJ
to_PIN
performance_NN
criteria_NN
being_VBG [WZPRES] [BEMA]
satisfied_JJ
prior_RB
to_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Subsequent_JJ
to_PIN
the_DT
passing_GER
of_PIN
this_DEMO
resolution_NOMZ
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
based_VBN
on_PIN
performance_NN
criteria_NN
being_VBG [WZPRES] [PASS]
satisfied_VBN
before_IN
grant_NN
,_,
namely_CONJ
that_DEMO
the_DT
Companys_NN
share_NN
price_NN
had_VBD [PEAS]
increased_VBN
by_PIN
an_DT
annualised_JJ
compound_NN
rate_NN
of_PIN
20.5_CD
%_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
period_NN
._.
During_PIN
2002_CD
,_,
the_DT
performance_NN
criteria_NN
were_VBD [SPAU] [PASS]
again_TIME
reviewed_VBN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
criteria_NN
reflected_VBD [PRIV]
the_DT
market_NN
in_PIN
which_WDT [PIRE]
the_DT
Company_NN
operates_VPRT
._.
Given_VBN
the_DT
Companys_NN
development_NOMZ
it_PIT
was_VBD [PASS]
felt_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
EPS_NN
based_VBN
measure_NN
should_NEMD
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
Therefore_CONJ
option_NOMZ
grants_NN
made_VBN
after_IN
July_NN
2002_CD
will_PRMD [SPAU]
only_DWNT
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
the_DT
Companys_NN
EPS_NN
growth_NN
exceeds_VPRT
the_DT
RPI_NN
over_IN
a_DT
three-year_JJ
period_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
3_CD
%_NN
directors_NN
,_,
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
7_CD
%_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
The_DT
adoption_NOMZ
of_PIN
the_DT
new_JJ
criteria_NN
applies_VPRT
to_PIN
all_QUAN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
from_PIN
August_NN
2002_CD
onwards_NN
._.
vii_FW
Following_VBG
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
on_PIN
11_CD
May_POMD
2001_CD
,_,
the_DT
BioChem_NN
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChems_NN
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
._.
All_QUAN
BioChem_NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD
not_XX0
already_RB
exercisable_PRED
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
conditions_NOMZ
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
BioChem_NN
Plan_NN
._.
viii_FW
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
The_DT
offering_GER
period_NN
is_VPRT [BEMA]
for_PIN
27_CD
months_NN
._.
The_DT
exercise_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
plan_NN
is_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
condition_NOMZ
._.
The_DT
market_NN
price_NN
of_PIN
the_DT
ordinary_JJ
shares_NN
at_PIN
31_CD
December_NN
2002_CD
was_VBD [BEMA]
3.975_CD
and_CC
the_DT
range_NN
during_PIN
the_DT
year_NN
was_VBD [BEMA]
8.835_CD
to_PIN
3.755_CD
._.
Performance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
awards_NN
made_VBN
under_IN
the_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
are_VPRT [PASS]
detailed_VBN
on_PIN
page_NN
39_CD
._.
46_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Directors_NN
pension_NN
entitlements_NOMZ
Four_CD
directors_NN
are_VPRT
members_NN
of_PIN
money_NN
purchase_NN
schemes_NN
._.
Contributions_NOMZ
paid_VBN [WZPAST]
by_PIN
the_DT
Company_NN
in_PIN
respect_NN
the_DT
current_JJ
year_NN
were_VBD
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Director_NN
000_CD
000_CD
Mr_NN
Rolf_NN
Stahel_NN
216_CD
48_CD
Dr_NN
Wilson_NN
Totten_NN
46_CD
29_CD
Mr_NN
Angus_NN
Russell_NN
56_CD
26_CD
Dr_NN
Francesco_NN
Bellini_NN
65 383 103_CD
The_DT
pension_NN
payment_NOMZ
to_PIN
Dr_NN
Bellini_NN
,_,
the_DT
former_JJ
Chief_NN
Executive_NN
of_PIN
BioChem_NN
Pharma_NN
Inc_NN
,_,
arises_VPRT
from_PIN
Dr_NN
Bellinis_NN
termination_NOMZ
arrangement_NOMZ
,_,
which_WDT [SERE]
is_VPRT [PASS]
based_VBN
on_PIN
his_TPP3
pre-merger_JJ
employment_NOMZ
contract_NN
._.
The_DT
Companys_NN
obligation_NOMZ
to_TO
make_VB
pension_NN
payment_NOMZ
to_PIN
Dr_NN
Bellini_NN
shall_PRMD
end_VB
on_PIN
13_CD
May_POMD
2003_CD
._.
Approval_NN
This_DEMO
report_NN
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
on_PIN
1_CD
May_POMD
2003_CD
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
Dr_NN
Barry_NN
Price_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
47_CD
Corporate_JJ
governance_NN
statement_NOMZ
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_PIN
high_JJ
standards_NN
of_PIN
corporate_JJ
Committees_NN
of_PIN
the_DT
Board_NN
governance_NN
The_DT
standing_GER
Board_NN
committees_NN
are_VPRT [BEMA]
the_DT
Audit_NN
Committee_NN
,_,
the_DT
The_DT
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
appended_VBD
to_PIN
the_DT
Listing_GER
Remuneration_NOMZ
Committee_NN
,_,
the_DT
Nomination_NOMZ
Committee_NN
and_CC
the_DT
Executive_NN
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
requires_VPRT [SUAV] [THATD]
companies_NN
listed_VBN [WZPAST]
on_PIN
Committee_NN
._.
Each_QUAN
committee_NN
has_VPRT
its_PIT
own_JJ
written_VBN [PUBV]
terms_NN
of_PIN
reference_NN
that_TOBJ
the_DT
London_NN
Stock_NN
Exchange_NN
to_TO
make_VB
a_DT
disclosure_NN
statement_NOMZ
on_PIN
its_PIT
have_VPRT [PEAS]
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
._.
Details_NN
of_PIN
each_QUAN
committee_NN
are_VPRT
as_IN
application_NOMZ
of_PIN
the_DT
principles_NN
of_PIN
and_CC
compliance_NN
with_PIN
the_DT
provisions_NN
of_PIN
follows_VPRT
:_:
good_JJ
governance_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
Combined_NN
Code_NN
._.
Throughout_PIN
the_DT
period_NN
i_FPP1
The_DT
Audit_NN
Committee_NN
is_VPRT [BYPA]
chaired_VBN
by_PIN
Mr_NN
Ronald_NN
Nordmann_NN
and_CC
under_IN
review_NN
the_DT
Company_NN
has_VPRT [PEAS]
been_VBN [PASS]
committed_VBN
to_PIN
high_JJ
standards_NN
of_PIN
usually_RB
meets_VPRT
four_CD
times_NN
a_DT
year_NN
._.
Other_JJ
members_NN
of_PIN
the_DT
Committee_NN
corporate_JJ
governance_NN
and_CC
,_,
in_PIN
the_DT
directors_NN
opinion_NN
,_,
has_VPRT [PEAS]
complied_VBN
,_,
are_VPRT
Dr_NN
James_NN
Cavanaugh_NN
and_PHC
Dr_NN
Barry_NN
Price_NN
._.
Under_IN
its_PIT
terms_NN
of_PIN
subject_JJ
as_IN
below_PLACE
,_,
with_PIN
the_DT
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
._.
reference_NN
the_DT
Committee_NN
is_VPRT [PASS]
required_VBN [SUAV]
,_,
amongst_PIN
other_JJ
things_NN
,_,
to_TO
review_VB
The_DT
Board_NN
the_DT
effectiveness_NOMZ
of_PIN
internal_JJ
control_NN
systems_NN
,_,
to_TO
monitor_VB
the_DT
The_NN
Board_NN
,_,
which_WDT [SERE]
comprises_VPRT
three_CD
executive_NN
and_CC
six_CD
non-executive_JJ
relationship_NN
with_PIN
external_JJ
auditors_NN
,_,
including_VBG
discussing_VBG
the_DT
scope_NN
of_PIN
directors_NN
,_,
meets_VPRT
at_PIN
least_JJ
four_CD
times_NN
a_DT
year_NN
and_CC
the_DT
meetings_GER
are_VPRT [BEMA]
well_RB
the_DT
audit_NN
and_CC
any_QUAN
issues_NN
arising_VBG [WZPRES]
from_PIN
it_PIT
,_,
to_TO
review_VB
the_DT
Companys_NN
attended_VBD
._.
The_DT
Board_NN
seeks_VPRT
to_TO
provide_VB
effective_JJ
leadership_NN
and_CC
the_DT
statutory_JJ
accounts_NN
and_CC
other_JJ
financial_JJ
statements_NOMZ
and_PHC
information_NOMZ
,_,
control_NN
required_VBN [SUAV] [WZPAST]
for_PIN
a_DT
listed_VBN
company_NN
and_CC
in_PIN
so_RB
doing_EMPH
has_VPRT
formally_RB
and_CC
to_TO
review_VB
the_DT
business_NOMZ
risks_NN
faced_VBN [WZPAST]
by_PIN
the_DT
Company_NN
._.
reserved_VBN
specific_JJ
matters_NN
to_PIN
itself_PIT
for_PIN
determination_NOMZ
._.
Specific_JJ
powers_NN
ii_VPRT
The_DT
Remuneration_NOMZ
Committee_NN
,_,
under_IN
the_DT
chairmanship_NN
of_PIN
Dr_NN
Barry_NN
and_PHC
authorities_NOMZ
are_VPRT [SPAU] [PASS]
also_RB
delegated_VBN
to_PIN
the_DT
Executive_NN
Committee_NN
and_PHC
Price_NN
,_,
usually_RB
meets_VPRT
four_CD
times_NN
a_DT
year_NN
._.
Dr_NN
James_NN
Cavanaugh_NN
and_CC
to_PIN
various_JJ
other_JJ
Board_NN
committees_NN
set_VBD
out_PIN
below_PLACE
._.
Mr_NN
Grard_NN
Veilleux_NN
are_VPRT [BEMA]
the_DT
other_JJ
members_NN
of_PIN
this_DEMO
Committee_NN
._.
Under_IN
The_DT
Company_NN
views_VPRT
all_QUAN
of_PIN
the_DT
non-executive_JJ
directors_NN
as_IN
independent_JJ
its_PIT
terms_NN
of_PIN
reference_NN
the_DT
Committee_NN
is_VPRT [PASS]
required_VBN [SUAV]
,_,
amongst_PIN
other_JJ
of_PIN
management_NOMZ
and_CC
free_JJ
from_PIN
any_QUAN
business_NOMZ
or_CC
other_JJ
relationship_NN
which_WDT [WHOBJ]
things_NN
,_,
to_TO
determine_VB [SUAV] [PRIV]
the_DT
policy_NN
for_PIN
the_DT
remuneration_NOMZ
and_CC
could_POMD [SPAU]
materially_RB
interfere_VB
with_PIN
the_DT
exercise_NN
of_PIN
their_TPP3
independent_JJ
judgement_NOMZ
._.
The_DT
remuneration_NOMZ
of_PIN
nonexecutive_JJ
directors_NN
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Board_NN
._.
The_DT
directors_NN
The_DT
Company_NN
does_VPRT
,_,
however_CONJ
,_,
accept_VB [PRIV]
that_THVC
on_PIN
a_DT
strict_JJ
interpretation_NOMZ
of_PIN
remuneration_NOMZ
report_NN
appears_VPRT [SMP]
on_PIN
pages_NN
38_CD
to_PIN
47_CD
and_CC
provides_VPRT
further_RB
the_DT
Combined_NN
Code_NN
the_DT
interests_NN
that_TSUB
Dr_VPRT
Cavanaugh_NN
has_VPRT
as_IN
President_NN
information_NOMZ
on_PIN
this_DEMO
Committee_NN
._.
of_PIN
HealthCare_NN
Ventures_NN
LLC_NN
and_CC
the_DT
position_NOMZ
The_DT
Hon_NN
James_NN
Grant_NN
has_VPRT
as_IN
a_DT
partner_NN
of_PIN
Stikeman_NN
Elliot_NN
,_,
a_DT
law_NN
firm_NN
retained_VBN [WZPAST]
by_PIN
BioChem_NN
prior_RB
to_TO
iii_VB
The_DT
Nomination_NOMZ
Committee_NN
has_VPRT [PEAS]
been_VBN [PASS]
delegated_VBN
with_PIN
responsibility_NOMZ
the_DT
merger_NN
,_,
prevents_VPRT
the_DT
strict_JJ
application_NOMZ
of_PIN
independence_NN
._.
The_DT
same_JJ
for_PIN
nominations_NOMZ
of_PIN
directors_NN
to_PIN
the_DT
Board_NN
._.
This_DEMO
Committee_NN
meets_VPRT
is_VPRT [BEMA]
also_RB
relevant_PRED
to_PIN
Dr_NN
Francesco_NN
Bellini_NN
by_PIN
virtue_NN
of_PIN
the_DT
executive_NN
as_IN
required_VBN [SUAV]
and_PHC
is_VPRT [BYPA]
chaired_VBN
by_PIN
Dr_NN
James_NN
Cavanaugh_NN
._.
Mr_NN
Ronald_NN
directorship_NN
that_TOBJ
Dr_NN
Bellini_NN
held_VBD [PRIV]
with_PIN
BioChem_NN
._.
Nordmann_NN
,_,
The_DT
Hon_NN
James_NN
Grant_NN
and_PHC
Dr_NN
Barry_NN
Price_NN
also_RB
serve_VPRT
on_PIN
this_DEMO
Committee_NN
._.
All_QUAN
directors_NN
have_VPRT
access_NN
to_PIN
the_DT
advice_NN
and_PHC
guidance_NN
of_PIN
the_DT
Company_NN
Secretary_NN
and_CC
are_VPRT [PASS]
encouraged_VBN
to_TO
seek_VB
independent_JJ
advice_NN
at_PIN
the_DT
iv_NN
The_DT
Executive_NN
Committee_NN
has_VPRT
the_DT
day-to-day_TIME
management_NOMZ
of_PIN
the_DT
Companys_NN
expense_NN
,_,
where_RB
they_TPP3
feel_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
appropriate_PRED
._.
No_SYNE
such_JJ
Company_NN
delegated_VBD
to_PIN
it_PIT
by_PIN
the_DT
Board_NN
and_CC
operates_VPRT
within_PIN
clear_JJ
independent_JJ
advice_NN
has_VPRT [PEAS]
been_VBN [PASS]
sought_VBN
._.
The_DT
Board_NN
is_VPRT [BEMA]
confident_PRED
that_THAC
all_QUAN
its_PIT
and_CC
formal_JJ
parameters_NN
._.
The_DT
Chief_NN
Executive_NN
is_VPRT [BEMA]
the_DT
Chairman_NN
of_PIN
the_DT
members_NN
have_VPRT
the_DT
knowledge_NN
,_,
aptitude_NN
and_PHC
experience_NN
to_TO
perform_VB
the_DT
Committee_NN
,_,
which_WDT [SERE]
consists_VPRT
of_PIN
nine_CD
senior_JJ
executives_NN
including_VBG [WZPRES]
the_DT
functions_NOMZ
required_VBN [SUAV] [WZPAST]
of_PIN
a_DT
director_NN
of_PIN
a_DT
listed_VBN
company_NN
._.
Biographical_NN
details_NN
of_PIN
the_DT
Board_NN
are_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
page_NN
35_CD
._.
Directors_NN
remuneration_VPRT
Chairman_NN
and_PHC
Chief_NN
Executive_NN
The_NN
Companys_NN
remuneration_NOMZ
policy_NN
appears_VPRT [SMP]
as_IN
part_NN
of_PIN
the_DT
directors_NN
The_DT
offices_NN
of_PIN
Chairman_NN
and_PHC
Chief_NN
Executive_NN
are_VPRT [PASS]
held_VBN [PRIV]
separately_RB
._.
The_DT
report_NN
details_NN
the_DT
level_NN
of_PIN
The_DT
non-executive_JJ
Chairman_NN
,_,
Dr_NN
James_NN
Cavanaugh_NN
,_,
is_VPRT [BEMA]
responsible_PRED
for_PIN
remuneration_NOMZ
for_PIN
directors_NN
and_CC
the_DT
basis_NN
upon_PIN
which_WDT [PIRE]
executive_NN
the_DT
conduct_NN
of_PIN
the_DT
Board_NN
and_CC
ensures_VPRT [SUAV] [PRIV]
that_THVC
Board_NN
discussions_NN
are_VPRT
remuneration_NOMZ
is_VPRT [PASS]
fixed_VBN
._.
conducted_VBN [PASTP]
in_PIN
such_EMPH
a_NULL
way_NN
that_TOBJ
all_QUAN
views_NN
are_VPRT [PASS]
taken_VBN
into_PIN
account_NN
,_,
so_OSUB
that_NULL
no_SYNE
individual_JJ
director_NN
or_CC
small_JJ
group_NN
of_PIN
directors_NN
dominates_VPRT
proceedings_GER
._.
Relations_NOMZ
with_PIN
shareholders_NN
The_DT
Chief_NN
Executive_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
running_VBG
the_DT
business_NOMZ
and_PHC
chairs_NN
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
maintaining_VBG [PUBV]
good_JJ
relations_NOMZ
with_PIN
the_DT
Executive_NN
Committee_NN
._.
shareholders_NN
through_PIN
the_DT
announcement_NOMZ
of_PIN
quarterly_JJ
results_NN
and_CC
the_DT
provision_NN
of_PIN
annual_JJ
reports_NN
._.
The_DT
Company_NN
also_RB
arranges_VPRT [SUAV]
individual_JJ
and_PHC
Senior_JJ
non-executive_JJ
director_NN
group_NN
meetings_GER
with_PIN
its_PIT
institutional_JJ
shareholders_NN
in_PIN
order_NN
to_TO
discuss_VB
Dr_NN
Barry_NN
Price_NN
is_VPRT [BEMA]
the_DT
nominated_VBN
senior_JJ
independent_JJ
non-executive_JJ
relevant_JJ
communications_NOMZ
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
investing_VBG
community_NOMZ
director_NN
._.
receives_VPRT
a_DT
balanced_JJ
and_PHC
complete_JJ
view_NN
of_PIN
the_DT
Companys_NN
performance_NN
Supply_NN
of_PIN
information_NOMZ
and_PHC
issues_NN
faced_VBN [WZPAST]
by_PIN
the_DT
business_NOMZ
._.
The_DT
Company_NN
holds_VPRT [PRIV]
its_PIT
Annual_JJ
The_DT
executive_NN
directors_NN
and_CC
the_DT
Company_NN
Secretary_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
General_NN
Meeting_VBG [WZPRES]
in_PIN
London_NN
and_CC
all_QUAN
shareholders_NN
are_VPRT [PASS]
given_VBN
the_DT
ensuring_VBG [SUAV] [PRIV] [THATD]
that_DEMP
detailed_VBN
information_NOMZ
is_VPRT [PASS]
provided_VBN
to_PIN
the_DT
Board_NN
at_PIN
least_JJ
one_CD
opportunity_NOMZ
to_TO
ask_VB [SUAV]
questions_NOMZ
of_PIN
the_DT
Board_NN
._.
week_NN
before_IN
any_QUAN
scheduled_VBN
meeting_GER
of_PIN
the_DT
Board_NN
._.
Before_IN
decisions_NN
are_VPRT [BEMA]
The_DT
Companys_NN
website_NN
at_PIN
www_NN
._.
com_NN
provides_VPRT
Company_NN
made_VBN
,_,
consideration_NOMZ
is_VPRT [PASS]
given_VBN
to_PIN
the_DT
adequacy_NN
of_PIN
information_NOMZ
available_JJ
to_PIN
information_NOMZ
and_CC
is_VPRT [SPAU] [PASS]
regularly_RB
updated_VBN
._.
the_DT
Board_NN
and_CC
,_,
if_COND
necessary_JJ
,_,
decisions_NN
are_VPRT [PASS]
deferred_VBN
if_COND
further_JJ
information_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
._.
Balanced_JJ
and_PHC
understandable_JJ
assessment_NOMZ
of_PIN
positions_NOMZ
and_PHC
prospects_NN
Re-appointment_JJ
The_DT
Company_NN
strives_VPRT
to_TO
give_VB
full_JJ
,_,
timely_JJ
and_PHC
realistic_JJ
assessments_NOMZ
of_PIN
Non-executive_JJ
directors_NN
are_VPRT [PASS]
appointed_VBN
for_PIN
a_DT
term_NN
of_PIN
two_CD
years_NN
._.
matters_NN
that_TSUB
impact_VPRT
on_PIN
its_PIT
business_NOMZ
and_CC
financial_JJ
position_NOMZ
and_CC
to_TO
present_VB
Re-appointment_NOMZ
of_PIN
non-executive_JJ
directors_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
scientific_JJ
and_PHC
other_JJ
price-sensitive_JJ
data_NN
in_PIN
a_DT
balanced_JJ
way_NN
._.
Before_IN
it_PIT
was_VBD [BEMA]
such_JJ
two-year_JJ
period_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
Board_NN
approval_NN
._.
required_VBN [SUAV]
under_IN
SEC_NN
rules_NN
,_,
the_DT
Company_NN
voluntarily_RB
adopted_VBD
quarterly_JJ
financial_JJ
reporting_GER
,_,
which_WDT [SERE]
is_VPRT [BEMA]
not_XX0
obligatory_PRED
in_PIN
the_DT
UK_NN
._.
48_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statement_NOMZ
Financial_NN
disclosure_NN
,_,
internal_JJ
control_NN
and_CC
the_DT
role_NN
of_PIN
the_DT
auditors_NN
These_DEMO
reviews_NN
,_,
together_RB
with_PIN
regular_JJ
reports_NN
on_PIN
financial_JJ
performance_NN
,_,
The_NN
Board_NN
has_VPRT
,_,
through_PIN
the_DT
Audit_NN
Committee_NN
,_,
established_VBD [PRIV]
formal_JJ
and_CC
represent_VB
the_DT
main_JJ
elements_NOMZ
in_PIN
establishing_VBG [PRIV]
the_DT
effectiveness_NOMZ
of_PIN
the_DT
transparent_JJ
arrangements_NOMZ
for_PIN
financial_JJ
reporting_GER
,_,
internal_JJ
control_NN
and_PHC
system_NN
of_PIN
internal_JJ
control_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
has_VPRT
a_DT
system_NN
external_JJ
auditing_GER
._.
The_DT
Audit_NN
Committees_NN
terms_NN
of_PIN
reference_NN
extend_VPRT
of_PIN
control_NN
procedures_NN
and_PHC
compliance_NN
with_PIN
these_DEMO
procedures_NN
is_VPRT [BEMA]
to_PIN
the_DT
Groups_NN
risk_NN
management_NOMZ
activities_NOMZ
as_IN
a_DT
whole_JJ
and_CC
not_XX0
just_EMPH
the_DT
monitored_VBN
through_PIN
a_DT
system_NN
of_PIN
internal_JJ
review_NN
._.
Any_QUAN
significant_JJ
issues_NN
financial_JJ
aspects_NN
of_PIN
internal_JJ
control_NN
._.
arising_VBG
are_VPRT [PASS]
reported_VBN [PUBV]
to_PIN
the_DT
Audit_NN
Committee_NN
for_PIN
review_NN
._.
All_QUAN
employees_NN
can_POMD
raise_VB
any_QUAN
concerns_NN
in_PIN
any_QUAN
of_PIN
these_DEMO
areas_NN
with_PIN
the_DT
During_PIN
the_DT
year_NN
,_,
the_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
continued_VBN
to_TO
examine_VB
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
in_PIN
the_DT
strictest_JJ
confidence_NN
._.
The_DT
how_RB
it_PIT
obtains_VPRT
assurance_NN
that_TOBJ
risks_NN
are_VPRT [PASS]
managed_VBN
effectively_RB
by_PIN
Company_NN
has_VPRT [PEAS]
introduced_VBN
a_DT
new_JJ
whistle-blowing_JJ
policy_NN
._.
This_DEMP
provides_VPRT
the_DT
Company_NN
and_CC
the_DT
necessary_JJ
internal_JJ
controls_NN
are_VPRT [BEMA]
in_PIN
place_NN
._.
a_DT
confidential_JJ
process_NN
through_PIN
which_WDT [PIRE]
all_QUAN
employees_NN
are_VPRT [BEMA]
able_PRED
to_TO
report_VB [PUBV]
During_PIN
2002_CD
,_,
the_DT
internal_JJ
audit_NN
function_NOMZ
,_,
which_WDT [SERE]
is_VPRT [PASS]
outsourced_VBN
,_,
has_VPRT
concerns_NN
relating_VBG [WZPRES]
to_PIN
financial_JJ
disclosure_NN
,_,
internal_JJ
control_NN
and_CC
other_JJ
reviewed_VBN
the_DT
overall_JJ
assurance_NN
framework_NN
and_CC
has_VPRT [PEAS]
reported_VBN [PUBV]
to_PIN
the_DT
compliance_NN
issues_NN
in_PIN
good_JJ
faith_NN
without_PIN
fear_NN
of_PIN
discrimination_NOMZ
or_CC
reprisal_NN
._.
Executive_NN
Committee_NN
and_CC
the_DT
Audit_NN
Committee_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
introduced_VBN
a_DT
procedure_NN
for_PIN
the_DT
iii_FW
External_NN
auditing_GER
receipt_NN
and_PHC
monitoring_GER
of_PIN
complaints_NN
relating_VBG [WZPRES]
to_PIN
internal_JJ
controls_NN
._.
The_DT
Audit_NN
Committee_NN
reviews_VPRT
the_DT
scope_NN
and_PHC
results_NN
of_PIN
the_DT
audit_NN
i_FPP1
Financial_NN
reporting_GER
and_CC
non-audit_JJ
services_NN
provided_VBN [WZPAST]
by_PIN
the_DT
auditors_NN
,_,
the_DT
cost_NN
The_DT
Board_NN
has_VPRT
ultimate_JJ
responsibility_NOMZ
for_PIN
the_DT
preparation_NOMZ
of_PIN
accounts_NN
effectiveness_NOMZ
and_CC
the_DT
independence_NN
and_PHC
objectivity_NOMZ
of_PIN
the_DT
auditors_NN
._.
and_ANDC
for_PIN
the_DT
monitoring_GER
of_PIN
systems_NN
of_PIN
internal_JJ
financial_JJ
control_NN
._.
The_DT
In_PIN
recognition_NOMZ
of_PIN
the_DT
importance_NN
of_PIN
maintaining_VBG [PUBV]
the_DT
independence_NN
of_PIN
Board_NN
strives_VPRT
to_TO
present_VB
a_DT
balanced_JJ
and_PHC
understandable_JJ
assessment_NOMZ
the_DT
auditors_NN
,_,
the_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
put_VBN
in_PIN
place_NN
new_JJ
procedures_NN
of_PIN
the_DT
Companys_NN
position_NOMZ
and_CC
its_PIT
prospects_NN
and_PHC
endeavors_NN
to_PIN
for_PIN
the_DT
pre-approval_JJ
of_PIN
the_DT
provision_NN
of_PIN
non-audit_JJ
services_NN
by_PIN
the_DT
present_JJ
scientific_JJ
and_PHC
other_JJ
price-sensitive_JJ
information_NOMZ
in_PIN
a_DT
balanced_JJ
auditors_NN
._.
The_DT
Company_NN
publishes_VPRT
quarterly_JJ
financial_JJ
reports_NN
so_OSUB
that_NULL
its_PIT
Going_VBG
concern_NN
basis_NN
shareholders_NN
can_POMD
monitor_VB
the_DT
Companys_NN
financial_JJ
position_NOMZ
regularly_RB
._.
After_IN
making_VBG
enquiries_NN
,_,
the_DT
directors_NN
have_VPRT [PEAS]
formed_VBN
a_DT
judgement_NOMZ
,_,
at_PIN
the_DT
On_PIN
behalf_NN
of_PIN
the_DT
Board_NN
,_,
the_DT
Audit_NN
Committee_NN
examines_VPRT
the_DT
time_NN
of_PIN
approving_VBG
the_DT
financial_JJ
statements_NOMZ
,_,
that_THVC
there_EX
is_VPRT
a_DT
reasonable_JJ
effectiveness_NOMZ
of_PIN
systems_NN
of_PIN
internal_JJ
financial_JJ
control_NN
on_PIN
a_DT
regular_JJ
expectation_NOMZ
that_TOBJ
the_DT
Group_NN
has_VPRT
adequate_JJ
resources_NN
to_TO
continue_VB
in_PIN
basis_NN
._.
This_DEMP
includes_VPRT
having_VBG
independent_JJ
access_NN
to_PIN
the_DT
auditors_NN
operational_JJ
existence_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
For_PIN
this_DEMO
reason_NN
the_DT
throughout_PIN
the_DT
year_NN
in_CONJ
addition_NULL
to_PIN
presentations_NOMZ
from_PIN
the_DT
auditors_NN
on_PIN
directors_NN
continue_VPRT
to_TO
adopt_VB
the_DT
going_VBG
concern_NN
basis_NN
in_PIN
preparing_VBG
the_DT
a_DT
quarterly_JJ
basis_NN
._.
Any_QUAN
significant_JJ
findings_GER
or_CC
identified_VBN
risks_NN
are_VPRT [BEMA]
closely_RB
financial_JJ
statements_NOMZ
._.
examined_VBD
and_PHC
are_VPRT [PASS]
reported_VBN [PUBV]
to_PIN
the_DT
Board_NN
with_PIN
recommendations_NOMZ
for_PIN
action_NOMZ
._.
During_PIN
2002_CD
,_,
certain_JJ
requirements_NOMZ
of_PIN
the_DT
Sarbanes-Oxley_NN
Act_NN
came_VBD
into_PIN
force_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
line_NN
with_PIN
these_DEMO
requirements_NOMZ
,_,
the_DT
Chief_NN
Executive_NN
and_CC
the_DT
Group_NN
Finance_NN
Director_NN
have_VPRT [SPAU] [PEAS]
formally_RB
certified_VBN [PUBV]
that_THVC
the_DT
Annual_JJ
Report_NN
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
US_FPP1
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
and_CC
fairly_RB
represents_VPRT
the_DT
financial_JJ
condition_NOMZ
and_PHC
results_NN
of_PIN
the_DT
Company_NN
._.
ii_FW
Internal_NN
control_NN
In_PIN
applying_VBG
the_DT
principle_NN
that_TOBJ
the_DT
Board_NN
should_NEMD
maintain_VB [PUBV]
a_DT
sound_JJ
system_NN
of_PIN
internal_JJ
control_NN
to_TO
safeguard_VB
shareholders_NN
investment_NOMZ
and_CC
the_DT
Companys_NN
assets_NN
and_CC
in_PIN
accordance_NN
with_PIN
the_DT
Turnbull_NN
Committees_NN
guidance_NN
on_PIN
internal_JJ
control_NN
,_,
the_DT
directors_NN
recognize_VPRT [PRIV]
that_THVC
they_TPP3
have_VPRT
overall_JJ
responsibility_NOMZ
for_PIN
the_DT
Companys_NN
system_NN
of_PIN
internal_JJ
control_NN
and_CC
for_PIN
regularly_RB
reviewing_VBG
its_PIT
effectiveness_NOMZ
._.
The_DT
directors_NN
believe_VPRT [PRIV]
that_THVC
the_DT
Company_NN
has_VPRT [PEAS]
applied_VBN
this_DEMO
principle_NN
during_PIN
the_DT
year_NN
under_IN
review_NN
and_CC
up_RB
to_PIN
the_DT
date_NN
of_PIN
signing_VBG
these_DEMO
accounts_NN
._.
However_CONJ
,_,
there_EX
are_VPRT
limitations_NOMZ
in_PIN
any_QUAN
system_NN
of_PIN
internal_JJ
control_NN
and_CC
accordingly_RB
even_RB
the_DT
most_EMPH
effective_JJ
system_NN
can_POMD
provide_VB
only_DWNT
reasonable_JJ
and_CC
not_XX0
absolute_JJ
assurance_NN
._.
Such_EMPH
a_NULL
system_NN
is_VPRT [PASS]
designed_VBN
to_TO
manage_VB
rather_RB
than_PIN
eliminate_VB
the_DT
risk_NN
of_PIN
failure_NN
to_TO
achieve_VB
business_NOMZ
objectives_NN
and_CC
can_POMD [SPAU]
only_DWNT
provide_VB
reasonable_JJ
and_CC
not_XX0
absolute_JJ
assurance_NN
against_PIN
material_NN
misstatement_NOMZ
or_CC
loss_NN
._.
The_DT
Company_NN
has_VPRT
an_DT
ongoing_JJ
process_NN
for_PIN
identifying_VBG
,_,
evaluating_VBG
and_PHC
managing_VBG
the_DT
significant_JJ
risks_NN
that_TOBJ
it_PIT
faces_VPRT
._.
This_DEMO
process_NN
has_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
operation_NOMZ
throughout_PIN
the_DT
period_NN
under_IN
review_NN
and_CC
up_RB
to_PIN
the_DT
date_NN
of_PIN
the_DT
signing_GER
of_PIN
the_DT
accounts_NN
._.
In_CONJ
particular_NULL
,_,
the_DT
Executive_NN
Committee_NN
,_,
the_DT
Audit_NN
Committee_NN
and_CC
the_DT
Board_NN
have_VPRT [PEAS]
reviewed_VBN
the_DT
schedule_NN
of_PIN
risks_NN
faced_VBN [WZPAST]
by_PIN
the_DT
Company_NN
._.
This_DEMP
includes_VPRT
analysis_NN
of_PIN
the_DT
impact_NN
of_PIN
the_DT
operation_NOMZ
of_PIN
key_JJ
risks_NN
and_CC
the_DT
action_NOMZ
being_VBG [WZPRES] [PASS]
taken_VBN
to_TO
avoid_VB
or_CC
reduce_VB
each_QUAN
risk_NN
._.
In_CONJ
particular_NULL
,_,
the_DT
schedule_NN
of_PIN
risks_NN
allocates_VPRT
responsibility_NOMZ
for_PIN
management_NOMZ
of_PIN
each_QUAN
key_JJ
risk_NN
to_PIN
senior_JJ
executives_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
49_CD
Statement_NOMZ
of_PIN
directors_NN
responsibilities_NOMZ
Report_NN
of_PIN
independent_JJ
auditors_NN
English_JJ
company_NN
law_NN
requires_VPRT [SUAV]
the_DT
directors_NN
to_TO
prepare_VB
financial_JJ
To_PIN
the_DT
shareholders_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
statements_NOMZ
for_PIN
each_QUAN
financial_JJ
year_NN
which_WDT [WHSUB]
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
We_FPP1
have_VPRT [PEAS]
audited_VBN
the_DT
accompanying_VBG
consolidated_JJ
balance_NN
sheets_NN
of_PIN
the_DT
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
and_CC
the_DT
Group_NN
as_IN
at_PIN
the_DT
end_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_CC
its_PIT
subsidiaries_NN
as_IN
of_PIN
December_NN
31_CD
,_,
the_DT
financial_JJ
year_NN
and_CC
of_PIN
the_DT
profit_NN
or_CC
loss_NN
of_PIN
the_DT
Group_NN
for_PIN
that_DEMO
period_NN
._.
2002_CD
and_CC
2001_CD
,_,
and_ANDC
the_DT
related_JJ
consolidated_JJ
statements_NOMZ
of_PIN
operations_NOMZ
,_,
In_PIN
preparing_VBG
those_DEMO
financial_JJ
statements_NOMZ
,_,
the_DT
directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
:_:
comprehensive_JJ
income_NN
,_,
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
,_,
and_ANDC
cash_NN
flows_NN
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
ended_VBD
December_NN
31_CD
,_,
select_JJ
suitable_JJ
accounting_GER
policies_NN
and_CC
then_RB
apply_VB
them_TPP3
consistently_RB
:_:
2002_CD
._.
These_DEMO
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
the_DT
responsibility_NOMZ
of_PIN
the_DT
Companys_NN
management_NOMZ
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
express_VB
an_DT
opinion_NN
on_PIN
these_DEMP
make_VPRT
judgements_NOMZ
and_PHC
estimates_NN
that_TSUB
are_VPRT [BEMA]
reasonable_PRED
and_PHC
prudent_PRED
:_:
financial_JJ
statements_NOMZ
based_VBN [WZPAST]
on_PIN
our_FPP1
audits_NN
._.
The_DT
consolidated_JJ
financial_JJ
and_CC
statements_NOMZ
give_VPRT
retroactive_JJ
effect_NN
to_PIN
the_DT
merger_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
state_NN
whether_IN
applicable_JJ
accounting_GER
standards_NN
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
._.
Group_NN
plc_NN
and_PHC
BioChem_NN
Pharma_NN
,_,
Inc._NN
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
pooling_VBG
of_PIN
interests_NN
,_,
as_IN
described_VBN
in_PIN
Note_NN
3_CD
to_PIN
the_DT
consolidated_JJ
The_DT
directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
keeping_VBG
proper_JJ
accounting_GER
records_NN
financial_JJ
statements_NOMZ
._.
which_WDT [SERE]
disclose_VPRT [PUBV]
with_PIN
reasonable_JJ
accuracy_NN
at_PIN
any_QUAN
time_NN
the_DT
financial_JJ
We_FPP1
did_VBD
not_XX0
audit_VB
the_DT
balance_NN
sheet_NN
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
a_DT
position_NOMZ
of_PIN
the_DT
Company_NN
and_CC
enable_VB
them_TPP3
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
financial_JJ
company_NN
acquired_VBN [WZPAST]
in_PIN
2001_CD
in_PIN
a_DT
transaction_NOMZ
accounted_VBD
for_PIN
as_IN
a_DT
pooling_VBG
statements_NOMZ
comply_VB
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
They_TPP3
are_VPRT [BEMA]
also_RB
of_PIN
interests_NN
,_,
as_IN
of_PIN
December_NN
31_CD
,_,
2000_CD
,_,
or_CC
the_DT
related_JJ
statements_NOMZ
of_PIN
responsible_JJ
for_PIN
safeguarding_VBG
the_DT
assets_NN
of_PIN
the_DT
Company_NN
and_ANDC
hence_CONJ
income_NN
,_,
shareholders_NN
equity_NOMZ
and_PHC
cash_NN
flows_NN
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
for_PIN
taking_VBG
reasonable_JJ
steps_NN
for_PIN
the_DT
prevention_NOMZ
and_PHC
detection_NOMZ
of_PIN
fraud_NN
for_PIN
the_DT
year_NN
then_RB
ended_VBD
,_,
which_WDT [SERE]
statements_NOMZ
reflect_VPRT [PRIV]
total_JJ
assets_NN
of_PIN
and_CC
other_JJ
irregularities_NOMZ
._.
$_$
578.1_CD
million_CD
and_CC
total_JJ
revenues_NN
of_PIN
$_$
517.6_CD
million_CD
._.
Those_DEMO
statements_NOMZ
were_VBD [BYPA]
audited_VBN
by_PIN
other_JJ
auditors_NN
whose_WPS [WHOBJ]
report_NN
has_VPRT [PEAS]
been_VBN [PASS]
furnished_VBN
to_PIN
us_FPP1
,_,
and_ANDC
our_FPP1
opinion_NN
,_,
insofar_OSUB
as_NULL
it_PIT
relates_VPRT
to_PIN
amounts_NN
included_VBN [WZPAST]
for_PIN
BioChem_NN
Pharma_NN
Inc._NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2000_CD
,_,
is_VPRT [PASS]
based_VBN
solely_RB
upon_PIN
the_DT
report_NN
of_PIN
such_JJ
other_JJ
auditors_NN
._.
We_FPP1
also_RB
audited_VBD
the_DT
accounting_GER
policy_NN
alignments_NOMZ
described_VBN [WZPAST]
in_PIN
Note_NN
4_CD
that_DEMP
were_VBD [PASS]
applied_VBN
to_PIN
the_DT
2000_CD
audited_VBD
financial_JJ
statements_NOMZ
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
._.
In_PIN
our_FPP1
opinion_NN
,_,
such_JJ
adjustments_NOMZ
are_VPRT [BEMA]
appropriate_PRED
and_CC
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
properly_RB
applied_VBN
._.
We_FPP1
conducted_VBD
our_FPP1
audits_NN
in_PIN
accordance_NN
with_PIN
auditing_GER
standards_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
United_NN
States_NN
of_PIN
America_NN
._.
Those_DEMO
standards_NN
require_VPRT [SUAV]
that_THVC
we_FPP1
plan_VPRT
and_PHC
perform_VPRT
the_DT
audit_NN
to_TO
obtain_VB
reasonable_JJ
assurance_NN
about_IN
whether_IN
the_DT
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
free_PRED
of_PIN
material_NN
misstatement_NOMZ
._.
An_DT
audit_NN
includes_VPRT
examining_VBG
,_,
on_PIN
a_DT
test_NN
basis_NN
,_,
evidence_NN
supporting_VBG [WZPRES]
the_DT
amounts_NN
and_PHC
disclosures_NN
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
An_DT
audit_NN
also_RB
includes_VPRT
assessing_VBG
the_DT
accounting_GER
principles_NN
used_VBN
and_CC
significant_JJ
estimates_NN
made_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
as_RB
well_RB
as_IN
evaluating_VBG
the_DT
overall_JJ
financial_JJ
statement_NOMZ
presentation_NOMZ
._.
We_FPP1
believe_VPRT [PRIV]
that_THVC
our_FPP1
audits_NN
and_CC
the_DT
report_NN
of_PIN
the_DT
other_JJ
auditors_NN
provide_VPRT
a_DT
reasonable_JJ
basis_NN
for_PIN
our_FPP1
opinion_NN
._.
In_PIN
our_FPP1
opinion_NN
,_,
based_VBN [PASTP]
on_PIN
our_FPP1
audit_NN
and_CC
the_DT
report_NN
of_PIN
the_DT
other_JJ
auditors_NN
,_,
the_DT
financial_JJ
statements_NOMZ
referred_VBD
to_PIN
above_PLACE
present_JJ
fairly_RB
,_,
in_PIN
all_QUAN
material_NN
respects_VPRT
,_,
the_DT
financial_JJ
position_NOMZ
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_PHC
subsidiaries_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2002_CD
and_CC
2001_CD
,_,
and_ANDC
the_DT
results_NN
of_PIN
their_TPP3
operations_NOMZ
and_CC
their_TPP3
cash_NN
flows_VPRT
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
ended_VBD
December_NN
31_CD
,_,
2002_CD
,_,
in_PIN
conformity_NOMZ
with_PIN
accounting_GER
principles_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
United_NN
States_NN
of_PIN
America_NN
._.
As_IN
explained_VBN [PUBV]
in_PIN
note_NN
12_CD
,_,
effective_JJ
January_NN
1_CD
,_,
2002_CD
,_,
the_DT
Company_NN
adopted_VBN
SFAS_NN
No._NN
._.
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
._.
Deloitte_NN
&_CC
Touche_NN
Reading_VBG [WZPRES]
,_,
England_NN
February_NN
26_CD
,_,
2003_CD
50_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
balance_NN
sheets_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
share_NN
data_NN
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Assets_NN
Current_JJ
assets_NN
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
897,718_CD
118,040_CD
Marketable_JJ
securities_NOMZ
6_CD
316,126_CD
723,911_CD
Accounts_NN
receivable_NN
,_,
net_JJ
7_CD
138,397_CD
193,913_CD
Inventories_NN
8_CD
49,216_CD
44,911_CD
Deferred_JJ
tax_NN
asset_NN
34,849_CD
19,430_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
9_CD
30,790_CD
38,571_CD
Total_JJ
current_JJ
assets_NN
from_PIN
continuing_VBG
operations_NOMZ
1,467,096_CD
1,138,776_CD
Current_JJ
assets_NN
from_PIN
discontinued_VBN
operations_NOMZ
5_CD
1,779_CD
Total_JJ
current_JJ
assets_NN
1,467,096_CD
1,140,555_CD
Investments_NOMZ
10_CD
71,962_CD
68,743_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
11_CD
135,234_CD
113,347_CD
Goodwill_NN
,_,
net_JJ
12_CD
203,767_CD
175,341_CD
Other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
12_CD
301,084_CD
308,355_CD
Deferred_JJ
tax_NN
asset_NN
6,216_CD
20,274_CD
Other_JJ
non-current_JJ
assets_NN
13_CD
23,264_CD
26,168_CD
Total_JJ
long-term_JJ
assets_NN
from_PIN
continuing_VBG
operations_NOMZ
741,527_CD
712,228_CD
Long-term_JJ
assets_NN
from_PIN
discontinued_VBN
operations_NOMZ
5_CD
57,948_CD
Total_JJ
assets_NN
2,208,623_CD
1,910,731_CD
Liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
Current_JJ
liabilities_NOMZ
:_:
Current_JJ
installments_NOMZ
of_PIN
long-term_JJ
debt_NN
16_CD
888_CD
4,325_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
14_CD
184,107_CD
167,152_CD
Unearned_JJ
income_NN
17,409_CD
Other_JJ
current_JJ
liabilities_NOMZ
15_CD
15,492_CD
42,730_CD
Total_JJ
current_JJ
liabilities_NOMZ
from_PIN
continuing_VBG
operations_NOMZ
200,487_CD
231,616_CD
Current_JJ
liabilities_NOMZ
from_PIN
discontinued_VBN
operations_NOMZ
5_CD
12,784_CD
Total_JJ
current_JJ
liabilities_NOMZ
213,271_CD
231,616_CD
Long-term_JJ
debt_NN
,_,
excluding_VBG
current_JJ
instalments_NOMZ
16_CD
407,302_CD
402,481_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
17_CD
14,884_CD
13,645_CD
Total_JJ
liabilities_NOMZ
635,457_CD
647,742_CD
Shareholders_NN
equity_NOMZ
:_:
Common_JJ
stock_NN
,_,
5p_JJ
par_NN
value_NN
:_:
800,000,000_CD
shares_NN
authorised_VBN
:_:
and_ANDC
484,344,412_CD
2001_CD
:_:
481,817,487_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
40,051_CD
39,861_CD
Exchangeable_JJ
shares_NN
:_:
5,874,112_CD
2001_CD
:_:
5,978,902_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
272,523_CD
277,386_CD
Additional_JJ
paid-in_PIN
capital_NN
1,027,499_CD
1,014,796_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
losses_NN
41,431_CD
93,009_CD
Retained_VBN
earnings_GER
274,524_CD
23,955_CD
Total_JJ
shareholders_NN
equity_NOMZ
1,573,166_CD
1,262,989_CD
Total_JJ
liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
2,208,623_CD
1,910,731_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
51_CD
Consolidated_NN
statements_NOMZ
of_PIN
operations_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
share_NN
and_CC
per_PIN
share_NN
data_NN
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Revenues_NN
:_:
Product_NN
sales_NN
859,388_CD
699,351_CD
496,775_CD
Licensing_GER
and_PHC
development_NOMZ
3,064_CD
5,498_CD
14,147_CD
Royalties_NN
174,812_CD
145,155_CD
135,470_CD
Other_JJ
revenues_NN
34_CD
2,952_CD
1,262_CD
Total_JJ
revenues_NN
22_CD
1,037,298_CD
852,956_CD
647,654_CD
Costs_NN
and_PHC
expenses_NN
:_:
Cost_NN
of_PIN
product_NN
sales_NN
133,682_CD
112,006_CD
95,071_CD
Research_NN
and_PHC
development_NOMZ
inclusive_NN
of_PIN
stock_NN
option_NOMZ
compensation_NOMZ
charge_NN
on_PIN
warrants_NN
of_PIN
$_$
4,502_CD
for_PIN
2001_CD
189,179_CD
171,029_CD
155,145_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
inclusive_NN
of_PIN
stock_NN
option_NOMZ
compensation_NOMZ
credit_NN
charge_NN
of_PIN
$_$
166_CD
,_,
$_$
2,278_CD
and_CC
$_$
21,914_CD
for_PIN
2002_CD
,_,
2001_CD
and_CC
2000_CD
respectively_RB
386,023_CD
303,480_CD
230,216_CD
Other_JJ
charges_NN
:_:
23_CD
In_PIN
process_NN
research_NN
and_PHC
development_NOMZ
26,947_CD
Asset_NN
impairments_NOMZ
and_PHC
restructuring_GER
charges_NN
29,699_CD
Merger_NN
transaction_NOMZ
expenses_NN
83,470_CD
Loss_NN
on_PIN
disposition_NOMZ
of_PIN
assets_NN
1,376_CD
10,164_CD
Total_JJ
operating_GER
expenses_NN
710,260_CD
709,848_CD
507,379_CD
Operating_GER
income_NN
22_CD
327,038_CD
143,108_CD
140,275_CD
Interest_NN
income_NN
19,536_CD
19,667_CD
19,232_CD
Interest_NN
expense_NN
9,252_CD
8,315_CD
16,413_CD
Other_JJ
expense_NN
income_NN
,_,
net_JJ
24_CD
8,262_CD
52,933_CD
109,023_CD
Total_JJ
other_JJ
income_NN
expense_NN
,_,
net_JJ
2,022_CD
41,581_CD
111,842_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
,_,
equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
and_CC
extraordinary_JJ
items_NN
329,060_CD
101,527_CD
252,117_CD
Income_NN
taxes_NN
26_CD
88,350_CD
68,897_CD
43,564_CD
Equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_VPRT
27_CD
1,668_CD
1,985_CD
3,809_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
item_NN
242,378_CD
34,615_CD
204,744_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
income_NN
tax_NN
expense_NN
of_PIN
$_$
3,588_CD
,_,
$_$
3,963_CD
and_CC
$_$
4,100_CD
respectively_RB
5_CD
6,108_CD
6,748_CD
6,983_CD
Gain_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
income_NN
tax_NN
expense_NN
of_PIN
$_$
1,224_CD
5_CD
2,083_CD
Extraordinary_JJ
item_NN
,_,
net_NN
of_PIN
income_NN
tax_NN
2,604_CD
Net_JJ
income_NN
250,569_CD
38,759_CD
211,727_CD
Earnings_GER
per_PIN
share_NN
basic_JJ
21_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
item_NN
48.4_CD
7.0_CD
42.4_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
1.6_CD
1.4_CD
1.4_CD
Extraordinary_JJ
item_NN
,_,
net_NN
of_PIN
tax_NN
0.5_CD
50.0_CD
7.9_CD
43.8_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
21_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
item_NN
47.4_CD
6.9_CD
41.4_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
1.6_CD
1.3_CD
1.4_CD
Extraordinary_JJ
item_NN
,_,
net_NN
of_PIN
tax_NN
0.5_CD
49.0_CD
7.7_CD
42.8_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
:_:
Basic_JJ
500,687,594_CD
492,594,226_CD
482,890,070_CD
Diluted_NN
522,418,246_CD
504,875,587_CD
494,691,805_CD
The_DT
results_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
include_VB
the_DT
results_NN
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
the_DT
merger_NN
with_PIN
whom_WP [PIRE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
pooling_VBG
of_PIN
interests_NN
in_PIN
accordance_NN
with_PIN
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
No._NN
._.
16_CD
Accounting_GER
for_PIN
Business_NOMZ
Combinations_NOMZ
APB_NN
16_CD
._.
The_DT
results_NN
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2001_CD
and_CC
2000_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
disposal_NN
of_PIN
the_DT
Over-The-Counter_NN
OTC_NN
business_NOMZ
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
._.
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
52_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
except_PIN
share_NN
data_NN
Common_JJ
Exchangeable_NN
Common_NN
stock_NN
Exchangeable_JJ
shares_NN
Additional_JJ
deficit_NN
other_JJ
Total_JJ
stock_NN
number_NN
shares_NN
number_NN
paid-in_PIN
retained_VBD
comprehensive_JJ
shareholders_NN
amount_NN
of_PIN
shares_NN
amount_NN
of_PIN
shares_NN
capital_NN
earnings_GER
losses_NN
equity_NOMZ
$_$
000_CD
000s_CD
$_$
000_CD
000s_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
At_PIN
31_CD
December_NN
1999_CD
39,241_CD
474,400_CD
1,097,567_CD
226,531_CD
30,391_CD
879,886_CD
Net_JJ
income_NN
211,727_CD
211,727_CD
Foreign_JJ
currency_NN
translation_NOMZ
31,467_CD
31,467_CD
Issue_NN
of_PIN
common_JJ
stock_NN
137_CD
1,843_CD
11,720_CD
11,857_CD
Issue_NN
costs_NN
3,385_CD
3,385_CD
Options_NOMZ
exercised_VBN
914_CD
11,772_CD
50,850_CD
51,764_CD
Stock_NN
option_NOMZ
compensation_NOMZ
21,914_CD
21,914_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
30,782_CD
30,782_CD
Reclassification_NOMZ
of_PIN
realized_VBN [PRIV] [THATD]
loss_NN
included_VBN [WZPAST]
in_PIN
net_JJ
income_NN
1,356_CD
1,356_CD
Unrealised_JJ
holding_VBG [PRIV]
loss_NN
on_PIN
available_JJ
for_PIN
sale_NN
investments_NOMZ
48_CD
48_CD
At_PIN
31_CD
December_NN
2000_CD
40,292_CD
488,015_CD
1,209,448_CD
14,804_CD
60,550_CD
1,174,386_CD
Net_JJ
income_NN
38,759_CD
38,759_CD
Foreign_JJ
currency_NN
translation_NOMZ
32,507_CD
32,507_CD
Issue_NN
of_PIN
shares_NN
for_PIN
acquisitions_NOMZ
3,662_CD
51,876_CD
802,256_CD
17,292_CD
798,594_CD
Issue_NN
of_PIN
common_JJ
stock_NN
for_PIN
conversion_NN
of_PIN
loan_NN
22_CD
295_CD
1,522_CD
1,544_CD
Issue_NN
costs_NN
18_CD
18_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
2,414_CD
33,940_CD
524,870_CD
11,313_CD
522,456_CD
Options_NOMZ
exercised_VBN
795_CD
11,443_CD
69,397_CD
70,192_CD
Stock_NN
option_NOMZ
compensation_NOMZ
and_PHC
warrants_NN
6,780_CD
6,780_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
3,805_CD
3,805_CD
Unrealised_JJ
holding_VBG [PRIV]
loss_NN
on_PIN
available_JJ
for_PIN
sale_NN
investments_NOMZ
48_CD
48_CD
At_PIN
31_CD
December_NN
2001_CD
39,861_CD
481,817_CD
277,386_CD
5,979_CD
1,014,796_CD
23,955_CD
93,009_CD
1,262,989_CD
Net_JJ
income_NN
250,569_CD
250,569_CD
Foreign_JJ
currency_NN
translation_NOMZ
50,314_CD
50,314_CD
Issue_NN
of_PIN
common_JJ
stock_NN
for_PIN
conversion_NN
of_PIN
loan_NN
note_NN
21_CD
268_CD
1,479_CD
1,500_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
22_CD
315_CD
4,863_CD
105_CD
4,841_CD
Options_NOMZ
exercised_VBN
147_CD
1,944_CD
5,861_CD
6,008_CD
Stock_NN
option_NOMZ
compensation_NOMZ
166_CD
166_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
688_CD
688_CD
Unrealised_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available_JJ
for_PIN
sale_NN
investments_NOMZ
1,264_CD
1,264_CD
At_PIN
31_CD
December_NN
2002_CD
40,051_CD
484,344_CD
272,523_CD
5,874_CD
1,027,499_CD
274,524_CD
41,431_CD
1,573,166_CD
The_DT
results_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
include_VB
the_DT
results_NN
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
the_DT
merger_NN
with_PIN
whom_WP [PIRE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
pooling_VBG
of_PIN
interests_NN
in_PIN
accordance_NN
with_PIN
APB_NN
16_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
53_CD
Consolidated_NN
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
losses_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
income_NN
250,569_CD
38,759_CD
211,727_CD
Other_JJ
comprehensive_JJ
income_NN
loss_NN
:_:
Foreign_JJ
currency_NN
translation_NOMZ
adjustments_NOMZ
50,314_CD
32,507_CD
31,467_CD
Reclassification_NOMZ
of_PIN
realized_VBN [PRIV] [THATD]
loss_NN
included_VBN [WZPAST]
in_PIN
net_JJ
income_NN
1,356_CD
Unrealised_NN
holding_VBG [PRIV] [WZPRES]
gains_NN
losses_NN
on_PIN
available_JJ
for_PIN
sale_NN
securities_NOMZ
1,264_CD
48_CD
48_CD
Comprehensive_JJ
income_NN
302,147_CD
6,300_CD
181,568_CD
The_DT
components_NN
of_PIN
accumulated_VBN
other_JJ
comprehensive_JJ
losses_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
and_CC
2001_CD
are_VPRT
as_IN
follows_VPRT
:_:
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Foreign_JJ
currency_NN
translation_NOMZ
adjustments_NOMZ
42,695_CD
93,009_CD
Unrealised_JJ
holding_GER
gains_NN
on_PIN
non-current_JJ
investments_NOMZ
1,264_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
losses_NN
41,431_CD
93,009_CD
There_EX
are_VPRT
no_SYNE
material_NN
tax_NN
effects_NN
related_VBN [WZPAST]
to_PIN
the_DT
items_NN
included_VBD
above_PLACE
._.
The_DT
results_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
include_VB
the_DT
results_NN
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
the_DT
merger_NN
with_PIN
whom_WP [PIRE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
pooling_VBG
of_PIN
interests_NN
in_PIN
accordance_NN
with_PIN
APB_NN
16_CD
._.
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
:_:
Net_JJ
income_NN
250,569_CD
38,759_CD
211,727_CD
Adjustments_NOMZ
to_TO
reconcile_VB
net_JJ
income_NN
to_PIN
net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
:_:
Acquired_VBN
in-process_JJ
research_NN
and_PHC
development_NOMZ
26,947_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
36,434_CD
45,809_CD
37,987_NN
Stock_NN
option_NOMZ
compensation_NOMZ
options_NOMZ
166_CD
2,278_CD
21,914_CD
Stock_NN
option_NOMZ
compensation_NOMZ
warrants_NN
4,502_CD
Tax_NN
benefit_NN
of_PIN
stock_NN
option_NOMZ
compensation_NOMZ
,_,
credited_VBD
directly_RB
to_PIN
equity_NOMZ
688_CD
3,805_CD
30,782_CD
Increase_VPRT
decrease_NN
in_PIN
deferred_JJ
tax_NN
asset_NN
8,761_CD
1,229_CD
3,782_CD
Non-cash_JJ
exchange_NN
gains_NN
and_PHC
losses_NN
12,495_CD
1,017_CD
1,676_CD
Gain_NN
on_PIN
sale_NN
of_PIN
long-term_JJ
investments_NOMZ
98,627_CD
Loss_NN
on_PIN
sale_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1,376_CD
8,112_CD
Loss_NN
on_PIN
sale_NN
of_PIN
intangible_JJ
assets_NN
2,052_CD
1,514_CD
Gain_NN
on_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
3,307_CD
Write-down_NN
of_PIN
long-term_JJ
investments_NOMZ
8,732_CD
61,596_CD
Write-down_NN
of_PIN
intangible_JJ
assets_NN
18,777_CD
25,393_CD
Equity_NOMZ
in_PIN
earnings_GER
losses_NN
of_PIN
equity_NOMZ
method_NN
investees_VPRT
1,668_CD
1,985_CD
3,809_CD
Other_JJ
elements_NOMZ
1,788_CD
1,102_CD
Changes_NN
in_PIN
operating_VBG
assets_NN
and_PHC
liabilities_NOMZ
,_,
net_NN
of_PIN
acquisitions_NOMZ
:_:
Decrease_NN
increase_NN
in_PIN
accounts_NN
receivable_JJ
61,159_CD
52,033_CD
52,570_CD
Increase_VPRT
decrease_NN
in_PIN
inventory_NN
5,327_CD
2,922_CD
7,916_CD
Decrease_NN
increase_NN
in_PIN
prepayments_NOMZ
and_CC
other_JJ
current_JJ
assets_NN
8,662_CD
26,109_CD
1,215_CD
Decrease_NN
in_PIN
other_JJ
assets_NN
2,905_CD
823_CD
Decrease_NN
increase_NN
in_PIN
accounts_NN
payable_JJ
and_PHC
other_JJ
liabilities_NOMZ
8,642_CD
61,504_CD
37,727_CD
Decrease_NN
increase_NN
in_PIN
unearned_JJ
income_NN
17,409_CD
17,409_CD
Reserve_NN
for_PIN
restructuring_VBG
charges_NN
83,608_CD
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
356,517_CD
196,837_CD
134,109_CD
54_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_NN
continued_VBD
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
:_:
Redemption_NOMZ
of_PIN
investment_NOMZ
in_PIN
marketable_JJ
securities_NOMZ
407,653_CD
367,206_CD
186,019_CD
Purchase_NN
of_PIN
subsidiary_NN
undertakings_GER
17,000_CD
Expenses_NN
of_PIN
acquisition_NOMZ
350_CD
1,461_CD
Net_JJ
cash_NN
acquired_VBN [WZPAST]
with_PIN
subsidiary_NN
undertakings_GER
50_CD
Additional_JJ
investment_NOMZ
in_PIN
existing_VBG
subsidiary_NN
32,302_CD
Purchase_NN
of_PIN
long-term_JJ
investments_NOMZ
5,933_CD
20,351_CD
16,995_CD
Purchase_NN
of_PIN
intangible_JJ
assets_NN
24,032_CD
35,986_CD
38,379_CD
Purchase_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
22,647_CD
13,604_CD
44,243_CD
Purchase_NN
of_PIN
other_JJ
assets_NN
6,658_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
long-term_JJ
investments_NOMZ
4,108_CD
123,327_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
721_CD
7,081_CD
12,007_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
assets_NN
4,556_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
71,000_CD
Collection_NOMZ
on_PIN
notes_NN
receivable_JJ
766_CD
Other_JJ
investing_GER
activities_NOMZ
1,427_CD
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
used_VBN
in_PIN
investing_VBG
activities_NOMZ
413,570_CD
425,510_CD
191,384_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
:_:
Proceeds_NN
from_PIN
issue_NN
of_PIN
long-term_JJ
debt_NN
400,000_CD
Payment_NOMZ
of_PIN
debt_NN
issuance_NN
costs_NN
9,000_CD
Changes_NN
in_PIN
long-term_JJ
debt_NN
,_,
capital_NN
leases_NN
and_PHC
notes_NN
3,381_CD
207,762_CD
8,514_CD
Proceeds_NN
from_PIN
issue_NN
of_PIN
common_JJ
stock_NN
,_,
net_JJ
1,526_CD
14,589_CD
Proceeds_NN
from_PIN
exercise_NN
of_PIN
options_NOMZ
6,008_CD
70,192_CD
45,647_CD
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
financing_VBG
activities_NOMZ
2,627_CD
254,956_CD
51,722_CD
Effect_NN
of_PIN
foreign_JJ
exchange_NN
rate_NN
changes_NN
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
6,964_CD
1,509_CD
1,975_CD
Net_JJ
increase_NN
decrease_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
779,678_CD
24,774_CD
7,528_CD
Cash_NN
flows_NN
used_VBN [WZPAST]
in_PIN
discontinued_VBN
operations_NOMZ
1,708_CD
Net_JJ
increase_NN
decrease_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
779,678_CD
24,774_CD
9,236_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
period_NN
118,040_CD
93,266_CD
102,502_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
period_NN
897,718_CD
118,040_CD
93,266_CD
Supplemental_NN
information_NOMZ
associated_VBN [WZPAST]
with_PIN
continuing_VBG
operations_NOMZ
:_:
Interest_NN
paid_VBD
8,101_CD
11,122_CD
12,264_CD
Income_NN
taxes_NN
paid_VBD
101,779_CD
65,773_CD
14,095_CD
Non_NN
cash_NN
activities_NOMZ
:_:
Common_JJ
stock_NN
issued_VBN [WZPAST]
for_PIN
product_NN
acquisitions_NOMZ
3,085_CD
Common_JJ
stock_NN
issued_VBN [WZPAST]
on_PIN
conversion_NN
of_PIN
zero-coupon_JJ
note_NN
1,500_CD
1,544_CD
8,772_CD
Capital_NN
leases_NN
assumed_VBD [PRIV]
on_PIN
acquisition_NOMZ
of_PIN
subsidiaries_NN
6,266_CD
The_DT
results_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
include_VB
the_DT
results_NN
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
the_DT
merger_NN
with_PIN
whom_WP [PIRE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
pooling_VBG
of_PIN
interests_NN
in_PIN
accordance_NN
with_PIN
APB_NN
16_CD
._.
Supplemental_NN
disclosures_NN
for_PIN
non-cash_JJ
transactions_NOMZ
:_:
see_VB [PRIV]
note_NN
29_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
55_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
1_CD
Description_NOMZ
of_PIN
operations_NOMZ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
,_,
and_ANDC
subsidiaries_NN
collectively_RB
,_,
the_DT
Company_NN
is_VPRT [BEMA]
an_DT
emerging_VBG
global_JJ
international_JJ
pharmaceutical_JJ
company_NN
with_PIN
a_DT
strategic_JJ
focus_NN
on_PIN
four_CD
therapeutic_JJ
areas_NN
:_:
central_JJ
nervous_JJ
system_NN
disorders_NN
,_,
gastro_NN
intestinal_NN
,_,
oncology_NN
and_PHC
anti-infectives_NN
._.
The_DT
Companys_NN
strategy_NN
is_VPRT [BEMA]
further_PRED
supported_VBN
by_PIN
three_CD
technology_NN
platforms_NN
:_:
advanced_VBN
drug_NN
delivery_NN
,_,
lead_NN
optimisation_NOMZ
for_PIN
small_JJ
molecules_NN
,_,
and_ANDC
biologics_NN
._.
Shire_NN
has_VPRT
sales_NN
and_PHC
marketing_GER
subsidiaries_NN
with_PIN
a_DT
portfolio_NN
of_PIN
products_NN
targeting_VBG [WZPRES]
the_DT
US_FPP1
,_,
Canada_NN
,_,
the_DT
UK_NN
,_,
the_DT
Republic_NN
of_PIN
Ireland_NN
,_,
France_NN
,_,
Germany_NN
,_,
Italy_NN
and_PHC
Spain_NN
._.
Shire_NN
also_RB
covers_VPRT
other_JJ
significant_JJ
pharmaceutical_JJ
markets_NN
indirectly_RB
through_PIN
distributors_NN
._.
The_DT
business_NOMZ
is_VPRT [PASS]
operated_VBN
and_PHC
managed_VBN
within_PIN
three_CD
individual_JJ
operating_GER
segments_NOMZ
:_:
US_FPP1
,_,
International_NN
,_,
and_ANDC
Global_NN
Research_NN
and_PHC
Development_NOMZ
._.
Within_PIN
these_DEMO
segments_NOMZ
,_,
revenues_NN
are_VPRT [PASS]
derived_VBN
primarily_RB
from_PIN
three_CD
sources_NN
:_:
sales_NN
of_PIN
products_NN
by_PIN
Shires_NN
own_JJ
sales_NN
and_PHC
marketing_GER
operations_NOMZ
,_,
royalties_NN
where_RB
Shire_NN
has_VPRT [PEAS]
out-licensed_VBN
to_PIN
third_JJ
parties_NN
and_PHC
licensing_GER
and_PHC
development_NOMZ
fees_NN
._.
The_DT
Company_NN
has_VPRT
a_DT
particular_JJ
interest_NN
in_PIN
innovative_JJ
therapies_NN
that_TSUB
are_VPRT [BYPA]
prescribed_VBN
by_PIN
specialist_NN
doctors_NN
as_IN
opposed_VBN
to_PIN
primary_JJ
care_NN
physicians_NN
._.
The_DT
Company_NN
follows_VPRT
two_CD
main_JJ
approaches_NN
:_:
firstly_RB
to_TO
start_VB
projects_NN
in-house_RB
through_PIN
research_NN
and_CC
advanced_VBN
drug_NN
delivery_NN
,_,
and_ANDC
secondly_RB
to_PIN
in-license_JJ
projects_NN
and_PHC
products_NN
on_PIN
reasonable_JJ
commercial_JJ
terms_NN
,_,
and_ANDC
then_RB
to_TO
develop_VB
them_TPP3
and_CC
launch_VB
them_TPP3
._.
To_TO
complete_VB
its_PIT
geographic_JJ
coverage_NN
of_PIN
the_DT
key_JJ
world_NN
pharmaceutical_JJ
markets_NN
,_,
Shire_NN
intends_VPRT [SUAV]
to_TO
build_VB
a_DT
presence_NN
in_PIN
Japan_NN
in_PIN
the_DT
future_NN
._.
The_DT
Companys_NN
principal_JJ
products_NN
include_VPRT
:_:
in_PIN
the_DT
US_FPP1
,_,
ADDERALL_NN
XR_NN
and_PHC
ADDERALL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
ADHD_NN
:_:
AGRYLIN_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
elevated_JJ
blood_NN
platelets_NN
:_:
PENTASA_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ulcerative_JJ
colitis_NN
:_:
CARBATROL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
epilepsy_NN
:_:
and_ANDC
PROAMATINE_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
orthostatic_JJ
hypotension_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
receives_VPRT
royalties_NN
on_PIN
sales_NN
of_PIN
REMINYL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
Alzheimers_NN
disease_NN
,_,
marketed_VBN [PASTP]
by_PIN
Johnson_NN
&_CC
Johnson_NN
,_,
and_ANDC
on_PIN
EPIVIR_NN
,_,
COMBIVIR_NN
and_PHC
TRIZIVIR_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
AIDS_NN
and_PHC
EPIVIR-HBV_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
hepatitis_NN
B_NN
,_,
each_QUAN
marketed_VBN
by_PIN
GlaxoSmithKline_NN
GSK_NN
:_:
in_PIN
the_DT
UK_NN
and_CC
the_DT
Republic_NN
of_PIN
Ireland_NN
,_,
the_DT
CALCICHEW_NN
range_NN
,_,
used_VBN [PASTP]
primarily_RB
as_IN
adjuncts_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
osteoporosis_NN
,_,
and_ANDC
REMINYL_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
launched_VBN
in_PIN
September_NN
2000_CD
and_CC
is_VPRT [BYPA]
co-promoted_VBN
by_PIN
Janssen-Cilag_NN
:_:
in_PIN
Canada_NN
,_,
3TC_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
AIDS_NN
,_,
COMBIVIR_NN
and_PHC
HEPTOVIR_NN
all_QUAN
marketed_VBN
in_PIN
partnership_NN
with_PIN
GSK_NN
:_:
AMATINE_NN
:_:
and_ANDC
FLUVIRAL_NN
S_NN
F_NN
,_,
a_DT
vaccine_NN
for_PIN
the_DT
prevention_NOMZ
of_PIN
influenza_NN
:_:
and_ANDC
in_PIN
the_DT
Rest_VB
of_PIN
the_DT
World_NN
,_,
royalties_NN
on_PIN
the_DT
sales_NN
of_PIN
ZEFFIX_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
hepatitis_NN
B_NN
,_,
marketed_VBN [PASTP]
by_PIN
GSK_NN
,_,
and_ANDC
royalties_NN
on_PIN
sales_NN
of_PIN
REMINYL_NN
marketed_VBN [WZPAST]
by_PIN
Johnson_NN
&_CC
Johnson_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
has_VPRT
a_DT
number_NN
of_PIN
products_NN
in_PIN
late_TIME
stage_NN
development_NOMZ
including_VBG [WZPRES]
FOSRENOL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
high_JJ
blood_NN
phosphate_NN
levels_NN
associated_VBN [WZPAST]
with_PIN
kidney_NN
failure_NN
and_PHC
TROXATYL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
leukemia_NN
and_CC
pancreatic_JJ
cancer_NN
._.
The_DT
Company_NN
submitted_VBD [PUBV]
the_DT
first_JJ
regulatory_JJ
submission_NN
for_PIN
FOSRENOL_NN
under_IN
the_DT
European_JJ
Mutual_JJ
Recognition_NOMZ
procedure_NN
on_PIN
13_CD
March_NN
2001_CD
and_CC
a_DT
New_NN
Drug_NN
Application_NOMZ
with_PIN
the_DT
US_FPP1
FDA_NN
on_PIN
30_CD
April_NN
2002_CD
._.
Registered_NN
trademark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
._.
Registered_NN
trademark_NN
of_PIN
GlaxoSmithKline_NN
Unless_COND
otherwise_CONJ
indicated_VBN [PRIV]
,_,
all_QUAN
product_NN
names_NN
set_VBN [WZPAST]
out_PIN
in_PIN
this_DEMO
document_NOMZ
are_VPRT
trademarks_NN
of_PIN
Shire_NN
or_CC
companies_NN
within_PIN
the_DT
Shire_NN
Group_NN
,_,
many_QUAN
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
the_DT
subject_NN
of_PIN
trade_NN
mark_NN
registrations_NOMZ
in_PIN
certain_JJ
territories_NN
._.
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
a_DT
Basis_NN
of_PIN
preparation_NOMZ
The_DT
accompanying_VBG
consolidated_JJ
financial_JJ
statements_NOMZ
include_VPRT
the_DT
accounts_NN
of_PIN
Shire_NN
and_CC
all_QUAN
of_PIN
its_PIT
subsidiary_NN
undertakings_GER
after_IN
elimination_NOMZ
of_PIN
intercompany_NN
accounts_NN
and_PHC
transactions_NOMZ
._.
b_NN
Use_NN
of_PIN
estimates_NN
in_PIN
financial_JJ
statements_NOMZ
The_DT
preparation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
,_,
in_PIN
conformity_NOMZ
with_PIN
US_FPP1
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
,_,
requires_VPRT [SUAV]
management_NOMZ
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
,_,
the_DT
disclosure_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
reported_VBD [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
Estimates_NN
and_PHC
assumptions_NOMZ
are_VPRT [SPAU] [PASS]
primarily_RB
made_VBN
in_PIN
relation_NOMZ
to_PIN
provisions_NN
for_PIN
product_NN
returns_NN
,_,
litigation_NOMZ
and_PHC
sales_NN
deductions_NOMZ
._.
c_NN
Revenue_NN
recognition_NOMZ
The_DT
Company_NN
recognizes_VPRT [PRIV]
revenue_NN
when_RB
:_:
there_EX
is_VPRT
persuasive_JJ
evidence_NN
of_PIN
an_DT
arrangement_NOMZ
:_:
delivery_NN
of_PIN
products_NN
has_VPRT [PEAS]
occurred_VBN
or_CC
services_NN
have_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
:_:
the_DT
sellers_NN
price_NN
to_PIN
the_DT
buyer_NN
is_VPRT [PASS]
fixed_VBN
or_CC
determinable_JJ
:_:
and_ANDC
collectibility_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
56_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
The_DT
Companys_NN
principal_JJ
revenue_NN
streams_NN
and_CC
their_TPP3
respective_JJ
accounting_GER
treatments_NOMZ
are_VPRT [PASS]
discussed_VBN
below_PLACE
:_:
i_FPP1
Product_NN
sales_NN
Revenue_NN
for_PIN
the_DT
sales_NN
of_PIN
products_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
upon_PIN
shipment_NOMZ
to_PIN
customers_NN
._.
Provisions_NN
for_PIN
certain_JJ
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
provided_VBN
for_PIN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
Approximately_RB
$_$
17.0_CD
million_CD
of_PIN
ADDERALL_NN
XR_NN
product_NN
launch_NN
shipments_NOMZ
made_VBN [WZPAST]
in_PIN
the_DT
last_JJ
quarter_NN
of_PIN
2001_CD
were_VBD [PASS]
not_XX0
recognized_VBN [PRIV]
as_IN
product_NN
revenue_NN
until_IN
the_DT
first_JJ
quarter_NN
of_PIN
2002_CD
,_,
in_PIN
accordance_NN
with_PIN
Staff_NN
Accounting_GER
Bulletin_NN
101_CD
,_,
as_IN
these_DEMO
sales_NN
had_VBD [PEAS]
not_XX0
been_VBN [PASS]
realized_VBN [PRIV]
and_PHC
earned_VBN
at_PIN
31_CD
December_NN
2001_CD
._.
ii_FW
Licensing_GER
and_PHC
development_NOMZ
fees_NN
Licensing_VBG [WZPRES]
and_CC
development_NOMZ
fees_NN
represent_VPRT
revenues_NN
derived_VBN [WZPAST]
from_PIN
licence_NN
agreements_NOMZ
and_CC
from_PIN
collaborative_JJ
research_NN
and_PHC
development_NOMZ
arrangements_NOMZ
._.
Initial_JJ
licence_NN
fees_NN
are_VPRT [SPAU] [PASS]
thus_CONJ
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
licence_NN
term_NN
,_,
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
agreement_NOMZ
._.
During_PIN
the_DT
term_NN
of_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
,_,
the_DT
Company_NN
receives_VPRT
non-refundable_JJ
milestones_NN
as_IN
certain_JJ
technical_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
._.
Revenues_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
achievement_NOMZ
of_PIN
milestones_NN
._.
The_DT
Company_NN
also_RB
receives_VPRT
non-refundable_JJ
clinical_JJ
milestones_NN
when_RB
certain_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
during_PIN
the_DT
clinical_JJ
phases_NN
of_PIN
development_NOMZ
,_,
such_JJ
as_IN
the_DT
submission_NN
of_PIN
clinical_JJ
data_NN
to_PIN
a_DT
regulatory_JJ
authority_NOMZ
._.
These_DEMO
clinical_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
received_VBN
._.
iii_FW
Royalty_NN
income_NN
Royalty_NN
income_NN
relating_VBG [WZPRES]
to_PIN
licensed_JJ
technology_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
earned_VBN
._.
Where_RB
applicable_JJ
,_,
all_QUAN
revenues_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
value_NN
added_VBD [PUBV]
tax_NN
and_CC
similar_JJ
taxes_NN
,_,
trade_NN
discounts_NN
and_PHC
intercompany_NN
transactions_NOMZ
._.
d_LS
Research_NN
and_PHC
development_NOMZ
Research_NN
and_PHC
development_NOMZ
expenditures_NN
include_VPRT
funded_VBN
and_CC
unfunded_JJ
expenditures_NN
and_CC
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
expense_NN
is_VPRT [PASS]
incurred_VBN
._.
e_LS
Leased_VBN
assets_NN
The_DT
costs_NN
of_PIN
operating_VBG
leases_NN
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
,_,
even_RB
if_COND
rental_JJ
payments_NOMZ
are_VPRT [PASS]
not_XX0
made_VBN
on_PIN
such_EMPH
a_NULL
basis_NN
._.
Assets_NN
acquired_VBN
under_IN
capital_NN
leases_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
as_IN
tangible_JJ
fixed_JJ
assets_NN
and_CC
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
period_NN
of_PIN
the_DT
lease_NN
or_CC
their_TPP3
useful_JJ
lives_NN
._.
The_DT
capital_NN
elements_NOMZ
of_PIN
future_JJ
lease_NN
payments_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
liabilities_NOMZ
,_,
while_OSUB
the_DT
interest_NN
elements_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
over_IN
the_DT
period_NN
of_PIN
the_DT
leases_NN
to_TO
produce_VB
a_DT
level_NN
yield_NN
on_PIN
the_DT
balance_NN
of_PIN
the_DT
capital_NN
lease_NN
obligation_NOMZ
._.
f_LS
Pensions_NN
The_NN
Group_NN
contributes_VPRT
to_PIN
personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_NN
of_PIN
employees_NN
._.
Contributions_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
as_IN
they_TPP3
become_VPRT
payable_JJ
._.
Details_NN
relating_VBG [WZPRES]
to_PIN
these_DEMO
contributions_NOMZ
and_CC
the_DT
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
are_VPRT [PASS]
given_VBN
in_PIN
note_NN
25_CD
._.
g_NN
Finance_NN
costs_NN
of_PIN
debt_NN
Finance_NN
costs_NN
of_PIN
debt_NN
are_VPRT [PASS]
recorded_VBN
as_IN
a_DT
deferred_JJ
asset_NN
and_CC
then_RB
amortised_VBD
to_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
over_IN
the_DT
term_NN
of_PIN
the_DT
debt_NN
,_,
using_VBG [PRESP]
the_DT
effective_JJ
interest_NN
method_NN
._.
Deferred_JJ
financing_GER
costs_NN
relating_VBG [WZPRES]
to_PIN
debt_NN
extinguishments_NOMZ
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
in_PIN
that_DEMO
period_NN
._.
h_NN
Income_NN
taxes_NN
The_DT
Company_NN
provides_VPRT
for_PIN
income_NN
taxes_NN
in_PIN
accordance_NN
with_PIN
Statement_NOMZ
of_PIN
Accounting_GER
Standards_NN
SFAS_NN
No._NN
._.
109_CD
,_,
Accounting_GER
for_PIN
Income_NN
Taxes_NN
SFAS_NN
No._NN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
provided_VBN
for_PIN
differences_NN
between_PIN
the_DT
carrying_VBG
amounts_NN
in_PIN
the_DT
financial_JJ
statements_NOMZ
and_PHC
tax_NN
bases_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
that_TSUB
will_PRMD
result_VB
in_PIN
future_JJ
taxable_JJ
or_CC
deductible_JJ
amounts_NN
._.
The_DT
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
measured_VBN
using_VBG
the_DT
enacted_VBN
tax_NN
laws_NN
and_PHC
rates_NN
applicable_JJ
to_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
differences_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
affect_VB
taxable_JJ
income_NN
._.
Income_NN
tax_NN
expense_NN
is_VPRT [PASS]
computed_VBN
as_IN
the_DT
tax_NN
payable_JJ
or_CC
refundable_JJ
for_PIN
the_DT
period_NN
,_,
plus_PIN
or_CC
minus_PIN
the_DT
change_NN
during_PIN
the_DT
period_NN
in_PIN
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [BYPA]
reduced_VBN
by_PIN
a_DT
valuation_NOMZ
allowance_NN
when_RB
,_,
in_PIN
the_DT
opinion_NN
of_PIN
management_NOMZ
,_,
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
some_QUAN
portion_NOMZ
or_CC
all_QUAN
of_PIN
the_DT
deferred_JJ
tax_NN
assets_NN
will_PRMD
not_XX0
be_VB [PASS]
realized_VBN [PRIV]
._.
i_FPP1
Earnings_GER
per_PIN
share_NN
Earnings_GER
per_PIN
share_NN
EPS_NN
is_VPRT [PASS]
computed_VBN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
128_CD
,_,
Earnings_GER
per_PIN
Share_NN
SFAS_NN
No._NN
._.
Basic_JJ
EPS_NN
is_VPRT [BYPA]
computed_VBN
by_PIN
dividing_VBG
consolidated_JJ
net_JJ
income_NN
available_JJ
to_PIN
common_JJ
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
common_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
period_NN
._.
Diluted_JJ
EPS_NN
is_VPRT [BYPA]
computed_VBN
by_PIN
dividing_VBG
consolidated_JJ
net_JJ
income_NN
available_JJ
to_PIN
common_JJ
shareholders_NN
by_PIN
the_DT
sum_NN
of_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
outstanding_JJ
and_CC
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
all_QUAN
potentially_RB
dilutive_JJ
common_JJ
shares_NN
._.
Such_JJ
potentially_RB
dilutive_JJ
common_JJ
shares_NN
are_VPRT [PASS]
excluded_VBN
when_RB
the_DT
effect_NN
would_PRMD
be_VB
to_TO
increase_VB
earnings_GER
per_PIN
share_NN
or_CC
reduce_VB
a_DT
loss_NN
per_PIN
share_NN
._.
j_NN
Advertising_GER
expense_NN
The_DT
Company_NN
expenses_NN
the_DT
cost_NN
of_PIN
advertising_GER
as_IN
incurred_VBN
._.
Advertising_GER
costs_NN
amounted_VBD
to_TO
$_$
45.6_CD
million_CD
,_,
$_$
21.8_CD
million_CD
and_CC
$_$
6.6_CD
million_CD
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
respectively_RB
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
57_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
k_NN
Foreign_JJ
currency_NN
The_DT
functional_JJ
currency_NN
of_PIN
each_QUAN
of_PIN
Shires_NN
subsidiaries_NN
is_VPRT [BEMA]
the_DT
local_JJ
currency_NN
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
relevant_JJ
functional_JJ
currency_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
relevant_JJ
functional_JJ
currency_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
Transaction_NOMZ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
arriving_VBG
at_PIN
operating_VBG
income_NN
._.
The_DT
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
,_,
whose_WPS
functional_JJ
currencies_NN
are_VPRT
not_XX0
US_FPP1
dollars_NN
,_,
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
rates_NN
of_PIN
exchange_NN
during_PIN
the_DT
period_NN
and_CC
their_TPP3
balance_NN
sheets_NN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
cumulative_JJ
effect_NN
of_PIN
exchange_NN
rate_NN
movements_NOMZ
is_VPRT [PASS]
included_VBN
in_PIN
a_DT
separate_JJ
component_NN
of_PIN
other_JJ
comprehensive_JJ
income_NN
._.
Foreign_JJ
currency_NN
exchange_NN
transaction_NOMZ
gains_NN
and_PHC
losses_NN
on_PIN
an_DT
after-tax_JJ
basis_NN
included_VBD
in_PIN
consolidated_JJ
net_JJ
income_NN
in_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
,_,
pursuant_JJ
to_PIN
SFAS_NN
No._NN
._.
52_CD
,_,
Foreign_NN
Currency_NN
Translation_NOMZ
SFAS_NN
No._NN
._.
52_CD
,_,
amounted_VBD
to_PIN
a_DT
$_$
0.3_CD
million_CD
loss_NN
,_,
$_$
0.5_CD
million_CD
loss_NN
and_CC
$_$
2.1_CD
million_CD
gain_NN
,_,
respectively_RB
._.
l_NN
Employee_NN
stock_NN
plans_NN
SFAS_NN
No._NN
._.
123_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Based_VBD
Compensation_NOMZ
SFAS_NN
No._NN
._.
123_CD
,_,
prescribes_VPRT
accounting_GER
and_PHC
reporting_GER
standards_NN
for_PIN
all_QUAN
stock-based_JJ
compensation_NOMZ
plans_NN
,_,
including_VBG
employee_NN
stock_NN
options_NOMZ
._.
123_CD
,_,
Shire_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
continue_VB
to_TO
account_VB
for_PIN
stock-based_JJ
compensation_NOMZ
using_VBG [WZPRES]
the_DT
intrinsic-value_JJ
method_NN
prescribed_VBN [WZPAST]
in_PIN
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
No._NN
._.
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Issued_NN
to_PIN
Employees_NN
APB_NN
No._NN
._.
Accordingly_RB
,_,
compensation_NOMZ
cost_NN
of_PIN
stock_NN
options_NOMZ
is_VPRT [PASS]
measured_VBN
as_IN
the_DT
excess_NN
,_,
if_COND
any_QUAN
,_,
of_PIN
the_DT
quoted_VBN
market_NN
price_NN
of_PIN
Shires_NN
stock_NN
at_PIN
the_DT
measurement_NOMZ
date_NN
over_IN
the_DT
option_NOMZ
exercise_NN
price_NN
and_CC
is_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
over_IN
the_DT
vesting_JJ
period_NN
._.
For_PIN
fixed_VBN
plans_NN
,_,
the_DT
measurement_NOMZ
date_NN
is_VPRT [BEMA]
the_DT
grant_NN
date_NN
._.
For_PIN
plans_NN
where_RB
the_DT
measurement_NOMZ
date_NN
occurs_VPRT
after_IN
the_DT
grant_NN
date_NN
,_,
referred_VBD
to_PIN
as_IN
variable_JJ
plans_NN
,_,
the_DT
compensation_NOMZ
cost_NN
is_VPRT [BEMA]
re-measured_PRED
on_PIN
the_DT
basis_NN
of_PIN
the_DT
current_JJ
market_NN
value_NN
of_PIN
the_DT
Companys_NN
stock_NN
at_PIN
the_DT
end_NN
of_PIN
each_QUAN
reporting_GER
period_NN
._.
Shire_NN
recognizes_VPRT [PRIV]
compensation_NOMZ
expense_NN
for_PIN
variable_JJ
plans_NN
with_PIN
performance_NN
conditions_NOMZ
if_COND
achievement_NOMZ
of_PIN
those_DEMO
conditions_NOMZ
becomes_VPRT
probable_JJ
._.
The_DT
Companys_NN
basis_NN
for_PIN
electing_VBG
accounting_GER
treatment_NOMZ
under_IN
APB_NN
No._NN
._.
25_CD
is_VPRT [BEMA]
principally_RB
due_PRED
to_PIN
the_DT
satisfactory_JJ
incorporation_NOMZ
of_PIN
the_DT
dilutive_JJ
effect_NN
of_PIN
these_DEMO
shares_NN
in_PIN
the_DT
reported_VBN [PUBV]
earnings_GER
per_PIN
share_NN
calculation_NOMZ
and_CC
the_DT
presence_NN
of_PIN
pro_PIN
forma_FW
supplemental_JJ
disclosure_NN
of_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
methodology_NN
prescribed_VBN [WZPAST]
by_PIN
SFAS_NN
No._NN
._.
148_CD
,_,
Accounting_GER
for_PIN
Stock-Based_NN
Compensation_NOMZ
Transition_NOMZ
and_PHC
Disclosure_NN
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
has_VPRT
nine_CD
stock-based_JJ
employee_NN
compensation_NOMZ
plans_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
described_VBN
more_EMPH
fully_AMP
in_PIN
note_NN
28_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
The_DT
following_VBG
table_NN
illustrates_VPRT
the_DT
effect_NN
on_PIN
net_JJ
income_NN
and_PHC
earnings_GER
per_PIN
share_NN
if_COND
the_DT
Company_NN
had_VBD [PEAS]
applied_VBN
the_DT
fair_JJ
value_NN
recognition_NOMZ
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
income_NN
As_IN
reported_VBN [PUBV]
250,569_CD
38,759_CD
211,727_CD
Pro_PIN
forma_FW
226,319_CD
8,791_CD
227,018_CD
Income_NN
per_PIN
share_NN
As_IN
reported_VBN [PUBV]
basic_JJ
50.0_CD
7.9_CD
43.8_CD
As_IN
reported_VBN [PUBV]
diluted_VBN
49.0_CD
7.7_CD
42.8_CD
Pro_PIN
forma_FW
basic_JJ
45.2_CD
1.8_CD
47.0_CD
Pro_PIN
forma_FW
diluted_VBN
44.4_CD
1.7_CD
45.9_CD
m_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
are_VPRT [PASS]
defined_VBN
as_IN
short-term_JJ
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
90_CD
days_NN
or_CC
less_JJ
._.
n_JJ
Marketable_JJ
securities_NOMZ
Marketable_JJ
securities_NOMZ
consist_VPRT
of_PIN
commercial_JJ
paper_NN
and_CC
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
._.
In_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
115_CD
Accounting_GER
for_PIN
Certain_NN
Investments_NOMZ
in_PIN
Debt_NN
and_PHC
Equity_NOMZ
Securities_NOMZ
SFAS_NN
No._NN
._.
115_CD
,_,
and_ANDC
based_VBN
on_PIN
the_DT
Companys_NN
intentions_NOMZ
regarding_VBG [WZPRES]
these_DEMO
instruments_NOMZ
,_,
the_DT
Company_NN
has_VPRT [PEAS]
classified_VBN
all_QUAN
marketable_JJ
securities_NOMZ
as_IN
held-to-maturity_NOMZ
and_CC
has_VPRT [PEAS]
accounted_VBN
for_PIN
these_DEMO
investments_NOMZ
at_PIN
amortised_JJ
cost_NN
._.
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
are_VPRT [BEMA]
short-term_JJ
money_NN
market_NN
instruments_NOMZ
,_,
including_VBG
bank_NN
and_PHC
building_GER
society_NN
term_NN
deposits_NN
from_PIN
a_DT
variety_NN
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
o_NN
Inventories_NN
Inventories_NN
,_,
consisting_VBG [PRESP]
primarily_RB
of_PIN
finished_VBN
goods_NN
,_,
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
or_CC
net_JJ
realisable_JJ
value_NN
._.
p_NN
Investments_NOMZ
The_NN
Company_NN
has_VPRT
certain_JJ
investments_NOMZ
in_PIN
equity_NOMZ
securities_NOMZ
._.
Investments_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
if_COND
the_DT
investment_NOMZ
gives_VPRT
the_DT
Company_NN
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
,_,
but_CC
not_XX0
control_VB
over_RP
,_,
the_DT
investee_NN
._.
Significant_JJ
influence_NN
is_VPRT [SPAU] [PASS]
generally_RB
deemed_VBN [PRIV]
to_TO
exist_VB
if_COND
the_DT
Company_NN
has_VPRT
an_DT
ownership_NN
interest_NN
in_PIN
the_DT
voting_NN
stock_NN
of_PIN
the_DT
investee_NN
between_PIN
20_CD
%_NN
and_CC
50_CD
%_NN
,_,
although_CONC
other_JJ
factors_NN
,_,
such_JJ
as_IN
representation_NOMZ
on_PIN
the_DT
investees_NN
Board_NN
of_PIN
Directors_NN
and_CC
the_DT
impact_NN
of_PIN
commercial_JJ
arrangements_NOMZ
,_,
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
is_VPRT [BEMA]
appropriate_PRED
._.
58_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
Under_IN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
,_,
the_DT
Company_NN
records_NN
its_PIT
investments_NOMZ
in_PIN
equity-method_JJ
investees_NN
on_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
as_IN
Investments_NOMZ
and_CC
its_PIT
share_NN
of_PIN
the_DT
investees_NN
earnings_GER
or_CC
losses_NN
together_RB
with_PIN
other-than-temporary_JJ
impairments_NOMZ
in_PIN
value_NN
as_IN
Equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
on_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
All_QUAN
other_JJ
equity_NOMZ
investments_NOMZ
,_,
which_WDT [SERE]
consist_VPRT
of_PIN
investments_NOMZ
for_PIN
which_WDT [PIRE]
the_DT
Company_NN
does_VPRT
not_XX0
have_VB
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
,_,
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
the_DT
cost_NN
method_NN
or_CC
at_PIN
fair_JJ
value_NN
._.
Investments_NOMZ
in_PIN
private_JJ
companies_NN
are_VPRT [PASS]
carried_VBN
at_PIN
cost_NN
,_,
less_JJ
provisions_NN
for_PIN
other_JJ
than_PIN
temporary_JJ
impairment_NOMZ
in_PIN
value_NN
._.
For_PIN
public_JJ
companies_NN
that_TSUB
have_VPRT
readily_RB
determinable_JJ
fair_JJ
values_NN
,_,
the_DT
Company_NN
classifies_VPRT
its_PIT
equity_NOMZ
investments_NOMZ
as_IN
available-forsale_JJ
and_CC
,_,
accordingly_RB
,_,
records_NN
these_DEMO
investments_NOMZ
at_PIN
their_TPP3
fair_JJ
values_NN
with_PIN
unrealised_JJ
gains_NN
and_PHC
losses_NN
included_VBD
in_PIN
Accumulated_NN
other_JJ
comprehensive_JJ
loss_NN
,_,
net_NN
of_PIN
any_QUAN
related_JJ
tax_NN
effect_NN
._.
Realised_VBN [PRIV]
gains_NN
and_PHC
losses_NN
and_PHC
declines_NN
in_PIN
value_NN
judged_VBN [PRIV]
to_TO
be_VB [BEMA]
other-than-temporary_PRED
on_PIN
available-for-sale_JJ
securities_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
expense_NN
income_NN
,_,
net_JJ
see_VPRT [PRIV]
note_NN
24_CD
._.
The_DT
cost_NN
of_PIN
securities_NOMZ
sold_VBN [WZPAST]
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
method_NN
._.
Interest_NN
and_PHC
dividends_NN
on_PIN
securities_NOMZ
classified_VBN
as_IN
available-for-sale_NN
are_VPRT [PASS]
included_VBN
as_IN
interest_NN
income_NN
._.
q_NN
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
i_FPP1
Goodwill_NN
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
subsidiary_NN
undertakings_GER
and_PHC
businesses_NOMZ
,_,
representing_VBG [PRESP]
any_QUAN
excess_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
consideration_NOMZ
given_VBN
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identifiable_JJ
assets_NN
and_PHC
liabilities_NOMZ
acquired_VBN
,_,
is_VPRT [PASS]
capitalized_VBN
._.
Periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
before_IN
31_CD
December_NN
2001_CD
For_PIN
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
before_IN
31_CD
December_NN
2001_CD
goodwill_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
respect_NN
of_PIN
each_QUAN
significant_JJ
business_NOMZ
combination_NOMZ
was_VBD [PASS]
amortised_VBN
over_IN
a_DT
period_NN
of_PIN
5_CD
to_PIN
30_CD
years_NN
weighted_VBN
average_JJ
19_CD
years_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
depending_VBG [WZPRES]
on_PIN
the_DT
nature_NN
of_PIN
the_DT
goodwill_NN
,_,
and_ANDC
was_VBD [PASS]
evaluated_VBN
for_PIN
impairment_NOMZ
when_RB
events_NN
or_CC
changes_NN
in_PIN
circumstance_NN
indicate_VPRT [PRIV]
,_,
in_PIN
managements_NOMZ
judgement_NOMZ
,_,
that_THVC
the_DT
carrying_VBG
value_NN
of_PIN
such_JJ
assets_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
Impairments_NOMZ
of_PIN
goodwill_NN
were_VBD [PASS]
recognized_VBN [PRIV]
if_COND
expected_VBN [PRIV]
undiscounted_JJ
cash_NN
flows_NN
were_VBD [BEMA]
not_XX0
sufficient_PRED
to_TO
recover_VB
the_DT
goodwill_NN
._.
If_COND
a_DT
material_NN
impairment_NOMZ
was_VBD [PASS]
identified_VBN
,_,
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
down_RP
to_PIN
its_PIT
estimated_VBN [PRIV]
fair_JJ
value_NN
._.
Fair_NN
value_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
the_DT
present_JJ
value_NN
of_PIN
expected_JJ
net_JJ
cash_NN
flows_VPRT
to_TO
be_VB [BYPA]
generated_VBN
by_PIN
the_DT
business_NOMZ
,_,
discounted_VBN
using_VBG
a_DT
rate_NN
commensurate_JJ
with_PIN
the_DT
risks_NN
involved_VBN
._.
Periods_NN
commencing_VBG [WZPRES]
1_CD
January_NN
2002_CD
Effective_NN
1_CD
January_NN
2002_CD
,_,
the_DT
Company_NN
adopted_VBN
SFAS_NN
No._NN
._.
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
SFAS_NN
No._NN
._.
The_DT
statement_NOMZ
directs_VPRT
that_DEMO
goodwill_NN
and_CC
intangible_JJ
assets_NN
that_TSUB
have_VPRT
indefinate_JJ
lives_NN
will_PRMD
not_XX0
be_VB [PASS]
amortised_VBN
but_CC
rather_RB
will_PRMD
be_VB [PASS]
tested_VBN
at_PIN
least_JJ
annually_RB
for_PIN
impairment_NOMZ
._.
Intangible_JJ
assets_NN
that_TSUB
have_VPRT
finite_JJ
lives_NN
will_PRMD
continue_VB
to_TO
be_VB [PASS]
amortised_VBN
over_IN
their_TPP3
useful_JJ
lives_NN
,_,
but_CC
without_PIN
the_DT
constraint_NN
of_PIN
an_DT
arbitrary_JJ
ceiling_GER
._.
Going_VBG [PRESP]
forward_RB
,_,
the_DT
Company_NN
will_PRMD
carry_VB
out_PIN
an_DT
annual_JJ
impairment_NOMZ
review_NN
of_PIN
goodwill_NN
as_IN
of_PIN
30_CD
September_NN
date_NN
unless_COND
any_QUAN
events_NN
occur_VPRT
which_WDT
trigger_VPRT
the_DT
need_NN
for_PIN
an_DT
earlier_TIME
impairment_NOMZ
review_NN
._.
ii_FW
Other_JJ
intangible_JJ
assets_NN
Other_JJ
intangible_JJ
assets_NN
,_,
which_WDT [SERE]
comprise_VPRT
intellectual_JJ
property_NN
including_VBG [WZPRES]
trademarks_NN
for_PIN
products_NN
with_PIN
an_DT
immediate_JJ
defined_VBN
revenue_NN
stream_NN
and_CC
acquired_VBN
for_PIN
valued_VBN
consideration_NOMZ
,_,
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
and_CC
amortised_VBN
in_PIN
equal_JJ
annual_JJ
installments_NOMZ
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
life_NN
of_PIN
the_DT
related_JJ
product_NN
which_WDT [WHSUB]
range_VPRT
from_PIN
5_CD
to_PIN
40_CD
years_NN
weighted_VBN
average_JJ
23_CD
years_NN
._.
Intellectual_NN
property_NN
with_PIN
no_DT
defined_VBN
revenue_NN
stream_NN
,_,
where_RB
the_DT
related_JJ
product_NN
has_VPRT [PEAS]
not_XX0
yet_RB
completed_VBN
the_DT
necessary_JJ
approval_NN
process_NN
,_,
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
operations_NOMZ
on_PIN
acquisition_NOMZ
._.
The_DT
following_VBG
factors_NN
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
estimating_VBG [PRIV]
the_DT
useful_JJ
lives_NN
._.
Where_RB
an_DT
intangible_JJ
asset_NN
is_VPRT [BEMA]
a_DT
composite_NN
of_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
the_DT
period_NN
of_PIN
amortisation_NOMZ
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
from_PIN
considering_VBG [PRIV]
these_DEMO
factors_NN
together_RB
:_:
regulatory_JJ
and_PHC
legal_JJ
provisions_NN
,_,
including_VBG [PRESP]
the_DT
regulatory_JJ
approval_NN
and_PHC
review_NN
process_NN
,_,
patent_NN
issues_NN
and_PHC
actions_NOMZ
by_PIN
government_NOMZ
agencies_NN
:_:
the_DT
effects_NN
of_PIN
obsolescence_NN
,_,
changes_NN
in_PIN
demand_NN
,_,
competing_VBG
products_NN
and_CC
other_JJ
economic_JJ
factors_NN
,_,
including_VBG [PRESP]
the_DT
development_NOMZ
of_PIN
competing_VBG
drugs_NN
that_TSUB
are_VPRT [BEMA]
more_EMPH
effective_JJ
clinically_RB
or_CC
economically_RB
:_:
and_ANDC
actions_NOMZ
of_PIN
competitors_NN
,_,
suppliers_NN
,_,
regulatory_JJ
agencies_NN
or_CC
others_NN
that_TSUB
may_POMD
eliminate_VB
current_JJ
competitive_JJ
advantages_NN
._.
r_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
,_,
less_JJ
accumulated_VBN
depreciation_NOMZ
and_CC
any_QUAN
provision_NN
for_PIN
impairment_NOMZ
._.
Cost_NN
of_PIN
significant_JJ
assets_NN
includes_VPRT
capitalized_JJ
interest_NN
incurred_VBN [WZPAST]
during_PIN
the_DT
construction_NOMZ
period_NN
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
less_JJ
estimated_VBN [PRIV]
residual_JJ
value_NN
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
as_IN
follows_VPRT
:_:
Buildings_GER
20_CD
to_PIN
50_CD
years_NN
Office_NN
furniture_NN
,_,
fittings_GER
and_PHC
equipment_NOMZ
4_CD
to_PIN
10_CD
years_NN
Warehouse_NN
,_,
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
4_CD
to_PIN
10_CD
years_NN
The_DT
cost_NN
of_PIN
land_NN
is_VPRT [PASS]
not_XX0
depreciated_VBN
._.
Expenditures_NN
for_PIN
maintenance_NN
and_PHC
repairs_NN
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
as_IN
incurred_VBN
._.
The_DT
costs_NN
of_PIN
major_JJ
renewals_NN
and_PHC
improvements_NOMZ
are_VPRT [PASS]
capitalized_VBN
._.
At_PIN
the_DT
time_NN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
retired_VBN
or_CC
otherwise_CONJ
disposed_JJ
of_PIN [STPR]
,_,
the_DT
cost_NN
and_CC
accumulated_VBN
depreciation_NOMZ
are_VPRT [PASS]
eliminated_VBN
from_PIN
the_DT
asset_NN
and_CC
accumulated_VBN
depreciation_NOMZ
accounts_NN
._.
The_DT
profit_NN
or_CC
loss_NN
on_PIN
such_JJ
disposition_NOMZ
is_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
operating_VBG
income_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
59_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
s_PRP
Impairment_NOMZ
of_PIN
long-lived_JJ
assets_NN
other_JJ
than_PIN
goodwill_NN
and_PHC
investments_NOMZ
The_DT
Company_NN
periodically_RB
evaluates_VPRT
the_DT
recoverability_NOMZ
of_PIN
long-lived_JJ
assets_NN
other_JJ
than_PIN
goodwill_NN
and_PHC
investments_NOMZ
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
144_CD
,_,
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
or_CC
Disposal_NN
of_PIN
Long-Lived_NN
Assets_NN
SFAS_NN
No._NN
._.
Whenever_NN
events_NN
or_CC
changes_NN
in_PIN
circumstances_NN
indicate_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amounts_NN
of_PIN
those_DEMO
assets_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
,_,
the_DT
Company_NN
compares_VPRT
undiscounted_JJ
net_JJ
cash_NN
estimated_VBN [PRIV]
to_TO
be_VB [BYPA]
generated_VBN
by_PIN
those_DEMO
assets_NN
to_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
those_DEMO
assets_NN
._.
When_RB
these_DEMO
undiscounted_JJ
cash_NN
flows_NN
are_VPRT [BEMA]
less_PRED
than_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
assets_NN
,_,
the_DT
Company_NN
records_NN
impairment_NOMZ
losses_NN
to_TO
write_VB [PUBV]
the_DT
asset_NN
down_IN
to_PIN
its_PIT
estimated_VBN [PRIV]
fair_JJ
market_NN
value_NN
._.
This_DEMP
is_VPRT [SPAU] [BYPA]
usually_RB
calculated_VBN [PRIV]
by_PIN
reference_NN
to_TO
discounted_VBN
estimated_VBN [PRIV]
cash_NN
flows_NN
._.
t_NN
Concentration_NOMZ
of_PIN
credit_NN
risk_NN
Revenues_NN
are_VPRT [SPAU] [PASS]
mainly_RB
derived_VBN
from_PIN
agreements_NOMZ
with_PIN
major_JJ
pharmaceutical_JJ
companies_NN
and_PHC
relationships_NN
with_PIN
pharmaceutical_JJ
wholesale_JJ
distributors_NN
and_CC
retail_JJ
pharmacy_NN
chains_NN
._.
Significant_JJ
customers_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
note_NN
22_CD
._.
Such_JJ
clients_NN
have_VPRT
significant_JJ
cash_NN
resources_NN
and_ANDC
therefore_CONJ
any_QUAN
credit_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
transactions_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
minimal_JJ
._.
Excess_JJ
cash_NN
is_VPRT [PASS]
invested_VBN
in_PIN
bank_NN
and_PHC
building_GER
society_NN
term_NN
deposits_NN
and_CC
commercial_JJ
paper_NN
from_PIN
a_DT
variety_NN
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
These_DEMO
investments_NOMZ
typically_RB
bear_VPRT
minimal_JJ
credit_NN
risk_NN
._.
A_DT
significant_JJ
proportion_NOMZ
of_PIN
revenue_NN
is_VPRT [PASS]
derived_VBN
from_PIN
the_DT
sale_NN
of_PIN
ADDERALL_NN
XR_NN
and_PHC
ADDERALL_NN
._.
During_PIN
2002_CD
and_CC
2001_CD
sales_NN
of_PIN
these_DEMO
products_NN
were_VBD
$_$
427.7_CD
million_CD
and_CC
$_$
350.3_CD
million_CD
respectively_RB
,_,
representing_VBG [PRESP]
41_CD
%_NN
of_PIN
total_JJ
revenues_NN
in_PIN
both_DT
years_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
factors_NN
affecting_VBG [WZPRES]
the_DT
sale_NN
or_CC
production_NOMZ
of_PIN
ADDERALL_NN
XR_NN
and_PHC
ADDERALL_NN
would_PRMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
our_FPP1
financial_JJ
condition_NOMZ
and_PHC
results_NN
of_PIN
operation_NOMZ
._.
u_NN
Reclassifications_NOMZ
Certain_NN
amounts_VPRT
reported_VBN [PUBV]
in_PIN
previous_JJ
years_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
to_TO
conform_VB
to_PIN
the_DT
2002_CD
presentation_NOMZ
._.
v_FW
New_NN
accounting_GER
pronouncements_NOMZ
In_PIN
June_NN
2001_CD
,_,
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
143_CD
,_,
Accounting_GER
for_PIN
Asset_NN
Retirement_NOMZ
Obligations_NOMZ
SFAS_NN
No._NN
._.
143_CD
requires_VPRT [SUAV]
that_THVC
the_DT
fair_JJ
value_NN
of_PIN
a_DT
liability_NOMZ
for_PIN
asset_NN
retirement_NOMZ
obligations_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
if_COND
a_DT
reasonable_JJ
estimate_NN
of_PIN
the_DT
fair_JJ
value_NN
can_POMD
be_VB [PASS]
made_VBN
._.
The_DT
associated_VBN
asset_NN
retirement_NOMZ
costs_NN
are_VPRT [PASS]
capitalized_VBN
as_IN
part_NN
of_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
related_JJ
long-lived_JJ
asset_NN
._.
143_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
financial_JJ
statements_NOMZ
issued_VBN [WZPAST]
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15_CD
June_NN
2002_CD
._.
The_DT
Company_NN
has_VPRT [PEAS]
assessed_VBN
the_DT
potential_JJ
impact_NN
of_PIN
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
143_CD
and_CC
concluded_VBD [PRIV]
that_THVC
there_EX
is_VPRT
no_SYNE
impact_NN
._.
In_PIN
April_NN
2002_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
145_CD
,_,
Rescission_NN
of_PIN
FASB_NN
Statements_NOMZ
No._NN
._.
4_CD
,_,
44_CD
and_CC
64_CD
,_,
Amendment_NOMZ
of_PIN
FASB_NN
Statement_NOMZ
No._NN
._.
13_CD
and_CC
Technical_NN
Corrections_NOMZ
SFAS_NN
No._NN
._.
The_DT
principal_JJ
change_NN
is_VPRT
that_DEMO
gains_NN
or_CC
losses_NN
from_PIN
extinguishment_NOMZ
of_PIN
debt_NN
which_WDT [WHSUB]
are_VPRT [PASS]
classified_VBN
as_IN
extraordinary_JJ
items_NN
by_PIN
SFAS_NN
No._NN
._.
4_CD
will_PRMD [SPAU]
no_RB
longer_RB
be_VB [PASS]
classified_VBN
as_IN
such_JJ
._.
The_DT
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
145_CD
are_VPRT [BEMA]
effective_PRED
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15_CD
May_POMD
2002_CD
although_CONC
early_TIME
application_NOMZ
of_PIN
the_DT
Statement_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
rescission_NN
of_PIN
SFAS_NN
No._NN
._.
The_DT
Company_NN
plans_VPRT
to_TO
adopt_VB
SFAS_NN
No._NN
._.
145_CD
for_PIN
its_PIT
fiscal_JJ
year_NN
ending_VBG [WZPRES]
31_CD
December_NN
2003_CD
._.
When_RB
adopted_VBN
,_,
prior_RB
extraordinary_JJ
items_NN
related_VBN [WZPAST]
to_PIN
the_DT
extinguishment_NOMZ
of_PIN
debt_NN
will_PRMD
need_VB
to_TO
be_VB [PASS]
reclassified_VBN
._.
The_DT
potential_JJ
impact_NN
of_PIN
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
145_CD
will_PRMD
be_VB
to_TO
reclassify_VB
$_$
2.6_CD
million_CD
from_PIN
extraordinary_JJ
items_NN
to_PIN
income_NN
expense_NN
._.
In_PIN
June_NN
2002_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
146_CD
,_,
Accounting_GER
for_PIN
Costs_NN
Associated_NN
with_PIN
Exit_NN
or_CC
Disposal_NN
Activities_NOMZ
SFAS_NN
No._NN
._.
146_CD
,_,
which_WDT [SERE]
addresses_VPRT
accounting_GER
and_PHC
processing_GER
for_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
and_PHC
nullifies_NN
Emerging_VBG [WZPRES]
Issues_NN
Task_NN
Force_NN
EITF_NN
Issue_NN
94-3_CD
,_,
Liability_NOMZ
Recognition_NOMZ
for_PIN
Certain_NN
Employee_NN
Termination_NOMZ
Benefits_NN
and_CC
Other_JJ
Costs_NN
to_PIN
Exit_NN
and_PHC
Activity_NOMZ
Including_VBG [WZPRES]
Certain_NN
Costs_NN
Incurred_VBN [WZPAST]
in_PIN
a_DT
Restructuring_GER
Issue_NN
94-3_CD
._.
146_CD
requires_VPRT [SUAV]
that_THVC
a_DT
liability_NOMZ
for_PIN
a_DT
cost_NN
associated_VBN [WZPAST]
with_PIN
an_DT
exit_NN
or_CC
disposal_NN
liability_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
liability_NOMZ
is_VPRT [PASS]
incurred_VBN
._.
Under_IN
Issue_NN
94-3_CD
,_,
a_DT
liability_NOMZ
for_PIN
an_DT
exit_NN
cost_NN
was_VBD [PASS]
recognized_VBN [PRIV]
at_PIN
the_DT
date_NN
of_PIN
an_DT
entitys_JJ
commitment_NOMZ
to_PIN
an_DT
exit_NN
plan_NN
._.
146_CD
,_,
fair_JJ
value_NN
is_VPRT [BEMA]
the_DT
objective_NN
for_PIN
initial_JJ
measurement_NOMZ
of_PIN
the_DT
liability_NOMZ
._.
146_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
that_TSUB
are_VPRT [PASS]
initiated_VBN
after_IN
31_CD
December_NN
2002_CD
,_,
with_PIN
early_TIME
application_NOMZ
encouraged_VBD
._.
We_FPP1
do_VPRT
no_DT
expect_VPRT [PRIV]
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
146_CD
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
our_FPP1
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
In_PIN
November_NN
2002_CD
,_,
the_DT
FASB_NN
issued_VBD
Interpretation_NOMZ
FIN_NN
No._NN
._.
45_CD
,_,
Guarantors_NN
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
for_PIN
Guarantees_NN
,_,
Including_VBG
Indirect_NN
Guarantees_NN
of_PIN
Indebtedness_NOMZ
of_PIN
Others_NN
FIN_NN
45_CD
._.
This_DEMO
interpretation_NOMZ
elaborates_VPRT
on_PIN
the_DT
disclosures_NN
to_TO
be_VB [BYPA]
made_VBN
by_PIN
a_DT
guarantor_NN
in_PIN
its_PIT
interim_JJ
and_PHC
annual_JJ
financial_JJ
statements_NOMZ
about_IN
its_PIT
obligations_NOMZ
under_IN
certain_JJ
guarantees_NN
that_TOBJ
it_PIT
has_VPRT [PEAS]
issued_VBN
._.
It_PIT
also_RB
clarifies_VPRT
that_DEMO
a_DT
guarantor_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
recognize_VB [PRIV]
,_,
at_PIN
the_DT
inception_NOMZ
of_PIN
a_DT
guarantee_NN
,_,
a_DT
liability_NOMZ
for_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
obligation_NOMZ
undertaken_VBN [WZPAST]
in_PIN
issuing_VBG
the_DT
guarantee_NN
._.
The_DT
disclosure_NN
requirements_NOMZ
of_PIN
FIN_NN
45_CD
are_VPRT [BEMA]
effective_PRED
for_PIN
interim_JJ
and_PHC
annual_JJ
periods_NN
after_IN
15_CD
December_NN
2002_CD
._.
The_DT
initial_JJ
recognition_NOMZ
and_CC
initial_JJ
measurement_NOMZ
requirements_NOMZ
of_PIN
FIN_NN
45_CD
are_VPRT [BEMA]
effective_JJ
prospectively_RB
for_PIN
guarantees_NN
issued_VBN
or_CC
modified_VBN
after_IN
31_CD
December_NN
2002_CD
._.
We_FPP1
are_VPRT
assessing_VBG
,_,
but_CC
at_PIN
this_DEMO
point_NN
do_VPRT
not_XX0
believe_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
the_DT
recognition_NOMZ
and_CC
initial_JJ
measurement_NOMZ
requirements_NOMZ
of_PIN
FIN_NN
45_CD
will_PRMD
have_VB
a_DT
material_NN
impact_NN
on_PIN
our_FPP1
financial_JJ
position_NOMZ
,_,
cash_NN
flows_NN
or_CC
results_NN
of_PIN
operations_NOMZ
._.
In_PIN
January_NN
2003_CD
,_,
the_DT
FASB_NN
issued_VBD
FIN_NN
No._NN
._.
46_CD
,_,
Consolidation_NOMZ
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
,_,
an_DT
Interpretation_NOMZ
of_PIN
APB_NN
No._NN
._.
This_DEMO
interpretation_NOMZ
requires_VPRT [SUAV]
certain_JJ
variable_JJ
interest_NN
entities_NOMZ
to_TO
be_VB [BYPA]
consolidated_VBN
by_PIN
the_DT
primary_JJ
beneficiary_NN
of_PIN
the_DT
entity_NOMZ
if_COND
the_DT
equity_NOMZ
investors_NN
in_PIN
the_DT
entity_NOMZ
do_VPRT
not_XX0
have_VB
the_DT
characteristics_NN
of_PIN
a_DT
controlling_VBG
financial_JJ
interest_NN
or_CC
do_VB
not_XX0
have_VB
sufficient_JJ
equity_NOMZ
at_PIN
risk_NN
for_PIN
the_DT
entity_NOMZ
to_TO
finance_VB
its_PIT
activities_NOMZ
without_PIN
additional_JJ
subordinated_JJ
financial_JJ
support_NN
from_PIN
other_JJ
parties_NN
._.
FIN_NN
46_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
all_QUAN
new_JJ
variable_JJ
interest_NN
entities_NOMZ
created_VBN
or_CC
acquired_VBN
after_IN
31_CD
January_NN
2003_CD
._.
For_PIN
variable_JJ
interest_NN
entities_NOMZ
created_VBN
or_CC
acquired_VBN
prior_RB
to_PIN
1_CD
February_NN
2003_CD
,_,
the_DT
provisions_NN
of_PIN
FIN_NN
46_CD
must_NEMD
be_VB [PASS]
applied_VBN
for_PIN
the_DT
first_JJ
interim_NN
or_CC
annual_JJ
period_NN
beginning_VBG [WZPRES]
after_IN
15_CD
June_NN
2003_CD
._.
The_DT
Company_NN
is_VPRT [SPAU]
currently_RB
evaluating_VBG
the_DT
effect_NN
that_TOBJ
the_DT
adoption_NOMZ
of_PIN
FIN_NN
46_CD
will_PRMD
have_VB
on_PIN
its_PIT
results_NN
of_PIN
operations_NOMZ
and_CC
financial_JJ
condition_NOMZ
._.
w_VB
Statutory_JJ
accounts_NN
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
as_IN
of_PIN
31_CD
December_NN
2002_CD
and_CC
2001_CD
and_CC
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
ended_VBD
31_CD
December_NN
2002_CD
do_VPRT
not_XX0
comprise_VB
statutory_JJ
accounts_NN
within_PIN
the_DT
meaning_GER
of_PIN
Section_NOMZ
240_CD
of_PIN
the_DT
UK_NN
Companies_NN
Act_NN
1985_CD
._.
Statutory_JJ
accounts_NN
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
in_PIN
the_DT
United_NN
Kingdom_NN
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2001_CD
and_CC
2000_CD
have_VPRT [PEAS]
been_VBN [PASS]
delivered_VBN
to_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
for_PIN
England_NN
and_PHC
Wales_NN
._.
The_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
was_VBD [BEMA]
unqualified_PRED
._.
60_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Business_NOMZ
combinations_NOMZ
and_PHC
reorganisations_NOMZ
Year_NN
ended_VBD
31_CD
December_NN
2002_CD
a_DT
Atlantic_NN
Pharmaceutical_NN
Services_NN
Inc._NN
acquisition_NOMZ
On_PIN
27_CD
September_NN
2002_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
acquisition_NOMZ
of_PIN
Atlantic_NN
Pharmaceutical_NN
Services_NN
Inc._NN
._.
APS_NN
from_PIN
Niro_NN
Inc._NN
for_PIN
cash_NN
consideration_NOMZ
of_PIN
$_$
17.3_CD
million_CD
,_,
including_VBG
$_$
0.3_CD
million_CD
costs_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
transaction_NOMZ
provided_VBD
the_DT
Company_NN
with_PIN
an_DT
in-house_JJ
facility_NOMZ
in_PIN
which_WDT [PIRE]
to_TO
manufacture_VB
several_QUAN
key_JJ
US_FPP1
products_NN
._.
The_DT
acquisition_NOMZ
was_VBD [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
purchase_NN
method_NN
and_PHC
goodwill_NN
of_PIN
$_$
10.2_CD
million_CD
was_VBD [PASS]
recorded_VBN
._.
The_DT
results_NN
of_PIN
operations_NOMZ
of_PIN
APS_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
results_NN
of_PIN
the_DT
Company_NN
since_OSUB
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
The_DT
purchase_NN
price_NN
of_PIN
$_$
17.3_CD
million_CD
was_VBD [PASS]
allocated_VBN
as_IN
follows_VPRT
:_:
Fair_NN
value_NN
$_$
000_CD
Total_JJ
current_JJ
assets_NN
3,188_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
11,620_CD
Current_JJ
installments_NOMZ
of_PIN
long-term_JJ
debt_NN
216_CD
Accounts_NN
payable_JJ
1,367_CD
Long-term_JJ
debt_NN
,_,
excluding_VBG
current_JJ
instalments_NOMZ
6,050_CD
Net_JJ
assets_NN
acquired_VBN
7,175_CD
Goodwill_NN
10,175_CD
17,350_CD
Represented_VBN
by_PIN
:_:
Purchase_NN
consideration_NOMZ
17,000_CD
Acquisition_NOMZ
fees_NN
350_CD
17,350_CD
The_DT
pro_PIN
forma_FW
effect_NN
in_PIN
2002_CD
and_CC
2001_CD
of_PIN
the_DT
APS_NN
acquisition_NOMZ
if_COND
acquired_VBN
on_PIN
1_CD
January_NN
2002_CD
and_CC
1_CD
January_NN
2001_CD
respectively_RB
would_PRMD
have_VB [PEAS]
resulted_VBN
in_PIN
revenues_NN
,_,
income_NN
before_IN
extraordinary_JJ
items_NN
,_,
net_JJ
income_NN
and_PHC
earnings_GER
per_PIN
share_NN
data_NN
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
Revenues_NN
1,042,748_CD
861,660_CD
Income_NN
before_IN
extraordinary_JJ
items_NN
248,983_CD
41,428_CD
Net_JJ
income_NN
248,983_CD
38,824_CD
Earnings_GER
per_PIN
share_NN
basic_JJ
49.7_CD
7.9_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
48.7_CD
7.7_CD
b_NN
Divestment_NOMZ
of_PIN
OTC_NN
products_NN
division_NN
On_PIN
27_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
a_DT
group_NN
of_PIN
non-strategic_JJ
US_FPP1
products_NN
,_,
known_VBN [PRIV] [PASTP]
collectively_RB
as_IN
the_DT
Over-TheCounter_NN
OTC_NN
products_NN
._.
The_DT
Company_NN
received_VBD
sale_NN
proceeds_NN
of_PIN
$_$
71.0_CD
million_CD
and_CC
recorded_VBD
a_DT
gain_NN
on_PIN
disposal_NN
of_PIN
$_$
2.1_CD
million_CD
._.
In_CONJ
addition_NULL
,_,
there_EX
are_VPRT
potential_JJ
warranties_NN
of_PIN
up_RB
to_TO
$_$
7.0_CD
million_CD
in_PIN
respect_NN
of_PIN
the_DT
divestment_NOMZ
,_,
of_PIN
which_WDT [PIRE]
the_DT
Company_NN
has_VPRT [PEAS]
provided_VBN
what_WP
it_PIT
deems_VPRT [PRIV]
necessary_JJ
at_PIN
this_DEMO
stage_NN
._.
Further_JJ
details_NN
of_PIN
this_DEMP
discontinued_VBN
operation_NOMZ
are_VPRT [PASS]
provided_VBN
in_PIN
note_NN
5_CD
below_PLACE
._.
Year_NN
ended_VBD
31_CD
December_NN
2001_CD
a_DT
BioChem_NN
merger_NN
On_PIN
11_CD
May_POMD
2001_CD
,_,
the_DT
Company_NN
acquired_VBD
100_CD
%_NN
of_PIN
the_DT
outstanding_JJ
stock_NN
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
._.
BioChem_NN
,_,
an_DT
international_JJ
specialty_NN
pharmaceutical_JJ
company_NN
based_VBN [WZPAST]
in_PIN
Laval_NN
,_,
Canada_NN
._.
The_DT
merger_NN
was_VBD [PASS]
achieved_VBN
through_PIN
an_DT
exchange_NN
of_PIN
shares_NN
._.
Shire_NN
issued_VBD
179,447,629_CD
common_JJ
shares_NN
and_CC
17,292,149_CD
exchangeable_JJ
shares_NN
in_PIN
order_NN
to_TO
effect_VB
the_DT
business_NOMZ
combination_NOMZ
._.
Each_QUAN
exchangeable_JJ
share_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
three_CD
common_JJ
shares_NN
and_CC
is_VPRT [BEMA]
exchangeable_PRED
into_PIN
common_JJ
shares_NN
or_CC
ADSs_NN
at_PIN
a_DT
rate_NN
of_PIN
one_CD
exchangeable_JJ
share_NN
for_PIN
three_CD
common_JJ
shares_NN
or_CC
one_CD
exchangeable_JJ
share_NN
for_PIN
one_CD
ADS_NN
,_,
at_PIN
any_QUAN
time_NN
at_PIN
the_DT
request_NN
of_PIN
the_DT
holder_NN
._.
Holders_NN
of_PIN
exchangeable_JJ
shares_NN
are_VPRT [PASS]
entitled_VBN
to_PIN
the_DT
dividend_NN
and_CC
other_JJ
rights_NN
that_TSUB
are_VPRT [BEMA]
economically_RB
equivalent_PRED
to_PIN
those_DEMO
of_PIN
common_JJ
shares_NN
._.
Exchangeable_JJ
shares_NN
are_VPRT [PASS]
included_VBN
in_PIN
deriving_VBG
the_DT
Companys_NN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
for_PIN
both_DT
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
see_VPRT [PRIV]
note_NN
20_CD
because_CAUS
they_TPP3
will_PRMD
become_VB
and_PHC
are_VPRT [BEMA]
equivalent_PRED
to_PIN
common_JJ
shares_NN
._.
This_DEMO
transaction_NOMZ
was_VBD [PASS]
accounted_VBN
for_PIN
by_PIN
the_DT
pooling-of-interests_NN
method_NN
in_PIN
accordance_NN
with_PIN
APB_NN
No._NN
._.
Consequently_CONJ
,_,
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
give_VPRT
retroactive_JJ
effect_NN
to_PIN
the_DT
merger_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
61_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Business_NOMZ
combinations_NOMZ
and_PHC
reorganisations_NOMZ
continued_VBD
Details_NN
of_PIN
the_DT
results_NN
of_PIN
operations_NOMZ
of_PIN
BioChem_NN
for_PIN
the_DT
period_NN
before_IN
the_DT
merger_NN
was_VBD [PASS]
consummated_VBN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
period_NN
from_PIN
1_CD
January_NN
2001_CD
to_PIN
11_CD
May_POMD
2001_CD
,_,
that_DEMP
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
combined_JJ
net_JJ
income_NN
of_PIN
the_DT
Company_NN
are_VPRT
as_IN
follows_VPRT
:_:
$_$
000_CD
Revenue_NN
51,592_CD
Net_JJ
income_NN
23,003_CD
Other_JJ
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
:_:
Issue_NN
of_PIN
common_JJ
shares_NN
on_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
2,170_CD
The_DT
revenues_NN
and_PHC
earnings_GER
previously_TIME
reported_VBN [PUBV]
by_PIN
the_DT
Company_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
can_POMD
be_VB [PASS]
reconciled_VBN
to_PIN
the_DT
combined_VBN
amounts_NN
presented_VBD
herein_NN
as_IN
follows_VPRT
:_:
Revenue_NN
Net_JJ
income_NN
$_$
000_CD
$_$
000_CD
As_IN
previously_TIME
reported_VBN [PUBV]
517,608_CD
76,171_CD
BioChem_NN
pooled_VBD
results_NN
198,478_CD
174,346_CD
Accounting_GER
policy_NN
alignment_NOMZ
see_VPRT [PRIV]
note_NN
4_CD
44,976_CD
38,790_CD
As_IN
restated_VBN
for_PIN
BioChem_NN
671,110_CD
211,727_CD
Discontinued_VBN
operations_NOMZ
see_VPRT [PRIV]
note_NN
5_CD
23,456_CD
As_IN
reported_VBN [PUBV]
647,654_CD
211,727_CD
b_NN
Dispositions_NOMZ
During_PIN
2001_CD
,_,
the_DT
Company_NN
recorded_VBD
a_DT
$_$
8.1_CD
million_CD
loss_NN
on_PIN
the_DT
sale_NN
of_PIN
its_PIT
manufacturing_GER
facility_NOMZ
in_PIN
Toronto_NN
,_,
Canada_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
with_PIN
BioChem_NN
,_,
the_DT
decision_NN
was_VBD [PASS]
made_VBN
to_TO
close_VB
the_DT
Toronto_NN
facility_NOMZ
and_CC
to_TO
eliminate_VB
duplicate_VB
positions_NOMZ
across_PLACE
the_DT
combined_VBN
organization_NOMZ
._.
The_DT
Companys_NN
existing_VBG [WZPRES]
Canadian_JJ
sales_NN
and_PHC
marketing_GER
operations_NOMZ
in_PIN
Toronto_NN
were_VBD [PASS]
combined_VBN
with_PIN
those_DEMO
of_PIN
BioChem_NN
in_PIN
Laval_NN
._.
During_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2001_CD
,_,
the_DT
Company_NN
disposed_VBD
of_PIN
certain_JJ
non-strategic_JJ
products_NN
for_PIN
net_JJ
proceeds_NN
of_PIN
approximately_RB
$_$
4.5_CD
million_CD
._.
A_DT
loss_NN
on_PIN
disposition_NOMZ
of_PIN
$_$
2.1_CD
million_CD
was_VBD [PASS]
recorded_VBN
in_PIN
operations_NOMZ
._.
4_CD
Accounting_GER
policy_NN
alignment_NOMZ
In_PIN
1998_CD
,_,
BioChem_NN
spun_VBD
off_PIN
its_PIT
investments_NOMZ
in_PIN
CliniChem_NN
to_PIN
its_PIT
shareholders_NN
._.
In_PIN
connection_NOMZ
with_PIN
this_DEMO
spin-off_PIN [STPR]
,_,
BioChem_NN
retained_VBD
rights_NN
in_PIN
CliniChem_NN
,_,
including_VBG [PRESP]
the_DT
option_NOMZ
to_TO
reacquire_VB
all_QUAN
shares_NN
in_PIN
CliniChem_NN
at_PIN
any_QUAN
time_NN
._.
Under_IN
EITF_NN
99-16_CD
,_,
this_DEMO
transaction_NOMZ
would_PRMD
result_VB
in_PIN
CliniChem_NN
continuing_VBG [WZPRES]
to_TO
be_VB [BYPA]
consolidated_VBN
by_PIN
BioChem_NN
,_,
as_IN
BioChem_NN
would_PRMD
have_VB
significant_JJ
continuing_VBG
involvement_NOMZ
in_PIN
the_DT
operation_NOMZ
of_PIN
CliniChem_NN
._.
However_CONJ
,_,
at_PIN
the_DT
time_NN
that_TOBJ
CliniChem_NN
was_VBD [PASS]
spun_VBN
off_PIN [STPR]
,_,
EITF_NN
99-16_CD
had_VBD [PEAS]
not_XX0
been_VBN [PASS]
issued_VBN
and_CC
BioChem_NN
elected_VBD
to_TO
fide-consolidate_VB
CliniChem_NN
,_,
an_DT
acceptable_JJ
accounting_GER
principle_NN
at_PIN
that_DEMO
time_NN
._.
The_DT
management_NOMZ
of_PIN
Shire_NN
believes_VPRT [PRIV]
that_THVC
its_PIT
accounting_GER
policies_NN
would_PRMD
have_VB [PEAS]
required_VBN [SUAV]
Shire_NN
to_TO
continue_VB
to_TO
consolidate_VB
CliniChem_NN
,_,
also_RB
an_DT
acceptable_JJ
accounting_GER
alternative_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
spin-off_PIN
and_CC
a_DT
policy_NN
that_TSUB
conforms_VPRT
with_PIN
the_DT
later_TIME
guidance_NN
issued_VBN
under_IN
EITF_NN
99-16_CD
._.
The_DT
effect_NN
of_PIN
this_DEMO
accounting_GER
policy_NN
alignment_NOMZ
is_VPRT
to_TO
reduce_VB
the_DT
net_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
previously_TIME
reported_VBN [PUBV]
by_PIN
BioChem_NN
now_TIME
included_VBD
in_PIN
the_DT
pooled_VBN
financial_JJ
statements_NOMZ
for_PIN
2000_CD
by_PIN
$_$
38.8_CD
million_CD
._.
On_PIN
15_CD
December_NN
2000_CD
BioChem_NN
reacquired_VBD
CliniChem_NN
._.
This_DEMO
acquisition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
accompanying_VBG
financial_JJ
statements_NOMZ
using_VBG [WZPRES]
purchase_NN
accounting_GER
._.
5_CD
Discontinued_VBN
operations_NOMZ
In_PIN
December_NN
1999_CD
the_DT
Company_NN
acquired_VBD
a_DT
group_NN
of_PIN
products_NN
,_,
collectively_RB
referred_VBD
to_PIN
as_IN
the_DT
OTC_NN
portfolio_NN
,_,
through_PIN
its_PIT
merger_NN
with_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
Roberts_NN
._.
The_DT
OTC_NN
portfolio_NN
consisted_VBD
of_PIN
non-prescription_JJ
laxatives_NN
and_CC
dietary_JJ
supplements_NOMZ
sold_VBN [WZPAST]
by_PIN
the_DT
Companys_NN
US_FPP1
operating_VBG [WZPRES]
segment_NOMZ
._.
As_IN
a_DT
specialty_NN
pharmaceuticals_NN
company_NN
that_TSUB
focuses_VPRT
on_PIN
prescription_NOMZ
only_DWNT
products_NN
,_,
this_DEMO
part_NN
of_PIN
the_DT
business_NOMZ
was_VBD [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
core_NN
part_NN
of_PIN
Shires_NN
long-term_JJ
strategy_NN
and_ANDC
hence_CONJ
the_DT
decision_NN
was_VBD [PASS]
made_VBN
to_TO
divest_VB
the_DT
OTC_NN
portfolio_NN
in_PIN
December_NN
2002_CD
._.
On_PIN
27_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
the_DT
OTC_NN
business_NOMZ
._.
The_DT
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
OTC_NN
business_NOMZ
as_IN
a_DT
discontinued_VBN
operation_NOMZ
for_PIN
all_QUAN
periods_NN
presented_VBN
._.
Operating_VBG
results_NN
of_PIN
the_DT
discontinued_VBN
operations_NOMZ
are_VPRT [PASS]
summarised_VBN
below_PLACE
._.
The_DT
amounts_NN
include_VPRT
income_NN
tax_NN
provisions_NN
based_VBN [WZPAST]
on_PIN
the_DT
stand-alone_JJ
results_NN
of_PIN
the_DT
OTC_NN
business_NOMZ
._.
There_EX
have_VPRT [PEAS]
been_VBN
no_SYNE
allocations_NOMZ
of_PIN
general_JJ
and_PHC
administrative_JJ
corporate_JJ
costs_NN
or_CC
interest_NN
expense_NN
related_VBN [WZPAST]
to_PIN
corporate_JJ
credit_NN
facilities_NOMZ
to_PIN
the_DT
discontinued_VBN
operation_NOMZ
._.
As_IN
the_DT
OTC_NN
business_NOMZ
functioned_VBD
within_PIN
Shire_NN
US_FPP1
,_,
which_WDT [SERE]
itself_PIT
essentially_RB
functions_NOMZ
as_IN
an_DT
independent_JJ
entity_NOMZ
,_,
no_SYNE
corporate_JJ
costs_NN
were_VBD [PASS]
eliminated_VBN
upon_PIN
discontinuance_NN
of_PIN
the_DT
operation_NOMZ
._.
Within_PIN
Shire_NN
US_FPP1
,_,
the_DT
OTC_NN
business_NOMZ
had_VBD
few_QUAN
dedicated_VBN
resources_NN
._.
All_QUAN
of_PIN
the_DT
products_NN
were_VBD [PASS]
manufactured_VBN
and_PHC
packaged_VBN
by_PIN
third-party_JJ
contract_NN
manufacturers_NN
._.
The_DT
products_NN
were_VBD [PASS]
distributed_VBN
through_PIN
a_DT
shared_VBN
warehouse_NN
facility_NOMZ
and_CC
sold_VBN
through_PIN
a_DT
small_JJ
sales_NN
team_NN
._.
62_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
5_CD
Discontinued_VBN
operations_NOMZ
continued_VBD
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Product_NN
sales_NN
24,010_CD
24,613_CD
23,456_CD
Cost_NN
of_PIN
product_NN
sales_NN
5,764_CD
6,279_CD
6,300_CD
Gross_NN
profit_NN
18,246_CD
18,334_CD
17,156_CD
Operating_GER
expenses_NN
:_:
Selling_VBG
,_,
general_JJ
and_PHC
administrative_JJ
8,550_CD
7,623_CD
6,073_CD
Operating_GER
income_NN
9,696_CD
10,711_CD
11,083_CD
Income_NN
taxes_NN
3,588_CD
3,963_CD
4,100_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
6,108_CD
6,748_CD
6,983_CD
Gain_NN
on_PIN
sale_NN
net_NN
of_PIN
tax_NN
2,083_CD
8,191_CD
6,748_CD
6,983_CD
The_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
discontinued_VBN
operation_NOMZ
are_VPRT [PASS]
summarised_VBN
below_PLACE
._.
31_CD
December_NN
31_CD
December_NN
31_CD
December_NN
2002 2001 2000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Current_JJ
assets_NN
:_:
Inventories_NN
1,779_CD
4,135_CD
Long-term_JJ
assets_NN
:_:
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
65,348_CD
67,340_CD
Deferred_JJ
tax_NN
liability_NOMZ
7,400_CD
6,354_CD
Total_JJ
long-term_JJ
assets_NN
57,948_CD
60,986_CD
Current_JJ
liabilities_NOMZ
:_:
Other_JJ
current_JJ
liabilities_NOMZ
12,784_CD
Total_JJ
current_JJ
liabilities_NOMZ
12,784_CD
Net_JJ
liabilities_NOMZ
assets_NN
12,784_CD
59,727_CD
65,121_CD
Included_VBN
in_PIN
the_DT
2002_CD
other_JJ
current_JJ
liabilities_NOMZ
are_VPRT
amounts_NN
for_PIN
ongoing_JJ
liabilities_NOMZ
that_TSUB
were_VBD [PASS]
not_XX0
transferred_VBN
to_PIN
the_DT
purchaser_NN
._.
6_CD
Marketable_JJ
securities_NOMZ
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Commercial_JJ
paper_NN
87,843_CD
246,174_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
228,283_CD
477,737_CD
316,126_CD
723,911_CD
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
Maturity_NOMZ
profile_NN
of_PIN
commercial_JJ
paper_NN
$_$
000_CD
$_$
000_CD
Less_RB
than_PIN
one_CD
month_NN
7,297_CD
168,678_CD
1-3_JJ
months_NN
12,981_CD
3-6_CD
months_NN
67,565_CD
77,496_CD
87,843_CD
246,174_CD
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
Maturity_NOMZ
profile_NN
of_PIN
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
$_$
000_CD
$_$
000_CD
Less_RB
than_PIN
one_CD
month_NN
63,600_CD
477,737_CD
1-3_JJ
months_NN
20,373_CD
3-6_CD
months_NN
45,090_CD
6-12_CD
months_NN
25,192_CD
More_EMPH
than_PIN
one_CD
year_NN
74,028_CD
228,283_CD
477,737_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
63_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
7_CD
Accounts_NN
receivable_NN
,_,
net_JJ
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Trade_NN
receivables_NN
130,210_CD
187,694_CD
Research_NN
and_PHC
development_NOMZ
contracts_NN
5,184_CD
3,998_CD
Other_JJ
receivables_NN
3,003_CD
2,221_CD
138,397_CD
193,913_CD
Trade_NN
receivables_NN
included_VBD
above_PLACE
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
a_DT
provision_NN
for_PIN
doubtful_JJ
debts_NN
of_PIN
$_$
0.8_CD
million_CD
31_CD
December_NN
2001_CD
:_:
$_$
1.1_CD
million_CD
._.
Included_VBN [PASTP]
within_PIN
trade_NN
receivables_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
is_VPRT
$_$
nil_CD
in_PIN
respect_NN
of_PIN
unearned_JJ
income_NN
relating_VBG [WZPRES]
to_PIN
ADDERALL_NN
XR_NN
product_NN
sales_NN
31_CD
December_NN
2001_CD
:_:
$_$
17.0_CD
million_CD
._.
Included_VBN [PASTP]
within_PIN
research_NN
and_PHC
development_NOMZ
contracts_NN
receivable_NN
are_VPRT
amounts_NN
due_JJ
in_PIN
respect_NN
of_PIN
an_DT
agreement_NOMZ
with_PIN
the_DT
Canadian_JJ
government_NOMZ
,_,
Technology_NN
Partnerships_NN
Canada_NN
TPC_NN
,_,
under_IN
which_WDT
a_DT
contribution_NOMZ
is_VPRT [PASS]
made_VBN
towards_PIN
certain_JJ
eligible_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
incurred_VBN [WZPAST]
by_PIN
Shires_NN
Canadian_NN
subsidiary_NN
,_,
Shire_NN
BioChem_NN
Inc._NN
._.
This_DEMP
was_VBD
$_$
1.0_CD
million_CD
at_PIN
31_CD
December_NN
2002_CD
._.
8_CD
Inventories_NN
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Finished_VBN
goods_NN
27,672_CD
18,101_CD
Work-in-process_JJ
13,716_CD
18,262_CD
Raw_NN
materials_NN
7,828_CD
8,548_CD
49,216_CD
44,911_CD
9_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Prepaid_NN
expenses_NN
14,558_CD
18,780_CD
Deferred_VBN
financing_GER
costs_NN
1,208_CD
1,077_CD
Income_NN
tax_NN
receivable_NN
12_CD
7,712_CD
Valued_VBN
added_VBD [PUBV]
taxes_NN
receivable_JJ
2,730_CD
5,407_CD
Other_JJ
current_JJ
assets_NN
12,282_CD
5,595_CD
30,790_CD
38,571_CD
The_DT
deferred_VBN
financing_GER
costs_NN
relate_VPRT
to_PIN
the_DT
$_$
400_CD
million_CD
convertible_JJ
loan_NN
note_NN
see_VPRT [PRIV]
note_NN
16_CD
._.
These_DEMO
costs_NN
are_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
ten_CD
years_NN
using_VBG [WZPRES]
the_DT
effective_JJ
interest_NN
rate_NN
method_NN
._.
10_CD
Investments_NOMZ
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Investments_NOMZ
in_PIN
private_JJ
companies_NN
47,255_CD
51,549_CD
Investments_NOMZ
in_PIN
public_JJ
companies_NN
14,129_CD
13,855_CD
Equity_NOMZ
method_NN
investments_NOMZ
10,578_CD
3,339_CD
71,962_CD
68,743_CD
64_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBD [PRIV] [THATD]
10_CD
Investments_NOMZ
continued_VBD
a_DT
Investments_NOMZ
in_PIN
private_JJ
companies_NN
i_FPP1
GeneChem_NN
funds_NN
We_FPP1
have_VPRT [PEAS]
made_VBN
investments_NOMZ
in_PIN
two_CD
venture_NN
capital_NN
funds_NN
._.
In_PIN
March_NN
1997_CD
,_,
we_FPP1
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
make_VB
an_DT
investment_NOMZ
of_PIN
CAN$_NN
30.0_CD
million_CD
in_PIN
the_DT
GeneChem_NN
Technologies_NN
Venture_NN
Fund_NN
L._NN
P._NN
a_DT
venture_NN
capital_NN
fund_NN
sponsored_VBN [WZPAST]
by_PIN
our_FPP1
subsidiary_NN
,_,
GeneChem_NN
Financial_NN
Corporation_NOMZ
._.
This_DEMO
CAN$_NN
100.0_CD
million_CD
fund_NN
invests_VPRT
in_PIN
advanced_JJ
academic_JJ
research_NN
projects_NN
and_CC
early-stage_JJ
private_JJ
or_CC
public_JJ
companies_NN
in_PIN
the_DT
area_NN
of_PIN
genomics_NN
and_CC
related_VBN
technologies_NN
for_PIN
human_JJ
application_NOMZ
._.
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
we_FPP1
have_VPRT [PEAS]
invested_VBN
CAN$_NN
27.0_CD
million_CD
in_PIN
the_DT
GeneChem_NN
Technologies_NN
Venture_NN
Fund_NN
L._NN
P._NN
and_CC
we_FPP1
are_VPRT
,_,
therefore_CONJ
,_,
committed_VBN
to_TO
investing_VBG
a_DT
further_JJ
$_$
1.9_CD
million_CD
CAN$_NN
3.0_CD
million_CD
into_PIN
this_DEMO
fund_NN
._.
In_PIN
September_NN
2000_CD
,_,
we_FPP1
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
invest_VB
CAN$_NN
15.0_CD
million_CD
in_PIN
the_DT
GeneChem_NN
Therapeutics_NN
Venture_NN
Fund_NN
L._NN
P._NN
which_WDT [WHSUB]
invests_VPRT
in_PIN
genomics_NN
companies_NN
focusing_VBG [WZPRES]
on_PIN
cancer_NN
and_CC
infectious_JJ
diseases_NN
._.
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
we_FPP1
have_VPRT [PEAS]
committed_VBN
to_TO
invest_VB
a_DT
further_JJ
$_$
4.3_CD
million_CD
CAN$_NN
6.8_CD
million_CD
in_PIN
the_DT
GeneChem_NN
Therapeutics_NN
Venture_NN
Fund_NN
L._NN
P._NN
The_NN
manager_NN
and_CC
general_JJ
partners_NN
of_PIN
these_DEMO
funds_NN
are_VPRT [BEMA]
fully-owned_JJ
subsidiaries_NN
of_PIN
the_DT
Company_NN
._.
These_DEMO
funds_NN
have_VPRT [PEAS]
not_XX0
been_VBN [BEMA]
consolidated_PRED
because_CAUS
the_DT
operational_JJ
substance_NN
of_PIN
the_DT
funds_NN
is_VPRT [BEMA]
such_OSUB
that_NULL
the_DT
other_JJ
partners_NN
have_VPRT
the_DT
ability_NOMZ
to_TO
veto_VB
investment_NOMZ
decisions_NN
._.
ii_FW
EGS_FW
healthcare_NN
funds_NN
In_PIN
November_NN
2000_CD
,_,
we_FPP1
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
invest_VB
up_RP
to_TO
$_$
10.0_CD
million_CD
in_PIN
various_JJ
EGS_NN
healthcare_NN
funds_NN
._.
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
we_FPP1
have_VPRT [PEAS]
invested_VBN
$_$
5.1_CD
million_CD
in_PIN
EGS_NN
healthcare_NN
funds_NN
and_CC
we_FPP1
are_VPRT
,_,
therefore_CONJ
,_,
committed_VBN
to_TO
invest_VB
a_DT
further_JJ
$_$
4.9_CD
million_CD
into_PIN
these_DEMO
funds_NN
._.
b_NN
Investments_NOMZ
in_PIN
public_JJ
companies_NN
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
there_EX
were_VBD
no_SYNE
new_JJ
investments_NOMZ
in_PIN
public_JJ
companies_NN
._.
In_PIN
July_NN
2002_CD
,_,
the_DT
Companys_NN
$_$
11.1_CD
million_CD
preference_NN
share_NN
investment_NOMZ
in_PIN
Immunogen_NN
Inc._NN
was_VBD [PASS]
converted_VBN
into_PIN
a_DT
common_JJ
stock_NN
holding_GER
._.
During_PIN
the_DT
year_NN
,_,
the_DT
Company_NN
wrote_VBD [PUBV]
down_RP
the_DT
cost_NN
of_PIN
investments_NOMZ
in_PIN
public_JJ
companies_NN
by_PIN
$_$
1.4_CD
million_CD
due_JJ
to_PIN
other-than-temporary_JJ
impairments_NOMZ
._.
This_DEMO
expense_NN
is_VPRT [PASS]
included_VBN
within_PIN
non-operating_JJ
other_JJ
expense_NN
income_NN
,_,
net_JJ
see_VPRT [PRIV]
note_NN
24_CD
._.
c_NN
Equity_NOMZ
method_NN
investments_NOMZ
The_DT
Company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
its_PIT
commercialisation_NOMZ
partnership_NN
with_PIN
GSK_NN
through_PIN
which_WDT [PIRE]
the_DT
products_NN
3TC_NN
and_PHC
ZEFFIX_NN
are_VPRT [PASS]
marketed_VBN
in_PIN
Canada_NN
using_VBG [WZPRES]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
._.
The_DT
Companys_NN
share_NN
of_PIN
the_DT
partnership_NN
is_VPRT [PASS]
included_VBN
within_PIN
Equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
and_CC
the_DT
related_JJ
equity_NOMZ
investment_NOMZ
of_PIN
$_$
2.9_CD
million_CD
is_VPRT [PASS]
included_VBN
above_PLACE
._.
In_PIN
September_NN
2002_CD
,_,
the_DT
Company_NN
sold_VBD
the_DT
net_JJ
assets_NN
of_PIN
its_PIT
CADx_NN
group_NN
of_PIN
companies_NN
,_,
to_PIN
Qualia_NN
Computing_GER
Inc._NN
in_PIN
exchange_NN
for_PIN
shares_NN
in_PIN
a_DT
newly_RB
formed_VBN
joint_JJ
venture_NN
._.
The_DT
common_JJ
stock_NN
of_PIN
the_DT
joint_JJ
venture_NN
,_,
Qualia_NN
Computing_GER
Inc._NN
is_VPRT [BEMA]
50_CD
%_NN
owned_VBN [WZPAST]
by_PIN
Shire_NN
._.
The_DT
initial_JJ
value_NN
of_PIN
the_DT
investment_NOMZ
was_VBD [BEMA]
equal_PRED
to_PIN
the_DT
book_NN
value_NN
of_PIN
assets_NN
sold_VBN
,_,
therefore_CONJ
,_,
no_SYNE
gain_NN
or_CC
loss_NN
was_VBD [PASS]
recognized_VBN [PRIV]
._.
The_DT
Company_NN
has_VPRT [PEAS]
applied_VBN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
as_IN
the_DT
Company_NN
owns_VPRT
but_CC
does_VPRT
not_XX0
exercise_VB
control_NN
over_IN
its_PIT
50_CD
%_NN
share_NN
of_PIN
the_DT
joint_JJ
venture_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
the_DT
Companys_NN
investment_NOMZ
is_VPRT [PASS]
valued_VBN
at_PIN
cost_NN
,_,
adjusted_VBN [PASTP]
for_PIN
its_PIT
share_NN
of_PIN
the_DT
earnings_GER
or_CC
losses_NN
of_PIN
the_DT
joint_JJ
venture_NN
._.
The_DT
Companys_NN
share_NN
of_PIN
the_DT
partnership_NN
is_VPRT [PASS]
included_VBN
within_PIN
Equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
and_CC
the_DT
related_JJ
equity_NOMZ
investment_NOMZ
of_PIN
$_$
7.7_CD
million_CD
is_VPRT [PASS]
included_VBN
above_PLACE
._.
There_EX
is_VPRT
no_SYNE
significant_JJ
difference_NN
between_PIN
the_DT
amount_NN
at_PIN
which_WDT [PIRE]
the_DT
investment_NOMZ
is_VPRT [PASS]
carried_VBN
and_CC
the_DT
amount_NN
of_PIN
the_DT
underlying_VBG
equity_NOMZ
in_PIN
net_JJ
assets_NN
of_PIN
the_DT
joint_JJ
venture_NN
._.
11_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Land_NN
and_PHC
buildings_GER
111,164_CD
95,921_CD
Office_NN
furniture_NN
,_,
fittings_GER
and_PHC
equipment_NOMZ
31,210_CD
12,659_CD
Warehouse_NN
,_,
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
46,706_CD
46,613_CD
189,080_CD
155,193_CD
Less_RB
:_:
Accumulated_VBN
depreciation_NOMZ
53,846_CD
41,846_CD
135,234_CD
113,347_CD
Depreciation_NOMZ
expense_NN
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
was_VBD
$_$
12.9_CD
million_CD
,_,
$_$
14.4_CD
million_CD
and_CC
$_$
10.7_CD
million_CD
respectively_RB
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
65_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
12_CD
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
businesses_NOMZ
acquired_VBN
254,207_CD
220,890_CD
Less_RB
:_:
accumulated_VBN
amortisation_NOMZ
50,440_CD
45,549_CD
203,767_CD
175,341_CD
Other_JJ
intangible_JJ
assets_NN
acquired_VBN
397,807_CD
379,986_CD
Less_RB
:_:
accumulated_VBN
amortisation_NOMZ
96,723_CD
71,631_CD
301,084_CD
308,355_CD
Total_JJ
504,851_CD
483,696_CD
The_DT
increase_NN
decrease_NN
in_PIN
the_DT
net_JJ
book_NN
value_NN
of_PIN
goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
,_,
2002_CD
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
Other_JJ
intangible_JJ
Goodwill_NN
assets_NN
$_$
000_CD
$_$
000_CD
Year_NN
ended_VBD
31_CD
December_NN
2002_CD
As_IN
at_PIN
1_CD
January_NN
2002_CD
175,341_CD
308,355_CD
Acquisitions_NOMZ
10,175_CD
23,467_CD
Amortisation_NOMZ
charged_VBD
23,493_CD
Asset_NN
impairments_NOMZ
18,777_CD
Foreign_JJ
currency_NN
translation_NOMZ
18,251_CD
11,532_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
203,767_CD
301,084_CD
The_DT
acquisition_NOMZ
of_PIN
goodwill_NN
is_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
APS_NN
see_VPRT [PRIV]
note_NN
3_CD
._.
Acquisitions_NOMZ
of_PIN
other_JJ
intangible_JJ
assets_NN
primarily_RB
related_VBN
to_PIN
SOLARAZE_NN
._.
The_DT
Company_NN
acquired_VBD
the_DT
exclusive_JJ
rights_NN
to_TO
manufacture_VB
,_,
distribute_VB
and_PHC
sell_VB
SOLARAZE_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
actinic_JJ
keratosis_NN
from_PIN
SkyePharma_NN
PLC._NN
._.
In_PIN
May_POMD
2002_CD
,_,
the_DT
Company_NN
paid_VBD
$_$
18.9_CD
million_CD
12.9_CD
million_CD
in_PIN
respect_NN
of_PIN
certain_JJ
European_JJ
territories_NN
,_,
followed_VBD
in_PIN
December_NN
2002_CD
by_PIN
a_DT
further_JJ
$_$
1.2_CD
million_CD
0.7_CD
million_CD
in_PIN
respect_NN
of_PIN
the_DT
rights_NN
for_PIN
Australia_NN
,_,
New_NN
Zealand_NN
,_,
South_NN
Africa_NN
and_CC
certain_JJ
other_JJ
countries_NN
in_PIN
the_DT
Pacific_NN
Rim_NN
._.
Amortisation_NOMZ
charged_VBD
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
was_VBD
$_$
23.5_CD
million_CD
,_,
$_$
31.4_CD
million_CD
and_CC
$_$
27.3_CD
million_CD
respectively_RB
._.
Goodwill_NN
was_VBD [SPAU] [PASS]
no_RB
longer_RB
amortised_VBN
with_PIN
effect_NN
from_PIN
1_CD
January_NN
2002_CD
following_VBG
the_DT
implementation_NOMZ
of_PIN
SFAS_NN
No._NN
._.
142_CD
As_IN
described_VBN
in_PIN
note_NN
2_CD
,_,
the_DT
Company_NN
adopted_VBN
SFAS_NN
No._NN
._.
A_DT
transitional_JJ
assessment_NOMZ
of_PIN
goodwill_NN
impairment_NOMZ
as_IN
of_PIN
1_CD
January_NN
2002_CD
was_VBD [BYPA]
completed_VBN
by_PIN
30_CD
June_NN
2002_CD
._.
Management_NOMZ
concluded_VBD [PRIV]
that_THVC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Companys_NN
individual_JJ
reporting_VBG [PUBV] [THATD]
units_NN
exceeded_VBD
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
net_JJ
assets_NN
including_VBG [WZPRES]
goodwill_NN
,_,
and_ANDC
hence_CONJ
this_DEMO
process_NN
did_VBD
not_XX0
result_VB
in_PIN
any_QUAN
impairment_NOMZ
to_TO
be_VB [PASS]
recorded_VBN
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
The_DT
Company_NN
completed_VBD
a_DT
second_JJ
goodwill_NN
impairment_NOMZ
review_NN
as_IN
of_PIN
30_CD
September_NN
2002_CD
and_CC
found_VBD [PRIV]
that_THVC
no_DT
adjusting_VBG
entries_NN
were_VBD [BEMA]
necessary_PRED
._.
A_DT
reconciliation_NOMZ
table_NN
is_VPRT [PASS]
provided_VBN
below_PLACE
to_TO
exclude_VB
the_DT
effect_NN
of_PIN
goodwill_NN
amortisation_NOMZ
in_PIN
accordance_NN
with_PIN
the_DT
transitional_JJ
disclosures_NN
relating_VBG [WZPRES]
to_PIN
SFAS_NN
No._NN
._.
Results_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
66_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
12_CD
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
continued_VBD
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
items_NN
as_IN
reported_VBN [PUBV]
242,378_CD
34,615_CD
204,744_CD
Add-back_NN
of_PIN
goodwill_NN
amortisation_NOMZ
charge_NN
10,763_CD
11,324_CD
Adjusted_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
items_NN
242,378_CD
45,378_CD
216,068_CD
Net_JJ
income_NN
as_IN
reported_VBN [PUBV]
250,569_CD
38,759_CD
211,727_CD
Add-back_NN
of_PIN
goodwill_NN
amortisation_NOMZ
charge_NN
10,763_CD
11,324_CD
Adjusted_VBN
net_JJ
income_NN
for_PIN
basic_JJ
earnings_GER
per_PIN
share_NN
250,569_CD
49,522_CD
223,051_CD
Interest_NN
charged_VBN [WZPAST]
on_PIN
convertible_JJ
debt_NN
,_,
net_NN
of_PIN
tax_NN
5,585_CD
Adjusted_VBN
net_JJ
income_NN
for_PIN
diluted_JJ
earnings_GER
per_PIN
share_NN
256,154_CD
49,522_CD
223,051_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
in_PIN
$_$
:_:
Net_JJ
income_NN
as_IN
reported_VBN [PUBV]
50.0_CD
7.9_CD
43.8_CD
Add-back_JJ
goodwill_NN
amortisation_NOMZ
charge_NN
2.2_CD
2.3_CD
Adjusted_VBN
net_JJ
income_NN
50.0_CD
10.1_CD
46.1_CD
Diluted_VBN
earnings_GER
per_PIN
share_NN
in_PIN
$_$
:_:
Net_JJ
income_NN
as_IN
reported_VBN [PUBV]
49.0_CD
7.7_CD
42.8_CD
Add-back_JJ
goodwill_NN
amortisation_NOMZ
charge_NN
2.1_CD
2.3_CD
Interest_NN
charged_VBN [WZPAST]
on_PIN
convertible_JJ
debt_NN
,_,
net_NN
of_PIN
tax_NN
0.1_CD
Adjusted_VBN
net_JJ
income_NN
49.1_CD
9.8_CD
45.1_CD
Number_NN
Number_NN
Number_NN
of_PIN
shares_NN
of_PIN
shares_NN
of_PIN
shares_NN
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
:_:
Basic_JJ
500,687,594_CD
492,594,226_CD
482,890,070_CD
Diluted_NN
522,418,246_CD
504,875,587_CD
494,691,805_CD
There_EX
is_VPRT
no_SYNE
tax_NN
effect_NN
related_VBN [WZPAST]
to_PIN
the_DT
goodwill_NN
amortisation_NOMZ
disclosed_VBN [PUBV]
above_PLACE
._.
The_DT
useful_JJ
economic_JJ
lives_NN
of_PIN
all_QUAN
intangible_JJ
assets_NN
that_TSUB
continue_VPRT
to_TO
be_VB [PASS]
amortised_VBN
under_IN
SFAS_NN
No._NN
._.
Management_NOMZ
estimates_VPRT [PRIV]
that_THVC
the_DT
annual_JJ
amortisation_NOMZ
charges_NN
in_PIN
respect_NN
of_PIN
intangible_JJ
fixed_JJ
assets_NN
held_VBN [PRIV] [WZPAST]
at_PIN
31_CD
December_NN
2002_CD
will_PRMD
be_VB
approximately_RB
$_$
13.2_CD
million_CD
for_PIN
each_QUAN
of_PIN
the_DT
five_CD
years_NN
to_PIN
31_CD
December_NN
2007_CD
._.
Estimated_VBN [PRIV]
amortisation_NOMZ
expense_NN
can_POMD
be_VB [BYPA]
affected_VBN
by_PIN
various_JJ
factors_NN
including_VBG [WZPRES]
future_JJ
acquisitions_NOMZ
and_PHC
disposals_NN
of_PIN
product_NN
rights_NN
._.
The_DT
net_JJ
book_NN
value_NN
of_PIN
goodwill_NN
by_PIN
operating_VBG
segment_NOMZ
is_VPRT
as_IN
follows_VPRT
:_:
US_FPP1
International_NN
R&D_NN
Total_NN
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000 2002 174_CD
,617_CD
29,150_CD
203,767_CD
2001_CD
148,660_CD
26,681_CD
175,341_CD
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
acquired_VBD
exclusive_JJ
rights_NN
to_TO
manufacture_VB
,_,
distribute_VB
and_PHC
sell_VB
SOLARAZE_NN
in_PIN
certain_JJ
countries_NN
._.
The_DT
purchase_NN
cost_NN
was_VBD
$_$
20.1_CD
million_CD
._.
The_DT
amortisation_NOMZ
period_NN
in_PIN
respect_NN
of_PIN
this_DEMO
product_NN
is_VPRT [BEMA]
ten_CD
years_NN
._.
13_CD
Other_JJ
non-current_JJ
assets_NN
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Deferred_VBN
financing_GER
costs_NN
7,915_CD
8,617_CD
SERP_NN
investment_NOMZ
12,070_CD
14,367_CD
Other_JJ
assets_NN
3,279_CD
3,184_CD
23,264_CD
26,168_CD
The_DT
deferred_VBN
financing_GER
costs_NN
at_PIN
31_CD
December_NN
2002_CD
and_CC
2001_CD
were_VBD [BEMA]
in_PIN
respect_NN
of_PIN
the_DT
$_$
400_CD
million_CD
convertible_JJ
loan_NN
note_NN
._.
These_DEMO
costs_NN
are_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
ten_CD
years_NN
._.
The_DT
current_JJ
element_NOMZ
of_PIN
these_DEMO
costs_NN
is_VPRT [PASS]
included_VBN
within_PIN
prepaid_JJ
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
note_VPRT [PRIV]
9_CD
._.
Further_JJ
details_NN
of_PIN
the_DT
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
investment_NOMZ
are_VPRT [PASS]
provided_VBN
in_PIN
note_NN
25_CD
._.
The_DT
amount_NN
shown_VBN [PRIV]
above_PLACE
is_VPRT [BEMA]
the_DT
cash_NN
surrender_NN
value_NN
of_PIN
life_NN
insurance_NN
policies_NN
which_WDT [WHSUB]
is_VPRT [BYPA]
backed_VBN
by_PIN
marketable_JJ
securities_NOMZ
._.
A_DT
liability_NOMZ
of_PIN
$_$
8.4_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
note_NN
17_CD
2001_CD
:_:
$_$
11.3_CD
million_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
67_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
14_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Trade_NN
accounts_NN
payable_JJ
46,912_CD
51,952_CD
Accrued_VBN
rebates_NN
and_PHC
charge-backs_NN
45,919_CD
41,086_CD
Accrued_VBN
expenses_NN
91,276_CD
74,114_CD
184,107_CD
167,152_CD
15_CD
Other_JJ
current_JJ
liabilities_NOMZ
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Income_NN
taxes_NN
payable_JJ
5,440_CD
25,604_CD
Payable_JJ
for_PIN
termination_NOMZ
of_PIN
licence_NN
agreement_NOMZ
738_CD
Interest_NN
on_PIN
long-term_JJ
debt_NN
2,893_CD
2,928_CD
Social_NN
security_NOMZ
liabilities_NOMZ
1,934_CD
7,237_CD
Value_NN
added_VBD [PUBV]
taxes_NN
1,957_CD
1,148_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
3,268_CD
5,075_CD
15,492_CD
42,730_CD
16_CD
Long-term_JJ
debt_NN
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Total_JJ
obligations_NOMZ
408,190_CD
406,806_CD
Current_JJ
maturities_NOMZ
of_PIN
long-term_JJ
obligations_NOMZ
888_CD
4,325_CD
Total_JJ
long-term_JJ
debt_NN
407,302_CD
402,481_CD
An_DT
analysis_NN
of_PIN
total_JJ
obligations_NOMZ
by_PIN
loan_NN
type_NN
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Convertible_JJ
notes_NN
due_JJ
2011_CD
400,000_CD
400,000_CD
Unsecured_JJ
convertible_JJ
zero_CD
coupon_NN
loan_NN
notes_NN
1,450_CD
Canadian_JJ
provincial_JJ
and_PHC
federal_JJ
government_NOMZ
loan_NN
1,880_CD
3,100_CD
Bank_NN
term_NN
loans_NN
2,256_CD
Capital_NN
leases_NN
6,310_CD
408,190_CD
406,806_CD
Principal_NN
payments_NOMZ
in_PIN
each_QUAN
of_PIN
the_DT
next_JJ
five_CD
years_NN
and_CC
thereafter_RB
on_PIN
total_JJ
obligations_NOMZ
outstanding_JJ
at_PIN
31_CD
December_NN
2002_CD
amount_NN
to_TO
:_:
31_CD
December_NN
2002_CD
$_$
000 2003 888 2004_CD
400,897_CD
2005 863 2006 254_CD
2007_CD
272_CD
Thereafter_RB
5,016_CD
408,190_CD
The_DT
principal_NN
payments_NOMZ
presented_VBN
above_PLACE
have_VPRT [PEAS]
been_VBN [PASS]
calculated_VBN [PRIV]
on_PIN
the_DT
basis_NN
that_TOBJ
the_DT
$_$
400_CD
million_CD
convertible_JJ
notes_NN
due_JJ
2011_CD
convert_VPRT
to_PIN
common_JJ
shares_NN
or_CC
will_PRMD
be_VB [PASS]
paid_VBN
as_IN
cash_NN
at_PIN
the_DT
earliest_JJ
opportunity_NOMZ
,_,
which_WDT [SERE]
is_VPRT [BEMA]
21_CD
August_NN
2004_CD
._.
Further_JJ
details_NN
in_PIN
respect_NN
of_PIN
the_DT
convertible_JJ
notes_NN
are_VPRT [PASS]
presented_VBN
below_PLACE
._.
68_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBD [PRIV] [THATD]
16_CD
Long-term_JJ
debt_NN
continued_VBD
i_FPP1
Convertible_JJ
notes_NN
due_JJ
2011_CD
The_DT
$_$
400.0_CD
million_CD
of_PIN
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
were_VBD [PASS]
issued_VBN
in_PIN
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
._.
On_PIN
or_CC
after_IN
21_CD
August_NN
2004_CD
,_,
the_DT
Company_NN
may_POMD
redeem_VB
,_,
for_PIN
cash_NN
,_,
all_QUAN
or_CC
part_NN
of_PIN
the_DT
notes_NN
providing_VBG [WZPRES]
the_DT
ordinary_JJ
share_NN
price_NN
has_VPRT [PEAS]
exceeded_VBN
$_$
26.20_CD
sterling_GER
equivalent_NN
at_PIN
the_DT
time_NN
for_PIN
20_CD
of_PIN
the_DT
30_CD
consecutive_JJ
dealing_VBG
days_NN
in_PIN
the_DT
period_NN
prior_RB
to_PIN
redemption_NOMZ
._.
The_DT
decision_NN
as_IN
to_PIN
whether_IN
a_DT
note_NN
holder_NN
should_NEMD
exercise_VB
a_DT
put_NN
option_NOMZ
will_PRMD
depend_VB
on_PIN
a_DT
number_NN
of_PIN
factors_NN
particularly_RB
the_DT
price_NN
of_PIN
Shire_NN
stock_NN
at_PIN
the_DT
put_JJ
date_NN
and_CC
the_DT
likelihood_NN
of_PIN
the_DT
Companys_NN
stock_NN
price_NN
exceeding_VBG [WZPRES]
the_DT
conversion_NN
threshold_NN
price_NN
._.
The_DT
conversion_NN
threshold_NN
price_NN
is_VPRT [BEMA]
equivalent_PRED
to_TO
$_$
20.15_CD
or_CC
12.52_CD
at_PIN
the_DT
closing_GER
exchange_NN
rate_NN
for_PIN
2002_CD
for_PIN
Shire_NN
common_JJ
shares_NN
and_CC
$_$
60.46_CD
for_PIN
Shire_NN
ADSs_NN
._.
If_COND
the_DT
price_NN
of_PIN
Shire_NN
common_JJ
shares_NN
at_PIN
the_DT
first_JJ
put_JJ
date_NN
of_PIN
21_CD
August_NN
2004_CD
remains_VPRT
at_PIN
a_DT
level_NN
similar_JJ
to_PIN
the_DT
year-end_JJ
price_NN
of_PIN
3.97_CD
$_$
18.89_CD
for_PIN
Shire_NN
ADSs_NN
it_PIT
is_VPRT [BEMA]
quite_RB
possible_PRED
that_THAC
note_NN
holders_NN
will_PRMD
choose_VB
to_TO
exercise_VB
their_TPP3
put_JJ
options_NOMZ
._.
The_DT
Company_NN
currently_RB
has_VPRT
adequate_JJ
resources_NN
from_PIN
which_WDT [PIRE]
it_PIT
could_POMD
satisfy_VB
repayment_NOMZ
of_PIN
the_DT
entire_JJ
convertible_JJ
debt_NN
principal_NN
of_PIN
$_$
400.0_CD
million_CD
._.
The_DT
interest_NN
expense_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
was_VBD
$_$
8.0_CD
million_CD
2001_CD
:_:
$_$
2.9_CD
million_CD
._.
ii_FW
Unsecured_JJ
convertible_JJ
zero_CD
coupon_NN
loan_NN
notes_VPRT [PRIV] [THATD]
The_DT
Company_NN
financed_VBN
the_DT
purchase_NN
of_PIN
intellectual_JJ
property_NN
relating_VBG [WZPRES]
to_PIN
the_DT
manufacture_NN
of_PIN
ADDERALL_NN
from_PIN
Arenol_NN
Corporation_NOMZ
by_PIN
a_DT
total_NN
of_PIN
$_$
11.8_CD
million_CD
in_PIN
loan_NN
notes_NN
._.
On_PIN
5_CD
March_NN
1999_CD
the_DT
Company_NN
issued_VBD
a_DT
$_$
5.8_CD
million_CD
principal_JJ
amount_NN
unsecured_JJ
convertible_JJ
zero_CD
coupon_NN
loan_NN
note_NN
due_JJ
30_CD
July_NN
2001_CD
the_DT
First_NN
Loan_NN
Note_NN
and_CC
a_DT
$_$
6.0_CD
million_CD
principal_JJ
amount_NN
unsecured_JJ
convertible_JJ
zero_CD
coupon_NN
loan_NN
note_NN
due_JJ
30_CD
July_NN
2004_CD
the_DT
Second_JJ
Loan_NN
Note_NN
._.
Both_DT
loan_NN
notes_NN
were_VBD [BEMA]
in_PIN
the_DT
name_NN
of_PIN
the_DT
parent_NN
company_NN
,_,
Shire_NN
._.
The_DT
agreement_NOMZ
provided_VBN [WZPAST]
for_PIN
the_DT
cancellation_NOMZ
of_PIN
certain_JJ
specified_VBN
amounts_NN
of_PIN
the_DT
aggregate_NN
principal_NN
amount_NN
of_PIN
the_DT
First_NN
Loan_NN
Note_NN
and_CC
of_PIN
such_JJ
amounts_NN
of_PIN
the_DT
Second_JJ
Loan_NN
Note_NN
on_PIN
certain_JJ
dates_NN
to_PIN
the_DT
extent_NN
of_PIN
certain_JJ
indemnified_JJ
losses_NN
or_CC
,_,
to_PIN
the_DT
extent_NN
that_TOBJ
such_JJ
amounts_NN
of_PIN
the_DT
First_NN
Loan_NN
Note_NN
or_CC
the_DT
Second_JJ
Loan_NN
Note_NN
together_RB
the_DT
Loan_NN
Notes_NN
were_VBD [PASS]
not_XX0
so_RB
canceled_VBN
,_,
for_PIN
their_TPP3
conversion_NN
into_PIN
common_JJ
shares_NN
._.
The_DT
number_NN
of_PIN
common_JJ
shares_NN
was_VBD [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
amount_NN
not_XX0
canceled_VBN
by_PIN
the_DT
lower_JJ
of_PIN
3.565_CD
approximately_RB
$_$
5.75_CD
and_CC
the_DT
midweek_JJ
closing_GER
price_NN
of_PIN
the_DT
common_JJ
shares_NN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
on_PIN
the_DT
relevant_JJ
date_NN
._.
Translation_NOMZ
from_PIN
pounds_NN
sterling_GER
to_PIN
US_FPP1
dollars_NN
was_VBD [PASS]
made_VBN
using_VBG
the_DT
exchange_NN
rate_NN
on_PIN
the_DT
relevant_JJ
date_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
issued_VBN
common_JJ
shares_NN
to_PIN
Arenol_NN
Corporation_NOMZ
or_CC
its_PIT
nominee_NN
broker_NN
,_,
as_IN
set_VBN
out_PIN
in_PIN
the_DT
table_NN
below_PLACE
,_,
in_PIN
consideration_NOMZ
of_PIN
the_DT
conversion_NN
of_PIN
each_QUAN
of_PIN
the_DT
Loan_NN
Notes_NN
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
there_EX
is_VPRT
no_SYNE
liability_NOMZ
remaining_VBG [WZPRES]
._.
Number_NN
of_PIN
common_JJ
Date_NN
of_PIN
conversion_NN
shares_NN
issued_VBD
$_$
000_CD
13_CD
March_NN
2000_CD
533,279_CD
3,000_CD
3_CD
August_NN
2000_CD
560,076_CD
2,800_CD
6_CD
November_NN
2000_CD
541,478_CD
3,000_CD
30_CD
July_NN
2001_CD
295,061_CD
1,500_CD
6_CD
August_NN
2002_CD
267,572_CD
1,500_CD
2,197,466_CD
11,800_CD
iii_FW
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
The_DT
Company_NN
has_VPRT
a_DT
Canadian_JJ
federal_JJ
and_PHC
provincial_JJ
government_NOMZ
loan_NN
outstanding_JJ
of_PIN
$_$
1.9_CD
million_CD
CAN$_NN
3.0_CD
million_CD
._.
This_DEMO
facility_NOMZ
is_VPRT [BEMA]
non-interestbearing_PRED
and_CC
is_VPRT [BEMA]
repayable_PRED
in_PIN
annual_JJ
instalments_NOMZ
of_PIN
$_$
0.6_CD
million_CD
CAN$_NN
1.0_CD
million_CD
._.
iv_NN
Bank_NN
term_NN
loans_NN
The_DT
Company_NN
had_VBD
a_DT
bank_NN
term_NN
loan_NN
at_PIN
31_CD
December_NN
2001_CD
bearing_GER
interest_NN
at_PIN
the_DT
lenders_NN
prime_JJ
rate_NN
,_,
which_WDT [SERE]
was_VBD [BYPA]
secured_VBN
by_PIN
a_DT
charge_NN
on_PIN
land_NN
and_PHC
buildings_GER
._.
The_DT
final_JJ
payment_NOMZ
in_PIN
respect_NN
of_PIN
this_DEMO
loan_NN
was_VBD [PASS]
made_VBN
in_PIN
May_POMD
2002_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
69_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBD [PRIV] [THATD]
16_CD
Long-term_JJ
debt_NN
continued_VBD
v_NN
Capital_NN
leases_VPRT
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
Obligations_NOMZ
under_IN
capital_NN
leases_NN
$_$
000_CD
$_$
000_CD
Current_JJ
261_CD
Non-current_JJ
6,049_CD
6,310_CD
The_DT
following_GER
is_VPRT [BEMA]
an_DT
analysis_NN
of_PIN
the_DT
leased_VBN
property_NN
under_IN
capital_NN
leases_NN
by_PIN
major_JJ
asset_NN
classes_NN
:_:
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
Classes_NN
of_PIN
property_NN
$_$
000_CD
$_$
000_CD
Land_NN
and_PHC
buildings_GER
6,259_CD
Office_NN
furniture_NN
,_,
fittings_GER
and_PHC
equipment_NOMZ
160_CD
6,419_CD
Less_RB
:_:
accumulated_VBN
depreciation_NOMZ
126_CD
6,293_CD
The_DT
following_GER
is_VPRT [BEMA]
a_DT
schedule_NN
by_PIN
years_NN
of_PIN
future_JJ
minimum_NN
lease_NN
payments_NOMZ
under_IN
capital_NN
leases_NN
together_RB
with_PIN
the_DT
present_JJ
value_NN
of_PIN
the_DT
net_JJ
minimum_NN
lease_NN
payments_NOMZ
as_IN
of_PIN
31_CD
December_NN
2002_CD
._.
31_CD
December_NN
2002_CD
$_$
000 2003 261 2004_CD
270 2005 237 2006_CD
254 2007 272_CD
Thereafter_RB
5,016_CD
6,310_CD
17_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
SERP_NN
note_NN
25_CD
8,364_CD
11,348_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
6,520_CD
2,297_CD
14,884_CD
13,645_CD
18_CD
Financial_NN
instruments_NOMZ
The_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
the_DT
Companys_NN
financial_JJ
instruments_NOMZ
at_PIN
31_CD
December_NN
is_VPRT [PASS]
summarised_VBN
below_PLACE
._.
Certain_JJ
estimates_NN
and_PHC
judgements_NOMZ
were_VBD [PASS]
required_VBN [SUAV]
to_TO
develop_VB
the_DT
fair_JJ
value_NN
amounts_NN
._.
The_DT
fair_JJ
value_NN
amounts_NN
shown_VBN [PRIV]
below_PLACE
are_VPRT
not_XX0
necessarily_RB
indicative_PRED
of_PIN
the_DT
amounts_NN
that_TOBJ
the_DT
Company_NN
would_PRMD
realize_VB [PRIV]
upon_PIN
disposition_NOMZ
nor_SYNE
do_VPRT
they_TPP3
indicate_VPRT [PRIV]
the_DT
Companys_NN
intent_NN
or_CC
ability_NOMZ
to_TO
dispose_VB
of_PIN
the_DT
financial_JJ
instrument_NOMZ
._.
The_DT
following_VBG
methods_NN
and_PHC
assumptions_NOMZ
were_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
each_QUAN
material_NN
class_NN
of_PIN
financial_JJ
instrument_NOMZ
:_:
Marketable_JJ
securities_NOMZ
the_DT
carrying_GER
value_NN
of_PIN
marketable_JJ
securities_NOMZ
approximates_VPRT
fair_JJ
value_NN
because_CAUS
of_PIN
the_DT
short-term_JJ
nature_NN
of_PIN
these_DEMO
investments_NOMZ
._.
Investments_NOMZ
non-current_JJ
investments_NOMZ
with_PIN
readily_RB
determinable_JJ
market_NN
values_NN
are_VPRT [PASS]
marked_VBN
to_PIN
market_NN
._.
Long-term_JJ
debt_NN
the_DT
fair_JJ
value_NN
of_PIN
long-term_JJ
debt_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
based_VBN
on_PIN
the_DT
discounted_JJ
future_JJ
cash_NN
flows_VPRT
using_VBG
currently_RB
available_JJ
interest_NN
rates_NN
or_CC
,_,
where_RB
the_DT
debt_NN
instrument_NOMZ
is_VPRT [PASS]
traded_VBN
,_,
by_PIN
reference_NN
to_PIN
the_DT
market_NN
price_NN
._.
70_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
18_CD
Financial_NN
instruments_NOMZ
continued_VBD
The_DT
carrying_VBG
amounts_NN
and_CC
corresponding_JJ
fair_JJ
values_NN
of_PIN
financial_JJ
instruments_NOMZ
at_PIN
31_CD
December_NN
2002_CD
and_CC
2001_CD
were_VBD
as_IN
follows_VPRT
:_:
Carrying_VBG
amount_NN
Fair_NN
value_NN
$_$
000_CD
$_$
000_CD
31_CD
December_NN
2002_CD
Financial_NN
assets_NN
:_:
Commercial_JJ
paper_NN
87,843_CD
87,843_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
228,283_CD
228,283_CD
Investments_NOMZ
14,129_CD
14,129_CD
Financial_NN
liabilities_NOMZ
:_:
Long-term_JJ
debt_NN
408,190_CD
376,883_CD
31_CD
December_NN
2001_CD
Financial_NN
assets_NN
:_:
Commercial_JJ
paper_NN
246,174_CD
246,174_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
477,737_CD
477,737_CD
Investments_NOMZ
13,855_CD
13,855_CD
Financial_NN
liabilities_NOMZ
:_:
Long-term_JJ
debt_NN
406,806_CD
394,206_CD
19_CD
Leases_NN
and_CC
other_JJ
commitments_NOMZ
a_DT
Leases_NN
The_NN
Company_NN
leases_VPRT
facilities_NOMZ
,_,
motor_NN
vehicles_NN
and_CC
certain_JJ
office_NN
equipment_NOMZ
under_IN
operating_VBG
leases_NN
._.
The_DT
Companys_NN
commitments_NOMZ
under_IN
the_DT
noncancellable_JJ
portion_NOMZ
of_PIN
all_QUAN
operating_VBG
leases_NN
for_PIN
the_DT
next_JJ
five_CD
years_NN
and_CC
thereafter_RB
as_IN
of_PIN
31_CD
December_NN
2002_CD
are_VPRT
as_IN
follows_VPRT
:_:
31_CD
December_NN
2002_CD
$_$
000_CD
2003_CD
7,215_CD
2004_CD
7,887_CD
2005_CD
5,855_CD
2006_CD
4,085_CD
2007_CD
3,038_CD
Thereafter_RB
12,805_CD
40,885_CD
Lease_NN
and_CC
rental_JJ
expense_NN
included_VBD
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
in_PIN
the_DT
accompanying_VBG
statements_NOMZ
of_PIN
operations_NOMZ
amounted_VBD
to_TO
$_$
6.7_CD
million_CD
,_,
$_$
6.1_CD
million_CD
and_CC
$_$
4.3_CD
million_CD
for_PIN
the_DT
fiscal_JJ
years_NN
ended_VBN
31_CD
December_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
respectively_RB
._.
b_NN
Contingent_JJ
liabilities_NOMZ
i_FPP1
Commitments_NOMZ
The_NN
Company_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
subscribe_VB
to_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totalling_VBG [WZPRES]
$_$
38.1_CD
million_CD
31_CD
December_NN
2001_CD
:_:
$_$
37.7_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
an_DT
amount_NN
of_PIN
$_$
20.3_CD
million_CD
31_CD
December_NN
2001_CD
:_:
$_$
20.1_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
subscribed_VBN
._.
ii_FW
FLUVIRAL_NN
The_NN
Company_NN
signed_VBD
a_DT
ten-year_JJ
contract_NN
with_PIN
the_DT
Government_NOMZ
of_PIN
Canada_NN
in_PIN
2001_CD
to_TO
assure_VB
a_DT
state_NN
of_PIN
readiness_NOMZ
in_PIN
the_DT
case_NN
of_PIN
an_DT
influenza_NN
pandemic_JJ
worldwide_NN
epidemic_NN
and_CC
to_TO
provide_VB
influenza_NN
vaccine_NN
for_PIN
all_QUAN
Canadian_JJ
citizens_NN
in_PIN
such_JJ
an_DT
event_NN
._.
Canada_NN
would_PRMD
require_VB [SUAV]
32_CD
million_CD
doses_NN
of_PIN
single-strain_JJ
monovalent_JJ
flu_NN
vaccine_NN
within_PIN
a_DT
production_NOMZ
period_NN
of_PIN
16_CD
weeks_NN
._.
Shire_NN
Biologics_NN
has_VPRT [SPAU] [PEAS]
therefore_CONJ
begun_VBN
to_TO
expand_VB
its_PIT
production_NOMZ
capacity_NOMZ
in_PIN
order_NN
to_TO
meet_VB
this_DEMO
objective_NN
within_PIN
a_DT
five-year_JJ
period_NN
._.
Shire_NN
Biologics_NN
is_VPRT [PASS]
committed_VBN
to_PIN
CAN$_NN
18_CD
million_CD
approximately_RB
$_$
11.3_CD
million_CD
of_PIN
capital_NN
expenditure_NN
on_PIN
immoveables_NN
for_PIN
the_DT
purpose_NN
of_PIN
achieving_VBG
the_DT
level_NN
of_PIN
pandemic_JJ
readiness_NOMZ
required_VBN [SUAV]
._.
In_CONJ
addition_NULL
,_,
a_DT
performance_NN
bond_NN
equal_JJ
to_PIN
10_CD
%_NN
of_PIN
the_DT
minimum_NN
estimated_VBN [PRIV]
contract_NN
value_NN
in_PIN
any_QUAN
year_NN
,_,
which_WDT [SERE]
for_PIN
2002_CD
2003_CD
will_PRMD
be_VB
CAN$_NN
19.2_CD
million_CD
approximately_RB
$_$
12_CD
million_CD
,_,
would_PRMD
become_VB
payable_JJ
to_PIN
the_DT
Government_NOMZ
of_PIN
Canada_NN
if_COND
contracted_VBN
penalty_NN
clauses_NN
were_VBD [PASS]
triggered_VBN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
71_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
19_CD
Leases_NN
and_CC
other_JJ
commitments_NOMZ
continued_VBD
c_NN
Legal_JJ
proceedings_GER
i_FPP1
General_NN
Shire_NN
accounts_VPRT
for_PIN
litigation_NOMZ
losses_NN
in_PIN
accordance_NN
with_PIN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standards_NN
SFAS_NN
No._NN
._.
5_CD
,_,
Accounting_GER
for_PIN
Contingencies_NN
SFAS_NN
No._NN
._.
5_CD
,_,
loss_NN
contingency_NN
provisions_NN
are_VPRT [PASS]
recorded_VBN
for_PIN
probable_JJ
losses_NN
when_RB
management_NOMZ
is_VPRT [BEMA]
able_JJ
reasonably_RB
to_TO
estimate_VB [PRIV]
the_DT
loss_NN
._.
Where_RB
the_DT
estimated_JJ
loss_NN
lies_VPRT
within_PIN
a_DT
range_NN
and_CC
no_SYNE
particular_JJ
amount_NN
within_PIN
that_DEMO
range_NN
is_VPRT [BEMA]
a_DT
better_JJ
estimate_NN
than_PIN
any_QUAN
other_JJ
amount_NN
the_DT
minimum_NN
amount_NN
is_VPRT [PASS]
recorded_VBN
._.
In_PIN
other_JJ
cases_NN
managements_NOMZ
best_JJ
estimate_NN
of_PIN
the_DT
loss_NN
is_VPRT [PASS]
recorded_VBN
._.
These_DEMO
estimates_NN
are_VPRT [PASS]
developed_VBN
substantially_RB
earlier_TIME
than_PIN
the_DT
ultimate_JJ
loss_NN
is_VPRT [PASS]
known_VBN [PRIV]
,_,
and_ANDC
the_DT
estimates_NN
are_VPRT [PASS]
refined_VBN
each_QUAN
accounting_GER
period_NN
,_,
in_PIN
light_NN
of_PIN
additional_JJ
information_NOMZ
being_VBG [WZPRES] [PASS]
known_VBN [PRIV]
._.
In_PIN
instances_NN
where_RB
Shire_NN
is_VPRT [BEMA]
unable_PRED
to_TO
develop_VB
a_DT
best_JJ
estimate_NN
of_PIN
loss_NN
,_,
no_SYNE
litigation_NOMZ
loss_NN
is_VPRT [PASS]
recorded_VBN
at_PIN
that_DEMO
time_NN
._.
As_IN
information_NOMZ
becomes_VPRT
known_VBN [PRIV]
a_DT
loss_NN
provision_NN
is_VPRT [PASS]
set_VBN
up_RP
when_RB
a_DT
best_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
._.
The_DT
best_JJ
estimates_NN
are_VPRT [PASS]
reviewed_VBN
quarterly_JJ
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
changed_VBN
when_RB
expectations_NOMZ
are_VPRT [PASS]
revised_VBN
._.
ii_FW
Phentermine_NN
Shire_NN
US_FPP1
Inc._NN
._.
SUS_NN
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
11_CD
lawsuits_NN
still_RB
pending_VBG
in_PIN
both_DT
US_FPP1
federal_JJ
and_CC
state_NN
courts_NN
which_WDT [WHSUB]
seek_VPRT
damages_NN
for_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
personal_JJ
injury_NN
arising_VBG [WZPRES]
from_PIN
phentermine_NN
products_NN
supplied_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
by_PIN
SUS_NN
and_CC
several_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
._.
SUS_NN
,_,
formerly_TIME
known_VBN [PRIV]
as_IN
Shire_NN
Richwood_NN
Inc._NN
has_VPRT [PEAS]
been_VBN [PASS]
sued_VBN
as_IN
a_DT
manufacturer_NN
and_PHC
distributor_NN
of_PIN
phentermine_NN
,_,
an_DT
anorectic_NN
used_VBN [WZPAST]
in_PIN
the_DT
short-term_JJ
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
one_CD
of_PIN
the_DT
products_NN
addressed_VBN [WZPAST]
by_PIN
the_DT
lawsuits_NN
._.
The_DT
lawsuits_NN
generally_RB
allege_VPRT [PUBV]
the_DT
following_VBG
claims_NN
:_:
the_DT
defendants_NN
marketed_VBN
phentermine_NN
and_CC
other_JJ
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
misled_VBD
users_NN
about_IN
the_DT
products_NN
and_PHC
dangers_NN
associated_VBN [WZPAST]
with_PIN
them_TPP3
:_:
the_DT
defendants_NN
failed_VBD
adequately_RB
to_PIN
test_NN
phentermine_NN
individually_RB
and_ANDC
when_RB
taken_VBN
in_PIN
combination_NOMZ
with_PIN
the_DT
other_JJ
drugs_NN
:_:
and_ANDC
the_DT
defendants_NN
knew_VBD [PRIV]
or_CC
should_NEMD
have_VB [PEAS]
known_VBN [PRIV]
about_IN
the_DT
negative_JJ
effects_NN
of_PIN
the_DT
drugs_NN
and_CC
should_NEMD
have_VB [PEAS]
informed_VBN
the_DT
public_JJ
about_IN
such_JJ
risks_NN
and_CC
or_CC
failed_VBD
to_TO
provide_VB
appropriate_JJ
warning_GER
labels_NN
._.
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
a_DT
total_NN
of_PIN
3,804_CD
such_JJ
phentermine_NN
lawsuits_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
as_IN
a_DT
defendant_NN
in_PIN
3,756_CD
cases_NN
._.
Shire_NN
is_VPRT
awaiting_VBG
the_DT
furtherance_NN
of_PIN
proceedings_GER
in_PIN
the_DT
remaining_VBG
37_CD
law_NN
suits_NN
._.
SUS_NN
became_VBD
involved_VBN
with_PIN
phentermine_NN
through_PIN
its_PIT
acquisition_NOMZ
of_PIN
certain_JJ
assets_NN
of_PIN
Rexar_NN
Pharmacal_NN
Corporation_NOMZ
Rexar_NN
in_PIN
January_NN
1994_CD
._.
In_CONJ
addition_NULL
to_PIN
SUS_NN
potentially_RB
incurring_VBG
liability_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
own_JJ
production_NOMZ
of_PIN
Oby-Cap_NN
,_,
a_DT
phentermine_JJ
product_NN
,_,
the_DT
plaintiffs_NN
may_POMD [SPAU]
additionally_RB
seek_VB
to_TO
impose_VB
liability_NOMZ
on_PIN
SUS_NN
as_IN
successor_NN
to_PIN
Rexar_NN
._.
SUS_NN
intends_VPRT [SUAV]
vigorously_RB
to_TO
defend_VB
all_QUAN
the_DT
lawsuits_NN
and_CC
pursue_VB
all_QUAN
available_JJ
reasonable_JJ
defences_NN
._.
SUS_NN
denies_VPRT [PUBV]
liability_NOMZ
on_PIN
a_DT
number_NN
of_PIN
grounds_NN
including_VBG [WZPRES]
lack_NN
of_PIN
scientific_JJ
evidence_NN
that_DEMO
phentermine_NN
,_,
properly_RB
prescribed_VBN
,_,
causes_VPRT
the_DT
alleged_JJ
side_NN
effects_NN
and_CC
that_THVC
SUS_NN
did_VBD
not_XX0
promote_VB
phentermine_NN
for_PIN
long-term_JJ
combined_VBN
use_NN
as_IN
part_NN
of_PIN
the_DT
fen_NN
phen_NN
diet_NN
._.
Accordingly_RB
,_,
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
any_QUAN
and_CC
all_QUAN
claims_NN
made_VBN [WZPAST]
against_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
phentermine_NN
and_CC
believes_VPRT [PRIV]
that_THVC
liability_NOMZ
is_VPRT [BEMA]
neither_SYNE
probable_JJ
nor_SYNE
quantifiable_JJ
at_PIN
this_DEMO
stage_NN
of_PIN
litigation_NOMZ
._.
Legal_JJ
expenses_NN
have_VPRT [PEAS]
been_VBN [BYPA]
paid_VBN
by_PIN
Eon_NN
Labs_NN
Manufacturing_GER
Inc._NN
._.
Eon_NN
,_,
the_DT
supplier_NN
to_PIN
SUS_NN
,_,
or_CC
Eons_NN
insurance_NN
carriers_NN
but_CC
such_JJ
insurance_NN
is_VPRT [SPAU] [PASS]
now_TIME
exhausted_VBN
._.
Eon_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
defend_VB
and_PHC
indemnify_VB
SUS_NN
in_PIN
this_DEMO
litigation_NOMZ
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
dated_VBN
30_CD
November_NN
2000_CD
between_PIN
Eon_NN
and_PHC
SUS_NN
._.
iii_FW
ADDERALL_NN
Shires_NN
extended-release_NN
once-daily_RB
version_NN
of_PIN
ADDERALL_NN
,_,
ADDERALL_NN
XR_NN
,_,
is_VPRT [BYPA]
covered_VBN
by_PIN
US_FPP1
patent_NN
No._NN
._.
However_CONJ
,_,
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
that_TOBJ
the_DT
Company_NN
will_PRMD
be_VB [BEMA]
successful_PRED
in_PIN
the_DT
suit_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Company_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Barr_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended-release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
application_NOMZ
._.
This_DEMP
may_POMD
have_VB
a_DT
material_NN
adverse_JJ
impact_NN
on_PIN
the_DT
Companys_NN
results_NN
and_CC
financial_JJ
position_NOMZ
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Company_NN
does_VPRT
not_XX0
prevail_VB
in_PIN
the_DT
suit_NN
,_,
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
could_POMD
not_XX0
be_VB [PASS]
launched_VBN
before_IN
October_NN
2004_CD
,_,
the_DT
current_JJ
expiry_NN
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
._.
In_PIN
November_NN
2002_CD
Shire_NN
received_VBD
approval_NN
from_PIN
the_DT
FDA_NN
for_PIN
a_DT
new_JJ
formulation_NOMZ
of_PIN
ADDERALL_NN
which_WDT [WHSUB]
is_VPRT [PASS]
patent_NN
protected_VBN
._.
In_PIN
January_NN
2003_CD
Shire_NN
received_VBD
a_DT
Paragraph_NN
IV_NN
notice_NN
from_PIN
Barr_NN
alleging_VBG [PUBV] [THATD] [WZPRES]
that_DEMP
this_DEMO
patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
not_XX0
infringed_VBN
by_PIN
Barrs_NN
7.5_CD
mg_NN
and_CC
15mg_JJ
mixed_JJ
amphetamine_NN
salt_NN
products_NN
._.
72_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
19_CD
Leases_NN
and_CC
other_JJ
commitments_NOMZ
continued_VBD
iv_JJ
Emory_NN
Shire_NN
BioChem_NN
was_VBD [PASS]
involved_VBN
in_PIN
worldwide_JJ
patent_NN
disputes_NN
with_PIN
Emory_NN
University_NOMZ
Emory_NN
relating_VBG [WZPRES]
to_PIN
lamivudine_JJ
wherein_NN
Shire_NN
BioChem_NN
opposed_VBD
certain_JJ
patents_NN
and_PHC
patent_NN
applications_NOMZ
of_PIN
Emory_NN
and_CC
wherein_JJ
Emory_NN
opposed_VBD
certain_JJ
patents_NN
and_PHC
patent_NN
applications_NOMZ
of_PIN
Shire_NN
BioChem_NN
._.
Shire_NN
BioChem_NN
was_VBD [SPAU] [PASS]
also_RB
involved_VBN
in_PIN
worldwide_JJ
patent_NN
disputes_NN
with_PIN
Emory_NN
and_CC
the_DT
University_NOMZ
of_PIN
Georgia_NN
Research_NN
Foundation_NOMZ
Georgia_NN
relating_VBG [WZPRES]
to_PIN
certain_JJ
dioxolane_NN
nucleoside_NN
analogs_NN
wherein_VPRT
Shire_NN
BioChem_NN
opposed_VBD
certain_JJ
patents_NN
and_PHC
patent_NN
applications_NOMZ
of_PIN
Emory_NN
and_PHC
Georgia_NN
and_CC
wherein_JJ
Emory_NN
opposed_VBD
a_DT
European_JJ
patent_NN
of_PIN
Shire_NN
BioChem_NN
._.
Pursuant_JJ
to_PIN
global_JJ
Settlement_NOMZ
and_PHC
Licence_NN
Agreements_NOMZ
finalized_VBD
in_PIN
August_NN
2002_CD
by_PIN
Shire_NN
BioChem_NN
,_,
Shire_NN
,_,
Georgia_NN
and_PHC
Triangle_NN
Pharmaceuticals_NN
Inc._NN
._.
Triangle_NN
,_,
Shire_NN
will_PRMD
grant_VB [SUAV]
an_DT
exclusive_JJ
royalty-bearing_GER
licence_NN
to_PIN
Emory_NN
,_,
sub_NN
licensable_JJ
to_PIN
Triangle_NN
,_,
for_PIN
certain_JJ
dioxolane_NN
nucleoside_NN
analogs_NN
,_,
including_VBG
diamino_NN
purine_NN
dioxolane_NN
DAPD_NN
._.
Emory_NN
,_,
Georgia_NN
and_PHC
Triangle_NN
will_PRMD
grant_VB [SUAV]
an_DT
exclusive_JJ
royalty-bearing_GER
licence_NN
to_PIN
Shire_NN
for_PIN
certain_JJ
dioxolane_NN
nucleosides_NN
,_,
including_VBG
SPD_NN
756_CD
._.
The_DT
compounds_NN
the_DT
subject_NN
of_PIN
these_DEMO
licences_NN
are_VPRT [BEMA]
in_PIN
development_NOMZ
._.
A_DT
low_JJ
royalty_NN
will_PRMD
be_VB [BEMA]
payable_PRED
by_PIN
Shire_NN
upon_PIN
commercialisation_NOMZ
of_PIN
SPD_NN
756_CD
._.
The_DT
Settlement_NOMZ
and_PHC
Licence_NN
Agreements_NOMZ
provide_VB
for_PIN
the_DT
resolution_NOMZ
of_PIN
all_QUAN
worldwide_JJ
patent_NN
disputes_NN
relating_VBG [WZPRES]
to_PIN
the_DT
licensed_JJ
patents_NN
._.
v_FW
Other_JJ
matters_NN
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
is_VPRT [PASS]
involved_VBN
in_PIN
claims_NN
and_PHC
lawsuits_NN
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
._.
It_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
at_PIN
this_DEMO
time_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
ultimate_JJ
outcome_NN
of_PIN
any_QUAN
of_PIN
these_DEMO
claims_NN
._.
20_CD
Related_VBN
parties_NN
a_DT
Mr_NN
Spitznagel_NN
Mr_NN
Spitznagel_NN
,_,
a_DT
former_JJ
director_NN
of_PIN
the_DT
Company_NN
,_,
who_WP
resigned_VBD
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2001_CD
,_,
entered_VBD
into_PIN
a_DT
consultancy_NN
agreement_NOMZ
with_PIN
the_DT
Company_NN
in_PIN
December_NN
1999_CD
,_,
which_WDT [SERE]
provided_VBD
that_DEMP
:_:
if_COND
he_TPP3
had_VBD
good_JJ
reason_NN
,_,
as_IN
defined_VBN
in_PIN
his_TPP3
service_NN
agreement_NOMZ
with_PIN
Roberts_NN
,_,
to_TO
terminate_VB
his_TPP3
employment_NOMZ
with_PIN
Roberts_NN
under_IN
his_TPP3
service_NN
agreement_NOMZ
,_,
the_DT
Company_NN
would_PRMD
cause_VB
Roberts_NN
to_TO
provide_VB
him_TPP3
with_PIN
the_DT
payments_NOMZ
and_PHC
benefits_NN
he_TPP3
would_PRMD
be_VB [PASS]
entitled_VBN
to_PIN
upon_PIN
a_DT
good_JJ
reason_NN
termination_NOMZ
:_:
Mr_NN
Spitznagel_NN
would_PRMD
provide_VB
consulting_VBG
services_NN
to_PIN
the_DT
Company_NN
for_PIN
at_PIN
least_JJ
42_CD
months_NN
following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
,_,
unless_COND
Mr_NN
Spitznagel_NN
terminated_VBD
the_DT
consultancy_NN
agreement_NOMZ
prior_RB
to_PIN
the_DT
end_NN
of_PIN
the_DT
42nd_NN
month_NN
upon_PIN
30_CD
days_NN
notice_NN
:_:
and_ANDC
the_DT
Company_NN
would_PRMD
pay_VB
Mr_NN
Spitznagel_NN
at_PIN
a_DT
rate_NN
of_PIN
$_$
400,000_CD
per_PIN
annum_NN
for_PIN
his_TPP3
consulting_GER
services_NN
,_,
$_$
150,000_CD
per_PIN
annum_NN
as_IN
an_DT
office_NN
allowance_NN
,_,
$_$
250,000_CD
per_PIN
annum_NN
to_TO
comply_VB
with_PIN
certain_JJ
restrictive_JJ
covenants_NN
contained_VBD
therein_RB
and_CC
$_$
150,000_CD
per_PIN
annum_NN
for_PIN
tax_NN
,_,
financial_JJ
and_CC
estate_NN
planning_GER
advice_NN
,_,
life_NN
insurance_NN
and_PHC
health_NN
insurance_NN
._.
The_DT
amount_NN
owed_VBN [WZPAST]
to_PIN
Mr_NN
Spitznagel_NN
at_PIN
31_CD
December_NN
2002_CD
was_VBD
$_$
0.5_CD
million_CD
at_PIN
31_CD
December_NN
2001_CD
it_PIT
was_VBD
$_$
1.4_CD
million_CD
._.
b_NN
Professional_NN
fees_NN
The_DT
Company_NN
incurred_VBN
professional_JJ
fees_NN
with_PIN
law_NN
firms_NN
,_,
in_PIN
which_WDT [PIRE]
The_DT
Hon_NN
James_NN
Grant_NN
,_,
a_DT
director_NN
of_PIN
the_DT
Company_NN
,_,
is_VPRT [BEMA]
a_DT
partner_NN
,_,
totalling_VBG
$_$
1,239_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
$_$
1.9_CD
million_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2001_CD
and_CC
$_$
0.4_CD
million_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
._.
No_SYNE
amounts_NN
were_VBD [BEMA]
due_PRED
to_PIN
from_PIN
the_DT
law_NN
firms_NN
in_PIN
which_WDT [PIRE]
The_DT
Hon_NN
James_NN
Grant_NN
is_VPRT [BEMA]
a_DT
partner_NN
at_PIN
31_CD
December_NN
2002_CD
,_,
or_CC
at_PIN
31_CD
December_NN
2001_CD
._.
c_NN
Immunosystems_NN
BioChem_NN
Immunosystems_NN
Inc._NN
._.
Immunosystems_NN
,_,
formally_RB
a_DT
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
BioChem_NN
,_,
was_VBD [PASS]
sold_VBN
in_PIN
February_NN
2000_CD
to_PIN
a_DT
third_JJ
party_NN
._.
Dr_NN
Bellini_NN
,_,
the_DT
former_JJ
Chief_NN
Executive_NN
Officer_NN
of_PIN
BioChem_NN
,_,
continued_VBD
as_IN
a_DT
director_NN
of_PIN
Immunosystems_NN
._.
In_PIN
December_NN
2001_CD
,_,
the_DT
Company_NN
acquired_VBD
a_DT
19.9_CD
%_NN
equity_NOMZ
interest_NN
in_PIN
Immunosystems_NN
in_PIN
consideration_NOMZ
for_PIN
the_DT
release_NN
of_PIN
a_DT
debt_NN
owing_NN
to_PIN
the_DT
Company_NN
from_PIN
Immunosystems_NN
._.
This_DEMO
debt_NN
existed_VBD
prior_RB
to_PIN
the_DT
Companys_NN
merger_NN
with_PIN
BioChem_NN
._.
As_IN
part_NN
of_PIN
the_DT
same_JJ
transaction_NOMZ
,_,
the_DT
Company_NN
was_VBD [PASS]
released_VBN
from_PIN
a_DT
pre-existing_JJ
BioChem_NN
guarantee_NN
over_IN
other_JJ
Immunosystems_NN
liabilities_NOMZ
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
73_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
21_CD
Earnings_GER
per_PIN
share_NN
The_DT
following_VBG
table_NN
reconciles_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
items_NN
and_CC
the_DT
weighted_JJ
average_JJ
common_JJ
shares_NN
outstanding_JJ
for_PIN
basic_JJ
and_PHC
diluted_JJ
EPS_NN
for_PIN
the_DT
periods_NN
presented_VBN
:_:
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
items_NN
242,378_CD
34,615_CD
204,744_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
8,191_CD
6,748_CD
6,983_CD
Extraordinary_JJ
item_NN
,_,
net_NN
of_PIN
tax_NN
2,604_CD
Net_JJ
income_NN
250,569_CD
38,759_CD
211,727_CD
Effect_NN
of_PIN
dilutive_JJ
securities_NOMZ
:_:
Interest_NN
charged_VBN [WZPAST]
on_PIN
convertible_JJ
debt_NN
,_,
net_NN
of_PIN
tax_NN
5,585_CD
Number_NN
Number_NN
Number_NN
of_PIN
shares_NN
of_PIN
shares_NN
of_PIN
shares_NN
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
outstanding_JJ
Earnings_GER
per_PIN
share_NN
basic_JJ
500,687,594_CD
492,594,226_CD
482,890,070_CD
Effect_NN
of_PIN
dilutive_JJ
securities_NOMZ
:_:
Share_NN
options_NOMZ
1,883,475_CD
11,362,332_CD
11,801,735_CD
Convertible_JJ
debt_NN
19,847,177_CD
Warrants_NN
919,029_CD
21,730,652_CD
12,281,361_CD
11,801,735_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
522,418,246_CD
504,875,587_CD
494,691,805_CD
Earnings_GER
per_PIN
share_NN
basic_JJ
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
items_NN
48.4_CD
7.0_CD
42.4_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
1.6_CD
1.4_CD
1.4_CD
Extraordinary_JJ
item_NN
,_,
net_NN
of_PIN
tax_NN
0.5_CD
Earnings_GER
per_PIN
share_NN
basic_JJ
50.0_CD
7.9_CD
43.8_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
extraordinary_JJ
items_NN
47.4_CD
6.9_CD
41.4_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
1.6_CD
1.3_CD
1.4_CD
Extraordinary_JJ
item_NN
,_,
net_NN
of_PIN
tax_NN
0.5_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
49.0_CD
7.7_CD
42.8_CD
The_DT
computation_NOMZ
of_PIN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
for_PIN
diluted_VBN
EPS_NN
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2001_CD
and_CC
2000_CD
does_VPRT
not_XX0
include_VB
convertible_JJ
debt_NN
because_CAUS
,_,
after_IN
eliminating_VBG
interest_NN
charged_VBN [WZPAST]
to_PIN
operations_NOMZ
from_PIN
the_DT
numerator_NN
,_,
the_DT
inclusion_NN
would_PRMD
be_VB [BEMA]
anti-dilutive_PRED
._.
The_DT
warrants_NN
are_VPRT [BEMA]
issuable_PRED
in_PIN
respect_NN
of_PIN
a_DT
research_NN
and_PHC
development_NOMZ
agreement_NOMZ
._.
A_DT
charge_NN
of_PIN
$_$
4.5_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
in_PIN
the_DT
results_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2001_CD
._.
The_DT
warrants_NN
and_PHC
share_NN
options_NOMZ
not_XX0
included_VBD
within_PIN
the_DT
calculation_NOMZ
of_PIN
the_DT
diluted_VBN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
,_,
because_CAUS
the_DT
exercise_NN
prices_NN
exceeded_VBD
the_DT
Companys_NN
average_JJ
share_NN
price_NN
during_PIN
the_DT
calculation_NOMZ
period_NN
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
._.
2002 2001 2000_CD
Number_NN
Number_NN
Number_NN
Year_NN
ended_VBD
31_CD
December_NN
of_PIN
shares_NN
of_PIN
shares_NN
of_PIN
shares_NN
Share_NN
options_NOMZ
17,492,575_CD
10,384,600_CD
Warrants_NN
1,346,407_CD
18,838,982_CD
10,384,600_CD
74_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
22_CD
Analysis_NN
of_PIN
revenues_NN
,_,
operating_VBG
income_NN
loss_NN
and_PHC
assets_NN
by_PIN
reportable_JJ
segments_NOMZ
The_DT
Company_NN
has_VPRT [PEAS]
disclosed_VBN [PUBV]
segment_NOMZ
information_NOMZ
for_PIN
the_DT
individual_JJ
operating_GER
areas_NN
of_PIN
the_DT
business_NOMZ
,_,
based_VBN [PASTP]
on_PIN
the_DT
way_NN
in_PIN
which_WDT [PIRE]
the_DT
business_NOMZ
is_VPRT [PASS]
managed_VBN
and_PHC
controlled_VBN
._.
Shires_NN
principal_JJ
reporting_VBG [PUBV] [THATD]
segments_NOMZ
are_VPRT [BEMA]
geographic_PRED
,_,
each_QUAN
being_VBG [PASS]
managed_VBN
and_PHC
monitored_VBN
separately_RB
and_CC
serving_VBG
different_JJ
markets_NN
._.
The_DT
Company_NN
evaluates_VPRT
performance_NN
based_VBN [WZPAST]
on_PIN
operating_VBG
income_NN
or_CC
loss_NN
before_IN
interest_NN
and_PHC
income_NN
taxes_NN
._.
The_DT
accounting_GER
policies_NN
of_PIN
each_QUAN
reportable_JJ
segment_NOMZ
are_VPRT [BEMA]
consistent_PRED
with_PIN
those_DEMO
of_PIN
the_DT
Company_NN
._.
Operating_VBG
income_NN
loss_NN
US_FPP1
International_NN
R&D_NN
Total_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Year_NN
ended_VBD
31_CD
December_NN
2002_CD
External_NN
revenues_NN
:_:
Product_NN
sales_NN
714,655_CD
144,733_CD
859,388_CD
Licensing_GER
and_PHC
development_NOMZ
2,661_CD
403_CD
3,064_CD
Royalties_NN
215_CD
174,597_CD
174,812_CD
Other_JJ
revenues_NN
34_CD
34_CD
Intersegment_NOMZ
revenues_NN
21,169_CD
127,823_CD
148,992_CD
738,700_CD
319,767_CD
127,823_CD
1,186,290_CD
Elimination_NOMZ
of_PIN
intersegment_NOMZ
sales_NN
21,169_CD
127,823_CD
148,992_CD
Total_JJ
revenues_NN
717,531_CD
319,767_CD
1,037,298_CD
Cost_NN
of_PIN
revenues_NN
63,356_CD
70,326_CD
133,682_CD
Research_NN
and_PHC
development_NOMZ
189,179_CD
189,179_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
238,810_CD
147,213_CD
386,023_CD
Loss_NN
on_PIN
disposition_NOMZ
of_PIN
assets_NN
1,221_CD
155_CD
1,376_CD
Total_JJ
operating_GER
expenses_NN
303,387_CD
217,694_CD
189,179_CD
710,260_CD
Operating_GER
income_NN
loss_NN
414,144_CD
102,073_CD
189,179_CD
327,038_CD
31_CD
December_NN
2002_CD
Total_JJ
assets_NN
818,383_CD
1,340,116_CD
50,124_CD
2,208,623_CD
Long-lived_JJ
assets_NN
260,751_CD
451,435_CD
29,341_CD
741,527_NN
Capital_NN
expenditure_NN
on_PIN
long-lived_JJ
assets_NN
8,188_CD
38,940_CD
7,152_CD
54,280_CD
Year_NN
ended_VBD
31_CD
December_NN
2001_CD
Product_NN
sales_NN
587,449_CD
111,902_CD
699,351_CD
Licensing_GER
and_PHC
development_NOMZ
4,507_CD
991_CD
5,498_CD
Royalties_NN
264_CD
144,891_CD
145,155_CD
Other_JJ
revenues_NN
2,952_CD
2,952_CD
Intersegment_NOMZ
revenues_NN
19,319_CD
36,705_CD
56,024_CD
611,539_CD
260,736_CD
36,705_CD
908,980_CD
Elimination_NOMZ
of_PIN
intersegment_NOMZ
sales_NN
19,319_CD
36,705_CD
56,024_CD
Total_JJ
revenues_NN
592,220_CD
260,736_CD
852,956_CD
Cost_NN
of_PIN
revenues_NN
58,655_CD
53,351_CD
112,006_CD
Research_NN
and_PHC
development_NOMZ
171,029_CD
171,029_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
195,438_CD
108,042_CD
303,480_CD
Asset_NN
impairments_NOMZ
and_PHC
restructuring_GER
charges_NN
29,699_CD
29,699_CD
Merger_NN
transaction_NOMZ
expenses_NN
83,470_CD
83,470_CD
Loss_NN
on_PIN
disposition_NOMZ
of_PIN
assets_NN
2,052_CD
8,112_CD
10,164_CD
Total_JJ
operating_GER
expenses_NN
256,145_CD
282,674_CD
171,029_CD
709,848_CD
Operating_GER
income_NN
loss_NN
336,075_CD
21,938_CD
171,029_CD
143,108_CD
31_CD
December_NN
2001_CD
Total_JJ
assets_NN
658,031_CD
1,223,604_CD
29,096_CD
1,910,731_CD
Long-lived_JJ
assets_NN
327,289_CD
419,601_CD
23,286_CD
770,176_CD
Capital_NN
expenditure_NN
on_PIN
long-lived_JJ
assets_NN
3,880_CD
65,558_CD
2,488_CD
71,926_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
75_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
22_CD
Analysis_NN
of_PIN
revenues_NN
,_,
operating_VBG
income_NN
loss_NN
and_PHC
assets_NN
by_PIN
reportable_JJ
segments_NOMZ
continued_VBD
US_FPP1
International_NN
R&D_NN
Total_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Year_NN
ended_VBD
31_CD
December_NN
2000_CD
Product_NN
sales_NN
391,168_CD
105,607_CD
496,775_CD
Licensing_GER
and_PHC
development_NOMZ
1,326_CD
12,821_CD
14,147_CD
Royalties_NN
266_CD
135,204_CD
135,470_CD
Other_JJ
revenues_NN
20_CD
1,242_CD
1,262_CD
Intersegment_NOMZ
revenues_NN
18,408_CD
51,666_CD
70,074_CD
411,188_CD
254,874_CD
51,666_CD
717,728_CD
Elimination_NOMZ
of_PIN
intersegment_NOMZ
sales_NN
18,408_CD
51,666_CD
70,074_CD
Total_JJ
revenues_NN
392,780_CD
254,874_CD
647,654_CD
Cost_NN
of_PIN
revenues_NN
47,093_CD
47,978_CD
95,071_CD
Research_NN
and_PHC
development_NOMZ
155,145_CD
155,145_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
116,761_CD
113,455_CD
230,216_CD
Asset_NN
impairments_NOMZ
and_PHC
restructuring_GER
charges_NN
26,947_CD
26,947_CD
Total_JJ
operating_GER
expenses_NN
163,854_CD
188,380_CD
155,145_CD
507,379_CD
Operating_GER
income_NN
loss_NN
228,926_CD
66,494_CD
155,145_CD
140,275_CD
31_CD
December_NN
2000_CD
Total_JJ
assets_NN
560,864_CD
943,687_CD
43,944_CD
1,548,495_CD
Long-lived_JJ
assets_NN
353,656_CD
475,361_CD
23,625_CD
852,642_CD
Capital_NN
expenditure_NN
on_PIN
long_JJ
lived_VBD
assets_NN
27,945_CD
50,435_CD
21,237_CD
99,617_CD
Material_NN
customers_NN
In_PIN
the_DT
periods_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
,_,
certain_JJ
customers_NN
accounted_VBD
for_PIN
greater_JJ
than_PIN
10_CD
%_NN
of_PIN
Shires_NN
total_JJ
revenues_NN
:_:
2002 2002 2001 2001_CD
2000_CD
2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
%_NN
revenue_NN
$_$
000_CD
%_NN
revenue_NN
$_$
000_CD
%_NN
revenue_NN
Customer_NN
A_DT
231,270_CD
22_CD
176,941_CD
21_CD
132,913_CD
21_CD
Customer_NN
B_NN
197,184_CD
19_CD
123,350_CD
14_CD
80,293_CD
12_CD
Customer_NN
C_NN
149,613_CD
14_CD
Amounts_NN
outstanding_JJ
at_PIN
31_CD
December_NN
in_PIN
respect_NN
of_PIN
these_DEMO
material_NN
customers_NN
were_VBD
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
At_PIN
31_CD
December_NN
$_$
000_CD
$_$
000_CD
Customer_NN
A_DT
4,354_CD
34,882_CD
Customer_NN
B_NN
9,189_CD
39,094_CD
Customer_NN
C_NN
9,738_CD
20,937_CD
76_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
23_CD
Other_JJ
charges_NN
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
In-process_JJ
research_NN
and_PHC
development_NOMZ
26,947_CD
Asset_NN
impairments_NOMZ
and_PHC
restructuring_GER
charges_NN
29,699_CD
Merger_NN
transaction_NOMZ
expenses_NN
83,470_CD
Losses_NN
on_PIN
disposition_NOMZ
of_PIN
assets_NN
1,376_CD
10,164_CD
Year_NN
ended_VBD
31_CD
December_NN
2001_CD
a_DT
BioChem_NN
merger_NN
The_DT
asset_NN
impairments_NOMZ
and_PHC
restructuring_GER
charges_NN
,_,
merger_NN
transaction_NOMZ
expenses_NN
and_CC
most_EMPH
of_PIN
the_DT
losses_NN
on_PIN
disposal_NN
of_PIN
assets_NN
in_PIN
2001_CD
related_VBN
to_PIN
the_DT
BioChem_NN
merger_NN
on_PIN
11_CD
May_POMD
2001_CD
._.
The_DT
asset_NN
impairments_NOMZ
and_PHC
restructuring_GER
charges_NN
included_VBD
an_DT
impairment_NOMZ
charge_NN
of_PIN
$_$
20.9_CD
million_CD
to_TO
adjust_VB
intangible_JJ
asset_NN
values_NN
,_,
primarily_RB
trademark_NN
and_PHC
patent_NN
costs_NN
but_CC
also_RB
an_DT
element_NOMZ
of_PIN
product_NN
rights_NN
,_,
to_PIN
their_TPP3
estimated_VBN [PRIV]
fair_JJ
value_NN
._.
These_DEMO
charges_NN
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
Companys_NN
accounting_GER
policy_NN
to_TO
review_VB
periodically_RB
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
intangibles_NN
and_CC
evaluate_VB
whether_IN
there_EX
has_VPRT [PEAS]
been_VBN
any_QUAN
impairment_NOMZ
in_PIN
the_DT
value_NN
of_PIN
those_DEMO
intangibles_NN
as_IN
compared_VBN
with_PIN
estimated_VBN [PRIV] [THATD]
undiscounted_JJ
future_JJ
cash_NN
flows_VPRT
relating_VBG
to_PIN
those_DEMO
intangibles_NN
._.
There_EX
was_VBD
also_RB
a_DT
total_NN
of_PIN
$_$
8.8_CD
million_CD
recorded_VBN
in_PIN
respect_NN
of_PIN
employee-related_JJ
costs_NN
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
employee_NN
terminations_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
closure_NN
of_PIN
the_DT
Toronto_NN
facility_NOMZ
and_CC
the_DT
elimination_NOMZ
of_PIN
duplicate_VB
positions_NOMZ
across_PLACE
the_DT
combined_VBN
organization_NOMZ
._.
Shires_NN
existing_VBG [WZPRES]
Canadian_JJ
sales_NN
and_PHC
marketing_GER
operations_NOMZ
in_PIN
Toronto_NN
have_VPRT [PEAS]
been_VBN [PASS]
combined_VBN
with_PIN
those_DEMO
of_PIN
BioChem_NN
in_PIN
Laval_NN
._.
A_DT
total_NN
of_PIN
57_CD
employees_NN
were_VBD [PASS]
identified_VBN
to_TO
be_VB [PASS]
terminated_VBN
._.
As_IN
of_PIN
31_CD
December_NN
2001_CD
all_QUAN
of_PIN
the_DT
planned_VBN
terminations_NOMZ
were_VBD [PASS]
completed_VBN
._.
The_DT
Company_NN
incurred_VBD
a_DT
loss_NN
on_PIN
the_DT
sale_NN
of_PIN
a_DT
duplicated_VBN
facility_NOMZ
in_PIN
Toronto_NN
,_,
Canada_NN
,_,
of_PIN
$_$
8.1_CD
million_CD
._.
b_NN
Product_NN
disposals_NN
During_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2001_CD
,_,
Shire_NN
disposed_VBD
of_PIN
certain_JJ
non-strategic_JJ
products_NN
for_PIN
net_JJ
proceeds_NN
of_PIN
approximately_RB
$_$
4.5_CD
million_CD
,_,
recording_VBG [PRESP]
a_DT
loss_NN
on_PIN
disposition_NOMZ
of_PIN
$_$
2.1_CD
million_CD
._.
Year_NN
ended_VBD
31_CD
December_NN
2000_CD
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
with_PIN
BioChem_NN
,_,
the_DT
Company_NN
incurred_VBD
a_DT
charge_NN
of_PIN
$_$
26.9_CD
million_CD
relating_VBG
to_PIN
the_DT
acquisition_NOMZ
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
24_CD
Other_JJ
expense_NN
income_NN
,_,
net_JJ
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
SERP_NN
valuation_NOMZ
adjustment_NOMZ
2,301_CD
2,018_CD
607_CD
Gain_NN
on_PIN
sale_NN
of_PIN
long-term_JJ
investments_NOMZ
104,000_CD
Write-down_NN
of_PIN
long-term_JJ
investments_NOMZ
due_JJ
to_PIN
impairment_NOMZ
8,680_CD
55,748_CD
GeneChem_NN
funds_NN
income_NN
3,333_CD
3,995_CD
6,773_CD
Other_JJ
614_CD
838_CD
1,143_CD
8,262_CD
52,933_CD
109,023_CD
In_PIN
2001_CD
,_,
the_DT
$_$
55.7_CD
million_CD
write-down_NN
of_PIN
investments_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
BioChem_NN
merger_NN
and_CC
comprised_VBD
the_DT
write-down_NN
of_PIN
long-term_JJ
unquoted_JJ
investments_NOMZ
$_$
24.9_CD
million_CD
and_CC
a_DT
write-down_NN
of_PIN
$_$
30.8_CD
million_CD
to_PIN
a_DT
debenture_NN
held_VBN [PRIV] [WZPAST]
by_PIN
BioChem_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
received_VBN
on_PIN
divestiture_NN
of_PIN
its_PIT
diagnostics_NN
subsidiary_NN
._.
These_DEMO
charges_NN
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
Companys_NN
policy_NN
to_TO
provide_VB
for_PIN
other-than-temporary_JJ
impairments_NOMZ
in_PIN
investment_NOMZ
by_PIN
reference_NN
to_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
investment_NOMZ
using_VBG [WZPRES]
established_VBN [PRIV]
financial_JJ
methodologies_NN
._.
The_DT
main_JJ
components_NN
of_PIN
other_JJ
income_NN
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
was_VBD [BEMA]
a_DT
$_$
104.0_CD
million_CD
gain_NN
resulting_VBG [WZPRES]
from_PIN
the_DT
sale_NN
of_PIN
long-term_JJ
investments_NOMZ
,_,
primarily_RB
in_PIN
respect_NN
of_PIN
North_PLACE
American_JJ
Vaccine_NN
,_,
Inc._NN
a_DT
publicly_RB
traded_VBN
biotechnology_NN
company_NN
listed_VBN [WZPAST]
on_PIN
the_DT
American_NN
Stock_NN
Exchange_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
77_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
25_CD
Retirement_NOMZ
benefits_NN
a_DT
Personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_VPRT
The_DT
Company_NN
makes_VPRT
contributions_NOMZ
to_TO
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
that_TSUB
together_RB
cover_VPRT
substantially_RB
all_QUAN
employees_NN
within_PIN
the_DT
Group_NN
._.
For_PIN
the_DT
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
,_,
the_DT
level_NN
of_PIN
Company_NN
contribution_NOMZ
is_VPRT [PASS]
fixed_VBN
at_PIN
a_DT
set_VBN
percentage_NN
of_PIN
employees_NN
pay_VPRT
._.
Company_NN
contributions_NOMZ
to_PIN
personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_NN
totalled_VBD
$_$
6.8_CD
million_CD
,_,
$_$
4.9_CD
million_CD
and_CC
$_$
2.6_CD
million_CD
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
respectively_RB
,_,
and_ANDC
were_VBD [PASS]
charged_VBN
to_PIN
operations_NOMZ
as_IN
they_TPP3
became_VBD
payable_JJ
._.
b_NN
Defined_VBN
benefit_NN
pension_NN
plan_NN
Roberts_NN
,_,
a_DT
company_NN
with_PIN
whom_WP [PIRE]
the_DT
Company_NN
merged_VBD
in_PIN
December_NN
1999_CD
,_,
operated_VBD
a_DT
defined_VBN
SERP_NN
for_PIN
certain_JJ
US_FPP1
employees_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
established_VBN [PRIV]
in_PIN
1998_CD
._.
This_DEMO
plan_NN
was_VBD [BEMA]
available_PRED
to_PIN
former_JJ
employees_NN
of_PIN
Roberts_NN
who_WP [WHSUB]
met_VBD
certain_JJ
age_NN
and_PHC
service_NN
requirements_NOMZ
._.
As_IN
part_NN
of_PIN
the_DT
restructuring_GER
of_PIN
the_DT
Group_NN
following_VBG [WZPRES]
the_DT
Roberts_NN
merger_NN
,_,
the_DT
SERP_NN
was_VBD [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
and_PHC
contributions_NOMZ
ceased_VBD
being_VBG [PASS]
paid_VBN
into_PIN
the_DT
plan_NN
for_PIN
existing_VBG
members_NN
._.
As_IN
part_NN
of_PIN
this_DEMO
arrangement_NOMZ
,_,
the_DT
Company_NN
paid_VBD
a_DT
lump_NN
sum_NN
contribution_NOMZ
into_PIN
the_DT
plan_NN
of_PIN
$_$
18.0_CD
million_CD
,_,
the_DT
result_NN
of_PIN
which_WDT [PIRE]
is_VPRT
that_DEMO
the_DT
Company_NN
has_VPRT
no_SYNE
future_JJ
contributions_NOMZ
under_IN
the_DT
plan_NN
._.
In_PIN
accordance_NN
with_PIN
EITF_NN
97-14_CD
,_,
the_DT
asset_NN
and_PHC
liability_NOMZ
of_PIN
$_$
12.1_CD
million_CD
and_CC
$_$
8.4_CD
million_CD
respectively_RB
are_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
within_PIN
the_DT
categories_NN
Other_JJ
non-current_JJ
assets_NN
and_CC
Other_JJ
non-current_JJ
liabilities_NOMZ
._.
26_CD
Income_NN
taxes_NN
The_DT
components_NN
of_PIN
income_NN
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
income_NN
of_PIN
associates_NN
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
are_VPRT
as_IN
follows_VPRT
:_:
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
UK_NN
50,520_CD
101,756_CD
37,577_CD
US_FPP1
218,139_CD
190,068_CD
70,700_CD
Other_JJ
jurisdictions_NOMZ
161,441_CD
13,215_CD
218,994_CD
Income_NN
before_IN
income_NN
taxes_NN
,_,
equity_NOMZ
in_PIN
net_JJ
income_NN
of_PIN
associates_NN
and_CC
extraordinary_JJ
items_NN
attributable_JJ
to_TO
continuing_VBG
operations_NOMZ
329,060_CD
101,527_CD
252,117_CD
Income_NN
before_IN
income_NN
taxes_NN
attributable_JJ
to_TO
discontinued_VBN
operations_NOMZ
9,696_CD
10,711_CD
11,083_CD
Total_JJ
income_NN
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
income_NN
of_PIN
associates_NN
and_CC
extraordinary_JJ
items_NN
338,756_CD
112,238_CD
263,200_CD
The_DT
provision_NN
for_PIN
income_NN
taxes_NN
by_PIN
location_NOMZ
of_PIN
the_DT
taxing_VBG
jurisdiction_NOMZ
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
consisted_VBD
of_PIN
the_DT
following_GER
:_:
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Current_JJ
income_NN
taxes_NN
:_:
UK_NN
corporation_NOMZ
tax_NN
US_FPP1
federal_JJ
tax_NN
67,686_CD
40,818_CD
22,434_CD
US_FPP1
state_NN
and_CC
local_JJ
taxes_NN
9,561_CD
8,988_CD
2,744_CD
Other_JJ
jurisdictions_NOMZ
19,864_CD
17,862_CD
14,604_CD
Total_JJ
current_JJ
taxes_NN
97,111_CD
67,668_CD
39,782_CD
Deferred_JJ
taxes_NN
UK_NN
corporation_NOMZ
tax_NN
US_FPP1
federal_JJ
tax_NN
1,136_CD
20,586_CD
4,268_CD
US_FPP1
state_NN
and_CC
local_JJ
taxes_NN
34 618 128_CD
Other_JJ
jurisdictions_NOMZ
9,931_CD
19,975_CD
614_CD
Total_JJ
deferred_JJ
taxes_NN
8,761_CD
1,229_CD
3,782_CD
Total_JJ
income_NN
taxes_NN
attributable_JJ
to_TO
continuing_VBG
operations_NOMZ
88,350_CD
68,897_CD
43,564_CD
Total_JJ
incomes_NN
taxes_NN
attributable_JJ
to_TO
discontinued_VBN
operations_NOMZ
4,812_CD
3,963_CD
4,100_CD
Total_JJ
income_NN
taxes_NN
93,162_CD
72,860_CD
47,664_CD
The_DT
reconciliation_NOMZ
of_PIN
income_NN
before_IN
income_NN
taxes_NN
,_,
equity_NOMZ
in_PIN
net_JJ
income_NN
of_PIN
associates_NN
and_CC
extraordinary_JJ
items_NN
attributing_VBG [WZPRES]
to_TO
continuing_VBG
operations_NOMZ
to_PIN
provision_NN
for_PIN
income_NN
taxes_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
following_VBG
table_NN
._.
78_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
26_CD
Income_NN
taxes_NN
continued_VBD
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Income_NN
before_IN
income_NN
taxes_NN
,_,
equity_NOMZ
in_PIN
net_JJ
income_NN
of_PIN
associates_NN
and_CC
extraordinary_JJ
items_NN
attributing_VBG [WZPRES]
to_TO
continuing_VBG
operations_NOMZ
329,060_CD
101,527_CD
252,117_CD
Corporation_NOMZ
tax_NN
rate_NN
30_CD
%_NN
30_CD
%_NN
30_CD
%_NN
Income_NN
tax_NN
expense_NN
at_PIN
corporation_NOMZ
tax_NN
rate_NN
98,718_CD
30,458_CD
75,635_CD
Adjustments_NOMZ
to_TO
derive_VB
effective_JJ
rate_NN
:_:
Non-deductible_JJ
items_NN
:_:
Goodwill_NN
amortisation_NOMZ
3,309_CD
3,783_CD
Permanent_JJ
differences_NN
4,280_CD
32,268_CD
963_CD
Other_JJ
items_NN
:_:
Change_NN
in_PIN
valuation_NOMZ
allowance_NN
13,948_CD
27,395_CD
8,238_CD
Difference_NN
in_PIN
taxation_NOMZ
rates_NN
36,450_CD
27,662_CD
33,181_CD
Prior_RB
year_NN
adjustment_NOMZ
2,317_CD
2,958_CD
1,950_CD
Other_JJ
5,537_CD
6,087_CD
2,652_CD
Provision_NN
for_PIN
income_NN
taxes_NN
on_PIN
continuing_VBG
operations_NOMZ
88,350_CD
68,897_CD
43,564_CD
Provision_NN
for_PIN
income_NN
taxes_NN
on_PIN
discontinued_VBN
operations_NOMZ
4,812_CD
3,963_CD
4,100_CD
Provision_NN
for_PIN
income_NN
taxes_NN
93,162_CD
72,860_CD
47,664_CD
The_DT
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
is_VPRT [BEMA]
the_DT
tax_NN
rate_NN
of_PIN
the_DT
parent_NN
company_NN
._.
The_DT
significant_JJ
components_NN
of_PIN
deferred_JJ
income_NN
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
and_CC
their_TPP3
balance_NN
sheet_NN
classifications_NOMZ
,_,
as_IN
of_PIN
31_CD
December_NN
,_,
are_VPRT
as_IN
follows_VPRT
:_:
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Deferred_VBN
tax_NN
assets_NN
:_:
Accrued_VBN
expenses_NN
not_XX0
currently_RB
deductible_JJ
7,847_CD
6,238_CD
Losses_NN
carried_VBD
forward_RB
188,937_CD
170,512_CD
Provisions_NN
5,347_CD
7,874_CD
Other_JJ
6,517_CD
6,267_CD
Gross_NN
deferred_VBN
tax_NN
assets_NN
208,648_CD
190,891_CD
Less_RB
:_:
valuation_NOMZ
allowance_NN
139,513_CD
125,565_CD
69,135_CD
65,326_CD
Excess_NN
of_PIN
tax_NN
value_NN
over_IN
book_NN
value_NN
of_PIN
assets_NN
28,070_CD
33,022_CD
Net_JJ
deferred_JJ
tax_NN
assets_NN
41,065_CD
32,304_CD
Balance_NN
sheet_NN
classifications_NOMZ
:_:
Continuing_VBG
operations_NOMZ
Deferred_VBN
tax_NN
assets_NN
current_JJ
34,849_CD
19,430_CD
Deferred_JJ
tax_NN
assets_NN
non-current_JJ
6,216_CD
20,274_CD
41,065_CD
39,704_CD
Discontinued_VBN
operations_NOMZ
Deferred_JJ
tax_NN
liability_NOMZ
non-current_JJ
7,400_CD
Net_JJ
deferred_JJ
tax_NN
assets_NN
41,065_CD
32,304_CD
The_DT
approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
as_IN
at_PIN
31_CD
December_NN
,_,
are_VPRT
as_IN
follows_VPRT
:_:
31_CD
December_NN
31_CD
December_NN
2002_CD
2001_CD
$_$
000_CD
$_$
000_CD
Approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
against_PIN
future_JJ
US_FPP1
federal_JJ
tax_NN
liabilities_NOMZ
33,386_CD
55,803_CD
Approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
against_PIN
future_JJ
US_FPP1
state_NN
and_CC
foreign_JJ
tax_NN
liabilities_NOMZ
639,756_CD
470,177_CD
Total_JJ
673,142_CD
525,980_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
79_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
26_CD
Income_NN
taxes_NN
continued_VBD
The_DT
tax_NN
losses_NN
shown_VBN [PRIV]
above_PLACE
have_VPRT
the_DT
following_VBG
expiration_NOMZ
dates_NN
:_:
31_CD
December_NN
2002_CD
$_$
000 2003 2004_CD
2,527_CD
2005_CD
30,362_CD
2006_CD
38,001_CD
2007_CD
20,731_CD
2008_CD
34,411_CD
2009_CD
27,245_CD
Available_JJ
indefinitely_RB
519,865_CD
673,142_CD
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
had_VBD
a_DT
valuation_NOMZ
allowance_NN
of_PIN
$_$
139.5_CD
million_CD
to_TO
reduce_VB
its_PIT
deferred_JJ
tax_NN
assets_NN
to_TO
estimated_VBN [PRIV]
realisable_JJ
value_NN
._.
The_DT
valuation_NOMZ
allowance_NN
relates_VPRT
to_PIN
the_DT
deferred_VBN
tax_NN
assets_NN
arising_VBG [WZPRES]
from_PIN
overseas_PLACE
tax_NN
operating_GER
loss_NN
carryforwards_NN
and_PHC
capital_NN
loss_NN
carryforwards_NN
,_,
which_WDT [SERE]
have_VPRT
no_SYNE
expiration_NOMZ
date_NN
._.
In_CONJ
addition_NULL
,_,
capital_NN
loss_NN
carryforwards_NN
can_POMD [SPAU]
only_DWNT
be_VB [PASS]
offset_VBN
against_PIN
capital_NN
gains_NN
._.
As_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
over_IN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
temporary_JJ
differences_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
reverse_VB
,_,
and_ANDC
prudent_JJ
and_PHC
feasible_JJ
tax-planning_JJ
strategies_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Company_NN
will_PRMD
realize_VB [PRIV]
the_DT
benefits_NN
of_PIN
these_DEMO
deductible_JJ
differences_NN
,_,
net_NN
of_PIN
the_DT
valuation_NOMZ
allowances_NN
._.
The_DT
Company_NN
recognizes_VPRT [PRIV]
a_DT
deferred_JJ
tax_NN
liability_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
undistributed_JJ
earnings_GER
of_PIN
subsidiaries_NN
when_RB
the_DT
Company_NN
expects_VPRT [PRIV]
that_THVC
it_PIT
will_PRMD
recover_VB
those_DEMO
undistributed_JJ
earnings_GER
in_PIN
a_DT
taxable_JJ
manner_NN
,_,
such_JJ
as_IN
through_PIN
receipt_NN
of_PIN
dividends_NN
or_CC
sale_NN
of_PIN
the_DT
investments_NOMZ
._.
The_DT
Company_NN
does_VPRT
not_XX0
,_,
however_CONJ
,_,
provide_VB
for_PIN
income_NN
taxes_NN
on_PIN
the_DT
unremitted_JJ
earnings_GER
of_PIN
certain_JJ
other_JJ
subsidiaries_NN
located_VBN
outside_PLACE
the_DT
UK_NN
where_RB
,_,
in_PIN
managements_NOMZ
opinion_NN
,_,
such_JJ
earnings_GER
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
indefinitely_RB
reinvested_VBN
in_PIN
these_DEMO
operations_NOMZ
,_,
will_PRMD
be_VB [PASS]
remitted_VBN
in_PIN
a_DT
tax-free_JJ
liquidation_NOMZ
,_,
or_CC
will_PRMD
be_VB [PASS]
remitted_VBN
as_IN
dividends_NN
with_PIN
taxes_NN
substantially_RB
offset_VBN
by_PIN
foreign_JJ
tax_NN
credits_NN
._.
27_CD
Equity_NOMZ
method_NN
investees_VPRT
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
GSK_NN
2,592_CD
1,985_CD
CADx_NN
Qualia_NN
924_CD
North_PLACE
American_JJ
Vaccine_NN
,_,
Inc._NN
3,809_CD
1,668_CD
1,985_CD
3,809_CD
The_DT
Company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
its_PIT
commercialisation_NOMZ
partnership_NN
with_PIN
GSK_NN
through_PIN
which_WDT [PIRE]
the_DT
products_NN
3TC_NN
and_PHC
ZEFFIX_NN
are_VPRT [PASS]
marketed_VBN
in_PIN
Canada_NN
using_VBG [WZPRES]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
._.
The_DT
Company_NN
owns_VPRT
,_,
but_CC
does_VPRT
not_XX0
exercise_VB
control_NN
over_IN
,_,
a_DT
50_CD
%_NN
share_NN
of_PIN
the_DT
partnership_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
applied_VBN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
as_IN
the_DT
Company_NN
owns_VPRT
,_,
but_CC
does_VPRT
not_XX0
exercise_VB
control_NN
over_IN
,_,
a_DT
50_CD
%_NN
share_NN
of_PIN
the_DT
new_JJ
joint_JJ
venture_NN
._.
80_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
28_CD
Stock_NN
incentive_NN
plans_VPRT
The_DT
Company_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
disclosure-only_DWNT
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
25_CD
and_CC
related_VBN
interpretations_NOMZ
in_PIN
accounting_GER
for_PIN
its_PIT
plans_NN
._.
In_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
the_DT
Company_NN
recognized_VBD [PRIV]
a_DT
credit_NN
charge_NN
under_IN
APB_NN
No._NN
._.
25_CD
of_PIN
$_$
0.2_CD
million_CD
,_,
$_$
2.3_CD
million_CD
and_CC
$_$
21.9_CD
million_CD
respectively_RB
._.
Had_VBD
compensation_NOMZ
for_PIN
stock_NN
options_NOMZ
awarded_VBN
under_IN
the_DT
plans_NN
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
123_CD
,_,
the_DT
Companys_NN
net_JJ
income_NN
and_CC
per_PIN
share_NN
data_NN
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
changed_VBN
to_PIN
the_DT
pro_PIN
forma_FW
amounts_VPRT
indicated_VBN [PRIV]
below_PLACE
:_:
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
income_NN
As_IN
reported_VBN [PUBV]
250,569_CD
38,759_CD
211,727_CD
Pro_PIN
forma_FW
226,319_CD
8,791_CD
227,018_CD
Income_NN
per_PIN
share_NN
As_IN
reported_VBN [PUBV]
basic_JJ
50.0_CD
7.9_CD
43.8_CD
As_IN
reported_VBN [PUBV]
diluted_VBN
49.0_CD
7.7_CD
42.8_CD
Pro_PIN
forma_FW
basic_JJ
45.2_CD
1.8_CD
47.0_CD
Pro_PIN
forma_FW
diluted_VBN
44.4_CD
1.7_CD
45.9_CD
The_DT
fair_JJ
value_NN
of_PIN
stock_NN
options_NOMZ
used_VBN
to_TO
compute_VB
pro_PIN
forma_FW
net_JJ
income_NN
and_CC
per_PIN
share_NN
disclosures_NN
is_VPRT [BEMA]
the_DT
estimated_VBN [PRIV]
present_JJ
value_NN
at_PIN
grant_NN
date_NN
using_VBG [WZPRES]
the_DT
Black-Scholes_NN
option-pricing_GER
model_NN
with_PIN
the_DT
following_VBG
weighted_JJ
average_JJ
assumptions_NOMZ
:_:
2002 2001 2000_CD
Year_NN
ended_VBD
31_CD
December_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Risk-free_JJ
interest_NN
rate_NN
1.90_CD
5.33_CD
%_NN
3.43_CD
5.22_CD
%_NN
5.68_CD
6.58_CD
%_NN
Expected_VBN [PRIV]
dividend_NN
yield_NN
0_CD
%_NN
0_CD
%_NN
0_CD
%_NN
Expected_VBN [PRIV]
life_NN
5_CD
years_NN
5_CD
years_NN
5_CD
years_NN
Expected_VBN [PRIV]
volatility_NOMZ
55.2_CD
%_NN
59.5_CD
%_NN
64.2_CD
%_NN
Directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
options_NOMZ
over_IN
common_JJ
shares_NN
under_IN
the_DT
following_VBG
nine_CD
stock_NN
option_NOMZ
plans_NN
:_:
i_FPP1
Shire_NN
Holdings_GER
Limited_NN
Share_NN
Options_NOMZ
Scheme_NN
SHL_NN
Scheme_NN
Options_NOMZ
issued_VBN
under_IN
the_DT
SHL_NN
Scheme_NN
were_VBD [SPAU] [PASS]
originally_TIME
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Shire_NN
Holdings_GER
Limited_NN
,_,
a_DT
previous_JJ
holding_VBG [PRIV]
company_NN
of_PIN
the_DT
Group_NN
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
common_JJ
shares_NN
in_PIN
Shire_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
SHL_NN
Plan_NN
._.
ii_FW
Shire_FW
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
On_PIN
28_CD
February_NN
2000_CD
,_,
the_DT
Remuneration_NOMZ
Committee_NN
of_PIN
the_DT
Board_NN
exercised_VBD
its_PIT
powers_NN
to_TO
amend_VB
the_DT
terms_NN
of_PIN
the_DT
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
so_RB
as_IN
to_TO
include_VB
a_DT
cliff_NN
vesting_VBG [WZPRES]
provision_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
._.
iii_FW
Shire_FW
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
2000_CD
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
unless_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
period_NN
._.
During_PIN
2002_CD
,_,
the_DT
performance_NN
criteria_NN
was_VBD [SPAU] [PASS]
again_TIME
reviewed_VBN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
criteria_NN
reflected_VBD [PRIV]
the_DT
market_NN
in_PIN
which_WDT [PIRE]
the_DT
Company_NN
operates_VPRT
._.
Therefore_CONJ
the_DT
performance_NN
criteria_NN
was_VBD [PASS]
amended_VBN
so_RB
that_DEMO
options_NOMZ
will_PRMD [SPAU]
only_DWNT
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
the_DT
Companys_NN
EPS_NN
growth_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
RPI_NN
over_IN
at_PIN
least_JJ
a_DT
three-year_JJ
period_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
3_CD
%_NN
RPI_NN
plus_PIN
5_CD
%_NN
for_PIN
Executive_NN
Directors_NN
per_PIN
annum_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
5_CD
%_NN
per_PIN
annum_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
7_CD
%_NN
per_PIN
annum_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
per_PIN
annum_NN
The_DT
adoption_NOMZ
of_PIN
the_DT
new_JJ
criteria_NN
applies_VPRT
to_PIN
all_QUAN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
from_PIN
August_NN
2002_CD
onwards_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
81_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
28_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
iv_JJ
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
v_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
,_,
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
vi_FW
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
Options_NOMZ
issued_VBN
under_IN
the_DT
SLI_NN
Plan_NN
were_VBD [SPAU] [PASS]
originally_TIME
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
SLI_NN
,_,
formerly_TIME
Pharmavene_NN
Inc._NN
a_DT
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Company_NN
on_PIN
23_CD
March_NN
1997_CD
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SLI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
share_NN
option_NOMZ
plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
SLI_NN
Plan_NN
._.
vii_FW
Roberts_NN
Stock_NN
Option_NOMZ
Plan_NN
Roberts_NN
Plan_NN
Options_NOMZ
issued_VBN
under_IN
the_DT
Roberts_NN
Plan_NN
were_VBD [SPAU] [PASS]
originally_TIME
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Roberts_NN
,_,
a_DT
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Company_NN
on_PIN
23_CD
December_NN
1999_CD
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
Roberts_NN
share_NN
option_NOMZ
plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Roberts_NN
Plan_NN
._.
viii_FW
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
Following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
,_,
Inc._NN
on_PIN
11_CD
May_POMD
2001_CD
,_,
the_DT
BioChem_NN
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChems_NN
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
All_QUAN
BioChem_NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD
not_XX0
already_RB
exercisable_PRED
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
._.
ix_FW
Richwood_NN
SRI_NN
Plan_NN
All_QUAN
options_NOMZ
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
SRI_NN
,_,
formerly_TIME
Richwood_NN
Pharmaceutical_NN
Company_NN
Inc._NN
a_DT
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
22_CD
August_NN
1997_CD
,_,
have_VPRT [PEAS]
been_VBN [PASS]
exercised_VBN
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
resulted_VBD
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SRI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
share_NN
option_NOMZ
plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
SRI_NN
Plan_NN
._.
In_PIN
a_DT
period_NN
of_PIN
ten_CD
years_NN
,_,
not_XX0
more_EMPH
than_PIN
10_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Shire_NN
may_POMD
be_VB [PASS]
placed_VBN
under_IN
option_NOMZ
under_IN
any_QUAN
employee_NN
share_NN
scheme_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
following_VBG
terms_NN
apply_VB
to_PIN
options_NOMZ
that_TSUB
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
various_JJ
plans_NN
:_:
2000_CD
Executive_NN
Scheme_NN
:_:
the_DT
maximum_JJ
number_NN
of_PIN
shares_NN
over_IN
which_WDT
incentive_NN
options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
Part_NN
3_CD
of_PIN
the_DT
scheme_NN
is_VPRT [BEMA]
25,000,000_CD
._.
Stock_NN
Purchase_NN
Plan_NN
:_:
up_RP
to_PIN
2,000,000_CD
common_JJ
shares_NN
._.
Options_NOMZ
outstanding_JJ
at_PIN
31_CD
December_NN
2002_CD
under_IN
the_DT
various_JJ
plans_NN
are_VPRT
as_IN
follows_VPRT
:_:
Expiry_JJ
period_NN
from_PIN
Scheme_NN
Number_NN
of_PIN
options_NOMZ
date_NN
of_PIN
issue_NN
Vesting_JJ
period_NN
Executive_NN
Scheme_NN
4,432,303_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
2000_CD
Executive_NN
Scheme_NN
8,104,356_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
Sharesave_NN
Scheme_NN
253,862_CD
6_CD
months_NN
after_IN
vesting_VBG
3_CD
or_CC
5_CD
years_NN
Stock_NN
Purchase_NN
Plan_NN
1,553,302_CD
27_CD
months_NN
SLI_NN
Plan_NN
40,084_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
Roberts_NN
Plan_NN
567,399_CD
6_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
BioChem_NN
Plan_NN
5,099,991_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
Total_NN
20,051,297_CD
Options_NOMZ
expire_VPRT
on_PIN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
._.
82_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
financial_JJ
consolidated_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
28_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
A_DT
summary_NN
of_PIN
the_DT
status_NN
of_PIN
the_DT
Companys_NN
stock_NN
option_NOMZ
plans_NN
as_IN
of_PIN
31_CD
December_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
,_,
and_ANDC
the_DT
related_JJ
transactions_NOMZ
during_PIN
the_DT
periods_NN
then_RB
ended_VBD
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
Weighted_JJ
average_JJ
exercise_NN
price_NN
Number_NN
of_PIN
$_$
shares_NN
Year_NN
ended_VBD
31_CD
December_NN
2002_CD
Outstanding_JJ
at_PIN
beginning_VBG
of_PIN
period_NN
10.80_CD
16,249,844_CD
Granted_VBN [SUAV]
8.49_CD
6,179,894_CD
Exercised_VBN
3.52_CD
1,940,546_CD
Forfeited_NN
11.07_CD
437,895_CD
Outstanding_JJ
at_PIN
end_NN
of_PIN
period_NN
11.55_CD
20,051,297_CD
Exercisable_JJ
at_PIN
end_NN
of_PIN
period_NN
9.24_CD
8,491,051_CD
4,539,529_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
issued_VBN
with_PIN
exercise_NN
prices_NN
equivalent_JJ
to_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
the_DT
Companys_NN
common_JJ
stock_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
as_IN
these_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
at_PIN
market_NN
prices_NN
._.
186,052_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
5.02_CD
approximately_RB
$_$
8.08_CD
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
were_VBD [PASS]
issued_VBN
to_PIN
employees_NN
._.
18,342_CD
and_CC
1,435,971_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
3.19_CD
and_CC
5.44_CD
approximately_RB
$_$
5.14_CD
and_CC
$_$
8.76_CD
respectively_RB
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
were_VBD [PASS]
issued_VBN
to_PIN
employees_NN
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
is_VPRT
$_$
8.91_CD
._.
Weighted_JJ
average_JJ
exercise_NN
price_NN
Number_NN
of_PIN
$_$
shares_NN
Year_NN
ended_VBD
31_CD
December_NN
2001_CD
Outstanding_JJ
at_PIN
beginning_VBG
of_PIN
period_NN
7.83_CD
24,790,322_CD
Granted_VBN [SUAV]
17.24_CD
4,405,089_CD
Exercised_VBN
6.29_CD
11,443,831_CD
Forfeited_NN
13.86_CD
1,501,736_CD
Outstanding_JJ
at_PIN
end_NN
of_PIN
period_NN
10.80_CD
16,249,844_CD
Exercisable_JJ
at_PIN
end_NN
of_PIN
period_NN
7.50_CD
9,054,150_CD
All_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
,_,
2000_CD
Executive_NN
Scheme_NN
and_PHC
BioChem_NN
Plan_NN
were_VBD [PASS]
issued_VBN
with_PIN
exercise_NN
prices_NN
equivalent_JJ
to_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
the_DT
Companys_NN
common_JJ
stock_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
as_IN
these_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
at_PIN
market_NN
prices_NN
._.
81,888_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
8.41_CD
approximately_RB
$_$
12.24_CD
._.
301,656_CD
,_,
120,819_CD
and_CC
6,551_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
8.06_CD
,_,
9.10_CD
and_CC
9.74_CD
approximately_RB
$_$
11.73_CD
,_,
$_$
13.24_CD
and_CC
$_$
14.18_CD
respectively_RB
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2001_CD
is_VPRT
$_$
17.51_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
83_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
28_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
Weighted_JJ
average_JJ
exercise_NN
price_NN
Number_NN
of_PIN
$_$
shares_NN
Year_NN
ended_VBD
31_CD
December_NN
2000_CD
Outstanding_JJ
at_PIN
beginning_VBG
of_PIN
period_NN
5.99_CD
32,540,132_CD
Granted_VBN [SUAV]
14.53_CD
4,386,258_CD
Exercised_VBN
4.30_CD
11,491,088_CD
Forfeited_NN
10.95_CD
644,980_CD
Outstanding_JJ
at_PIN
end_NN
of_PIN
period_NN
7.83_CD
24,790,322_CD
Exercisable_JJ
at_PIN
end_NN
of_PIN
period_NN
6.84_CD
13,385,095_CD
All_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
,_,
2000_CD
Executive_NN
Scheme_NN
and_PHC
BioChem_NN
Plan_NN
were_VBD [PASS]
issued_VBN
with_PIN
exercise_NN
prices_NN
equivalent_JJ
to_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
Shires_NN
common_JJ
stock_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
as_IN
these_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
at_PIN
market_NN
prices_NN
._.
79,424_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
8.56_CD
approximately_RB
$_$
12.79_CD
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
is_VPRT
$_$
8.80_CD
._.
This_DEMP
continues_VPRT
to_TO
be_VB [PASS]
included_VBN
within_PIN
investments_NOMZ
note_VPRT [PRIV]
10_CD
._.
Arenol_NN
loan_NN
note_NN
conversion_NN
In_PIN
1999_CD
the_DT
Company_NN
financed_VBN
the_DT
purchase_NN
of_PIN
intellectual_JJ
property_NN
relating_VBG [WZPRES]
to_PIN
the_DT
manufacture_NN
of_PIN
ADDERALL_NN
from_PIN
Arenol_NN
Corporation_NOMZ
by_PIN
a_DT
total_NN
of_PIN
$_$
11.8_CD
million_CD
in_PIN
unsecured_JJ
convertible_JJ
zero_CD
coupon_NN
loan_NN
notes_NN
._.
On_PIN
6_CD
August_NN
2002_CD
,_,
the_DT
Company_NN
issued_VBD
the_DT
final_JJ
instalment_NOMZ
of_PIN
267,572_CD
ordinary_JJ
shares_NN
to_PIN
Arenol_NN
Corporation_NOMZ
in_PIN
consideration_NOMZ
of_PIN
the_DT
conversion_NN
of_PIN
the_DT
loan_NN
notes_NN
in_PIN
the_DT
Company_NN
._.
Qualia_NN
Computing_GER
Inc._NN
joint_JJ
venture_NN
In_PIN
September_NN
2002_CD
,_,
the_DT
Company_NN
sold_VBD
the_DT
net_JJ
assets_NN
of_PIN
its_PIT
CADx_NN
group_NN
of_PIN
companies_NN
,_,
to_PIN
Qualia_NN
Computing_GER
Inc._NN
in_PIN
exchange_NN
for_PIN
50_CD
%_NN
of_PIN
the_DT
common_JJ
stock_NN
in_PIN
the_DT
joint_JJ
venture_NN
._.
The_DT
value_NN
of_PIN
the_DT
assets_NN
in_PIN
the_DT
CADx_NN
group_NN
of_PIN
companies_NN
at_PIN
the_DT
time_NN
of_PIN
transfer_NN
was_VBD
$_$
9.3_CD
million_CD
._.
Quarterly_JJ
results_NN
of_PIN
operations_NOMZ
unaudited_JJ
The_DT
following_VBG
table_NN
presents_NN
summarised_VBN
unaudited_JJ
quarterly_JJ
results_NN
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2002_CD
and_CC
2001_CD
._.
The_DT
unaudited_JJ
quarterly_JJ
results_NN
for_PIN
2001_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
merger_NN
with_PIN
BioChem_NN
._.
The_DT
results_NN
for_PIN
all_QUAN
quarterly_JJ
periods_NN
presented_VBN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
OTC_NN
divestment_NOMZ
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
._.
142_CD
with_PIN
effect_NN
from_PIN
1_CD
January_NN
2002_CD
,_,
the_DT
amortisation_NOMZ
expense_NN
shown_VBN [PRIV] [WZPAST]
for_PIN
2002_CD
in_PIN
the_DT
selected_VBN
consolidated_JJ
financial_JJ
data_NN
presented_VBN
below_PLACE
is_VPRT [BEMA]
not_XX0
on_PIN
a_DT
consistent_JJ
basis_NN
of_PIN
accounting_GER
with_PIN
earlier_TIME
periods_NN
._.
the_DT
impact_NN
of_PIN
this_DEMP
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
note_NN
12_CD
of_PIN
our_FPP1
consolidated_JJ
financial_JJ
statements_NOMZ
included_VBD
herein_NN
._.
Balance_NN
sheet_NN
data_NN
Total_JJ
current_JJ
assets_NN
1,467,096_CD
1,140,555_CD
695,853_CD
520,023_CD
445,972_CD
Total_JJ
assets_NN
2,208,623_CD
1,910,731_CD
1,548,495_CD
1,351,791_CD
1,210,153_CD
Total_JJ
current_JJ
liabilities_NOMZ
213,271_CD
231,616_CD
227,850_CD
233,818_CD
99,770_CD
Total_JJ
liabilities_NOMZ
635,457_CD
647,742_CD
374,109_CD
471,905_CD
236,921_CD
Total_JJ
shareholders_NN
equity_NOMZ
1,573,166_CD
1,262,989_CD
1,174,386_CD
879,886_CD
973,232_CD
86_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
General_NN
This_DEMO
summary_NN
financial_JJ
statement_NOMZ
does_VPRT
not_XX0
contain_VB
sufficient_JJ
information_NOMZ
to_TO
allow_VB [SUAV]
for_PIN
a_DT
full_JJ
understanding_GER
of_PIN
the_DT
results_NN
and_PHC
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
or_CC
Group_NN
._.
The_DT
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [PASS]
prepared_VBN
under_IN
UK_NN
GAAP_NN
._.
For_PIN
further_JJ
information_NOMZ
,_,
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
,_,
the_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
and_CC
the_DT
directors_NN
report_NN
should_NEMD
be_VB [PASS]
consulted_VBN
._.
In_PIN
accordance_NN
with_PIN
Section_NOMZ
239_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
shareholders_NN
have_VPRT
a_DT
right_NN
and_CC
can_POMD
elect_VB
to_TO
obtain_VB
the_DT
full_JJ
reports_NN
and_PHC
accounts_NN
free_JJ
of_PIN
charge_NN
by_PIN
writing_VBG [PUBV]
to_TO
:_:
The_DT
Company_NN
Secretary_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Chineham_NN
Basingstoke_NN
Hampshire_NN
RG24_NN
8EP_NN
The_NN
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
are_VPRT [PASS]
signed_VBN
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
by_PIN
A_DT
C_NN
Russell_NN
,_,
Group_NN
Finance_NN
Director_NN
._.
The_DT
Companys_NN
auditors_NN
have_VPRT [PEAS]
given_VBN
an_DT
unqualified_JJ
report_NN
on_PIN
the_DT
statutory_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
._.
The_DT
report_NN
did_VBD
not_XX0
contain_VB
a_DT
statement_NOMZ
under_IN
Section_NOMZ
237_CD
2_CD
or_CC
3_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
87_CD
Summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
Independent_NN
auditors_NN
statement_NOMZ
to_PIN
the_DT
members_NN
of_PIN
Summary_NN
directors_NN
report_VPRT [PUBV]
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
:_:
Results_NN
and_PHC
dividends_NN
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
summary_NN
financial_JJ
statement_NOMZ
which_WDT [WHSUB]
comprises_VPRT
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
of_PIN
the_DT
Group_NN
was_VBD [BEMA]
the_DT
summary_NN
directors_NN
report_NN
,_,
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
,_,
526.8_CD
million_CD
2001_CD
:_:
profit_NN
81.4_CD
million_CD
._.
The_DT
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
consolidated_JJ
balance_NN
sheet_NN
,_,
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
and_CC
as_RB
at_PIN
31_CD
December_NN
2002_CD
were_VBD [BEMA]
2,747.7_CD
million_CD
2001_CD
:_:
3,393.9_CD
million_CD
._.
notes_NN
1_CD
to_PIN
3_CD
of_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
._.
The_DT
directors_NN
do_VPRT
not_XX0
recommend_VB [SUAV]
the_DT
payment_NOMZ
of_PIN
a_DT
dividend_NN
._.
This_DEMO
statement_NOMZ
is_VPRT [PASS]
made_VBN
solely_RB
to_PIN
the_DT
Company_NN
's_POS
members_NN
,_,
as_IN
a_DT
body_NN
,_,
in_PIN
accordance_NN
with_PIN
section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Our_FPP1
work_NN
Business_NOMZ
review_NN
has_VPRT [PEAS]
been_VBN [PASS]
undertaken_VBN
so_OSUB
that_NULL
we_FPP1
might_POMD
state_VB [PUBV]
to_PIN
the_DT
companys_NN
members_NN
A_DT
review_NN
of_PIN
the_DT
Groups_NN
business_NOMZ
and_CC
important_JJ
events_NN
during_PIN
the_DT
year_NN
those_DEMO
matters_NN
we_FPP1
are_VPRT [PASS]
required_VBN [SUAV]
to_PIN
state_NN
to_PIN
them_TPP3
in_PIN
an_DT
auditors_NN
report_NN
and_CC
and_CC
likely_JJ
future_NN
developments_NOMZ
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Chairmans_NN
review_NN
,_,
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
To_PIN
the_DT
fullest_JJ
extent_NN
permitted_VBN [WZPAST]
by_PIN
law_NN
,_,
we_FPP1
do_VPRT
not_XX0
the_DT
Chief_NN
Executives_NN
review_NN
,_,
the_DT
financial_JJ
review_NN
and_CC
the_DT
directors_NN
accept_VPRT [PRIV]
or_CC
assume_VPRT [PRIV]
responsibility_NOMZ
to_PIN
anyone_QUPR
other_JJ
than_PIN
the_DT
Company_NN
and_PHC
remuneration_NOMZ
report_NN
in_PIN
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
,_,
which_WDT [SERE]
the_DT
Companys_NN
members_NN
as_IN
a_DT
body_NN
,_,
for_PIN
our_FPP1
audit_NN
work_NN
,_,
for_PIN
this_DEMO
report_NN
,_,
are_VPRT [BEMA]
similar_PRED
to_PIN
the_DT
statements_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
annual_JJ
review_NN
at_PIN
the_DT
front_NN
for_PIN
our_FPP1
audit_NN
report_NN
,_,
or_CC
for_PIN
the_DT
opinions_NN
we_FPP1
have_VPRT [PEAS]
formed_VBN
._.
of_PIN
this_DEMO
document_NOMZ
which_WDT [WHSUB]
form_VPRT
part_NN
of_PIN
this_DEMO
summary_NN
financial_JJ
statement_NOMZ
._.
Respective_JJ
responsibilities_NOMZ
of_PIN
directors_NN
and_PHC
auditors_NN
Directors_NN
The_DT
directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
summarised_JJ
annual_JJ
The_DT
directors_NN
who_WP [WHSUB]
served_VBD
during_PIN
the_DT
year_NN
were_VBD
as_IN
follows_VPRT
:_:
report_NN
in_PIN
accordance_NN
with_PIN
applicable_JJ
United_NN
Kingdom_NN
law_NN
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
consistency_NN
of_PIN
the_DT
Dr_NN
James_NN
Cavanaugh_NN
Chairman_NN
and_CC
Non-executive_JJ
Director_NN
summary_NN
financial_JJ
statement_NOMZ
with_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
the_DT
directors_NN
Chairman_NN
Nomination_NOMZ
Committee_NN
report_NN
and_CC
the_DT
directors_NN
remuneration_JJ
report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
Mr_NN
Matthew_NN
Emmens_NN
Chief_NN
Executive_NN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
Appointed_VBN
12_CD
March_NN
2003_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
summarised_JJ
annual_JJ
report_NN
as_IN
described_VBN
Mr_NN
Rolf_NN
Stahel_NN
Former_NN
Chief_NN
Executive_NN
in_PIN
the_DT
contents_NN
section_NOMZ
,_,
and_ANDC
consider_VB [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
Stepped_VBD
down_RP
19_CD
March_NN
2003_CD
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
Mr_NN
Angus_NN
Russell_NN
Group_NN
Finance_NN
Director_NN
inconsistencies_NN
with_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
._.
Dr_NN
Wilson_NN
Totten_NN
Group_NN
R&D_NN
Director_NN
Basis_NN
of_PIN
opinion_NN
We_FPP1
conducted_VBD
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
bulletin_NN
1999_CD
6_CD
The_DT
Auditors_NN
Dr_NN
Barry_NN
Price_NN
Senior_NN
Non-executive_JJ
Director_NN
Statement_NOMZ
on_PIN
the_DT
Summary_NN
Financial_NN
Statement_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
United_NN
Chairman_NN
Remuneration_NOMZ
Committee_NN
Kingdom_NN
Auditing_GER
Practices_NN
Board_NN
._.
Dr_NN
Francesco_NN
Bellini_NN
Non-executive_JJ
Director_NN
Opinion_NN
Dr_NN
Bernard_NN
Canavan_NN
Non-executive_JJ
Director_NN
In_PIN
our_FPP1
opinion_NN
,_,
the_DT
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [BEMA]
consistent_PRED
with_PIN
Deceased_JJ
8_CD
August_NN
2002_CD
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
the_DT
directors_NN
report_NN
and_CC
the_DT
directors_NN
remuneration_JJ
report_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
for_PIN
the_DT
year_NN
The_DT
Hon_NN
James_NN
Grant_NN
Non-executive_JJ
Director_NN
ended_VBD
31_CD
December_NN
2002_CD
and_CC
Companies_NN
Act_NN
1985_CD
,_,
and_ANDC
the_DT
Mr_NN
Ronald_NN
Nordmann_NN
Non-executive_JJ
Director_NN
regulations_NOMZ
made_VBD
thereunder_RB
._.
Chairman_NN
Audit_NN
Committee_NN
Deloitte_NN
&_CC
Touche_NN
Mr_NN
Grard_NN
Veilleux_NN
Non-executive_JJ
Director_NN
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
Reading_VBG [WZPRES]
1_CD
May_POMD
2003_CD
88_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
Consolidated_NN
profit_NN
and_PHC
loss_NN
account_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
31_CD
December_NN
2002 2001 000 000_CD
Turnover_NN
:_:
group_NN
and_PHC
share_NN
of_PIN
joint_JJ
venture_NN
696,661_CD
563,249_CD
Less_RB
:_:
share_NN
of_PIN
joint_JJ
ventures_NN
turnover_NN
762_CD
Group_NN
turnover_NN
on_PIN
continuing_VBG
operations_NOMZ
695,899_CD
563,249_CD
Acquisitions_NOMZ
653_CD
Continuing_VBG
operations_NOMZ
696,552_CD
563,249_CD
Discontinued_VBN
operations_NOMZ
15,975_CD
17,120_CD
Group_NN
turnover_NN
712,527_CD
580,369_CD
Cost_NN
of_PIN
sales_NN
95,042_CD
83,149_CD
Gross_NN
profit_NN
617,485_CD
497,220_CD
Net_JJ
operating_GER
expenses_NN
including_VBG [WZPRES]
613,983,000_CD
exceptional_JJ
goodwill_NN
impairment_NOMZ
1,150,630_CD
420,798_CD
Operating_GER
loss_NN
profit_NN
533,145_CD
76,422_CD
Continuing_VBG
operations_NOMZ
Group_NN
539,772_CD
68,972_CD
Acquisitions_NOMZ
1,831_CD
541,603_CD
68,972_CD
Discontinued_VBN
operations_NOMZ
8,458_CD
7,450_CD
533,145_CD
76,422_CD
Share_NN
of_PIN
joint_JJ
ventures_NN
operating_VBG [WZPRES]
loss_NN
559_CD
Finance_NN
charges_NN
,_,
net_JJ
6,931_CD
4,955_CD
Loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
526,773_CD
81,377_CD
Tax_NN
on_PIN
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
61,626_CD
45,668_CD
Retained_VBN
loss_NN
profit_NN
for_PIN
the_DT
year_NN
transferred_VBN [WZPAST]
from_PIN
to_PIN
reserves_NN
588,399_CD
35,709_CD
Loss_NN
earnings_GER
per_PIN
share_NN
basic_JJ
117.5_CD
p_NN
8.7_CD
p_NN
diluted_VBN
117.5_CD
p_NN
8.5_CD
p_NN
Consolidated_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
2002 2001 000 000_CD
Loss_NN
profit_NN
for_PIN
the_DT
year_NN
588,399_CD
35,709_CD
Translation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
overseas_PLACE
subsidiaries_NN
62,739_CD
6,640_CD
Total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
year_NN
651,138_CD
29,069_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
89_CD
Summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
Consolidated_NN
balance_NN
sheet_NN
31_CD
December_NN
31_CD
December_NN
2002 2001 000 000_CD
Fixed_JJ
assets_NN
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
183,404_CD
259,850_CD
Intangible_JJ
assets_NN
goodwill_NN
1,900,896_CD
2,643,578_CD
Tangible_JJ
assets_NN
84,001_CD
77,880_CD
Fixed_VBN
asset_NN
investments_NOMZ
37,345_CD
45,045_CD
Investment_NOMZ
in_PIN
joint_JJ
ventures_NN
share_NN
of_PIN
gross_JJ
assets_NN
5,082_CD
share_NN
of_PIN
gross_JJ
liabilities_NOMZ
342_CD
2,210,386_CD
3,026,353_CD
Current_JJ
assets_NN
Stocks_NN
30,571_CD
32,080_CD
Debtors_NN
due_JJ
within_PIN
one_CD
year_NN
excluding_VBG [WZPRES]
deferred_JJ
tax_NN
106,125_CD
159,586_CD
due_JJ
after_IN
one_CD
year_NN
deferred_VBN
tax_NN
21,646_CD
13,351_CD
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
excluding_VBG [WZPRES]
deferred_JJ
tax_NN
9,535_CD
11,953_CD
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
deferred_VBN
tax_NN
3,861_CD
8,845_CD
Current_JJ
asset_NN
investments_NOMZ
196,364_CD
497,397_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
558,432_CD
81,434_CD
926,534_CD
804,646_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Convertible_JJ
debt_NN
1,032_CD
Other_JJ
creditors_NN
131,885_CD
158,229_CD
131,885_CD
159,261_CD
Net_JJ
current_JJ
assets_NN
794,649_CD
645,385_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
3,005,035_CD
3,671,738_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Convertible_JJ
debt_NN
243,547_CD
268,178_CD
Other_JJ
creditors_NN
13,782_CD
9,654_CD
257,329_CD
277,832_CD
Net_JJ
assets_NN
2,747,706_CD
3,393,906_CD
Capital_NN
and_PHC
reserves_NN
Called-up_JJ
share_NN
capital_NN
24,217_CD
24,091_CD
Share_NN
premium_NN
3,214,512_CD
3,206,280_CD
Exchangeable_JJ
shares_NN
191,552_CD
194,972_CD
Capital_NN
reserve_NN
2,755_CD
2,755_CD
Other_JJ
reserves_NN
24,247_CD
24,247_CD
Profit_NN
and_PHC
loss_NN
account_NN
709,577_CD
58,439_CD
Equity_NOMZ
shareholders_NN
funds_NN
2,747,706_CD
3,393,906_CD
90_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
Consolidated_NN
cash_NN
flow_NN
statement_NOMZ
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
31_CD
December_NN
2002 2001 000 000_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
302,321_CD
202,876_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
:_:
Interest_NN
and_CC
other_JJ
income_NN
received_VBD
15,434_CD
13,077_CD
Interest_NN
paid_VBN
8,458_CD
8,122_CD
Interest_NN
element_NOMZ
of_PIN
finance_NN
lease_NN
rentals_NN
45_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
6,931_CD
4,955_CD
Taxation_NOMZ
:_:
Corporation_NOMZ
tax_NN
paid_VBN
73,145_CD
44,982_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
:_:
Purchase_NN
of_PIN
long-term_JJ
investment_NOMZ
2,957_CD
Purchase_NN
of_PIN
intangible_JJ
fixed_JJ
assets_NN
15,470_CD
20,159_CD
Purchase_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
15,014_CD
9,593_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
44,103_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
fixed_JJ
assets_NN
3,200_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
542_CD
4,974_CD
Net_JJ
cash_NN
inflow_NN
outflow_NN
for_PIN
capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
11,204_CD
21,578_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
:_:
Purchase_NN
of_PIN
subsidiary_NN
undertaking_GER
11,647_CD
Expenses_NN
of_PIN
acquisitions_NOMZ
235_CD
16,450_CD
Net_JJ
cash_NN
acquired_VBN [WZPAST]
with_PIN
subsidiary_NN
undertakings_GER
33_CD
44,452_CD
Net_JJ
cash_NN
outflow_NN
inflow_NN
from_PIN
acquisitions_NOMZ
11,849_CD
28,002_CD
Cash_NN
inflow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
235,462_CD
169,273_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
:_:
Decrease_NN
increase_NN
in_PIN
cash_NN
placed_VBN [WZPAST]
on_PIN
short-term_JJ
deposit_NN
254,561_CD
325,479_CD
Financing_GER
:_:
Issue_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
1,050_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
3,985_CD
46,961_CD
Expenses_NN
of_PIN
share_NN
issues_NN
23,584_CD
Capital_NN
element_NOMZ
of_PIN
finance_NN
leases_VPRT
74_CD
Net_JJ
decrease_NN
increase_NN
in_PIN
debt_NN
during_PIN
the_DT
year_NN
832_CD
182,808_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
financing_VBG
3,079_CD
207,235_CD
Increase_VPRT
in_PIN
cash_NN
in_PIN
the_DT
year_NN
493,102_CD
51,029_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
91_CD
Notes_NN
to_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
Notes_NN
to_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2002_CD
For_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2002_CD
1_CD
Basis_NN
of_PIN
preparation_NOMZ
The_DT
summary_NN
financial_JJ
statement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
policies_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
._.
2_CD
Directors_NN
remuneration_NOMZ
,_,
interests_NN
and_PHC
transactions_NOMZ
Aggregate_JJ
directors_NN
remuneration_VPRT
The_DT
total_JJ
amounts_NN
for_PIN
directors_NN
remuneration_NOMZ
and_CC
other_JJ
benefits_NN
were_VBD
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Years_NN
ended_VBD
31_CD
December_NN
000_CD
000_CD
Emoluments_NOMZ
2,300_CD
2,019_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
2,754_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
2,962_CD
22,005_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
383_CD
103_CD
Total_JJ
5,645_CD
26,881_CD
Directors_NN
emoluments_NOMZ
and_PHC
compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
Fees_NN
basic_JJ
Taxable_NN
Annual_JJ
salary_NN
benefits_NN
bonus_NN
2002_CD
2001_CD
Director_NN
000 000 000 000_CD
000_CD
Executive_NN
directors_NN
Mr_NN
Rolf_NN
Stahel_NN
559_CD
26_CD
559_CD
1,144_CD
726_CD
Mr_NN
Angus_NN
Russell_NN
290 26 128 444_CD
393_CD
Dr_NN
Wilson_NN
Totten_NN
310 30 141 481_CD
419_CD
Non-executive_JJ
directors_NN
Dr_NN
James_NN
Cavanaugh_NN
45_CD
45_CD
42_CD
Dr_NN
Barry_NN
Price_NN
37_CD
37_CD
31_CD
Dr_NN
Francesco_NN
Bellini_NN
30_CD
30_CD
3,012_CD
The_DT
late_TIME
Dr_NN
Bernard_NN
Canavan_NN
23_CD
23_CD
60_CD
The_DT
Hon_NN
James_NN
Grant_NN
30_CD
30_CD
19_CD
Dr_NN
Zola_NN
Horovitz_NN
7_CD
Mr_NN
Ronald_NN
Nordmann_NN
34_CD
34_CD
29_CD
Mr_NN
Joseph_NN
Smith_NN
7_CD
Mr_NN
John_NN
Spitznagel_NN
7_CD
Mr_NN
Grard_NN
Veilleux_NN
32_CD
32_CD
21_CD
Total_JJ
1,390_CD
82_CD
828_CD
2,300_CD
4,773_CD
92_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
For_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2002_CD
3_CD
Loss_NN
earnings_GER
per_PIN
share_NN
Loss_NN
earnings_GER
per_PIN
share_NN
EPS_NN
has_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
for_PIN
each_QUAN
period_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
during_PIN
those_DEMO
periods_NN
._.
The_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
fully_AMP
diluted_VBN
earnings_GER
per_PIN
share_NN
has_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
for_PIN
the_DT
effects_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
._.
The_DT
$_$
400_CD
million_CD
convertible_JJ
loan_NN
note_NN
is_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
calculation_NOMZ
of_PIN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
for_PIN
fully_AMP
diluted_VBN
earnings_GER
per_PIN
share_NN
in_PIN
2002_CD
and_CC
2001_CD
as_IN
it_PIT
was_VBD [BEMA]
not_XX0
dilutive_PRED
._.
The_DT
zero_CD
coupon_NN
convertible_JJ
loan_NN
note_NN
included_VBD
in_PIN
2001_CD
has_VPRT
no_SYNE
impact_NN
on_PIN
the_DT
numerator_NN
for_PIN
fully_AMP
diluted_VBN
earnings_GER
per_PIN
share_NN
._.
Years_NN
ended_VBD
31_CD
December_NN
2002_CD
2001_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
117.5_CD
p_VPRT
8.7_CD
p_JJ
Diluted_JJ
earnings_GER
per_PIN
share_NN
117.5_CD
p_NN
8.5_CD
p_NN
Basic_JJ
earnings_GER
per_PIN
share_NN
weighted_VBN
average_JJ
shares_NN
500,687,594_CD
412,183,058_CD
Conversion_NN
of_PIN
convertible_JJ
debt_NN
289,101_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
6,270,923_CD
Exercise_NN
of_PIN
warrants_NN
919,029_CD
Fully_AMP
diluted_VBN
earnings_GER
per_PIN
share_NN
weighted_VBN
average_JJ
shares_NN
500,687,594_CD
419,662,111_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
93_CD
Shire_NN
head_NN
office_NN
and_CC
main_JJ
operating_GER
locations_NOMZ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
Italia_NN
S._NN
p._NN
A_NN
Shire_NN
Biologics_NN
Inc._NN
._.
Chief_NN
Executive_NN
:_:
Matthew_NN
Emmens_NN
General_NN
Manager_NN
:_:
Riccardo_NN
Palmisano_NN
Canada_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Via_PIN
Lucchese_NN
70_CD
President_NN
:_:
Randal_NN
Chase_NN
Chineham_NN
,_,
Basingstoke_NN
Sesto_NN
Fiorentino_NN
50019_CD
Firenze_NN
,_,
Italy_NN
275_CD
,_,
Armand-Frappier_NN
Blvd_NN
Hampshire_NN
RG24_NN
8EP_NN
,_,
UK_NN
Laval_NN
,_,
Quebec_NN
,_,
Canada_NN
H7V_NN
4A7_NN
Tel_NN
39_CD
0_CD
5530_CD
250_CD
50_CD
Tel_NN
44_CD
0_CD
1256 894 000_CD
Fax_NN
39_CD
0_CD
5530_CD
250_CD
51_CD
Tel_NN
1_CD
450 978 7800_CD
Fax_NN
44_CD
0_CD
1256 894 708_CD
Fax_NN
1_CD
450 978 7755_CD
Shire_NN
Pharmaceuticals_NN
Iberica_NN
SL_NN
Shire_NN
Pharmaceuticals_NN
Limited_NN
Managing_VBG [WZPRES]
Director_NN
:_:
2323_CD
du_NN
Parc_NN
Technologique_NN
Blvd_NN
Managing_VBG [WZPRES]
Director_NN
:_:
John_NN
Freeman_NN
Jos_NN
Antonio_NN
Senz_NN
fide_NN
Broto_NN
Sainte-Foy_NN
,_,
Quebec_NN
,_,
Canada_NN
G1P_NN
4RB_NN
Tel_NN
1_CD
418 650 0010_CD
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
C_NN
Benito_NN
Gutierrez_NN
Fax_NN
1_CD
418 650 0080_CD
Chineham_NN
,_,
Basingstoke_NN
261B_NN
,_,
28008_CD
Madrid_NN
,_,
Spain_NN
Hampshire_NN
RG24_NN
8EP_NN
,_,
UK_NN
Tel_NN
34_CD
9_CD
1550_CD
0691_CD
US_FPP1
Tel_NN
44_CD
0_CD
1256 894 000_CD
Shire_NN
US_FPP1
,_,
Inc._NN
._.
Senior_JJ
Vice_NN
President_NN
R&D_NN
:_:
Ronald_NN
Ellis_NN
Fax_NN
44_CD
0_CD
1256 894 708_CD
President_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
:_:
30_CD
Bearfoot_NN
Rd_NN
William_NN
Nuerge_NN
Northborough_NN
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Limited_NN
Director_NN
and_PHC
General_NN
Manager_NN
:_:
Brian_NN
Martin_NN
One_CD
Riverfront_NN
Place_NN
MA_NN
01532_CD
,_,
USA_NN
Newport_NN
,_,
KY_NN
41071_CD
,_,
USA_NN
Tel_NN
1_CD
508 351-9944_CD
Pharmapark_NN
,_,
Chapelizod_NN
Tel_NN
1_CD
800 828 2088_CD
Fax_NN
1_CD
508 351-9675_CD
Dublin_NN
20_CD
,_,
Ireland_NN
Tel_NN
1_CD
859 669 8000_CD
Tel_NN
00_CD
353_CD
1_CD
630_CD
5411_CD
Fax_NN
1_CD
859 669 8414_CD
Shire_NN
BioChem_NN
Inc._NN
._.
Fax_NN
00_CD
353_CD
1_CD
623_CD
7469_CD
President_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
:_:
Shire_NN
US_FPP1
Manufacturing_GER
,_,
Inc._NN
._.
Joseph_NN
Rus_NN
Shire_NN
Pharmaceutical_NN
Contracts_NN
Limited_NN
Senior_NN
Vice_NN
President_NN
of_PIN
Operations_NOMZ
:_:
Singapore_NN
representative_JJ
office_NN
275_CD
,_,
Armand-Frappier_NN
Blvd_NN
John_NN
Lee_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Tony_NN
Ooi_NN
Laval_NN
,_,
Quebec_NN
,_,
Canada_NN
H7V_NN
4A7_NN
11200_CD
Gundry_NN
Lane_NN
Tel_NN
1_CD
450 978-7800_CD
LiFung_NN
Centre_NN
Owings_NN
Mills_NN
,_,
MD_NN
21117_CD
,_,
USA_NN
Fax_NN
1_CD
450 978-7755_CD
58_CD
Toh_NN
Guan_NN
Road_NN
#_#
03-03_CD
Tel_NN
1_CD
410 413 1000_CD
Singapore_NN
608829_CD
Fax_NN
1_CD
410 413 2000_CD
Tel_NN
65 568 0114_CD
Fax_NN
65 425 6330_CD
Shire_NN
Laboratories_NN
,_,
Inc._NN
._.
President_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
:_:
Shire_NN
Deutschland_NN
GmbH_NN
&_CC
Co_NN
KG_NN
Jack_NN
Khattar_NN
General_NN
Manager_NN
:_:
Leonhard_NN
Terp_NN
1550_CD
East_NN
Gude_NN
Drive_NN
Siegburger_NN
Strasse_NN
126_CD
Rockville_NN
,_,
MD_NN
20850_CD
,_,
USA_NN
D-50679_NN
Kln_NN
,_,
Germany_NN
Tel_NN
1_CD
301 838 2500_CD
Tel_NN
49 221 88047_CD
30_CD
Fax_NN
1_CD
301 838 2501_CD
Fax_NN
49 221 88047_CD
41_CD
Shire_NN
Pharmaceutical_NN
Development_NOMZ
,_,
Inc._NN
._.
Shire_NN
France_NN
S._NN
A._NN
Senior_NN
Vice_NN
President_NN
:_:
Simon_NN
Tulloch_NN
General_NN
Manager_NN
:_:
Vincent_NN
Lucet_NN
1901_CD
Research_NN
Boulevard_NN
160_CD
rue_NN
fide_NN
Paris_NN
Rockville_NN
,_,
MD_NN
20850_CD
,_,
USA_NN
92771_CD
Boulogne_NN
Cedex_NN
,_,
France_NN
Tel_NN
1_CD
240 453 6400_CD
Tel_NN
33_CD
1_CD
41_CD
10_CD
25_CD
25_CD
Fax_NN
1_CD
240 453 6404_CD
Fax_NN
33_CD
1_CD
41_CD
10_CD
92_CD
02_CD
94_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shareholder_NN
information_NOMZ
Registered_NN
office_NN
address_NN
US_FPP1
shareholders_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
i_FPP1
ADSs_NN
Chineham_NN
,_,
Basingstoke_NN
The_NN
Companys_NN
American_NN
Depository_NN
Shares_NN
Hampshire_NN
RG24_NN
8EP_NN
,_,
UK_NN
ADSs_NN
,_,
each_QUAN
representing_VBG
three_CD
ordinary_JJ
Registered_NN
in_PIN
England_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
Nasdaq_NN
national_JJ
No._NN
._.
2883758_CD
market_NN
under_IN
the_DT
symbol_NN
SHPGY_NN
._.
The_DT
Company_NN
files_VPRT
reports_NN
and_CC
other_JJ
documents_NOMZ
Investor_NN
relations_NOMZ
with_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
Global_NN
outside_PLACE
US_FPP1
and_PHC
Canada_NN
SEC_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
available_PRED
for_PIN
inspection_NOMZ
and_PHC
Cla_NN
Rosenfeld_NN
copying_GER
at_PIN
the_DT
SECs_NN
public_JJ
reference_NN
facilities_NOMZ
Tel_NN
44_CD
0_CD
1256 894 000_CD
or_CC
can_POMD
be_VB [BYPA]
obtained_VBN
by_PIN
writing_VBG [PUBV]
to_PIN
the_DT
Company_NN
Fax_NN
44_CD
0_CD
1256 894 716_CD
Secretary_NN
._.
com_NN
ii_FW
ADR_NN
Depositary_NN
www_NN
._.
com_NN
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
is_VPRT [BEMA]
the_DT
depositary_NN
for_PIN
Shire_NN
Pharmaceuticals_NN
Canada_NN
and_PHC
US_FPP1
Group_NN
plc._NN
._.
All_QUAN
enquiries_NN
concerning_VBG [WZPRES]
American_JJ
Gordon_NN
Ngan_NN
Depositary_NN
Receipts_NN
records_NN
,_,
certificates_NN
or_CC
Tel_NN
1_CD
450 978 7938_CD
transfer_NN
of_PIN
ordinary_JJ
shares_NN
into_PIN
ADSs_NN
should_NEMD
Fax_NN
1_CD
450 975 7755_CD
be_VB [PASS]
addressed_VBN
to_TO
:_:
Email_NN
ir@ca_NN
._.
com_NN
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
PO_NN
Box_NN
8205_CD
,_,
Boston_NN
Registrars_NN
and_CC
transfer_VB
office_NN
MA_NN
02266-8205_CD
,_,
USA_NN
All_QUAN
administrative_JJ
enquiries_NN
relating_VBG [WZPRES]
to_PIN
shareholdings_GER
should_NEMD
be_VB [PASS]
addressed_VBN
to_PIN
Lloyds_NN
Tel_NN
1_CD
781 575 4328_CD
TSB_NN
Registrars_NN
,_,
clearly_RB
stating_VBG [PUBV]
the_DT
registered_VBN
Fax_NN
1_CD
781 575 4088_CD
shareholders_NN
name_NN
and_PHC
address_NN
._.
Lloyds_NN
TSB_NN
Registrars_NN
The_DT
Causeway_NN
,_,
Worthing_GER
West_NN
Sussex_NN
BN99_NN
6DA_NN
,_,
UK_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
95_CD
Glossary_NN
5-hydroxytryptamine_JJ
5HT_NN
,_,
also_RB
known_VBN [PRIV]
as_IN
Dopamine_NN
A_NN
neurotransmitter_NN
that_TSUB
can_POMD
affect_VB
Pivotal_JJ
study_NN
A_DT
major_JJ
clinical_JJ
trial_NN
that_TSUB
has_VPRT
a_DT
enteramine_NN
or_CC
serotonin_NN
A_DT
neurotransmitter_NN
brain_NN
processes_VPRT
that_DEMO
control_NN
movement_NOMZ
,_,
significant_JJ
impact_NN
on_PIN
the_DT
labeling_VBG
approved_VBN
that_DEMP
can_POMD
affect_VB
mood_NN
,_,
aggression_NN
and_CC
other_JJ
emotional_JJ
response_NN
and_PHC
ability_NOMZ
to_TO
experience_VB
usage_NN
of_PIN
a_DT
drug_NN
CNS_NN
functions_NOMZ
pleasure_NN
and_PHC
pain_NN
Platelet_NN
A_NN
constituent_NN
of_PIN
blood_NN
that_TSUB
helps_VPRT
form_VB
ADHD_NN
See_VB [PRIV]
attention_NOMZ
deficit_NN
and_PHC
hyperactivity_NOMZ
Guanosine_NN
A_NN
nucleoside_NN
consisting_VBG [WZPRES]
of_PIN
clots_NN
to_TO
control_VB
bleeding_VBG
disorder_NN
guanine_NN
a_DT
component_NN
of_PIN
DNA_NN
and_PHC
RNA_NN
Preclinical_NN
Studies_NN
of_PIN
compounds_NN
conducted_VBN
Adverse_JJ
effects_NN
An_DT
undesirable_JJ
medical_JJ
linked_VBN
to_TO
ribose_VB
in_PIN
the_DT
laboratory_NN
,_,
in_PIN
isolated_JJ
tissues_NN
,_,
or_CC
in_PIN
living_VBG
occurrance_NN
in_PIN
a_DT
patient_NN
or_CC
clinical_JJ
trial_NN
subject_JJ
Meningitis_NN
An_DT
infection_NOMZ
of_PIN
the_DT
fluid_NN
of_PIN
animals_NN
Alzheimers_NN
disease_NN
A_DT
degenerative_JJ
brain_NN
a_DT
persons_NN
spinal_JJ
cord_NN
and_CC
the_DT
fluid_NN
that_TOBJ
Proof-of-concept_JJ
study_NN
A_DT
study_NN
intended_VBN [SUAV] [WZPAST]
to_PIN
disease_NN
that_TSUB
usually_RB
begins_VPRT
gradually_RB
,_,
causing_VBG
surrounds_NN
the_DT
brain_NN
show_NN
that_TOBJ
a_DT
hypothesis_NN
or_CC
concept_NN
is_VPRT [BEMA]
valid_PRED
a_DT
person_NN
to_TO
forget_VB [PRIV]
recent_JJ
events_NN
or_CC
familiar_JJ
Noradrenaline_NN
A_NN
neurotransmitter_NN
involved_VBD
Renal_JJ
osteodystrophy_NN
A_DT
bone_NN
disease_NN
that_TOBJ
tasks_NN
in_PIN
temperature_NN
regulation_NOMZ
,_,
appetite_NN
and_CC
occurs_VPRT
when_RB
the_DT
kidneys_NN
fail_VPRT
to_TO
maintain_VB [PUBV]
the_DT
Anemia_NN
A_NN
condition_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
number_NN
of_PIN
aggression_NN
proper_JJ
levels_NN
of_PIN
calcium_NN
and_PHC
phosphorus_NN
in_PIN
red_JJ
blood_NN
cells_NN
or_CC
the_DT
amount_NN
of_PIN
hemoglobin_NN
Nosocomial_NN
infection_NOMZ
An_DT
infection_NOMZ
originating_VBG [WZPRES]
the_DT
blood_NN
in_PIN
a_DT
given_VBN
volume_NN
of_PIN
blood_NN
is_VPRT [BEMA]
less_PRED
than_PIN
normal_JJ
from_PIN
a_DT
hospital_NN
environment_NOMZ
that_TSUB
was_VBD
not_XX0
Retrovirus_NN
A_NN
type_NN
of_PIN
virus_NN
containing_VBG [WZPRES]
RNA_NN
Analgesic_NN
A_NN
pain-relieving_JJ
agent_NN
that_TSUB
does_VPRT
not_XX0
present_JJ
when_RB
the_DT
patient_NN
was_VBD [PASS]
admitted_VBN [PUBV]
instead_CONJ
of_NULL
DNA_NN
cause_NN
loss_NN
of_PIN
consciousness_NOMZ
Nucleoside_NN
reverse_VB
transcriptase_NN
Ribonucleic_NN
acid_NN
RNA_NN
A_NN
nucleic_JJ
acid_NN
found_VBD [PRIV]
Attention_NOMZ
deficit_NN
and_PHC
hyperactivity_NOMZ
disorder_NN
inhibitors_NN
A_DT
family_NN
of_PIN
antiviral_JJ
compounds_NN
in_PIN
all_QUAN
living_VBG
cells_NN
that_TSUB
plays_VPRT
a_DT
role_NN
in_PIN
the_DT
flow_NN
of_PIN
ADHD_NN
A_NN
CNS_NN
disorder_NN
characterised_VBN [WZPAST]
by_PIN
which_WDT [PIRE]
interfere_VPRT
with_PIN
the_DT
activity_NOMZ
of_PIN
the_DT
viral_JJ
genetic_JJ
information_NOMZ
inattention_NOMZ
,_,
impulsiveness_NOMZ
and_PHC
hyperactivity_NOMZ
enzyme_NN
reverse_VB
transcriptase_NN
Septicemia_NN
A_NN
life-threatening_JJ
condition_NOMZ
in_PIN
CNS_NN
Central_NN
nervous_JJ
system_NN
Pharmacokinetics_NN
The_NN
movements_NOMZ
of_PIN
which_WDT [PIRE]
the_DT
blood_NN
is_VPRT [BYPA]
infected_VBN
by_PIN
bacteria_NN
Cytidine_NN
A_NN
nucleoside_NN
consisting_VBG [WZPRES]
of_PIN
cytosine_NN
drugs_NN
within_PIN
biological_JJ
systems_NN
,_,
as_IN
affected_JJ
Serogroup_NN
A_NN
group_NN
of_PIN
bacteria_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
a_DT
component_NN
of_PIN
DNA_NN
and_PHC
RNA_NN
linked_VBD
to_PIN
by_PIN
uptake_NN
,_,
distribution_NOMZ
,_,
elimination_NOMZ
and_CC
contain_VB
a_DT
common_JJ
element_NOMZ
antigen_NN
that_TSUB
can_POMD
ribose_VB
biotransformation_NOMZ
elicit_VB
an_DT
immune_JJ
response_NN
Deoxyribonucleic_JJ
acid_NN
DNA_NN
The_DT
chemical_NN
Phase_NN
I_FPP1
Clinical_JJ
trials_NN
usually_RB
conducted_VBN
in_PIN
Stimulant_NN
A_NN
compound_NN
which_WDT [WHSUB]
increases_VPRT
the_DT
basis_NN
of_PIN
heredity_NOMZ
and_CC
the_DT
carrier_NN
of_PIN
genetic_JJ
healthy_JJ
human_JJ
volunteers_NN
to_TO
determine_VB [SUAV] [PRIV]
if_COND
a_DT
level_NN
of_PIN
neurotransmitters_NN
in_PIN
the_DT
brain_NN
information_NOMZ
drug_NN
candidate_NN
is_VPRT [BEMA]
safe_PRED
for_PIN
more_EMPH
extensive_JJ
Trigeminal_NN
neuralgia_NN
A_DT
painful_JJ
condition_NOMZ
DNA_NN
chain_NN
terminator_NN
A_DT
compound_NN
which_WDT [WHOBJ]
testing_GER
involving_VBG [WZPRES]
the_DT
trigeminal_JJ
nerve_NN
,_,
one_CD
of_PIN
the_DT
blocks_NN
the_DT
continuation_NOMZ
of_PIN
a_DT
DNA_NN
chain_NN
Phase_NN
II_NN
Clinical_NN
trials_NN
conducted_VBN [WZPAST]
in_PIN
patients_NN
largest_JJ
nerves_NN
in_PIN
the_DT
head_NN
,_,
characterised_VBN [PASTP]
by_PIN
DNA_NN
polymerase_NN
An_DT
enzyme_NN
that_TSUB
catalyses_VPRT
with_PIN
relevant_JJ
disease_NN
to_TO
assess_VB
the_DT
safety_NN
and_CC
sudden_JJ
,_,
severe_JJ
pain_NN
in_PIN
areas_NN
surrounding_VBG [WZPRES]
the_DT
elongation_NOMZ
of_PIN
DNA_NN
chains_NN
efficacy_NN
of_PIN
the_DT
drug_NN
candidate_NN
this_DEMO
nerve_NN
Phase_NN
III_NN
Clinical_JJ
trials_NN
conducted_VBN [WZPAST]
in_PIN
the_DT
target_NN
patient_NN
population_NOMZ
to_TO
assess_VB
comprehensively_RB
the_DT
safety_NN
and_PHC
efficacy_NN
of_PIN
the_DT
drug_NN
candidate_NN
Designed_VBN
and_PHC
produced_VBN
by_PIN
C&FD_NN
._.
Printed_NN
in_PIN
England_NN
by_PIN
St_NN
Ives_NN
Westerham_NN
Press_NN
,_,
environmentally_RB
accredited_VBN
printers_NN
ISO_NN
14001_CD
._.
This_DEMO
report_NN
is_VPRT [PASS]
printed_VBN
on_PIN
paper_NN
which_WDT [WHSUB]
is_VPRT [PASS]
made_VBN
from_PIN
50_CD
%_NN
totally_AMP
chlorine-free_JJ
pulp_NN
from_PIN
plantation_NOMZ
forests_NN
,_,
and_ANDC
from_PIN
50_CD
%_NN
recycled_JJ
and_PHC
fide-inked_JJ
fibers_NN
._.
It_PIT
is_VPRT [BEMA]
recyclable_PRED
and_PHC
bio-degradable_PRED
._.
96_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Glossary_NN
Shire_NN
trade_NN
marks_NN
Third-party_JJ
trade_NN
marks_NN
ADDERALL_NN
XR_NN
mixed_JJ
amphetamine_NN
salts_VPRT
MICROTROL_NN
3TC_NN
lamivudine_NN
trade_NN
mark_NN
of_PIN
GSK_NN
ADDERALL_NN
mixed_JJ
amphetamine_NN
salts_NN
MICROTROL_NN
DR_NN
ADEPT_NN
4_CD
%_NN
icodextrin_NN
solution_NOMZ
trade_NN
mark_NN
of_PIN
AGRYLIN_NN
anagrelide_NN
hydrochloride_NN
MICROTROL_NN
PR_NN
ML_NN
Laboratories_NN
plc_NN
AMATINE_NN
midodrine_NN
hydrochloride_NN
MICROTROL_NN
XR_NN
AZT_NN
trade_NN
mark_NN
of_PIN
GSK_NN
CALCICHEW_NN
calcium_NN
carbonate_NN
OPTISCREEN_NN
BIO-HEP_NN
B_NN
trade_NN
mark_NN
of_PIN
Berna_NN
Biotech_NN
AG_NN
CARBATROL_NN
carbamazepine_NN
PENTASA_NN
mesalamine_NN
COMBIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
COLAZIDE_NN
balsalazide_NN
PROAMATINE_NN
midodrine_NN
hydrochloride_NN
EPIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
DEXTROSTAT_NN
dextroamphetamine_NN
salt_NN
PROSCREEN_NN
HEPAVAX_NN
GENE_NN
trade_NN
mark_NN
of_PIN
Berna_NN
Biotech_NN
AG_NN
DIRAME_NN
RAPITROL_NN
NEISVAC-C_NN
trade_NN
mark_NN
of_PIN
Baxter_NN
International_NN
Inc._NN
._.
EMUTROL_NN
SOLARAZE_NN
diclofenac_NN
sodium_NN
3_CD
%_NN
REMINYL_NN
galantamine_NN
hydrobromide_NN
trade_NN
ENSOTROL_NN
SOLUTROL_NN
mark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
FARESTON_NN
toremifene_NN
TROXATYL_NN
troxacitabine_NN
TRIZIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
FLUVIRAL_NN
S_NN
F_NN
split-virion_NN
influenza_NN
vaccine_NN
XAGRID_NN
anagrelide_NN
hydrochloride_NN
ZEFFIX_NN
lamivudine_NN
trade_NN
mark_NN
of_PIN
GSK_NN
FOSRENOL_NN
lanthanum_NN
carbonate_NN
METHYPATCH_NN
methylphenidate_NN
Cautionary_JJ
statement_NOMZ
Statements_NOMZ
included_VBD
herein_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
historical_JJ
facts_NN
are_VPRT [BEMA]
forward-looking_JJ
statements_NOMZ
._.
Such_JJ
forward-looking_JJ
statements_NOMZ
involve_VPRT
a_DT
number_NN
of_PIN
risks_NN
and_PHC
uncertainties_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_TO
change_VB
at_PIN
any_QUAN
time_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
such_JJ
risks_NN
or_CC
uncertainties_NN
materialise_NN
,_,
Shires_NN
results_NN
could_POMD
be_VB [SPAU] [PASS]
materially_RB
affected_VBN
._.
The_DT
risks_NN
and_PHC
uncertainties_NN
include_VPRT
,_,
but_CC
are_VPRT [PASS]
not_XX0
limited_VBN
to_TO
,_,
risks_NN
associated_VBN [WZPAST]
with_PIN
the_DT
inherent_JJ
uncertainty_NN
of_PIN
pharmaceutical_JJ
research_NN
,_,
product_NN
development_NOMZ
,_,
manufacturing_GER
and_PHC
commercialisation_NOMZ
,_,
the_DT
impact_NN
of_PIN
competitive_JJ
products_NN
,_,
including_VBG
,_,
but_CC
not_XX0
limited_VBN
to_TO
,_,
the_DT
impact_NN
on_PIN
Shires_NN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
ADHD_NN
franchise_NN
,_,
patents_NN
including_VBG [WZPRES]
,_,
but_CC
not_XX0
limited_VBN
to_TO
,_,
legal_JJ
challenges_NN
relating_VBG [WZPRES]
to_PIN
Shires_NN
ADHD_NN
franchise_NN
,_,
government_NOMZ
regulation_NOMZ
and_PHC
approval_NN
,_,
including_VBG
,_,
but_CC
not_XX0
limited_VBN
to_TO
,_,
the_DT
expected_VBN [PRIV]
approval_NN
date_NN
of_PIN
lanthanum_NN
carbonate_NN
FOSRENOL_NN
and_PHC
METHYPATCH_NN
,_,
product_NN
liability_NOMZ
claims_NN
,_,
insurance_NN
and_CC
other_JJ
risks_NN
and_PHC
uncertainties_NN
._.
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2002_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Chineham_NN
Basingstoke_NN
Hampshire_NN
RG24_NN
8EP_NN
Tel_NN
44_CD
0_CD
1256 894 000_CD
Fax_NN
44_CD
0_CD
1256 894 708_CD
www_NN
._.
